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Abstract: 
Duchenne muscular dystrophy (DMD) is a hereditary X-linked neuromuscular disease resulting from 
mutations across the DMD gene. The subsequent absence of the encoded dystrophin protein 
prevents the correct formation of the dystrophin-associated protein complex (DAPC), a structural 
link between the sarcolemmal actin cytoskeleton and the myofibre extracellular matrix. Dystrophin 
deficiency compromises myofibre stability giving rise to progressive muscle wasting, the prominent 
pathological feature of this disease. Over time, muscle deterioration results in loss of ambulation 
and upper body movement, decline in respiratory and cardiac function and ultimately premature 
death in the third decade of life. Current treatment is limited to corticosteroid use, which delays 
clinical manifestations but does not address the underlying aetiology of the disease. In addition, 
many therapies currently under development address specific mutation types or are reliant upon 
repeated administration; this serves to reduce their applicability to patients. 
Genome editing refers to modification of genetic material at a precise genomic locus using special 
enzymes called customisable endonucleases. Recently, interest in genome editing approaches has 
increased with the advent of the clustered regularly interspaced palindromic repeats - Cas9 system 
(CRISPR/Cas9), in which an RNA guide can be used to direct the Cas9 nuclease to cleave the genome 
at a specific sequence.   
In the present study a genome editing strategy was designed and evaluated to restore functional 
dystrophin expression from the endogenous DMD gene. The approach involved modifying intron 1 
of the locus to insert dystrophin cDNAs downstream of the endogenous full-length dystrophin 
promoter and exon 1 elements, and was developed and verified in HEK293T cell and human DMD 
patient myoblast cultures. The approach was developed to permit full-length, mini-dystrophin and 
microdystrophin cDNA insertions to be examined. Specific CRISPR/Cas9 and guide RNAs (gRNAs) 
were designed and assessed for their ability to introduce double strand breaks (DSBs) at the DMD 
intron 1 locus. An exogenous DNA repair template construct, targeted to the DSB region in intron 1 
was designed and further modified to contain a microdystrophin coding cDNA from DMD exon 2 
onwards 
Co-delivery of CRISPR/Cas9, gRNA and exogenous repair template constituents in HEK293T cells, 
resulted in specific integration of the microdystrophin cDNA at the DMD intron 1 site. This was 
confirmed at genomic, transcriptomic and protein levels in polyclonal and zeocin-selected clonal cell 
populations. Application of the genome editing system in human DMD myoblasts also gave rise to 
evidence of specific microdystrophin cDNA integration, although further refinement of the 
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methodology is required to ensure myoblast survival following positive selection with the zeocin 
antibiotic.  
The research reported demonstrates the potential of genome editing the 5’ end of the DMD gene 
and offers a strategy towards permanent corrective gene therapy applicable to almost all DMD 
patient genotypes. 
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Chapter 1 Introduction 
1.1 Muscular Dystrophies 
Muscular Dystrophies (MDs) is an encompassing term for more than 30 genetically distinct 
conditions that affect muscle-associated proteins, culminating in alterations in muscle 
morphology, muscle wasting and paralysis (Emery, 2002; Mercuri & Muntoni 2013). Classified 
on the basis of the clinical manifestation, muscle wasting, these dystrophies have 
heterogeneous clinical onset, progression and varying degrees of cardiac involvement (Emery 
2002; Mercuri & Muntoni 2013). Currently, there is no cure for muscular dystrophies, only 
palliative care such as corticoid steroids to treat the secondary manifestations; leaving an 
unmet medical need to treat the underlying genetic aetiology of the disease (Bushby et al. 
2010a; Bushby et al, 2010b). 
1.2 Duchenne Muscular Dystrophy (DMD):  
Duchenne Muscular Dystrophy (DMD) is an X-linked inherited condition affecting 1 in 5000 live 
male births (Guiraud et al, 2015; Bladen et al. 2015). The condition arises from mutations 
across the DMD gene that results in the destruction or premature termination of the DMD 
open reading frame, as a consequence, dystrophin protein is not synthesised (Monaco et al. 
1988). The complex expression profile of the DMD gene, being driven by multiple promoters 
and producing multiple isoforms, accounts for the progressive muscle wasting and non-
progressive neurological manifestations of the disease observed in patients (Nudel, 2005). 
Whilst the full gene was cloned three decades ago, and identified as a candidate for gene 
therapy, the genetic aetiology of the disease has proved challenging to address. This is due to 
the large size of the gene, with 79 exons spanning 2.4Mbs of the genome and encoding an 
11.2kb mRNA (Koenig et al. 1987).  
Another challenge to the effective treatment of this disease is the diverse mutation profile 
exhibited by DMD patients, with mutation subsets and their occurrence being: large deletions 
68%, duplications 12% and small mutations 20% (Bladen et al. 2015). These mutations are 
observed to show clustering between exons 2-20 and 45-55, but can occur  throughout the full 
length of the DMD gene, being either inherited or arising spontaneously (Bladen et al. 2015). In 
contrast, Becker Muscular Dystrophy (BMD), a clinically milder form of muscular dystrophy,  
occurs in instances where the mutation is present without the disruption of the reading frame 
(Monaco et al. 1988; England et al. 1990). Subsequently, an internally truncated form of 
dystrophin is synthesised with partial function; the discovery of this allelic form, prompted 
interest towards mutation-specific therapeutic approaches that would restore the DMD 
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reading frame. This would enable the conversion from a Duchenne to a Becker Muscular 
phenotype, with the outlook of stabilising or slowing disease progression. 
1.3 Molecular Pathogenesis of DMD 
In muscle, dystrophin protein forms a structural link between F-actin and the sarcolemmal 
dystrophin-associated protein complex (DAPC) and thus an indirect connection to laminin, a 
component of extracellular matrix (Hoffman et al. 1987; Koenig et al. 1988; Ervasti et al. 1990). 
It speculated that dystrophin, allows for lateral dispersion of mechanical stress throughout the 
muscle, that occurs during exercise; thereby preventing contractile-induced injury (Lovering & 
De Deyne 2004; Bushby et al. 2010a; Ervasti et al. 1990). However, growing research has 
implicated dystrophin in signalling roles, in addition to the maintenance of muscle integrity as 
reviewed by (Allen et al. 2016). 
1.3.1 Calcium Dysregulation and Protease Activation: 
In muscle contraction, stimulation at the neuromuscular junction (NMJ), causes electrical 
excitation of the voltage sensing dihydropyridine receptor (DHPR) a modified L-type calcium 
channel, in the T-tubules (Allen et al. 2016; Anderson & Meissner 1995).  These 
dihydropyridine receptors interact with the ryanodine receptor (RYR1), promoting calcium 
release from the sarcoplasmic reticulum (Blat & Blat 2015). Ultimately, within a sarcomere this 
culminates in calcium binding to troponin, the displacement of tropomyosin and myosin-actin 
mediated muscle contraction. As a consequence of this contraction mechanism, cytosolic 
concentrations of calcium are tightly regulated in muscle. 
Interestingly, the cytosolic concentration of calcium ions appears to be elevated in dystrophin-
deficient muscle (Turner et al. 1991; Turner et al. 1993; Hopf et al. 1996); this is speculated to 
be due to microlesions in the sarcolemma  (Clarke et al. 1993; Blat & Blat 2015) or the localised 
effects of mechanosensitive channels (Whitehead et al. 2006; Iwata et al. 2009), which serve 
to increase sarcolemma permeability. The prolonged increase in intracellular calcium 
concentration, in turn, is implicated in the interference of normal excitation-contraction 
coupling and is thought to render muscle more susceptible to necrosis (Allen et al. 2016). In 
combination, this would give rise to muscle weakness, the most prominent clinical 
manifestation of DMD (Bushby et al. 2010a).   
Evidence in support of high calcium levels interfering with excitation-contraction coupling was 
afforded by observations in the mdx mouse muscle where calcium ion release was reduced 
following stimulation at the NMJ by both single and successive action potentials (Hollingworth 
et al. 2008). Further studies indicated that the reduced release of calcium ions could be 
accounted for by less frequent RYR1 opening or a depleted calcium store as a consequence of 
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impaired calsequestrin buffering (Doran et al. 2004). Interestingly, this trend is speculated to 
be retained in human muscle, where following strenuous exercise the increased cytosolic 
concentration of calcium, is associated with a reduction in muscle force following low 
frequency stimulation at the NMJ (Edwards et al. 1977). Thus in dystrophic muscle, where the 
sarcolemma is speculated to be more permeable, this could provide one explanation of muscle 
weakness. 
An alternative theory is that calcium cytotoxicity, renders muscle more susceptible to necrosis 
(Tidball & Spencer 2000). Whilst evidence suggests calpains play a role in muscular 
dystrophies, the exact mechanism of action remains to be elucidated. It is theorised these 
proteases could directly target and degrade muscle proteins or target transcriptional factors 
resulting in dysregulated muscle protein expression patterns (Allen et al. 2016). One 
interesting study implicated calpain in the direct destruction of junctophilin 1 and 2 proteins, a 
structural protein that maintains correct separation between the sarcoplasmic reticulum and 
the T-Tubules (Murphy et al. 2013). If the structural integrity of this protein were compromised 
it could certainly account for depleted sarcoplasmic and higher cytosolic calcium levels. While 
a plethora of theories exist as to molecular mechanisms, the research undertaken certainly 
suggests the perturbation of calcium homeostasis has a role to play in muscular dystrophy 
pathogenesis.  
1.3.2 Reactive Oxygen Species  
Oxidative stress largely refers to increased cytosolic concentrations of reactive oxygen species 
(ROS), a reduction in ROS scavengers and ROS-mediated dysregulation of signalling pathways 
(Allen et al. 2016; Jones 2006). Interestingly, dystrophic muscles are theorised to fulfil these 
criteria, with an increase in NADH (oxidase) NOX2 and resultant ROS (Whitehead et al. 2010), a 
depletion of glutathione a ROS scavenger (Renjini et al. 2012) and dysregulation of 
inflammatory and autophagy pathways all having been described.   
Early evidence in support of the oxidative stress theory, provided by Rando et al , indicated 
that mdx myotubes were more susceptible to oxidative stress, with diminished viability 
observed on exposure to lower concentrations of reactive oxygen species, relative to wild type 
(Rando et al. 1998). Interestingly, when the group performed the same experiments on 
myoblast precursor cells, no difference in mdx and wild-type susceptibility to ROS was 
observed. As dystrophin protein is expressed in wild-type myotubes, they suggested a link 
between dystrophin and the modulation of ROS in muscle. Further evidence in support of this 
putative linkage, was afforded in studies expressing minidystrophins or microdystrophins, 
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these being partial dystrophin transgenes bearing internal deletions, in  mdx myotubes which 
demonstrated an improved resilience to reactive oxygen species (Disatnik et al. 1998).  
Although the exact mechanism by which dystrophin absence causes in elevation of ROS in 
muscle has not yet been fully elucidated, the dysregulation of NOX2, a sarcolemma protein 
with mechanosensitive activation is implicated (Whitehead et al. 2010).  One theory indicates 
that aberrant arrangement of microtubules may cause increased activation of NOX2 and 
subsequently increased production of ROS and calcium dysregulation (Khairallah et al. 2012). 
Alternatively, the localisation of nNOS to the cytosol, which is usually bound to spectrin 
repeats 16 and 17 on dystrophin protein, has also been implicated in the activation of NOX2 
(Lai et al. 2009; Allen et al. 2016).  
Regardless of the source of activation, studies of NOX2 have illustrated that its activation 
results in increased ROS production and its inhibition reduces ROS concentration in dystrophic 
muscle (Khairallah et al. 2012). Important to the pathology of DMD, reactive oxygen species 
are implicated in the activation of stretch-activated calcium channels causing calcium influx, 
protein (Hauser et al. 1995) and lipid damage (Messina et al. 2006), activation of inflammatory 
pathways and reduction in autophagy of damaged organelles (Allen et al. 2016). In 
combination, these outcomes are anticipated to lead to an increase in the muscle cell death.  
1.3.3 Fibrosis and Inflammation 
Fibrosis refers to the excessive deposition of extracellular matrix (ECM) proteins into tissues 
during regenerative processes that follow injury (Kharraz et al. 2014). In the context of DMD, 
chronic degeneration-regeneration cycles cause muscle fibrosis. This contributes to dystrophic 
muscle pathology in two main ways. Firstly, the direct replacement of skeletal muscle with 
non-functional fibrotic tissue serves to reduce contractility. Secondly, fibrotic tissue forms a 
physical barrier serving to impede blood perfusion (Blat & Blat 2015). By extension these 
effects also provide potential limitations for many therapeutic strategies being trialled by 
forming a physical barrier and reducing blood flow to the muscle tissue,  thus reducing the 
access of therapeutics (Negroni et al. 2016).  
Two principle growth factors are implicated in the causation of fibrosis, these being 
transforming growth factor β1 (TGFβ1) and connective tissue growth factor (CTGF). TGFβ1 is 
present in a latent form in the ECM and evidence indicates it is activated both in response to 
muscle damage and by invading cells of the immune system (Horiguchi et al. 2012; Wynn 
2008). This activation normally occurs as a natural regenerative response to muscle injury, but 
occurs continuously or repetitively in DMD progression. Once activated TGFβ1 binds through 
two receptors called activin linked kinase 5 (ALK5) and TGFβ type II receptor, the downstream 
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phosphorylation cascade causes SMAD protein mediated changes in gene expression 
(Massague et al. 2005). The net result is stimulation of fibroblastic production of profibrogenic 
proteins and the downregulation of tissue inhibitors or metalloproteases (TIMP), which 
culminates in excessive deposition of extracellular matrix proteins in muscle (Kharraz et al. 
2014). Observations on the administration of TGFβ1 in both in vitro and in vivo systems show 
that TGFβ1 induces further TGFβ1 expression in other cells in a positive cycle, and promotes 
the production of connective tissue (Brandan et al. 2008; Li et al. 2004).  Importantly, it was 
also demonstrated that transfected cells expressing TGFβ1 that were then intramuscularly 
injected into SCID mice, differentiated to form myofibroblastic cells. Interestingly, this could be 
reversed upon sequestration of  TGFβ1 with decorin, which directly binds to the growth factor 
interfering with downstream activation processes (Li et al. 2004). The second factor involved in 
fibrosis, CTGF, is induced by TGFβ1, and is also present in the ECM. CTGF was shown to be 
more potent than TGFβ1 in inducing the production of connective proteins in fibroblasts 
(Frazier et al. 1996; Kharraz et al. 2014).  
In addition to the activation of fibrosis, the infiltration of immune cells such as macrophages, 
T-cells and neutrophils  are implicated in heightening muscle lesions and dystrophic pathology 
(Evans et al. 2009). Interestingly, inflammatory signalling could be a major influence on the 
balance of muscle degeneration and regeneration processes. Macrophages as a case in point 
are present in mdx muscle in two distinct populations, M1 and M2, these being pro- and anti-
inflammatory respectively (Shin et al. 2013). Interestingly, treatment of mice with IFN-γ, an 
inflammatory cytokine, was found to heighten muscle damage and deactivate M2 
macrophages (Villalta, Deng, et al. 2011); contrastingly treatment with the anti-inflammatory 
cytokine, IL-10, promoted regeneration (Villalta, Rinaldi, et al. 2011). Thus the modulation of 
macrophages could be a potential therapeutic strategy in DMD.  
Furthermore, nuclear factor-кβ (NF-кβ) proteins, a family of transcription factors, have been 
implicated to heighten dystrophic pathology in muscle.  The NF-кβ family comprises five 
members: RelA (p65), Rel-B, c-Rel, p100/p50 and p52, which can undergo homo- or hetero-
dimerisation depending upon the source of stimulation.  Under normal conditions , NF-кβ is 
inactivated in the cytosol by association with Iкβa, which masks the nuclear localisation signal 
(NLS) (Karin 1999).  In the presence of pro-inflammatory signals, such as interleukin-1, Iкβ 
kinase causes Iкβa and NF-кβ to dissociate liberating the NF-кβ and enabling translocation to 
the nucleus and modification of gene expression (Karin 1999).  Importantly, NF-кβ was 
implicated to worsen muscle pathology in three main ways: i) augmentation of the ubiquitin-
proteasome system, which would promote the degradation of muscle proteins; ii) 
enhancement of  expression of pro-inflammatory mediators such as cytokines and chemokines 
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which heighten muscle damage and loss; iii) reduced myofibre regeneration (for a review see 
(Li et al. 2008). Studies have shown that deletion of a single allele of the NF-кβ p65 subunit 
reduces infiltration of macrophages and associated fibrosis (Acharyya et al. 2007). Consistent 
with this, inhibition of NF-кβ was also associated with improved regenerative capacity of 
muscle derived stem-cells post transplantation (Lu et al. 2012). Thus the modulation of this 
factor is currently under investigation with the outlook of slowing clinical progression in  DMD 
patients (Mah et al. 2014). 
1.3.4 Multiple Combined Pathogenic Mechanisms: 
The above theories highlight that the pathogenesis of DMD is a multifaceted process and the 
summative effects of impaired calcium homeostasis, ROS dysregulation and inflammation 
provides a continual cycle of muscle damage and subsequent muscle necrosis. This muscle 
damage stimulates satellite cells, denoted as adult muscle stem cells, to activate and promote 
muscle regeneration (Lipton & Schultz 1979). Importantly, after chronic cycles of muscle 
degeneration and  regeneration the response can become insufficient to address the muscle 
fibrosis and necrosis resulting in muscle wasting (Boldrin et al. 2015). The reasons for this are 
still a source of debate: original theories suggested that satellite cells may become exhausted 
with reduced regenerative propensity (Morgan & Zammit 2010)  or depleted (Heslop et al. 
2000). However, later observations that satellite cell numbers were elevated in DMD patients, 
and that satellite cells derived from both adult and young mdx mice have the same 
regenerative capacity on engraftment placed these theories under scrutiny (Kottlors & 
Kirschner 2010; Boldrin et al. 2015). Current theories suggest that the dystrophic muscle 
environment, such as chronic inflammation and fibrosis negatively impact upon satellite cell 
regeneration, reducing their ability to effectively regenerate muscle following injury (Boldrin et 
al. 2015). A flow chart linking the pathogenesis can be seen in Figure 1-1. 
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Figure 1-1 Multifaceted pathogenesis of DMD and routes to therapeutic intervention. 
A) Immunohistochemistry staining from transverse 10μM, muscle sections from C57 Black 6 wild type 
and H2kb mdx Tibialis Anterior. Importantly, laminin is stained in red, dystrophin in green and nuclei in 
blue with DAPI. Images were taken at 200x magnification and kindly provided by Dr. Ngoc Lu-Nguyen. 
Importantly they showcase hallmarks of dystrophic muscle, with mdx showing inconsistent fibre size, an 
absence of dystrophin stain and central nucleation a marker of regeneration. B) A schematic flow-chart 
to illustrate DMD pathogenesis and proposed links between dystrophin absence and muscle wasting. 
Notably, proposed interventions and at what stage they would treat the pathology is also shown, 
denoted by green arrows.  These include: gene-editing (Popplewell et al. 2013), gene therapy (Le Guiner 
et al. 2017; Koo et al. 2014; Tinsley et al. 2011), calcium antagonists (Phillips & Quinlivan 2008), 
antioxidants (Stern et al. 1982), vasodilators (Martin et al. 2012), myostatin Inhibition (Lu-Nguyen et al. 
2015), anti-fibrosis and inflammatory therapies (Traynor 2017), and corticosteroids (Mercuri & Muntoni 
2013). 
A 
B 
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1.4 DMD Diagnosis, Clinical Signifiers and Disease Progression and 
Treatment: 
Importantly, DMD patients are born with a genetic mutation in the DMD gene; in two thirds of 
cases there is a familial history and in one third the mutation occurs spontaneously (Bladen et 
al. 2015).  However, DMD often goes undiagnosed until 2 - 5 years of age, where delayed 
locomotor milestones, walking with an unsteady gait or delayed attainment of cognitive 
milestones present as the initial symptoms (Emery 2002; Bushby et al. 2010a; Allen et al. 
2016). 
Further indicators of disease, leading to diagnosis include: (i) the ‘Gower manoeuvre’, in which 
during rising from the floor, a child  with DMD uses his arms to walk up his thighs, pushing up 
off of them to extend his hip and trunk muscles to attain a standing position (Emery 2002); (ii) 
blood samples taken for examination of creatine kinase (CK) levels,  which can be elevated 
100-fold in DMD patients (Zatz et al. 1991); (iii) muscle biopsy taken and histological analysis 
performed with an antibody for dystrophin, to assess presence or absence of the protein and 
finally genetic screening in an attempt to identify the mutation type (Bushby et al. 2010a). 
Notably, the CK levels are a non-specific clinical marker, indicating general muscle damage in 
the case of DMD. This stated, CK can be elevated in response to exercise, alcohol and cardiac 
conditions (Allen et al. 2016).  Thus additional forms of confirmation including muscle biopsy 
are necessitated. During childhood, ambulation and mobility of the child will continue to 
decline and the use of a wheelchair normally occurs between 7-12 years of age (Allen et al. 
2016). As muscle degeneration becomes more prominent in teenage years and up to the 20s, 
severe respiratory and cardiac involvement arises. Respiratory support is provided in the form 
of antibiotic treatments for respiratory infections, Surgical intervention for spinal curvature, 
manual and assisted cough techniques, non-invasive daytime and nocturnal ventilation and as 
a final resort, a tracheostomy is undertaken (Birnkrant et al. 2010).  
Cardiac involvement normally manifests in DMD as cardiomyopathy or arrhythmia (Bushby et 
al. 2010b; Fayssoil et al. 2017). The current multidisciplinary management of DMD, and 
advancements in care in terms of corticosteroids use and non-invasive ventilation has served 
to improve life expectancy in DMD patient to 20-30 years of age (Bushby et al. 2010b; Allen et 
al. 2016). Currently cardiomyopathy is the leading cause of mortality in DMD patients and 
requires further investigation (Bushby et al. 2010b; Allen et al. 2016). 
Corticosteroids are currently the mainstay treatment regime of DMD (Bushby et al. 2010a; 
NICE 2016). These are used to dampen the inflammatory responses in muscle resulting from 
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continual muscle damage and cycles of degeneration and regeneration, serving to slow the 
clinical progression of the disease. Whilst adherence to a corticosteroid programme, such as 
prednisolone serves to maintain muscle strength and function, prolonging ambulation, long 
term administration is associated with a multitude of undesirable side effects. These include: 
stunted growth, bone demineralisation, increased mood-swings and weight gain (NICE 2016). 
This side-effects may independently require management including, dietetic advice to address 
bone fragility and psychosocial support. Various dosing regimens are utilised in an attempt to 
mitigate these side effects (Bushby et al. 2010a). 
1.5 Gene Augmentation and Gene-Editing 
Gene Therapy is defined as ‘a set of strategies that modify the expression of an individual’s 
genes or repair abnormal genes’ (ASGCT 2014). This definition is reflective of  the subdivision 
of gene therapy into two broad approaches: firstly, gene augmentation, which aims to deliver 
a new  functional copy or variant of a gene, to enhance protein expression in place of the 
endogenous mutated gene;  and secondly, gene editing, which aims to directly modify the 
genome for the purpose of gene repair (ASGCT 2014). Both have the common goal of 
ameliorating disease-causing genetic mutations.  
Gene augmentation therapies utilise non-viral or viral systems to deliver a functional copy of 
the gene (Nayerossadat et al. 2012). Viral systems are the more efficient platform used for the 
delivery of genetic material (Nayerossadat et al. 2012). Notable examples include 
Adenoviruses, these viruses have large transgene   capacity of up to 37kb particularly if the 
gutted format is used (Gonçalves & de Vries 2006; DelloRusso et al. 2002). This makes them 
the most suited for large transgenes, however, some serotypes are associated with 
immunogenic side effects upon administration, which has served to limit their use (Machitani 
et al. 2011; Alonso-Padilla et al. 2016; Teigler et al. 2014). Adeno-associated viruses (AAV), this 
small parvovirus can encode a DNA transgene of approximately 4.7kb (Wu et al. 2010a). They 
are favoured for use in the field of gene therapy  on the basis of not being associated with any 
diseases in humans,  dependence on another virus for replication and their low pathogenicity 
relative to Adenoviruses (Buller et al. 1981; Rose & Koczot 1972; Nayerossadat et al. 2012). 
Lentiviruses, this subclass of the retroviruses has a natural ability to integrate into non-dividing 
cells (Nayerossadat et al. 2012). The integration proficient and deficient variants, of this 
system in combination with their approximately 9kb transgene capacity make them  an 
attractive viral vector for use in the DMD field (Meng et al. 2016). In contrast non-viral 
methods, with slightly lower efficiencies comprise chemical methods such as cationic 
liposomes and polymers and physical methods such as electroporation and magnetofection 
(Nayerossadat et al. 2012). 
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Importantly, with the exception of the gutted Adenoviral vectors, the 11.2kb dystrophin cDNA 
theoretically exceeds the packaging capacity of many viral vectors. In an effort to utilise the 
limited packaging capacity lentiviral and AAV systems mini and microdystrophin cDNA 
constructs were generated. These constructs encoded shortened but functional dystrophin 
proteins, with internal deletions across the central rod domain.  The microdystrophin 
constructs, are diverse but encode the minimal necessary domains for dystrophin protein 
functionality. The main MD1 variant used throughout this investigation  R4-24 ΔCT 
(nomenclature to indicate the deletion of spectrin repeats and a truncated C-terminal)  was 
previously described by (Athanasopoulos et al. 2011; Le Guiner et al. 2017). Finally, a 
minidystrophin harbouring the well characterised BMD Δ45-55 mutation was also used 
throughout this investigation (Taglia et al. 2015).  Notably, during the production of this 
manuscript the insertion of full length dystrophin into a lentiviral template was achieved 
(Counsell et al. 2017) 
Notably, the first clear demonstration of the clinical benefit afforded by gene therapy was 
achieved by retroviral vector treatment of severe combined immunodeficiency (SCID) (Hacein-
Bey-Abina et al. 2002; Hacein-Bey-Abina et al. 2010). Since then there have been several 
successes in the field, including Glybera, an AAV vector engineered to express lipoprotein 
lipase, used in the treatment of lipoprotein lipase deficiency. Glybera was the first gene 
therapy to gain EU approval, although recently withdrawn on the basis of high associated cost 
and limited use of treatment (Ylä-Herttuala 2012; Regalado 2016). Strimvelis is another 
registered gene therapy product in which CD34+cells  transduced with retroviral vector to 
express human adenosine deaminase (ADA) are administered intravenously to treat ADA 
deficiency (Aiuti et al. 2017).  These advances are encouraging, in addition other gene 
therapies using non-viral  delivery systems such liposomes encoding the cystic fibrosis 
transmembrane conductance regulator (CFTR) also appear promising (Alton et al. 2016; Alton 
et al. 2015).  
 Therapeutic Gene-editing approaches are also being developed. Sangamo are currently 
undertaking a pilot study to assess the safety and efficacy of CR5 Modified CD34+ 
Hematopoietic Progenitor Cells in HIV patients (NCT02500849). This followed promising 
evidence obtained from a small study of 12 patients, that were given and infusion of Zinc 
Finger Nuclease (ZFN) modified autologous CD34+ T- cells. Interestingly T-cells, were 
significantly elevated per cubic millimetre of serum from 448 pre-infusion to 1517 one week 
later. Furthermore, T-cells post treated and were shown to persist longer and modulate 
viremia even during treatment interruption(Tebas et al. 2014). Secondly, in vivo administration 
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of ZFNs has very recently been announced in the treatment of Hunter’s syndrome, the results 
of which will be eagerly awaited by the field (Grens, 2017).   
1.6 Experimental Therapeutic Strategies for the Treatment of DMD: 
1.6.1 Gene Augmentation Approaches: 
Following the identification of the genetic causation of Duchenne muscular dystrophy 30 years 
ago, it was quickly identified as a candidate for gene therapy (Koenig et al. 1987).  However, 
the large size of the dystrophin cDNA being approximately 11.2kb largely hindered the 
utilisation of this approach, exceeding the packaging capacity of many viral vectors (Hoffman 
et al. 1987). In response to this, minidystrophin and microdystrophin genes were designed; 
these encoding functional albeit internally-deleted dystrophin proteins, that can be coded for 
by minimally sized cDNA, suitable for packaging into lentiviral (LV) and adeno associated viral 
vectors (AAV) respectively (Harper et al. 2002). The basis of this approach was based upon two 
central premises: the modular nature of the dystrophin protein, permissive to the introduction 
of deletions, and the identification of a Becker patient, who appeared to be largely 
asymptomatic, despite 46% of the DMD gene being deleted, producing a highly truncated 
albeit functional dystrophin protein (Harper et al. 2002; England et al. 1990).  
The earliest microdystrophin designs aimed to include the minimal necessary constituents for 
dystrophin function (Harper et al. 2002). This stated, they have continued to demonstrate 
promising findings in mouse and canine preclinical models; both in terms of dystrophin 
restoration and improved muscle strength (Foster et al. 2008; Bostick et al. 2008; Pichavant et 
al. 2010; Koo et al. 2011; Le Guiner et al. 2017). One phase I clinical trial was undertaken to 
examine the therapeutic effects of a particular microdystrophin construction (R2+H3-R22-ΔCT) 
described by Xiao Xiao, in 6 DMD patients (Mendell et al. 2010). Notably minimal and transient 
expression of the microdystrophin protein was observed, alongside immune responses to 
dystrophin  in 4 of 6 patients (Mendell et al. 2010). This study was performed using a CMV 
promoter to control microdystrophin expression, and it is speculated that the use of a muscle 
restrictive promoter and reducing the immunogenicity of AAV capsids could all improve upon 
the outcomes observed (Mendell et al. 2012; Rodino-Klapac et al. 2013). It is important to 
realise that this microdystrophin construct is distinct from the format utilised in this study (R4-
24ΔCT). Recently, studies have focused upon the inclusion of more protein domains and 
altered architecture of both mini and microdystrophins to improve the functionality of 
resultant proteins (Reza et al. 2016; Hakim et al. 2017).  
An alternative approach to overcoming the large transgene size is triple trans-splicing in which 
the dystrophin transgene is divided into three sequential fragments, packaging into AAVs and 
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co-transduced (Koo et al. 2014; Lai et al. 2005), the premise being that dystrophin will 
reconstitute upon the association of these three vectors. Although promising, the current 
systems show low efficiency and are still in the preclinical stages of development. 
1.6.2 Utrophin Modulation Strategies 
The utrophin gene is a homologue of the DMD gene; the resultant protein produced from this 
locus exhibits similar sequence, structural and binding properties to dystrophin (Love et al. 
1993; Love et al. 1989).  Early studies highlighted that utrophin was expressed at the 
sarcolemma of regenerating myofibres following muscle injury, and is upregulated in mdx mice 
during regeneration (Helliwell et al. 1992). Furthermore, the expression of full-length utrophin 
in transgenic dystrophin-deficient mdx mice was sufficient to prevent the development of 
muscular dystrophy in an expression dependent manner (Tinsley et al. 1998).  A second related 
study, in a canine X-linked disease model highlighted that delivery of a mini-utrophin by an 
adenoviral vector was able to compensate for the absence of dystrophin. It was speculated 
that utrophin and mini-utrophin expression allowed for the restoration and correct formation 
of the DAPC, as indicated by higher levels of sarcolemmal β-dystrogylcan and β-sarcoglycan 
(Cerletti et al. 2003). These observations suggested that utrophin protein could act as a 
functional surrogate for dystrophin, enabling the reconstitution of the structural link between 
intracellular F-actin and the DAPC. The reconstitution of such a link was speculated to improve 
structural integrity of the muscle and ameliorate dystrophic pathology, and led to 
investigations to identify drugs that would upregulate utrophin in skeletal muscle.  
In light of the potential benefits of utrophin upregulation, an exhaustive screen was performed 
to identify compounds with the ability to selectively upregulate utrophin, and SMTC1100 was 
selected (Tinsley et al. 2011).  Upon daily dosing of this compound in 4 week old mdx mice, an 
age when muscle characterised by necrosis and degeneration, a 2 fold increase in utrophin 
RNA was observed, and a subsequent increase in utrophin protein synthesis. Functionally, 
SMTC1100 treatment translated to a 75% reduction in serum CK levels, protection against 
forelimb exercise-induced weakness and improved resistance to fatigue in mdx mice. 
Furthermore an additive effect was observed when this compound was used in combination 
with the corticosteroid prednisolone (Tinsley et al. 2011). 
These findings were sufficient to enable SMTC1100 to progress to a Phase I human clinical trial 
assessing the drug for safety and tolerability in healthy volunteers (Tinsley et al. 2015). This 
comprised of two main investigations, a single administration dose escalation, and a twice 
daily administration regimen. Promisingly, the drug was found to be safe and well tolerated, 
the only adverse side effect being stool discolouration attributed to unabsorbed drug passing 
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through the gastrointestinal tract. Furthermore, the drug was rapidly absorbed and produced 
serum levels comparable to those required to produce a 50% upregulation of utrophin in vitro.  
This stated, a high level of variation in serum concentration of the drug was observed despite 
similar levels of absorption. Investigators posited that the patient’s diet maybe an influential 
factor in drug persistence and clearance, recommending the drug should be administered with 
food, preferably with a high fat content in future studies.  
Similar trends persisted in a later clinical trial performed in paediatric patients with DMD 
where despite patients being instructed to eat 10 minutes prior to SMTC1100 administration, a 
large variability in drug serum concentration was still observed. Intriguingly, the SMTC1100 
plasma concentration was more rapidly reduced over 11 days of treatment in DMD patients 
relative to healthy volunteers falling 56-62% relative to the 23-40% previously reported. 
However a number of biochemical markers indicative of muscle damage declined over the 
course of the study, which was interpreted as a positive outcome (Ricotti et al. 2016). These 
findings have subsequently prompted further on-going clinical trials. Firstly, the examination of 
SMTC1100 in paediatric patients with DMD following a balanced diet (Clinical Trial Number: 
NCT02383511). Interim reports indicate this trial has been completed with a new formulation 
of SMTC1100 that can attain the same serum concentration as the previous formulation at 
1/10th of the dose, but formal results are currently awaited (Summit Therapeutics Plc 2016; 
Guiraud, Squire, et al. 2015).  In the meantime, this trial has been extended to a 48 week Phase 
2 clinical trial (Clinical Trial number: NCT02858362).  
1.6.3 Nonsense Mutation Read-Through Therapies: 
It is estimated that approximately 10% of DMD cases are caused by the presence of a 
nonsense mutation (Bladen et al. 2015; Welch et al. 2007). This causes the premature 
termination of translation, and the resultant mRNA is subject to degradation through the 
nonsense mediated decay pathway.  This prompted the examination of compounds that could 
enable selective read-through of nonsense codons (Welch et al. 2007). 
Early observations indicated aminoglycoside-based antibiotics could promote read-through of 
premature stop codons, but concerns related to drug toxicity hindered further therapeutic 
development (Malik et al. 2010). However these findings prompted high-through screening of 
800,000 novel drug compounds to be undertaken to identify high efficacy read-through 
compounds with lessened toxicity (Welch et al. 2007). The results of this screen identified the 
compound PTC124 (Trade names Ataluren /Translana). Notably, this compound shows no 
structural similarity to aminoglycosides but is able to elicit selective read-through of premature 
termination codons at relatively low doses (Welch et al. 2007). 
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Importantly, the initial screening highlighted that Ataluren was able to promote dystrophin 
production in primary myoblast cultures from DMD patients and mdx mice (Welch et al. 2007).  
Furthermore a combined regime of oral administration and intraperitoneal injections in mdx, 
showed a reduction in CK levels, a restoration of dystrophin to 25% wild-type levels and 
improved EDL muscle resilience to eccentric contraction (Welch et al. 2007). These preclinical 
findings were enough to support two subsequent Phase I trials in 62 mixed gender healthy 
volunteers (Hirawat et al. 2007). Importantly, single dosing regimens of 100, 150 and 
200mg/kg and repeated doses of 50mg/kg 12 hours apart were safe and well tolerated. The 
findings that the drug specifically targeted premature stop codons and had no evidence of 
accumulation or toxicity prompted phase II clinical trials in DMD patients (Hirawat et al. 2007), 
and eventually suggested potential therapeutic benefit of Ataluren (Finkel et al. 2013; Bushby 
et al. 2014).  
In the first phase IIa proof of concept trial, all patient myoblasts derived from biopsies, and 
cultured in the presence of Ataluren, showed evidence of dystrophin restoration. Furthermore, 
on administration of Ataluren, 23 of 38 patients (61%) showed evidence of dystrophin 
restoration in pre and post-treatment comparisons. The mean dystrophin restoration was 
estimated to be 11% and there was a concomitant decline in serum CK levels.  Over this 28 day 
trial, the treatment was well tolerated (Finkel et al. 2013). A longer 48 week Phase IIb 
randomised, double blind trial, mirrored the beneficial findings of the former with the use of 
functional endpoints. Promisingly, patients with a mean baseline 6 minute walk test distance 
(6MWD) of 350m ± 97.6m enrolled in a 40mg/kg/day dose regime of Ataluren showed a mean 
improvement of 31.3m relative to the placebo group. Although not statistically significant, this 
prolonged ambulation and improved muscle function was deemed meaningful and advocated  
Ataluren’s progression to a Phase III clinical trial (Bushby et al. 2014). 
Although the mean 31.3m improvement in the walk test in the Phase IIb trial was not 
statistically significant; two independent studies of the 6MWT, a primary end point assessing 
locomotion, deemed the finding as meaningful (McDonald et al. 2010; Mcdonald et al. 2013). 
This was instrumental to Ataluren  becoming the first drug to gain marketing and approval in 
Europe (Haas et al. 2015). The Phase III clinical trial continues to develop upon this trend of 
success, on the division of groups on the basis of the 6MW test (<300m, 300-400m and 
400m+). Notably, significant improvement was observed in the 300-400m 6MW Ataluren-
treated group relative to the placebo, with a mean 42m difference in walking distance. In the 
other groups a slower more stabilised rate of decline was observed. The cumulative efforts of 
these studies demonstrate that Ataluren is promising treatment for DMD patients with a 
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nonsense mutation, providing conservative benefit or stabilisation of disease progression. As a 
consequence an additional long term trial is planned (NCT03179631). 
1.6.4 Exon Skipping by Antisense Oligonucleotides  
The rationale of antisense oligonucleotide (AON) exon-skipping is to convert an out-of-frame 
DMD mutation to an in-frame BMD mutation at the transcriptomic level. Importantly, exons 
adjacent to deletion mutations in DMD are generally not in-phase with each other, meaning 
when they are transcribed, the mRNA will not form complete wild-type codons. The resultant 
out-of-frame mRNA sequence will quickly generate a downstream stop codon, and be subject 
to nonsense-mediated decay. AONs are short synthetic nucleic acid stretches, with modified 
backbone chemistries that bind to and sterically hinder the splicing of  a target exon within the 
dystrophin pre-mRNA (Aartsma-Rus et al. 2017). The net result is the exclusion of a target 
exon, the splicing of in-phase exons and restoration of the downstream open reading frame. 
For example, deletion of DMD exons 48-50, results in an out-of-frame mutation, as exon 
splicing being  47-51  are not in-phase. Targeting exon 51 with an exon skipping AON, to 
promote its exclusion from the transcript would result in exon 47-52 splicing. These exons are 
in-phase and  would result in the restoration of the dystrophin open reading frame , enabling 
translation of a functional dystrophin protein harbouring an internal deletion (Jarmin et al. 
2014; Verhaart & Aartsma-Rus 2012; Aartsma-Rus et al. 2017). 
Due to it having the highest therapeutic applicability with 13-15% of DMD patients being 
eligible for treatment, AON therapy targeted to exon 51 is the most advanced in development. 
Two distinct AON chemistries, have been developed to target exon 51 (Aartsma-Rus et al. 
2009). The first  product was a 2’ O-methyl phosphorothiorate (2’OMePS) AON, Drisapersen 
(Goemans et al. 2011; van Deutekom et al. 2007; Voit et al. 2014), and the second product a 
phosphorodiamidate morpholino oligomer (PMO) Eteplirsen (Mendell et al. 2013). [For a 
review of a range of AON chemistries see (Chan et al. 2006)]. These AONs were subject to a 
plethora of clinical trials and recurrent trends observed included variable dystrophin 
restoration observed across patients enrolled and marginal but largely non-significant 
Improvements in the 6 minute walk test in patients (Cirak et al. 2011; Cirak et al. 2012; 
Goemans et al. 2011; Goemans et al. 2016; Kinali et al. 2009; Mendell et al. 2013; Mendell et 
al. 2016; van Deutekom et al. 2007; Voit et al. 2014; Mendell et al. 2017). In the case of 
Drisapersen, a recent long term open-label extension study indicated that the treatment was 
well tolerated with the most common adverse events reported being injection site reactions.  
Finally, this study also indicated that for a small cohort of patients this treatment appeared 
particularly promising as natural history comparisons indicated a 100m decline in comparable 
untreated patients (Goemans et al. 2016). Recently and rather controversially Eteplirsen 
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gained accelerated FDA approval, pending further assessments due in 2021 (Aartsma-Rus & 
Krieg 2017). The approval proved controversial on the basis that despite dystrophin positive 
myofibres appearing elevated from 9.4 – 22.6% post treatment; the overall increases in 
dystrophin protein determined by western blot showed a marginal mean increase from 0.28-
0.93%, which was not observed in all patients (Aartsma-Rus & Krieg 2017).  This finding 
suggests that whilst myofibres may be dystrophin positive they express dystrophin at very low 
amounts. In combination these studies emphasise that more research is warranted to assess 
whether such small changes in dystrophin protein could serve to stabilise disease progression. 
Eteplirsen gaining accelerated FDA approval and being under evaluation by the EMA, 
represents an exciting advancement for Exon51 skipping, however a number of hurdles still 
remain for this therapeutic strategy. Whilst, AONs have been developed for all possible 
therapeutic exon skips in the DMD gene, distinct AON sequences and chemistries constitute 
separate medicinal compounds under current EU legislature (Aartsma-rus et al. 2005; Wilton 
et al. 2007; Aartsma-Rus et al. 2017). As a consequence each compound will require individual 
clinical testing  as exemplified by AONs designed to Exons 45 and 53 (Clinical Trial: 
NCT02310906) (Aartsma-Rus et al. 2017). This format of clinical development could prove 
challenging to the field, particularly in the context of AONs with low patient applicability of less 
than 1%. Furthermore, not all patients would be eligible for this form of treatment with  64% 
of patients potentially eligible for single exon skip therapy, 79% for double exon skipping, and 
90% for multi-exon skipping (Verhaart & Aartsma-Rus 2012). The screening of all reagents for 
multi-exon skipping would likely prove very labour intensive. Moreover, multiple exon skips 
could theoretically be hindered by variable efficacy of AONs administered. Finally, whilst this 
strategy could ameliorate some of the morbidity associated with DMD, attaining exon skipping 
in the heart still remains challenging for which tricyclo AONs and peptide-lined PMOs are 
currently being investigated (Relizani et al. 2017; Betts et al. 2012). Promisingly, in vivo delivery 
of tricyclo AONs targeted to the 5’ splice site of intron 23 achieved exon 23 skipping and 
restoration of dystrophin to 38% wild type levels in the mdx heart. This stated, the doses of 
tricyclo AONs used (200mg/kg) are considerably higher than the therapeutic ranges used for 
Drisapersen(6mg/kg) or Eteplirsen (50mg/kg) (Relizani et al. 2017; Goemans et al. 2016; 
Mendell et al. 2013). 
1.6.5 Myostatin Inhibition Studies: 
Myostatin, also referred to as growth and differentiation factor 8 (GDF8), is a member of the 
TGF-β superfamily, but is considered unique due to its muscle specific expression (Schuelke et 
al. 2004). Physiologically, GDF8 is transcribed as an immature precursor protein, this 
undergoes proteolytic cleavage to release a 24kDa homodimer, which remains associated with 
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its pro-peptide in a non-covalent manner (Latres et al. 2015).  This homodimeric form of 
myostatin persists in serum, complexed to proteins such as follistatin and growth and 
differentiation factor associated serum protein (GASP-1) that maintain it in an inactive form 
(Latres et al. 2015). Finally, a BMP1/tolloid serum metalloprotease disrupts bonding between 
the pro-peptide and mature peptide, and liberates mature active GDF8 (Lee et al. 2010).  
The mature GDF8 is able to interact with activin receptor IIB (ActRIIB) for which it is exhibits 
high affinity, and leads to Smad 2/3 becoming  phosphorylated, entering the nucleus and 
ultimately modulating downstream gene expression (McPherron et al. 1997; Lee 2004). The 
net result of this process is the negative regulation of muscle mass. As muscle wasting is 
prominent in a range of muscular dystrophies and atrophic neuromuscular diseases and 
conditions, inactivation or inhibition of myostatin or subsequent myostatin signalling was 
identified as a potential therapeutic target (Thomas et al. 2000). Evidence in support of this 
premise was afforded by the hypertrophy present in a range of naturally-occurring and 
transgenic animal models where loss-of-function mutations are present in the myostatin gene, 
including one human precedent of myostatin knock-out (McPherron & Lee 1997; Chen & Lee 
2016; Schuelke et al. 2004). Furthermore, it was demonstrated that mdx mice harbouring a 
myostatin knock-out not only showed hypertrophy but an increase in strength (Wagner et al. 
2002). 
As a consequence of this observation many strategies have been undertaken in exploration of 
myostatin inhibition in DMD. In preclinical models, AONs have been used to induce out-of-
frame skipping in myostatin mRNA. Studies combining AONs to restore the dystrophin reading 
frame and induce out-of-frame skipping in myostatin, demonstrated that a reduction of 
myostatin had an additive effect on dystrophin restoration (Lu-Nguyen et al. 2015). In light of 
Eteplirsen gaining FDA approval, this is one strategy that could be used to improve the efficacy 
of AON therapies. 
 An alternative strategy for myostatin inhibition is use of therapeutic myostatin antibodies, the 
premise being these would bind to myostatin protein preventing its downstream signalling. 
The first myostatin antibody tested, Myo29, demonstrated suitable safety margins for 
intravenous delivery to patients with muscular dystrophies. However, the antibody failed to 
meet clinical endpoints, based upon both physical and biological assessments leading to its 
discontinuation (Wagner et al. 2008). However, post-hoc analyses indicated that the antibody 
dose and serum concentration in the study may have been insufficient to elicit an effect, due 
to blood clearance being higher in patients that first anticipated (Singh et al. 2016). 
Nonetheless two further antibody constructs are currently in phase II trials for DMD these 
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being PF-06252616, (NCT02310763) and BMS-986089, (NCT02515669) respectively. 
Promisingly, both showed high affinity to myostatin and evidence of muscle hypertrophy in 
healthy volunteers in phase I trials results of Phase II in DMD patients are anticipated in 2020 
(Bhattacharya et al. 2017; Spinazzola & Kunkel 2016). Finally, continuing with the trend, 
myostatin soluble receptor moieties have been tested in preclinical models and in clinical trial. 
The trial of one formulation, ACE-031, was halted due to bleeding and dilation of blood vessels, 
but a new formulation, ACE-081,  is now in clinical trial for facioscapulohumeral muscular 
dystrophy (FSHD: NCT02927080), and a phase 1/2a follistatin gene therapy has been recently 
been completed (Campbell et al. 2017; Mendell et al. 2015) Both studies aim to prevent 
myostatin binding to its endogenous receptor and eliciting negative regulation of muscle mass.  
1.7 Gene Editing Background and the DNA Damage Response  
The mammalian genome is subject to continual assault from both endogenous sources such 
damage caused by DNA metabolism and reactive oxygen species (Klungland et al. 1999; 
Kirkwood 2005), and environmental sources such as exposure to DNA-damaging chemicals or 
radiation (Harman 1956). Strikingly, it is estimated that a single cell could experience up to 105 
spontaneous DNA lesions per day (Hoeijmakers 2009). In the context of DNA as a genetic 
blueprint, the maintenance of eukaryotic genome integrity is vital, ensuring the correct 
transmission of genetic material to progeny and the prevention of disease causing mutations 
(Ciccia & Elledge 2010).  
In response to this threat eukaryotes have evolved the DNA damage response (DDR) system, a 
multifaceted signal transduction pathway to identify and resolve DNA lesions, safeguarding the 
genome against deleterious mutations (Ciccia & Elledge 2010). Importantly, the DDR comprises 
many distinct DNA repair pathways, the activation of which is under stringent regulation and is 
influenced by the nature of the DNA lesion, whether it is a single stranded break (SSB) or a 
double stranded break (DSB) (Heyer et al. 2010; Bothmer et al. 2017; Ciccia & Elledge 2010). 
This DNA lesion specificity is perhaps anticipated on the basis that erroneous repair could 
cause fragmentation, non-disjunction or deleterious mutations (De Jager et al. 2001).  
Importantly, gene-editing or genome editing, aims to exploit these natural mechanisms of DNA 
repair, to effect a change in the genome that corrects the disease causing mutation. 
Four main pathways that are routinely utilised in the field of gene editing including:  
1. Canonical Non-Homologous End Joining (NHEJ),  
2. Alternative NHEJ (alt-NHEJ) also referred to as Microhomology End Joining (MMEJ),  
3. Single Strand Annealing (SSA) 
4. Homology Directed Repair (HDR).  
36 
 
The current studies in this thesis will largely focus on canonical NHEJ in the assessment of gene 
modification at a defined genomic locus, and HDR in attempts to facilitate the integration of 
dystrophin transgene cDNAs within intron 1 of the DMD gene, with the aim of restoring spatial 
and temporal expression of dystrophin in DMD cells. Thus these two DNA repair pathways will 
be discussed in great detail. 
1.7.1 The Canonical Non-Homologous End Joining Pathway (NHEJ) 
The NHEJ pathway is the main mechanism of DSB repair in proliferating mammalian cells (Mao 
et al. 2008; Velic et al. 2015). This is because, relative to HDR which is constrained to late G2 
and S-phases of the cell cycle, when a sister chromatid is present to function as a repair 
template, the NHEJ pathway occurs throughout the cell cycle (Mao et al. 2008; Heyer et al. 
2010). Notably HDR and NHEJ can be thought of as working antagonistically, as during the 
activation of HDR in G2 and S phases, NHEJ is transiently suppressed (Heyer et al. 2010; Velic 
et al. 2015).  
At the simplest mechanistic level, the NHEJ pathway can be considered as the binding of 
terminal DNA ends liberated by the DSB and their direct ligation (Hoeijmakers 2009) (Figure 
1-2). This process is achieved by four core protein mediators: Ku70/ Ku80 heterodimeric 
complex; DNA dependent kinases (DNA-PKcs); Ligase IV (LIG4); and X-Ray Cross-
Complementing protein 4 (XRCC4) (Ciccia & Elledge 2010; Decottignies 2013; Weterings & 
Chen 2008). 
The Ku70/Ku80 heterodimeric complex is a circular protein with a central pore, which enables 
its loading onto exposed DNA termini. Once bound this binding of Ku70/Ku80 serves to 
sterically hinder and prevent the binding of alternative sensors of such as PARP1 which would 
promote DNA end processing. Furthermore, it enables loading of DNA-Pkcs, DNA dependent 
phosphokinases, which act to further stabilise DNA ends and prevent processing by auto-
phosphorylation. Ultimately this serves to recruit LIG4 and XRCC4, which enable end ligation 
with XLF4, which functions as a stimulatory factor. If the DNA termini are not compatible for 
direct ligation, then Artemis, a substrate for DNA-PKcs, becomes phosphorylated. Once 
phosphorylated, Artemis functions as an exo- and endo-nuclease, promoting DNA-end 
processing until the DNA ends are suitable for ligation (Velic et al. 2015; Ciccia & Elledge 2010). 
Inherent in this process is the potential for subtle sequence alterations at the junction of the 
DSB, these are known as micro-insertions or -deletions (InDels). Importantly, following delivery 
of customisable endonucleases, InDels are used frequently in gene- editing studies as a proxy 
for the presence of DSBs (Qiu et al. 2004; Liu et al. 2016a). This stated, InDels can serve to 
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underestimate the extent of DNA cleavage occurring as the DNA can be directly ligated 
without the requirement for further end processing and without the emergence of InDels. 
1.7.2 The Homology Directed Repair Pathway: 
In contrast to the NHEJ DNA repair pathway, which is considered to repair DSB with relatively 
low fidelity, the HDR pathway enables precise correction. Crucially, in this form of repair the 
DSB termini are processed to form 3’ ssDNA overhangs that can invade isogenic sequences 
promoting the repair of DNA from a genetic template (Velic et al. 2015; Decottignies 2013; 
Jasin & Rothstein 2013).  See (Figure 1-2) 
Importantly, the process of HDR is tightly regulated by phosphorylation signalling cascades 
involving many protein mediators.  Initially, DNA damage is sensed by the MRN protein 
complex, which comprises three protein components, RAD50, MRE11, and Nibrin (NBS1). The 
Rad50 protein, a member of structural maintenance of chromosomes (SMC) family, is 
implicated in tethering DNA ends resulting from DSBs, in close proximity (De Jager et al. 2001; 
Velic et al. 2015). In addition, the Rad50-associated ATPase and coiled coil domains enable 
interaction with MRE11, a protein with a range of functions including DNA endonuclease, 
exonuclease and unwinding activities (Assenmacher & Hopfner 2004; Williams et al. 2007). 
This complex serves to stabilise the free DNA ends, initiate end processing and association with 
the final component of the MRN complex, the NBS1 protein. NBS1 recruits the ataxia-
telangiectasia mutated (ATM) protein to the DSB, interacting with ATM via its C-terminal 
domain.  
The ATM protein becomes activated by the MRN complex and further signal transduction 
occurs via phosphorylation of CtBP-interacting protein (CtIP), and the breast and ovarian 
cancer type 1 susceptibility protein (BRCA1) (Paull 2015). These protein mediators serve to 
promote DNA end resection, and the generation of 3’ ssDNA overhangs. Notably, if this form of 
repair occurs in the G1 phase of cell cycle, then DNA end processing is constrained by the 
absence of the BRCA1 protein. In this instance, limited resection and 3’ssDNA overhangs are 
generated by the action of CtIP alone, which forms the basis of the alternative NHEJ DNA 
repair / MMEJ repair (Ciccia & Elledge 2010; Nakamae et al. 2017).  In contrast at the G2 phase 
of the cell cycle, BRCA1 protein is present and interacts with the CtIP protein, inactivating it 
after initial DNA resection has occurred (Huen et al. 2010). This primes the DNA end for more 
extensive resection, as mediated by Exo1 and BLM following ATM phosphorylation (Ciccia & 
Elledge 2010). 
The exposed 3’ ssDNA overhang becomes coated in and stabilised by replication protein A 
(RPA), this enables the binding of RAD51 or RAD52. If the 3’ ssDNA overhangs harbour 
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repetitive sequences, the break could be resolved by the 3’ overhangs annealing, overhangs 
being resected and ligated by a RAD52 and an enzymatic complex of XPF/ ERCC1. This process 
is called single strand annealing (Ciccia & Elledge 2010).   
In contrast, the full HDR pathway is characterised by a 3’ssDNA strand invasion of an 
exogenous isogenic sequence, a process initiated by a Rad51 heterogenic filamentous protein 
complex binding and stabilising of the overhang (Jasin & Rothstein 2013). Interestingly, many 
protein mediators are also implicated in this process, the two main ones being casein kinase 1 
(CK1) and RRCA2. CK1 serves to phosphorylate Rad51 and aid in its recruitment to sites of DNA 
damage, where it subsequently displaces Rad51 (San Filippo et al. 2008). BRCA2 directly 
associates with Rad51, and one theory indicates this could serve to modulate this DNA repair 
pathway, with the temporal BRCA2 expression constraining it to late G2, S-phases of the cell 
cycle (Moynahan et al. 2001). The result of these interactions is the formation of an 
intermediate D loop- structure (West 2003). Importantly if the second DNA end remains 
uncaptured, the invading 3 ssDNA can be extended by DNA polymerases, dissolution of the D-
loop structure occurs as mediated by regulation telomere elongation helicase 1 (RTEL1) and 
the newly synthesised strand anneals to the second DNA end, a repair process referred to as 
synthesis dependent strand annealing (SDSA) (Ciccia & Elledge 2010) 
For completion of conventional HDR, the 3’ ssDNA needs to invade the exogenous repair 
template, the second strand needs to be captured and form a double holliday junction (dHJ) 
(Jasin & Rothstein 2013). Importantly, this genomic structure can also be resolved in numerous 
ways including dHj dissolution and genomic cross-over or non-crossover events. These 
processes are mediated by further protein complexes BLM/TOPOIII, GEN1, MUS81/ EME1 or 
SLX1/SLX4 (Ciccia et al. 2008; Fekairi et al. 2009; Ip et al. 2008) which promote the remodelling 
and/or subsequent cleavage of DNA ends in the pursuit of DNA repair. Notably, a cross-over 
event refers to the exchange of markers of genomic material flanked by the dHJ and in the 
context of gene therapy can be used to confer precise disease ameliorating DNA modifications 
(Musunuru, 2017). 
Importantly, this presentation of the HDR mechanism showcases the complexity of this DNA 
repair pathway. The multiple exit points preceding the desired genomic cross-over and the 
dependence on a plethora of mediatory proteins are salient considerations in the inherent low 
efficiency of HDR. Furthermore, an awareness of mediatory proteins provides potential drug 
targets to modulate the activity of DNA repair pathways and improve HDR efficiency.  
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Figure 1-2 A schematic diagram showing the various DNA repair pathways, employed in the resolution 
of a DSB: Taken from (Ciccia & Elledge 2010).  
A) The NHEJ pathway, the Ku70/ Ku80 heterodimeric complex quickly associated with DNA termini, 
preventing end processing. The association with DNA Pkcs causes a phosphorylation cascade that 
resolves DNA breaks by direct ligation with ligase IV or by subsequent processing with Artemis and ligase 
IV. B) The HDR pathway (sometimes referred to as Homologous Recombination or HR pathway), PARP 
out competes Ku70/ Ku80 binding allowing the MRN complex: MR11, RAD50, and NBS1 to be recruited. 
This in turn forms MRN/CtIP/BRCA1 complex notably, the constituents of this complex are only available 
at late G2/ S phases of the cell cycle and initiate end resection. More extensive end resection is achieved 
by ExoI and BLM, to achieve a 3’ ssDNA overhang that becomes coated in RPA. Eventually this is 
displaced by RAD51, a filamentous protein that mediates strand invasion as regulated by BRCA2. D-loop 
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structures are formed following strand invasion, these can be resolved by cleavage mediated by 
MUS81/EME1 or subject to dissolution with the RTEL1, this form of repair SDSA can result in cross-over 
or non-crossover events. If the second strand is captured, then a double holliday junction is formed; this 
structure in turn can be subject to dissolution by BLM/TOPOIII complex or subject to crossover or non-
crossover events with by the nucleases GEN1 and SLX1/SLX4, which associate with MUS81/EME1. C) The 
alternative NHEJ pathway occurs as a result of a CtIP partial end resection process independent of 
BRCA1, this generates short overhangs. D) The single stranded annealing pathway, this occurs after 
partial end resection when the 3’ssDNA can be coated in Rad52 and the DNA ends directly ligated 
together. 
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1.8 Gene Editing Background: Customisable Nucleases and the 
Induction of a DSB: 
A major milestone to the field of gene editing was the observation by Maria Jasin et al in 1998 
was that  the HDR DNA repair pathway could be stimulated more than 100-fold following the 
induction of a DSB at the target locus (Liang et al. 1998). Crucially, for the exploitation of this 
finding in the correction of disease causing mutations, endonucleases were required that could 
be engineering to introduce precise DSBs at user-defined genomic locations. Multiple variants 
of these so-called ‘customisable endonucleases’ have since been engineered or discovered 
including meganucleases (MGN), zinc finger nucleases (ZFNs), transcriptional activator like 
effector nucleases (TALENs) and Clustered Regularly Interspaced Palindromic Repeat/Cas9 
nucleases (CRISPR/Cas9). The advent of these nucleases have served to advance reverse 
genetics through the generation of mouse models with conditional or permanent gene knock-
out (Collins et al. 2007). In a broader sense they have also been explored in the correction of 
disease causing mutations  (Prakash et al. 2016).  
1.8.1 Meganucleases 
Meganucleases (MGN) represent the first generation of customisable endonucleases, derived 
from homing endonucleases, with large DNA recognition sites spanning 12-45bps (Epinat et al. 
2003; Thierry & Dujon 1992) (Figure 1-3). Initially the 5 families of homing endonucleases,  
LAGLIDADG, GIY-YIG, HNH, His-Cys box and PD-(D/E)XK (Orlowski et al. 2007; Zhao et al. 2007),  
found to be naturally occurring in phages, bacteria, archea and some eukaryotes, were 
examined for their application to gene targeting. However this was hindered by the low 
repertoire of 300 naturally occurring proteins and the reliance on homing endonuclease sites 
being present within the mammalian genome. As a consequence focus shifted to engineering 
the protein structure of the homing endonuclease (Epinat et al. 2003).  
From three dimensional structural modelling of LAGLIDADG family proteins it was identified 
that two alpha-helices confer the main propensity to cleave DNA. Either side of these helices 
are four stranded beta sheets which provide an additional DNA binding interface (Epinat et al. 
2003). Interestingly however, it was noted that both domains in part contribute to DNA 
binding and cleavage activity of the MGN (Moure et al. 2003). On this basis, many strategies 
were proposed for expanding the DNA targeting repertoire of MGNs, including computational 
structure-based designs, and domain swap engineering (Chevalier et al. 2002; Ashworth et al. 
2010). Notably, the design of MGNs to target distinct genomic locations proved challenging, 
often resulting in diminished efficacy which was attributed to the non-modular nature of the 
protein, with binding and catalytic activity not appearing functionally distinct (Stoddard 2014; 
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Guha et al. 2017). As a consequence of these limitations further gene-editing platforms were 
developed.  
1.8.2 Zinc Finger Nucleases  
The first generation of artificial nucleases using this platform fuses the CH2 Zinc Finger DNA 
binding modules in tandem to a type IIS nonspecific DNA cleavage domain of FokI. Together 
these domains form a ZFN monomer (Kim et al. 1996; Tupler et al. 2001; Li et al. 1992) (Figure 
1-3). Individual zinc finger protein modules identify 3 nucleotides of genomic sequence, and 3-
6 of these modules are combined sequentially within each monomer (Kim et al. 1996; 
Pavletich & Pabo 1991). Thus each monomer is involved in binding 9 -18 nucleotides of 
genomic DNA.  Importantly the FokI nuclease, originally isolated from Flavobacterium 
okeanokoites, = is tethered to the termini of the ZF monomer and require obligatory 
dimerization in order to cleave DNA; the net result being staggered DSB in DNA (Li et al. 1992; 
Bitinaite et al. 1998). As a consequence monomers are situated either side of a genomic target 
site, designated left and right ZFNs, with a 5-7 nucleotide spacer region between them (Kim & 
Kim 2014a).  The obligatory dimerization, with two arms and a spacer significantly improve the 
specificity of this gene editing system (Kim & Kim 2014a).  
This ZFN platform has been used broadly by Sangamo Biosciences and shows promise in the 
development of gene editing therapies for HIV and Hunter’s syndrome (Tebas et al. 2014; 
Grens, 2017). This stated, construction of Zinc Finger nucleases continues to be challenging 
with those generated from  zinc finger module libraries showing evidence of low efficacy and 
cytotoxicity due to off-target effects (Ramirez et al. 2008; Cornu et al. 2008). Whilst production 
processes have improved to try and select for high functioning zinc finger nucleases and 
reduce off-target effects, the production of ZFN is costly and has limited the breadth and scale 
of their  use (Miller et al. 2007; Szczepek et al. 2007; Sander et al. 2011; Gupta et al. 2012; 
Bhakta et al. 2013). 
1.8.3 Transcriptional Affector Like Effector Nucleases (TALENs) 
This gene editing platform fuses transcription activator-like effectors (TALEs), a family of 
proteins from pathogenic plant bacteria to the type-IIS FokI nuclease sub-units to form the 
TALENs.  in this manner they are structurally akin to ZFNs (Miller et al. 2011; Zhang et al. 2011). 
(Figure 1-3) In nature, TALE proteins are employed by pathogenic bacterium such as 
Xanthomonas oryzae during the infection process to subvert plant host transcription 
machinery to produce a cellular environment favourable to survival (Boch 2011; Kay et al. 
2007; Sugio et al. 2007). Structurally, TALEs comprise an N-terminal domain , a central repeat 
region and a C-terminal domain encoding a nuclear localisation signal (NLS) and an acidic 
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activation domain (Mussolino et al. 2011; Kay et al. 2007; Römer et al. 2007). Distinct from 
ZFNs, TALENs are composed of 17.5 tandem repeats/monomers each of 35 amino acids, with  
one monomer recognising a single nucleotide in the major groove of DNA (Mak et al. 2012; 
Deng et al. 2012). Furthermore from experimental studies, it was found that deletion of amino 
acids at positions 11 -14 ablated the activity of a TALE monomer (Römer et al. 2007). In this 
manner, it was identified that amino acids at R12 and 13 within the central repeat region 
determined the specificity of each domain; these repeats were then identified as Repeat 
Variable Di-residues (RVDs) (Boch et al. 2009; Moscou & Bogdanove 2009). The four main 
RVDs, ranked in their experimentally determined hierarchy of binding are Asn-Glycine (NG), 
His-Asp (HD), Asn-Asn (NN) and Asn-Ile (NI), which recognise thymine, cytosine, guanine and 
adenine respectively (Meckler et al. 2013; Streubel et al. 2012).  
This 1:1 ratio of RVD to nucleotide makes computational design of TALENs relatively straight-
forward (Kim & Kim 2014a). This stated, the protein engineering required to construct a TALEN 
remains a challenging and time consuming process, despite many construction methods 
including golden gate cloning, solid phase assembly and ligation independent cloning (Cermak 
et al. 2011; Reyon et al. 2012; Schmid-Burgk et al. 2012; Briggs et al. 2012). Crucially, this gene 
editing platform has extensive and diverse targeting capabilities, with the only pre-requisite of 
conventional targeting being a thymine at the 5’ end of the target sequence (Kim & Kim 
2014a). This only stands to improve with the production of TALENs that can dispense with this 
criterion able to bind with alternative bases at the 5’ end (Lamb et al. 2013).  Similar to ZFNS, 
the main limitation of this system is challenging and relatively costly construction and 
screening required.  
1.8.4 CRISPR/Cas9 
The newest advent to the gene-editing repertoire is CRISPR/Cas9, this utilises two components 
a RNA guide to direct DNA binding and the Cas9 nuclease to cleave a genomic site (Jinek et al. 
2012) (Figure 1-3). The novel RNA to DNA binding interface underpinning this platform is 
distinctive from its predecessors, making this system both  simple to construct and versatile in 
application (Kim & Kim 2014b). First discovered in bacterial and archaeal genomes almost 30 
years ago, it has since been characterised to confer adaptive immunity to prokaryotes from 
foreign nucleic acids (Ishino et al. 1987; Mojica et al. 2000). In the endogenous system, the 
initial exposure of bacteria to phage DNA is resolved by non-specific cleavage of the phage 
genome. Subsequently small fragments 20 nucleotides in length, referred to as protospacers, 
are integrated into the bacterial genome between adjacent flanking repeats.  Upon re-
exposure to the same phage, after this ‘immunisation’ process, the 20 nucleotide sequence is 
transcribed and processed to form CRISPR RNA (crRNA). This crRNA then associates with trans-
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activating CRISPR RNA (tracrRNA), forming a complete guide that can recruit the Cas9 
nuclease. The crRNA confers DNA binding specificity to the nuclease, introducing targeted 
DSBs into the phage genome, neutralising the immunological threat posed to the bacteria 
(Horvath & Barrangou 2010; Barrangou et al. 2007; Makarova et al. 2006).  
Notably, examination of this system across prokaryotes classified CRISPR into three main 
classes, Type I, II and III. Interestingly type I and III use multiprotein complexes, while type II 
utilises a single protein Cas9 (Makarova et al. 2011). On the basis of these observations, focus 
was placed upon re-purposing the type II Streptococcus Pyrogenes Cas9 system for the 
purpose of genomic engineering in mammalian cells. In pursuit of this, co-expression of crRNA 
and tracrRNA was attempted, alongside a humanised Cas9 protein (Jinek et al. 2013; Mali, 
Esvelt, et al. 2013; Cong et al. 2013). The low efficiency of this three component system 
attributed to limitations with delivery, promoted a single chimeric guide fusing crRNA and 
tracrRNA via a hairpin loop to be engineered downstream of a U6 RNA III polymerase 
promoter (Jinek et al. 2013). Whilst this structure has been subsequently revised (Chen et al. 
2013; Dang et al. 2015), it served to simplify the constituents of guide delivery, with the 20 
nucleotide crRNA region being interchangeable.  Oligonucleotides could be designed, self-
annealed  and cloned into U6 expression cassettes to confer new DNA binding specificity to the 
Cas9 nuclease  (Ran et al. 2013).  
On association of crRNA and tracrRNA or the newly developed format of a chimeric sgRNA, the 
Cas9 protein undergoes conformational change providing a central pore for the loading of the 
Cas9 protein onto DNA at the defined genomic locus (Nishimasu et al. 2014; Jinek et al. 2014). 
The summation of this process is the correct positioning of two catalytic domains within the 
Cas9 protein, the HNH and RuvC, which cleave complementary and non-complementary 
strands of the DNA respectively (Nishimasu et al. 2014). This process results in a blunt cut 3 
nucleotides upstream of the Protospacer Adjacent Motif (PAM), a recognition motif that binds 
to the C-terminal of the Cas9  facilitating protein-DNA association and subsequent DNA 
cleavage (Anders et al. 2014; Nishimasu et al. 2014; Hsu et al. 2013b; Mali et al. 2013). 
Notably, the PAM for Streptococcus Pyrogenes is 5’ NGG or 3’ NCC, where N denotes any 
nucleic acid base, but alternative PAM recognition sites are utilised by bacterial orthologues of 
Cas9 (Ran et al. 2015; Zetsche et al. 2015; Hou et al. 2013).  Importantly, the propensity for the 
Cas9 system to cleave a genome site is governed by the presence of PAM throughout the 
genome. In addition to this PAM feature, RNA guides must initiate with a 5’ guanine whether 
this is native sequence or appended nucleotide due to the nature of the U6 promoter (Ma et 
al. 2014; Gagnon et al. 2014). Since the initial demonstration of its use, the Cas9 protein been 
engineered to include a range of alterations, with the outlook to improve its specificity or 
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broaden its function. These include, inactivation of a single catalytic domain to produce 
nickases that introduce a single stranded break (SSB) or DNA lesion, which  when paired in a 
dimeric fashion can cause a DSB (Ran et al. 2013). Also there has been the modification of 
internal amino acids responsible for DNA binding to produce enhanced SpCas9, a nuclease 
with greater specificity and reduced off-target effects (Slaymaker et al. 2016). Advancements 
in the CRISPR/Cas9 field remains dynamic and on-going, and a detailed current review is 
provided by (Tycko et al. 2016). 
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Figure 1-3 A schematic diagram of each of the four main classes of Endonuclease used in gene-editing. 
Taken from (Gao et al. 2018) 
A)  Meganuclease (MGN): this is engineering from the naturally occurring homing endonucleases with a 
recognition site spanning 12-45bps. Notably at a crystal level this comprises of alpha helices and beta 
sheets, which are contiguous. This served to prove challenging to protein engineering as the binding and 
cleavage functions did not appear distinct or modular. B) Zinc Finger Nuclease (ZFN), this comprising of 
CH2 Zinc finger DNA binding domains/monomers, 3-6 of which are attached in tandem prior to the 
fusion to FokI nuclease at the carboxyl terminus. A single domain or monomer forms an interaction with 
three nucleotides. Importantly, the left and right zinc finger nuclease are spaced 5-7 nucleotides apart to 
enable nonspecific FokI type II DNA endonuclease to dimerise and form staggered  DNA cuts. C) 
Transcriptional Activator Like Effector Nucleases (TALENs), in which TALE domains, are attached in 
tandem prior to the fusion of the FokI nuclease at the carboxyl end.  Importantly, 1 TALE monomer 
identifies 1 Nucleotide of DNA.  The FokI nuclease dimerises in a space to produce a double stranded 
break, akin to ZFN. D) CRISPR/Cas9 comprised of two main components an RNA guide 20 nucleotides in 
the SpCas9 system and a Cas9 nuclease.  The RNA guide confers DNA binding specificity, by Watson-
Crick base pairing. The RNA:  DNA interface causes conformational changes in the Cas9 nuclease, 
bringing the RuvC and HNH catalytic domains together upstream of a Protospacer Adjacent Motif 
recognition site in the genome.  This orchestrates DNA cleavage. 
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1.9 Current Gene-Editing Attempts in the Context of DMD:  
In the context of human genetic disease, and as distinct from gene-augmentation, genome 
editing involves the direct modification of chromosomal DNA with the prospect of providing 
permanent repair of disease-causing mutations.  In the example of DMD this could overcome 
current life-long adherence to therapeutics, required with corticosteroids and other strategies 
under development such as Ezutromid, Translana and immunosuppressive drugs (a 
concomitant therapy with allograft transplantation). Furthermore, theoretically requiring only 
a single administration, it could overcome immunological complications associated with viral 
vector gene augmentation strategies, such as AAV-based microdystrophin gene transfer, or 
full-length dystrophin cDNA gene transfer via AAV-based  triple-transplicing mechanisms. As a 
consequence of these perceived advantages, numerous gene editing therapeutic strategies are 
being developed for DMD, but are currently confined to in vitro and pre-clinical models.  This 
stated, the recent human clinical trials of gene editing in patients with HIV infection, by 
Sangamo emphasise the therapeutic promise of this evolving field and by extension the 
approaches under development for the treatment of DMD.  
Early demonstration of gene editing approaches for DMD include reading frame restoration by 
utilising low fidelity of NHEJ DNA repair and the resultant INDELs at a DSB junction to correct 
the dystrophin reading frame (Figure 1-4). The first demonstration of this was afforded by 
Ousterout et al (2013a), in which TALENs were directed to an DMD exon 51 sequence, thus 
generating a DMD myoblast clone bearing INDELs anticipated to restore the dystrophin 
reading frame (Ousterout et al. 2013a). Notably, this type of therapeutic strategy would be 
eligible to 13% of patients. Being akin to AON-mediated exon skipping , therapeutic 
development would face similar challenges requiring efficacious guide designs to a range of 
target exons and in a clinical setting requiring many individual therapeutic approvals (Aartsma-
Rus et al. 2017). Moreover, as INDEL profiles at a DSB are variable, being either additions or 
deletions of one or more bases, this approach is likely to repair the reading frame in only a 
third of events (Ousterout et al. 2013a). This stated, recent evidence presented by Overbeek 
suggests that INDELs resulting from Cas9 cleavage events results in a defined non-random 
profile retained across replicates. In light of this, the design of CRISPR guides with INDEL 
profiles biased to the restoration of the dystrophin reading frame could be envisaged (van 
Overbeek et al. 2016). 
Developing upon this approach, NHEJ mediated chromosomal DNA deletion was next 
developed, in a strategy which multiplexes or uses multiple guides to flank an exon or exons 
that render the DMD gene out of frame (Figure 1-5). The cleavage at both sites subsequently 
results in the removal of the flanked exons and the restoration of reading frame, to generate 
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BMD-type dystrophins. Demonstrations of this strategy include deletions of exon 51 
(Ousterout et al. 2015), exon 2 duplication (Lattanzi et al. 2017), exon 44 (Li et al. 2015) and 
exons 45-55 (Ousterout et al. 2013b; Maggio et al. 2016) in human myoblast cultures  or  iPSCs 
in (Li et al. 2015). These various gene-editing mediated deletions would have applicability to 
~13%, ~15%, ~8% and ~62% of DMD patients respectively. Strikingly, with the exception of 
Ousterout who used ZFNs, all of these studies used CRISPR/Cas9, thus giving a demonstration 
of the relative ease with which the Cas9 system can be multiplexed (Cong et al. 2013; Mali, 
Esvelt, et al. 2013). The final two studies by Ousterout 2013b and Maggio 2016, represent  
milestones in the field of gene editing not only focusing upon increasing patient applicability 
but also packaging Streptococcus Pyrogenes Cas9 (SpCas9) into lentiviral and adenoviral 
vectors respectively. This trend towards vectorisation has continued with expression of SpCas9 
into a dual AAV vector system, and a smaller bacterial orthologue SaCas9 into single AAV 
vectors (Wright et al. 2015; Ran et al. 2015). Thus the CRISPR/Cas9 system was quickly 
transitioned to in vivo mouse models of DMD with multiple demonstrations of exon 23 
removal in mdx mice,  and a single exon 53 removal in mdx4cv mice (Bengtsson et al. 2017). 
This approach appears to be favoured in the field currently due to the high efficiency of the 
NHEJ pathway, however, the inclusion of two guides brings with it inherent risk of increased 
off-target effects. Moreover, both guides need to cleave at high and comparable efficacy to 
provide a high occurrence of the desired deletion. 
The final type of these gene editing strategies aiming to modify and correct chromosomal 
sequences is reliant upon HDR which whilst less efficient than NHEJ, orchestrates more precise 
correction of the genome (Heyer et al. 2010). Furthermore, this HDR-mediated process can 
substitute or restore genetic material lost in the endogenous genetic mutation. The simplest of 
these strategies uses single stranded oligonucleotides (ssODNs) as the repair template to 
correct subtle point mutations within the genome (Figure 1-4). A notable example of this was 
recently achieved in mdx zygotes using an ssODN to introduce a point mutation into the 
endogenous nonsense mutation in exon 23 and thus inducing mosaicism in mice and 2%-100% 
dystrophin expression restoration. This type of approach could be used to address point 
mutations which occur in 20% of DMD patients. Alternatively, exogenous repair templates 
encoding a range of replacement cDNA sequences flanked by isogenic sequences upstream 
and downstream of the DSB in the genome could be designed to introduce larger sequence 
elements (Figure 1-5). Demonstrations of this include insertion of exon 44 in iPSCs (Li et al. 
2015), exons 45-52 in immortalised patient myoblasts harbouring for this deletion (Popplewell 
et al. 2013) and exon 53 in mdx4c (Bengtsson et al. 2017).  Research by Popplewell et al (2013) 
was important to this field of therapeutics as the first demonstration; using patient myoblasts 
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harbouring a major deletion that restoration of the dystrophin reading frame could be 
achieved by a MGN mediated knock-in of a 4.2kb cDNA encoding exons 45-52.   
The investigations presented in this thesis aim to assess the feasibility of a CRISPR/Cas9 
mediated knock-in of an exon sequence based on the microdystrophin cDNA (MD1; Le Guiner 
at al, 2017) at the 5’ end of the DMD gene. Notably, the exogenous repair template is 
promoter less and would utilise the endogenous full length dystrophin Dp427m promoter to 
drive expression.  This work has potential therapeutic applicability to 95% of patients. 
Moreover, a novel exogenous repair template was constructed with the propensity to be 
adapted for other exonic cDNA insertions notably of Δ45-55 minidystrophin and full-length 
dystrophin. This approach could provide permanent correction of diverse disease-causing 
mutations across the DMD gene, providing a correction strategy for a patient cohort in which 
there is currently an unmet clinical need. 
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Figure 1-4 Diagrams highlighting NHEJ-reading frame restoration and ssODN integration gene-editing strategies that could be employed to fix a variety of DMD mutations. 
 A) Utilising NHEJ to overcome the deletion of Exon 7 and restore of the dystrophin reading frame. In the absence of exon 7, exons 6 and 8 are ‘out of phase’ with one another and 
the resultant mRNA is incorrect and degraded, resulting in the absence of dystrophin.  Following the introduction of a DSB by Cas9, the DNA can be repaired by the efficient but 
error prone NHEJ pathway. This causes random small insertions or deletions in the local DNA, which in some instances can restore the reading frame and by extension dystrophin 
expression by ‘chance’. B) HDR mediated repair of point mutations using single stranded oligo nucleotide. In this instance a nonsense mutation in Exon 23, causes premature 
termination of dystrophin transcription. The subsequent transcript then undergoes decay and no full length dystrophin is produced. By cleaving DNA in the nearby area and 
delivering a ssODN with subtle mutations this can be corrected. Once broken HDR can occur in which the ssODN can ‘invade’ the DNA displacing the mutated sequence and 
integrating in the correct nucleotide. This stops the formation of the premature stop codon allowing full length dystrophin to be transcribed (Long et al. 2014). Taken from Moore 
et al. 2015. 
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Figure 1-5 Schematic diagrams highlighting HDR-reading frame restoration by cDNA exogenous repair template integration and NHEJ-mediated deletion gene-editing strategies 
that could be employed to fix a variety of DMD mutations. 
A) HDR Mediated repair utilising a cDNA repair template, can be used to insert pieces of the DMD gene that have been lost. In this instance production of a DSB and a cDNA donor 
containing exons 45 -52 can restore the reading frame and full-length dystrophin expression (Popplewell et al. 2013). B) Multiplexing CRISPR guides can be used to remove exons 
in the restoration of the reading-frame and the expression of truncated dystrophin.  The deletions of exons 50-52 in this example can be overcome by cutting out exons between 
Intron 44 and 55. The removal of the exons included within this region enables the restoration of the reading frame, with exon 44 and 56 being spliced together. This removes a 
mutational hotspot accounting for 62% of patient mutations and enables the production of a shortened dystrophin with some function that could provide therapeutic benefit 
(Kabadi et al. 2014; Maggio et al. 2016). Taken from Moore et al. 2015. 
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1.10 Project Aims: 
Duchenne Muscular Dystrophy (DMD) is a complex neuromuscular disease with multisystem 
manifestations including muscular wasting, impaired cognitive functioning, reduced 
gastrointestinal functioning, cardiac conduction defects and respiratory impairment (Mercuri 
& Muntoni 2013; Bushby et al. 2010a). Whilst clinical management requires a multidisciplinary 
team, care is palliative treating only the secondary manifestations of the disease rather than 
the underlying genetic aetiology. Furthermore the only current treatment option is 
corticosteroids. Whilst administration of corticosteroids dampens muscle inflammation, 
prolonged use is contraindicated due to side effects including: bone demineralisation, weight 
gain and behavioural changes (Mercuri & Muntoni 2013).  
There is a clear unmet medical requirement for improved treatment options which has spurred 
the development of pharmacological, cell-based and gene therapies. Importantly, this has 
resulted in a number of DMD therapeutic strategies advancing to clinical trial, examples 
include: Ataluren (TM Translana), exon skipping (Drisapersen and Eteplirsen/ExonDys51) and 
SMTC1100 (Ezutromid). Notably, Ataluren has gained conditional marketing authorisation and 
drug approval in Europe, and Eteplirsen/ExonDys51 FDA approval. These treatment strategies 
are mutation specific with application limited to specific patient cohorts. Ataluren treats 
nonsense mutations, thought to account for 13-15% of DMD cases (Bushby et al. 2014). Exon 
skipping of exon 51, by Eteperlisen could confer benefit to ~13% of patients (Aartsma-Rus et al. 
2009). Furthermore, 64% of patients would be eligible for single exon skip antisense reagents, 
79% for double exon skip and 90% for multi-exon skipping therapies (Verhaart & Aartsma-Rus 
2012). Notably, this is not applicable to all patients and gaining approval of AONs on an 
individual basis represents a significant hurdle to surmount, particularly in exons skips with 
very low patient applicability. 
Awareness of the limited number of DMD patients amenable to mutation specific treatments 
has prompted the scientific community to consider more universal approaches to achieve the 
amelioration of dystrophic phenotypes. Two strategies that exemplify this are AAV-
microdystrophin gene augmentation and utrophin upregulation by SMTC1100 (Ezutromid).  
Importantly, microdystrophin gene augmentation has shown promising results when trialled in 
a range of pre-clinical models of DMD (Foster et al. 2008; Koo et al. 2011; Le Guiner et al. 
2017); although one clinical trial has been completed that failed to show suitable efficacy, 
revisions to the study design have been highlighted by the investigators that would likely 
improve clinical outcomes (Mendell et al. 2012). In contrast SMTC1100 has advanced through 
safety and efficacy phase I trials and is currently progressing to phase II (NCT02858362) 
(Tinsley et al. 2015). Whilst promising, these approaches have inherent limitations. In the case 
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of AAV- microdystrophin, repeated administration may likely be required, increasing the risk of 
adverse immunological side effects. Furthermore, being an internally truncated form of 
dystrophin, these recombinant microdystrophins may not retain all of the necessary 
functionality of wild type dystrophin In contrast, studies using SMTC1100 indicate that 
attaining optimal serum concentrations of the drug remains challenging and such a therapy 
would require life-long adherence to drug administration. Furthermore, despite structural 
similarity to dystrophin, utrophin has a distinct expression profile, is unlikely to interact 
directly with microtubules like dystrophin or localise nNOS correctly (Belanto et al. 2014; Li et 
al. 2010). In light of this, utrophin upregulation may prove compensatory but is unlikely to 
address all dystrophic pathology. 
The research described in this thesis, was based upon a novel gene-editing approach in which 
intron 1 of the DMD gene was targeting.  This approach hinged upon the successful 
introduction of a DSB by a genome editing designer endonucleases and co-delivery of an 
exogenous repair template. Notably, the promoter less exogenous repair template employed 
in this study was constructed to enable cloning of microdystrophin (MD1; le Guiner et al 2017), 
minidystrophin (deleted for exons 45-55: Δ45-55) and full length dystrophin cDNA variants, 
from dystrophin exon 2 onwards. In this manner, the HDR repair pathway will be exploited to 
enable integration of these cDNA elements into DMD intron 1 as a large artificial exon 
downstream of the native exon 1 DMD gene sequences.  This targeting of the exogenous 
repair template to intron 1 has the advantage of utilising the endogenous full-length 
dystrophin promoter, Dp427m, to drive expression. Furthermore being close to the start of the 
DMD gene, it provides a near universal and permanent therapeutic strategy to potentially 
overcome most DMD mutations.  In order to contribute towards this goal our aims were 
defined as follows: 
 Customisable endonucleases were designed to intron 1 of the DMD gene (Chapter 3). 
Intron 1 was identified as most desirable as it would maximise patient applicability to 
95% of patients.  
 Efficacy of endonuclease designs were assessed using mismatch detection assays 
(Chapter 4).  
 Assessment of the effects of cDNA coding sequence optimisation on full length, Δ45-55 
and MD1 protein expression was undertaken and an appropriate exogenous repair 
template designed (Chapter 5).  
 Finally, these reagents were combined and tested in both HEK293T and immortalised 
DMD patient myoblasts.  
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These aims were designed to provide a proof-of-principle demonstration of this near universal 
genome editing strategy to counter DMD mutations, assessing whether targeting DMD intron 
1 and utilising the endogenous full-length promoter is a feasible strategy for future in vivo 
development and testing. 
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Chapter 2 Materials and Methods 
2.1 General Laboratory Reagents 
All general chemical reagents were purchased from Sigma, Invitrogen, BDH or VWR (unless 
stated otherwise) with standard chemical purity graded as AnalaR (Analytical Reagents for 
analysis applications): As listed below.  All of the reagents were dissolved in double distilled 
H20 (ddH20), unless stated otherwise. The solutions required for tissue culture were autoclaved 
at 1210C for 15 min, except for the solutions containing protein, detergents or glucose which 
required passing through a 0.22 µm filter (Falcon). All solutions were stored at room 
temperature unless indicated otherwise.  
 
Reagent : Manufacturer: 
Acetic acid (CH3COOH)   VWR 
Agarose Invitrogen 
Ammonium acetate AcO(NH4)2 BDH 
Bovine Serum Albumin Invitrogen 
Boric acid Sigma 
CaCl2 Sigma 
Citric acid Sigma 
Dimethyl sulphoxide (DMSO) Sigma 
EDTA Sigma 
Ethanol (EtOH) VWR 
Glucose Sigma 
Hydrochloric acid (HCl)  BDH 
Liquid broth (LB) Sigma 
Methanol VWR 
Magnesium chloride (MgCl2) Sigma 
Magnesium sulphate (MgSO4) BDH 
NaOH Sigma 
Na2HPO4 Sigma 
NP-40 Fluka Biochemica 
Paraformaldehyde (PFA) Sigma 
Potassium chloride (KCl) Sigma 
Phosphate buffered saline (PBS) pH 7.3  Gibco 
Sodium chloride (NaCl) Sigma 
Sodium dodecylsulphate (SDS)  Sigma 
Sodium bicarbonate (NaHC03) Sigma 
Sucrose Sigma 
Tri-sodium citrate Sigma 
Trizma Base Sigma 
Trizma hydrochloride (HCl) Sigma 
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2.2 Bioinformatics Assessments of the 5’ End of the DMD gene 
2.2.1 Common Intron 1 Sequence Identification 
2.2.1.1 Dystrophin Isoforms 
 Dp427c NM_000109.3  
 Dp427m NM_00406.2  
 Dp427p1 NM_004009.3  
 Dp427p2 NM_004010.3 
2.2.1.2 Genomic Builds 
 Homo Sapien Chromosome X, GRCh37.p13 Primary Assembly (Accession 
NC_000023.10) 
 C57BL/6J Chromosome X, GRCm38.p1 C57BL/6J Primary Assembly (Accession 
NC_000086.7) 
The first exon of all full length isoforms and exon 2 of Dp427m where they converge was 
downloaded in standard FASTA format.  This was then aligned to the genomic builds using 
NCBI BLAST, accessed here: https://blast.ncbi.nlm.nih.gov/Blast.cgi. The genomic co-ordinates 
were then used to identify and download a genomic region between Dp427p2 and Exon 2 for 
both human and mouse genomes.  
2.2.2 Rigorous Local Sequence Alignment: 
The human and mouse common intron 1 sequences and the subsequent 345bp region of 
interest identified, were both aligned using EMBOSS matcher from the EMBL-EBI 
bioinformatics suite(McWilliam et al. 2013). Under default parameters: BLOSUM62 Matrix, 
Gap Open 14, Gap extend 4, Alternative matches 1, Output pair. 
2.2.3 Endonuclease Design 
Sequences identified as candidates for the design of endonucleases, were subject to analysis 
for TALEN and guide design using TALEN Hit Software: (Cellectis Bioresearch 2011) and CRISPR 
MIT (Optimised CRISPR Design 2013). The only selection made was for the human or mouse 
genome builds on the CRISPR MIT tool otherwise, all parameters were default.  
2.3 Bacterial Cultures 
2.3.1 Materials 
 Ampicillin (Sigma): prepared as 1000x stock in ddH2O at 50 mg/ml concentration, 
filtered through 0.22 µm filter (Falcon) and stored at -200C.   
 Kanamycin (Sigma): prepared as 200x stock in ddH2O at 20 mg/ml concentration, 
filtered through 0.22 µm filter (Falcon) and stored at -200C.   
 Agar (Fisher Scientific) 
 Glycerol (Sigma) 
 Lysogeny Broth (LB) (Sigma). 
 LB agar: 3g agar was added to 4g LB solution made up to 200ml with ddH20. The LB-
agar solution was incubated at 60°C for at least an hour and subsequently cooled 
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before the addition of desired antibiotic. ~25ml of LB-agar was added into 100 mm 
petri dish in proximity to the Bunsen burner. Once solidified the plates were sealed in 
cling film and stored at 40C for no longer than 1 month. 
 LB SOC medium: 100 µl of 1 M MgSO4 and 20 µl 1 M glucose (0.22μm filtered) were 
added to 10 ml LB medium.  
 TOP 10 (E.coli) competent cells (Invitrogen/ NEB) 
 
2.3.2 Heat Shock Transformation of Bacteria: 
A plasmid concentration of between 100-200ng of DNA contained within 5μl, 1/10th of the 
volume of bacterial competent cells was added to 50μl of competent cells, flicked gently to 
agitate the suspension and incubated at 4°C on ice for 30 minutes. The bacterial suspension 
was then shocked at 42°C for 30 seconds, and allowed to recover at 4°C on ice for 2 minutes. 
Subsequently, 250μl of antibiotic-free LB SOC media, an enriched media, was added to the 
bacterial suspension.  This was then incubated at either 32°C or 37°C degrees for 1 hour 
shaking at 200rpm. This is then plated at alternative volumes 50 or 100μl, in an attempt to 
attain correct bacterial densities and incubated overnight on agar plates with appropriate 
antibiotic selection.   
2.3.3 Production of Starter Cultures and Glycerol Stocks 
If bacterial colonies were present, after overnight incubation at 37°C, they were transferred to 
5ml LB in a universal tube and supplemented with a corresponding antibiotic. This was 
performed with either a sterile loop or a Gilson pipette. Once a starter culture had been 
inoculated, this was incubated at 37°C for 8-16 hours, shaking continuously at 200rpm.  
Post incubation 750μl of Bacterial suspension was mixed with 250μl of 80% sterile glycerol; the 
resultant glycerol stock was stored at -80°C. The remaining 4.25ml of bacterial suspension 
could either be used to inoculate a larger Maxi or Mega-prep culture or centrifuged at 
3000rpm for 15minutes (Beckmann Centrifuge). If centrifuged, the bacterial pellet was subject 
to DNA extraction using the Qiagen Mini-Prep kit or stored for later extraction at -20°C. 
2.3.4 Mini, Maxi and Mega Preparations:  
To produce small amounts of plasmid DNA, for the purposes of restriction-digest mapping, a 
bacterial pellet from the centrifugation of the starter culture was processed using the Qiagen 
Miniprep Kit. Larger and purer DNA preparations were produced by Maxi and Mega prep 
cultures: Maxi 500μl of starter culture inoculated into 250ml of LB supplemented with 
antibiotic, Mega 1000μl of starter culture inoculated into 500ml of LB with antibiotic. These 
bacterial suspensions were grown for 16 hours prior to being centrifuged at 3000rpm for 45 
minutes (Beckmann coulter) and processed with Qiagen Maxi or Mega prep kits respectively.  
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2.3.5 Picking Colonies for Colony PCR: 
If colonies were to be selected for screening by colony PCR, the colony in question would be 
picked and inoculated into 10μl of LB media. This was performed for 8 colonies using a labelled 
8-tube PCR strip, and each suspension mixed. Then using a multiple pipette boy, 5μl of all 
samples was aliquoted into fresh tubes to ensure samples were produced in duplicate. One 
group was then be boiled at 98°C for 2 minutes to lyse bacteria and provide a crude DNA 
suspension prior to being stored at 4°C in the PCR thermocycler. The second group was stored 
at 4°C and used to produce at starter culture if the colony was identified as consistent.  
2.4 Plasmids 
All plasmids for this investigation were either Maxi or Mega prepped, eluted in water or TE 
buffer and working stocks diluted to approximately 1μg/μl prior to storage at -20°C. It should 
be noted that in all cases ampicillin resistance genes are within the plasmid backbone, thus 
this was used in bacterial culture methods, during plasmid production. 
2.4.1 Gene- Editing Plasmids 
2.4.1.1 U6 Guide Plasmid: 
The plasmid was kindly gifted by Dr. Taeyoung Koo, from Professor Jin Soo Kim’s lab. This 
comprises of a U6 RNA polymerase III promoter upstream of a guide cloning site, consisting of 
a 677bp spacer region flanked at the 5’ and 3’ end with asymmetric BsaI restriction sites. 
Immediately downstream of the 3’ BsaI restriction site is the invariant tracrRNA sequence. 
Upon cloning of a 20 nucleotide ‘crRNA’ or spacer region, between the BsaI sites a full chimeric 
single guide RNA will be formed. This plasmid was used as the backbone for the production of 
all U6-driven guide sequences in this investigation.  
2.4.1.2 HC-Cas9 Plasmid 
The plasmid was kindly gifted by Dr. Taeyoung Koo, from Profesor Jin Soo Kim’s lab. This 
contains human codon optimised Streptococcus Pyrogenes Cas9 downstream of 
Cytomegalovirus (CMV) and a T7 RNA polymerase promoter (T7). Finally, the 3’ end of Cas9 
has a HA tag and nuclear localisation signal (NLS), prior to terminating in a bovine growth 
hormone polyA. This plasmid was used for the T7 RNA polymerase and was used for Cas9 In 
Vitro transcription experiments.   
2.4.1.3 CBh-Cas9 (Px165) 
This plasmid was ordered from Addgene (Plasmid Number #48137), where it had kindly been 
donated by the Zhang lab group (Ran et al. 2013). It contains human sequence-optimised 
Streptococcus Pyrogenes Cas9 (SpCas9), under the control of the Chicken Beta Actin (CBh) 
promoter. This is a modified CAG promoter with validated robust expression in a range of 
mammalian cells. Importantly, the SpCas9 transgene is 3x flag-tagged at the 5’ end and 
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contains (NLSs) at both the 5’ and 3’ termini, prior to terminating in a bovine growth hormone 
poly A site. This construct requires dual transfection alongside a U6-driven guide plasmid to 
mediate gene-modification. 
2.4.1.4 U6- Guide- CBh-Cas9-2A-GFP (Px458) 
This plasmid was ordered from Addgene (Plasmid Number #48138), where it had kindly been 
donated by the Zhang lab group (Ran et al. 2013). This is a sister plasmid to the Px165. Distinct 
from the Px165 it contains a U6 RNA III polymerase, with BbsI two asymmetric restriction sites 
spaced 22bps apart, immediately downstream of this is the invariant tracrRNA sequence. Upon 
cloning of a 20 nucleotide ‘crRNA’ or spacer region, between the BsaI sites a full chimeric 
single guide RNA will be formed.  Similarly to the Px165 downstream of this site the plasmid 
comprised the same CBh promoter, followed by 3x flag tags and NLSs at both the 5’ and 3’ 
ends. However, immediately after this is a 2A viral peptide linker, followed by an eGFP and a 
bovine growth hormone polyA. Thus this plasmid is particularly useful as an All-in-one Cas9 
delivery system.  Furthermore the bicistrionic Cas9 and eGFP expression proved useful in 
allowing fluorescence to function as a proxy for transient transfection efficiency.   
2.4.1.5 pet-MBP-Cas9  
Custom Pet plasmid was used in Paris with Dr. Jean Paul Concordert and Dr. Anne De-Cian to 
transform Rosetta BL2 competent bacterial cells and induced Cas9 protein production. It 
comprises of an N-terminal terminal hexahistidine maltose binding protein (His-MBP), 
sequence optimised SpCas9 and a C-terminal Histidine tag. This plasmid was modified from a 
plasmid on Addgene (plasmid number #39312) kindly donated by Doudna’s lab (Jinek et al. 
2012). Importantly, additional nuclear localisation signals were sub-cloned at 5’ and 3’ ends of 
the Cas9 transgene, in an effort to enhance protein production. 
2.4.1.6 pBIGT-VGEJ-AAV  
This plasmid was used in Paris with Dr. Jean Paul Concordert and Dr. Anne De-Cian during an in 
vitro cleavage assay with Cas9 protein. The main constituent of interest to this investigation 
was a unique XmnI site, allowing for the 5.8kb plasmid to be linearised and a recognition site 
for a published GFP T2 guide (Mali, Yang, et al. 2013). 
2.4.1.7 pCI-GFP 
This plasmid was kindly gifted by Dr. Susan Jarmin. It comprises of a Cytomegalovirus (CMV) 
promoter, which drives enhanced Green fluorescent protein (eGFP). This terminates on an 
SV40 PolyA signal. This resultant green fluorescent signal was used as a proxy for transient 
transfection efficiency.  
60 
 
2.4.2 Dystrophin Plasmids 
Investigations using dystrophin were concerned with the examination of sequence optimised 
and native dystrophin constructs. In the former the sequence has been optimised to enhance 
dystrophin transcription. As such three main dystrophin variants were examined in both 
sequence optimised and native formats including: Full length dystrophin, Δ45-55 
minidystrophin with the in-frame deletions of Exons 45-55 and finally MD1 R4-23 ΔCT. The 
latter, MD1 contains the minimal necessary constituents for functional dystrophin, with 
deletions of spectrin-like repeats R4-23 and the C-terminal domain.  
Native variants – The cDNA of dystrophin variants is that physiologically present /naturally 
occurring. This was constructed from consensus sequence. 
Optimised Variants – The cDNA of dystrophin variants has been subject to the GeneArt ‘sliding 
window’ algorithm to optimise codon usage to species, avoid sequence motifs detrimental to 
transcription in order to boost expression.  
Crucial to understanding these constructs, the experiments were undertaken in two plasmid 
backbones: pCI and pAAV. The full length and Δ45-55 minidystrophin variants were tested in 
both plasmid backbones respectively. In contrast, the MD1 was tested in pAAV in alone.  
2.4.2.1 pCI Backbone: 
The standard pCI backbone contains a cytomegalovirus (CMV) promoter which was used to 
drive expression of full length and Δ45-55 dystrophin transgenes respectively. The individual 
constructs are tabulated below: 
Native and Sequence Optimised Dystrophin Variants, in a standard pCI-Backbone driven by a 
CMV promoter 
Full Length  CMV- Nat hDys  CMV-HuDys- SO 
Δ45-55 CMV- Nat hDys Δ45-55 CMV-HuDys Δ45-55 – SO 
MD1  N/A N/A 
 
2.4.2.2 pAAV Backbone 
The standard pAAV backbone was used for the expression of dystrophin cDNA variants. It 
contains, a muscle restrictive Spc5-12 promoter, upstream of dystrophin cDNA variants, an 
SV40 PolyA, an ampicillin cassette and two inverted terminal repeats necessary for packaging 
into AAVs.  
Native and Sequence Optimised Dystrophin Variants, in a standard pCI-Backbone driven by a 
Spc5-12 Muscle restrictive promoter 
Full Length  Spc5-12-  Nat hDys  Spc5-12 -HuDys- SO 
Δ45-55 Spc5-12 - Nat hDys Δ45-55 Spc5-12 -HuDys Δ45-55 - SO 
MD1  Spc5-12- Nat- hMD1 Spc5-12 – HuMD1 –SO 
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All aforementioned dystrophin native and sequence optimised variants were cloned and kindly 
gifted to me by Dr. Susan Jarmin.  
2.4.3 Repair Template Plasmids 
2.4.3.1 pUC57-hINT1-RT 
This plasmid was synthesised by GenScript, in accordance with the exogenous repair template 
sequence provided, with avoidance of the unique restriction sites as requested. This is a 
promoter-less plasmid comprising: a 1kb left arm of homology, a β-globin splice acceptor, 
sequence optimised dystrophin exons 2-6, a Cyan Fluorescent Protein (CFP) with the initiating 
methionine residue removed, flanked between 5’ FseI and 3’ NotI restriction sites, a mutated 
Woodchuck Hepatitis Virus Post-transcriptional regulatory element (mWPRE) and polyA, a 
Sv40-Zeocin-Sv40 polyA and a 1kb right arm of homology. The sequence for this plasmid was 
constructed throughout the course of the investigation and formed the foundation of the 
exogenous repair template. The FseI and NotI, restriction sites enabled directional cloning of 
all of the sequence optimised dystrophin variants. 
2.4.3.2 pUC57-hINT1-MD1-RT (MD1 RT) 
This is the daughter plasmid of Puc57-hINT1-RT. The only distinction is the CFP between the 
FseI and NotI restriction sites has been removed and MD1 Exon 6 onwards has been sub-
cloned into the construct. As a consequence, MD1ΔEx1 was reconstituted downstream of the 
β-globin splice acceptor. This is used for all of the integration-based experiments in this 
investigation.  
2.4.3.3 Lentiviral ISce-IT-hINT1-RT 
This plasmid was kindly gifted by Prof. Rafael Yanez. It encodes the same variants as the Puc57-
hINT1-RT between the 1kb left and right arms of homology. This aforementioned sequence 
was sub-cloned in reverse orientation between AgeI and KpnI restriction sites within the 
lentiviral backbone; this was to avoid any aberrant splicing events that could occur during viral 
synthesis. The lentiviral backbone contained: the Gag gene, Primer binding site (PBS), Rev 
Responsive element, a central polypurine tract and long terminal repeats; all sequences 
necessary for lentiviral production.    
2.5 Computer Software used throughout Thesis: 
 Vector NTI / Snap Gene – to visualise and analyse plasmids of interest.  
 GraphPad Prism – for graphical presentation and statistical analysis of samples.  
2.6 Descriptive Statistical analysis: 
All graphical portrayals of the datasets use mean as a measure of the central tendency, and 
standard error of the mean (SEM) as a measure of deviation within the samples. Where 
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appropriate, a Shipiro-Wilks test was used to establish the normal distribution of datasets in 
question, the null hypothesis being that the data input follows a normal or Gaussian 
distribution. Thus in instances where the p-value derived is greater than the alpha value 
(<p=0.05) the true null hypothesis cannot be rejected and the data is deemed normally 
distributed. In instances of a normal distribution the data sets were subject to a parametric 
statistical analysis.  
2.6.1 Inferential Data Analysis 
Comparison of two groups: a comparison of two groups was performed if by unpaired t-test if 
the datasets adhered to a normal distribution.  
Comparison of multiple groups: If the conditions of normality were met between multiple 
conditions. Then a one-way or two-way ANOVA was performed.  
2.7 Molecular Sub-Cloning Methods 
2.7.1.1 Materials 
 Restriction enzymes and buffers (All NEB products). 
 50x TAE: 242 g Tris Base, 57.1 ml Glacial Acetic Acid, 100 ml of 0.5 M EDTA pH 8.0 were 
brought to a total volume of 1 L with ddH2O. 
 UltraPure Agarose (Invitrogen) 
 1000x SYBR Safe DNA gel stain (Invitrogen). 
 5x Loading buffer (Bioline). 
 DNA molecular weight markers, Hyperladders I, IV and V (Bioline):  
 Qiaquick gel extraction kit (Qiagen). 
 Qiaquick PCR Purification Kit (Qiagen) 
 High Salt Buffer (Roche) 
 T4 DNA ligase (NEB/ Promega/ Fermentas). 
 
2.7.1.2 Endonuclease Restriction Digest 
To confirm the identity of plasmids produced, restriction digests were designed using 
SnapGene and restriction digest conditions checked on the NEB website 
(https://nebcloner.neb.com/#!/redigest). Once designed a 1μg aliquot was subject to 
restriction digest mapping using a variety of single and multiple cutters. Restriction digest 
reactions comprised of: 1x Cutsmart Buffer (NEB), 1μl of Enzyme (~10U, adjusted if necessary), 
1μg of plasmid DNA preparation and ddH20 to attain a 20μl volume. This was then incubated 
at 37°C for 3 hours to ensure digestion had continued to completion prior to the restriction 
enzyme being inactivated at 80°C for 20 minutes. The latter step being optional as inactivation 
is not suitable for all enzymes. 
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2.7.1.3 Gel Electrophoresis  
To permit examination of plasmid digestion profiles, the samples were loaded on agarose gels.  
Agarose percentages of 0.5%, 1% and 2% (mass: volume) in 1x TAE buffer, were routinely used 
in the separation of DNA, with selection being influenced by the anticipated band fragments 
sizes. Following microwaving and agitating the solution to ensure agarose had completely 
dissolved, it was cooled slightly and inoculated with SYBR® Safe DNA stain to attain a final 
concentration of 0.01%. This was then poured in a 10cm dish and allowed to set.  An 8μl 
aliquot of DNA samples were then mixed with 2μls of 5x loading dye, and loaded in to the 
wells, alongside 5μl of a  hyperladder of appropriate range to determine DNA size. The samples 
were then electrophoresed at 50v for 1 hour, and at 70v for sequential 20 minute intervals 
until DNA fragments had separated adequately for determination of size. The DNA fragments 
were then visualised under U.V as permitted by the SYBR® Safe, the sizes determined by 
comparison to hyperladder were then compared with those anticipated from SnapGene. 
2.7.1.4 Gel and PCR Purification: 
Desirable DNA fragments for sub-cloning either in the form of the destination vector or the 
insert, required purification to ensure the maximal success for sub-cloning projects. If the 
products were separated on an agarose gel, the fragment was excised and solubilised using 
Qiaquick Gel-extraction protocols in accordance with manufacturer’s protocols, to attain DNA 
of interest. In contrast, if the DNA was amplified, it was subject to Qiaquick PCR purification, in 
accordance with manufacturer’s protocols. 
2.7.1.5 T4 DNA Ligation  
T4 DNA ligase facilitates the phosphodiester linkage formation between an insert and a 
destination vector. Molar ratios of 1:5 and 1:10 of destination vector: insert are used, in which 
the destination vector is used at a concentration of either 50 or 100ng. Standard reactions 
comprised: 2μl of 10x ligase buffer and 1μl of T4 ligase, and ddH20 to attain a constant total 
reaction volume of 20μl. Ligations were commonly incubated at 22°C for 1 hour and then 16°C 
overnight, heat inactivated at 65°C for 10 minutes. If the concentration of destination vector 
and insert permitted, this 20μl reaction was reduced proportionately to a 10μl volume, to 
improve ligation efficiency.  
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2.8 Guide Sub-Cloning Methods 
2.8.1 Background 
In order to produce U6-driven guides that could be co-transfected alongside a plasmid 
expressing Cas9 nuclease, oligonucleotides were ordered from Eurofins MWG or IDT, annealed 
and ligated into either the U6 guide or the Px458 plasmids. Overhangs 5’ CACCG’ were 
appended to the forward 20 nucleotide guide oligo and 5’AAAC’ appended to the reverse 
guide oligo. Notably, a ‘C’ appended at 3’ end of the 20 nucleotide guide sequence, to permit 
the addition of the 5’ Guanine. In these investigations a GX20  guide format was utilised. 
2.8.2 Human Primers 
Primer Name Primer Sequence 5’-3’ 
hINT G1 F:  
hINT G1 R:  
CACCGAGACTAAGAACCAGATGCTA 
AAACTAGCATCTGGTTCTTAGTCTC 
hINT1 G4 F: 
hINT1 G4 R: 
CACCGTCTGTCTAATTACATTATAA 
AAACTTATAATGTAATTAGACAGAC 
2.8.3 Mouse Primers  
Primer Name Primer Sequence 5’-3’ 
mINT G1 F:  
mINT G1 R:  
CACCGAGACTAAGGACCAGATGCTA 
AAACTAGCATCTGGCCTTAGTCTC 
mINT1 G2 F: 
 mINT1 G2 R: 
CACCGTAATGCAATTAGACAGACTA 
AAACTAGTCTGTCTAATTGCATTAC 
mINT1 G3 F:  
mINT1 G3 R: 
CACCGTCTGTCTAATTGCATTATAA 
AAACTTATAATGCAATTAGACAGAC 
mINT1 G4 F:  
mINT1 G4 R: 
CACCGTATGAAGCATGGTATTATTT 
AAACAAATAATACCATGCTTCATAC 
mINT1 G5 F: 
mINT1 G5 R: 
CACCGTATTTTGCTTCCTTAGCATC 
AAACGATGCTAAGGAAGCAAAATAC 
 
2.8.4 Preparation of the U6 Guide Plasmid 
Standard BsaI digests were performed on 2μg of U6- guide plasmid in triplicate; digests were 
undertaken for 2 hours at 37°C.  This was performed alongside 1μg internal controls of uncut 
(enzyme substituted with water), linearized with NotI enzyme (cuts once) and 1μg BsaI digest. 
Post digestion enzymes were inactivated. Then 10μl of internal controls and the full 20μl of 
BsaI digest was resolved on a 0.8% agarose gel.  This was visualised by the white light as 
opposed to U.V to prevent degradation. The 2464bp, corresponding to the U6 vector with the 
removal of the 677bp spacer region, was subject to Qiaquick gel extraction for the 3 triplicates. 
If the 1st sample had low yield, below 10ng/μl the resultant mixtures were pooled. 
2.8.5 Self- Annealing Oligonucleotides 
A reaction mixture of oligonucleotides was produced comprised of: 5μl Roche high Salt (H 
buffer), 10μl of forward and reverse primers at a concentration of 100pmol/μl and 75μl of 
ddH20. This was then subject to the ‘Surveyor hybridisation programme’. See section 1.15. 
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2.8.6 Ligation 
This was then subject to a 10μl ligation, comprising: 1μl T4 ligation buffer, 1μl of plasmid 
backbone, 1μl of annealed oligos, 1μl T4 ligase and 6μl of ddH20. 
2.8.7 U6 Guide Colony PCR 
2.8.7.1 Materials 
 2x PCR Mastermix (GeneSys Ltd) 
 Primers 
Primer Name Primer Sequence 5’-3’ Amplicon Size (Bp) 
U6 Colony PCR F 
U6 Colony PCR R 
CATATGCTTACCGTAACTTGAAAG 
CGGACTAGCCTTATTTTAACTTGC 
787bps (with U6 guide 
plasmid spacer) 
144bp (if a 20 nucleotide 
guide was cloned in). 
 
A 1μl aliquot of crude DNA extract produced from boiling a bacterial colony in 5μl of LB (see 
section 1.3.5), was added to a 2x Mastermix PCR (GeneSys Ltd). This was produced in 
accordance with the standard PCR method (section: 15.1.1). 
The cycling conditions: Denaturation 98°C 2 minutes, 35 cycles – (98°C 30s, 60°C 30s, 72°C 
45s), Final Extension 72°C 10 minutes and held at 4°C. 
This resultant amplicon was then resolved on a 2% agarose gel alongside hyperladder IV.  
2.8.7.2 U6 Guide plasmid Sequencing 
If colonies screened, indicated the insertion of self-annealed primers by colony PCR, bacterial 
starter cultures were produced and mini preps undertaken. The resultant DNA preparation 
was diluted to 5ng/μl for a 15μl volume and supplemented with 2μl 10pmol/μl [10μM] U6 
sequencing primer 5’ ‘GACTATCATATGCTTACCGT’3’. This was then submitted to Eurofins for 
overnight sequencing, to fully confirm the identity and presence of the guide. 
2.9 Sub-cloning Microdystrophin into the pUC57-hINT1-RT. 
2.9.1 Preparation of plasmids 
 A 2μg concentration of both Puc57-hINT1-RT and Spc512-HuMD1-SO plasmids were double 
digested in 4 repetitions, with FseI and NotI restriction enzymes. The reaction mixtures were 
incubated at 37°C for 2 hours prior to heat inactivation at 80°C for 20 minutes. This was 
performed alongside 1μg internal controls consisting of: Uncut (enzyme substituted with 
water), linearised with SpeI-HF enzyme (this cuts once) and a double digest of FseI and NotI. 
Samples were resolved on 1% agarose gel against hyperladder I.  
Pu57-hINT1-RT: Destination vector backbone: 6638bps 
Spc512-HuMD1-SO: Provides the MD1 exon 6 onwards insert: 3213bps 
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These DNA fragments were visualised by white light as opposed to U.V, to prevent 
degradation. The above fragments were extracted by Qiaquick gel extraction and eluted in 
30μl. If the 1st sample was observed to be of low yield below 10ng/μl, samples were pooled. 
The resultant mixtures were ligated at a variety of ratios, see section 1.6.1.5. 
2.9.2 Microdystrophin Colony PCR 
Primer Name Primer Sequence 5’-3’ Amplicon Size (Bp) 
HuDys CO Seq 1 
nTTS HuDys  F1 R2  
GGGCCTGATCTGGAACATCATC 
CGAACAGGTCGGGTCTGTGGC 
221bps (If MD1 is present) 
No amplification if MD1 was 
not successfully cloned. 
 
These primers span the FseI 5’ restriction site junction of the pUC57 hINT Repair template, 
initiating in the repair template backbone and extending into MD1 exon 6 onwards sequence. 
The amplicon will only be present  if MD1 has been cloned successfully. 
Colony PCR mixture was produced as described (see section: 15.1.1) 
The cycling conditions: Denaturation 98°C 2 minutes, 35 cycles – (98°C 30s, 65°C 30s, 72°C 
45s), Final Extension 72°C 10 minutes and held at 4°C. 
2.10 Tissue Culture 
2.10.1 General Tissue Culture Reagents: 
 Sterile PBS: 1 PBS Tablet (Gibco) dissolved in 500ml of ddH20. This was either 
autoclaved or filtered with a 0.22μM filter, with Class II Lamina flow hood. 
 Trypan blue (Gibco) 
 Trypsin (10x)- 0.5% trypsin in PBS (Sigma) 
 T175cm3, T75 cm3 Tissue Culture Flasks (Corning) 
 Tissue Grade DMSO (Sigma) 
 Sterile Glass Stripettes 5, 10 and 25ml (Starlabs) 
 15ml and 25ml Falcon Tubes (Corning) 
 Mr Freezie  
 Screw Top Cryovials (Corning) 
 
2.10.1.1 Growth Media for Culturing HEK293T 
 Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/l glucose and glutamax 
(Gibco). 
 10% Heat Inactivated Foetal Calf Serum (PAA / Gibco). Vol. 50ml. Heat inactivation of 
FCS is achieved by heating the 500ml bottle to 56°C for 30 minutes. 
 Penicillin-streptomycin 100 Units/ml (Sigma) Vol. 5ml 
 
2.10.1.2 Growth Media for Culturing Immortalised Patient myoblasts (Δ45-52) 
 Skeletal Muscle Cell Growth Media (Promocell) 
 Skeletal Muscle Cell Growth Supplement Mix (Promocell) 
 20% Heat Inactivated Foetal Calf Serum (PAA / Gibco) Vol. 100ml 
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 1.4 % L-Glutamine (Sigma) Vol. 7ml 
 5% Gentamycin (Sigma) Vol. 25ml 
 
2.10.1.3 Growth Media for Culturing H2kb.mdx 
 Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/l glucose and glutamax 
(Gibco) 
 20% Heat Inactivated Foetal Calf Serum (PAA / Gibco). Heat inactivation of FCS is 
achieved by heating the 500ml bottle to 56°C for 30 minutes. 
 0.5% Chick Embryo Extract (Sera Laboratories International) Vol. 2.5ml 
 0.2% Gamma Interferon (Peprotech) Vol. 1ml 
 Penicillin-streptomycin 100 Units/ml (Sigma) Vol. 5ml 
 
2.10.1.4 Cell Lines: 
Human Embryonic Kidney 293T (HEK293T) –Cells were obtained from ATCC. These were 
expanded and stored in liquid nitrogen. HEK293T used for the experimenters were usually in 
the range of passage 6 -16. 
Cas9 expressing Human Embryonic Kidney 293T (HEK293T.Cas9) – Cells were attained from 
Genocopeia. This cell line harbours the stable integration of the bi-cistronic CBh-Cas9-Ef1a-
eGFP cassette, at the AAVSI locus 
Immortalised Patient Myoblasts Δ45-52 – These human myoblast cells were derived from 
patient biopsies bearing deletions of exons 45-52 inclusive. These cells were transduced with 
retroviral vectors expressing telomerase and cyclin-dependent kinase 4 (CDK4), to immortalise 
the cells (Mamchaoui et al. 2011). Upon successful transduction and stable integration, these 
vectors conferred the cells both puromycin and neomycin resistance. These myoblasts with 
greater proliferative capacity than conventional myoblasts provide a suitable in-vitro 
dystrophic model for the investigation of therapeutic approaches. These were kindly gifted to 
the lab by Dr. Vincent Mouley and maintained in a passage range of passage 9 – 17. 
H2kb mdx: This mouse cell line was derived from the production of a transgenic mouse model, 
by crossing the H2kb-tsA58 background, with an mdx mouse (Morgan et al. 1994). The H2kb-
tsA58 encodes a variant of the large T-antigen tsA58 downstream of a H2kb promoter, which 
upon induction with interferon gamma at 33°C serves to immortalise the cells. The mdx mouse 
contains a nonsense mutation in exon 23, serving to make the mouse dystrophin negative and 
exhibit a dystrophic pathology(Sicinski et al. 1989). Thus this immortalised dystrophic cell line 
represents an in-vitro mouse model for the investigation of therapeutic approaches. These 
cells were gifted by Dr Mike Antoniou, maintained in the passage of 13-19.  
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2.10.1.5 Thawing Cells 
Cells were taken from liquid nitrogen, incubated in the 37°C water bath and thawed quickly. 
They were partially submersed in 37°C water and visually inspected until a ‘rice size grain of 
ice’ was visible normally after 2 -3 minutes.  
HEK293T and H2kb.mdx:  Once almost thawed the 1ml of cell suspension was aliquoted into 
9mls of an appropriate pre-warmed growth media. This was then centrifuged at 1,000 rpm for 
5 minutes (Beckmann, coulter at room temperature). The supernatant aspirated, the cell pellet 
re-suspended and transferred to a T175cm3 flask to make a total media volume of 25ml. Cells 
are then incubated: HEK293T - 37°C 5% CO2,  H2kb mdx - 33°C 5% CO2. 
Immortalised Patient myoblasts: Post thawing patient myoblasts are too fragile for 
centrifugation; rather the 1ml is applied directly to 24ml of warmed skeletal growth medium 
and transferred to a T175cm3 flask. This is then incubated for 24 hours and media is replaced 
the following day. Importantly, this process removes DMSO from the freezing solution, which 
may reduce cell viability.  
2.10.1.6 Culturing Cell Lines 
Cells were monitored daily until 70-80% confluency was attained after approximately 2-3 days 
of growth. The media was aspirated, the cells washed with 1X PBS, prior to the of 5ml addition 
of pre-warmed 1x Trypsin (5x Trypsin for patient myoblasts). This was then incubated at 37°C 
for approximately 2 minutes to liberate the cells from the flask surface, then neutralised with 
10mls of appropriate growth media, and centrifuged in a 50ml falcon tube at 1,000 rpm for 5 
minutes. Cells were re-suspended in an appropriate volume of fresh media, cells were then 
counted using a haemocytometer. This was repeated 3 times to attain an accurate cell number 
then cells were seeded at a density of 8x105 per 25ml in a T175 flask.  
2.10.1.7 Freezing Cell Lines 
A 10% DMSO freezing solution was prepared for cells, comprised of: 9ml heat inactivated Fetal 
Calf Serum and 1ml of DMSO. A defined cell density of 1x106 was centrifuged at 1000rpm for 5 
minutes (Beckmann coulter) and pelleted in a sterile eppendorf. This pellet was re-suspended 
in 1ml of freezing solution and transferred to a screw-top cryovial.  Once all cryovials prepared, 
these were placed in a Mr freezie, with a controlled cooling system or filled with absolute 
Isopropanol. This allowed the cells to gradually cool to -80°C by leaving overnight in a -80 
freezer, prior to being transferred to liquid nitrogen for long term storage. 
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2.11 Transient Transfection Protocols 
2.11.1 Cell Densities for 6 well Plate 
Cell Line Cell 
Density  
Notes 
HEK293T  5 x 105 70-80% confluency in 24 hours 
Careful media change undertaken, if evidence of de-
attachment was observed. Cells were re-seeded. 
HEK293T.Cas9 3 x 105  70-80% Confluency in 24 hours  
Immortalised 
Patient 
Myoblasts Δ45-
55 
8.3 x 104  60-70% Confluency in 48 hours. 
Low seeding was to avoid the occurrence of 
differentiation. Visually inspect cells to ensure this.  
Media change necessitated at 6 hours. 
H2kb.mdx 1.25x 105  70-80% Confluency is attained in 24 hours.  
The six well plates were coated with ECM. 
ECM Preparation: 9mls DMEM and 1ml of ECM. A 
350μl aliquot of this suspension was applied per well. 
This was then incubated at 37°C for 1 hour. Then 
aspirated.  
 
2.11.2 Transfection Reagents and Ratios: 
Cell Line Transfection Reagent and 
Ratio Used 
HEK293T  Viafect 5:1 
Lipofectamine Reagents:  
Messenger Max 3:1 
CRISPR Max 3:1 
HEK293T.Cas9 Viafect 5:1 
Lipofectamine Reagents: 
Messenger Max 3:1 
Immortalised Patient 
Myoblasts Δ45-55 
Viafect 3:1 
Lipofectamine Reagents: 
3000 3:1 
Messenger Max 1.5:1 
H2kb.mdx Viafect 3:1 
 
2.11.3 Viafect Transient Transfection 
 Viafect Transient Transfection Reagent (Promega) 
 Serum Free Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) 
Cells were seeded on a six well plate at Day 0 to attain 70-80% confluency by Day 1 or 2 as 
noted above. Once 70-80% confluency was reached, media was changed 1 hour prior to 
transient transfection. A master mix containing an experimentally defined transfection reagent 
volume (μl): DNA mass (μg) ratio was prepared. A 200μl volume transfection mixture was 
prepared for a single well, on a 6 well plate. The volume was scaled up proportionality for the 
number of repetitions required, with an additional 200μl volume in excess of that required 
prepared to account for pipetting error that may occur.   
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In the production of a single mastermix, a calculated volume of serum free DMEM at room 
temperature was pipetted into an eppendorf. Shortly, following this a defined DNA mass was 
added to the DMEM e.g. 4μg and the DNA-DMEM suspension agitated. This was incubated at 
room temperature for 5 minutes as per the manufacture’s protocol. Then a defined volume of 
Viafect transfection reagent was added drop-wise with continual agitation of the suspension 
then incubated at room temperature for 15 minutes. Post incubation, the transient 
transfection mixture was added to the well in a dropwise circular motion to ensure maximum 
cell coverage. 
Due to the non-toxic nature of Viafect transfection reagent a media change was not 
necessitated. Cells were routinely incubated for 48 hours if harvested for DNA and 72 hours if 
harvested for protein. 
2.11.4 Lipofectamine Based Transient Transfection: 
2.11.4.1 Lipofectamine Reagents 
 Lipofectamine 3000 (Invitrogen) 
 Lipofectamine mRNA Messenger Max (Invitrogen) 
 Lipofectamine CRISPR Max (Invitrogen) 
 Opti-Mem (Gibco) 
 GFP mRNA positive control (Trilink) 
 Cas9 mRNA (Trilink) 
For lipofectamine based transfections, two separate stocks were produced in accordance with 
the manufacturer’s protocol:  i) A set mass of DNA or RNA was diluted in serum free DMEM 
with a transfection additive e.g. p3000 at 2μl/μg of DNA and ii) A volume of Lipofectamine 
transfection reagent required to produce the appropriate transfection reagent (μl): DNA (μg) 
ratio and was diluted in serum free DMEM. The appropriate ratios being either: 1.5:1 or 3:1, 
the latter being used more routinely. Both stocks were prepared to a final volume of 125μl per 
well, and the master mix was scaled for further repetitions and adjusted to include half a 
transfection volume in excess to account for pipetting error. The diluted DNA or RNA sample 
was then added to the transfection reagent mixture and incubated for 10 minutes at room 
temperature.  This was then added in a circular dropwise fashion to the well. For patient 
myoblasts, which appeared susceptible to lipofectamine 3000 toxicity, the media was changed 
6 hours post transfection.  
2.11.4.2  Production of Ribonucleotide Proteins and Additional Considerations for 
Protein Transfections. 
Prior to the transient transfection of Cas9 protein, the production of ribonucleotide protein 
(RNP) complex was required; this being the Cas9 protein complexed to an appropriate mRNA 
guide.  In pursuit of this an appropriate concentration of guide mRNA was aliquoted to a fresh 
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eppendorf tube and heated to 90°C for 2 minute. This was then subject to a 10 second pulse 
centrifugation of max speed and cooled for 5 minutes at 4°C.  The Cas9 protein was then 
added to guide and it is incubated at room temperature for 10 minutes. 
This step was performed once lipofectamine CRISPRMax mixtures had been prepared to 
ensure that the Cas9 RNP complex was not left for prolonged periods at room temperature. In 
addition, Lipofectamine CRISPRMax solutions were made using Opti-MEM; this was to prevent 
the Cas9 protein precipitating out of solution.  Transfections with the CRISPRMax used at a 3:1 
transfection reagent (μl) to Cas9 nuclease (μg) ratio. In this instance Cas9: guide complexes 
were transfected at either a 2:1 or 4:1 ratio: referring to 2.5μg Cas9: 1.25μg guide RNA and 
2.5μg Cas9: 625μg of guide RNA per well respectively. Transfections were performed in 6 well 
plates when cells had achieved approximately 50% confluency (in line with the 30-70% 
indicated by the manufacturer’s protocol), and DNA was harvested 24 hours later for 
assessment with mismatch detection assays.  
2.12 Flow Cytometric Analysis 
2.12.1 Materials 
 4% Paraformaldehyde (PFA) (Sigma) 
 FACs Beads (BD Falcon) 
 FACs Buffer:  500ml of PBS,  2ml of 0.5M EDTA and 5ml 10% NaN3 
 5ml round bottom snap cap FACs  Tubes (BD Falcon) 
 FACs Canto II (BD Biosciences) 
 Clean and Rise Solutions (BD Falcon) 
 FlowJo Software (BD Falcon) 
2.12.2 Analysis of GFP Expression in Cell Culture: 
Flow cytometric analysis was routinely used throughout this investigation to determine a 
subpopulation of cells expressing Green Fluorescent Protein (GFP).  This was used as a proxy 
for transient transfection efficiency, when using GFP tagged plasmids: pCI-eGFP or U6-Guide-
CBh-Cas9-2A-GFP (Px458).  
In order to assess the proportion of transiently transfected cells, cell cultures were pelleted 
(see section 1.12.2). This process was performed using 5ml round bottom FACs snap tubes, 
rather than 15ml falcon tubes. Once the cells were pelleted, the media was removed and the 
cells were subject to a 500μl 1x PBS wash. Following which, 400μl of 2% PFA was applied. The 
cells were agitated to re-suspend and stored at 4°C in the cold room wrapped in foil for no 
longer than 1 week prior to analysis. 
The FACs machine was calibrated with the FACs beads, in which two drops of FACs beads was 
suspended in 600μl of FACs buffer. The samples were analysed using the FACs Canto II, using 
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three graphical plots FSC/SSC (Live population), FSC-A/FSC-H (Single cells) and a FITC Histogram 
(GFP positive populations). Initially, mock samples were analysed to determine and refine 
gating voltages. Once a single dense population was centrally positioned on the FSC/SSC plot, 
this was gated to determine the number of live cells (gate p1). This population was then 
presented in the FSC-A/FSC-H graph, if the population was dense and approximately at a 45 
angle these were gated to determine the number of single cells (gate p2). Finally, this sub-
population of cells was displayed on an FITC histogram: cell count/FITC log. The voltages were 
adjusted so the peak population of the mock sample was positioned above 102, as is 
convention with FACs analysis. Once gating was achieved, all samples were analysed on a 
medium flow rate, using 10,000 events in the P2 gate as an end point for each analysis.   
2.12.3 Analysis of Flow Cytometric Data 
Once the analysis had been performed, the outputs were exported and analysed with the use 
of FlowJo software. The samples would be gated once again; on the FITC histogram, mock 
samples would be gated to give approximately 1% GFP positive cells. If the proportion of cells 
in the FITC histogram gating was higher than this baseline in subsequent samples, they were 
deemed GFP positive.  This was used to determine a percentage of GFP positive cells per 
transfection.  
2.13 DNA/RNA Extraction and Quantification from Cell Culture: 
2.13.1 Materials: 
 1X Sterile PBS 
 1X Trypsin 
 Centrifuge  
 Qiagen DNAeasy Kit 
 Qiagen Qiashredder 
 Qiagen RNAeasy Kit 
 Nanodrop ND-1000 spectrophotometer. (Labtech) 
 
2.13.2 Cell Pelleting for Extraction 
Cells were washed in 500μl of room temperature sterile 1X PBS and removed from 6 well 
plates with 500μl of 1X pre-warmed trypsin. This was incubated for 2 minutes at 37°C at 5% 
CO2, the trypsin was then pipetted gently over the surface of the well to remove maximal 
numbers of cells. This trypsin was then neutralised with 2ml of 10% DMEM. The number of 
cells was quantified and a suitable suspension in the range of 1 – 5x106 cells was then 
transferred to a 15ml falcon tube and centrifuged at 0.6g for 5 minutes. The cell pellet was 
washed with 2ml of 1x PBS and centrifuged once more. In the short-term if extraction was 
undertaken that day the cell pellet was stored at 4°C. If extraction was pursued at a later date, 
the pellet was stored at -80°C. 
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2.13.3 DNA Extraction 
 Pelleted cells within the suitable range were subject to Qiagen DNAeasy extraction, in 
accordance with the manufacturer’s protocol. Resultant DNA was eluted in AE buffer: a 200μl 
was routinely used for HEK293T cell pellets and 100μl for Δ45-55 Immortalised Patient 
Myoblast cell pellets. 
2.13.4 RNA Extraction: 
Pelleted cells within the suitable range were re-suspended in 350μl of RLT buffer and subject 
to Qiagen Qiashredder; this served to homogenise and purify the crude mRNA lysate. The 
resultant eluate was then subject to an RNA extraction using a Qiagen RNAeasy kit.   
2.13.5 Nucleic Acid Quantification 
A 1μl aliquot of DNA or RNA preparation was pipetted onto the nanodrop. The amount of light 
absorbed by this solution at a wavelength of 260nm is converted to estimates of DNA or RNA 
concentration and purity. The ratios of 230:260 and 260:280 were used as provisional 
indicators of DNA purity; if ratios obtained were in the range of 1.8-2.0 and 2.0-2.2 then the 
DNA sample was deemed pure. Notably, pure RNA samples generally absorb slightly higher at 
2.0 and 2.2. If uncertainty about the purity of the sample persisted, then a 2μl aliquot was 
resolved by gel electrophoresis. 
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2.14 Protein Extraction and Quantification: 
2.14.1 Materials  
 Sterile PBS: 1 PBS Tablet (Gibco) dissolved in 500ml of ddH20. This was either 
autoclaved or filtered with a 0.22μM filter, with Class II Lamina flow hood. 
 PAPBNI RIPA Buffer: NaCl 0.15M, HEPES 0.05M, NP-40.1%, Sodium Deoxycholate 
(SOC) 0.5%, SDS 0.10%, EDTA 0.01M, Protease Inhibitor tablet 1 in 50ml (Roche). This 
was aliquoted into 5mls, and stored at -20. 
 Cells Scrappers (Invitrogen) 
 Eppendorfs 
 Benchtop Microcentrifuge 
 DC Assay Protein kit: Reagent A, S and B (BioRad). 
 2μg BSA Standard (Invitrogen) 
 96 Well plate (Corning) 
 96 Well plate reader (Genbank) 
2.14.2 Protein Extraction: 
Cells were washed with 500μl ice cold PBS, prior to the addition of 100μl PABPN1 RIPA Buffer. 
The cells were then scrapped down to the bottom of the well, with the plate held at a 45° 
angle, before being incubated at 4°C on ice for 5 minutes. The sample was then transferred to 
pre-chilled and labelled eppendorfs, prior to being vortexed every 30 seconds for a further 15 
minutes. The resultant protein lysates were then centrifuged at 13,000 rpm for 15 minutes at 
4°C, to allow cell debris to pellet. The supernatant was then transferred to a fresh pre-chilled 
and labelled 0.5ml screw top tube, and stored at -20°C. 
2.14.3 Protein Quantification: 
A defined dilution series of BSA in the protein extraction PABPN1 Buffer was prepared 
providing concentrations ranging from 0- 2μg of BSA respectively as shown below: 
 
 
 
These protein standards were loaded at a volume of 0.5μl, alongside extracted protein 
samples at a volume of 5μl in a 96 well plate. All samples were loaded in triplicate to assert the 
accuracy/ ensure reliability of the resulting absorption readings obtained. 
In the fume hood, 25μl Reagent A +S (1ml of A to 20μl of S) was added to each of the samples 
from a low to high concentration wherever possible; this being a precautionary measure to 
prevent contamination. Subsequently, 200μl of Reagent B is applied and the resultant mixture 
is agitated and incubated for 15 minutes at room temperature.  A colorimetric analysis is 
undertaken at 750nm using the (Gen) 96 well plate reader. The absorption readings were then 
Conc (μg) 2 1.8 1.5 1.2 1 0.8 0.6 0.4 0.2 0 
RIPA buffer μl 0 4 10 16 20 24 28 32 36 40 
BSA μl  40 36 30 24 20 16 12 8 4 0 
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used to calculate an average protein concentration of the three samples from the standard 
curve.  
2.15 Western Blotting 
2.15.1 Materials 
 NuPage 10X Reducing Agent (ThermoFisher) 
 NuPage 4x Loading Dye Sample (ThermoFisher) 
 NuPage 3-8% Tris Acetate precast gradient gels (ThermoFisher) 
 NuPage Antioxidant (ThermoFisher) 
 Prestained HiMark Ladder (Life technologies) 
 NuPage 3-8% Tris Acetate Running Buffer (ThermoFisher) 
 NuPage 20X Transfer Buffer (ThermoFisher)  
 Absolute Methanol (VWR) 
 X-Cell sure lock mini cell and Tank (Thermo Fisher) 
 0.45μM Nitrocellulose membrane (GE Healthcare) 
 Ponceau Stain (ThermoFisher) 
 Filter paper  
 Marvel Milk Powder  
 Tween 20 Detergent (Sigma) 
 ECL solution 1 and 2 (Promega) 
 Amersham Hyperfilm 18cm x 24cm (GE Healthcare) 
 
2.15.2  Antibodies 
2.15.2.1 Primary Antibodies 
Antibody name Raised in  Dilution Used Binds to  
6C5 
(Dr. Glenn Morris) 
Mouse  
 
1 in 100 17a.a C-Terminal 
MannEx 1011C 
(Dr. Glenn Morris) 
Mouse 
 
1 in 100 Hinge/Spectrin 
repeats (Exon 10-11)  
Cas9 
(Diagenode) 
Mouse  
 
1 in 5000 Cas9 
Alpha-Tubulin  
(Abcam 40774) 
Rabbit  1 in 2500 Alpha Tubulin 
Subunit 
 
2.15.2.2 Secondary Antibodies 
Antibody name Dilution Used 
Goat α Mouse HRP 
(Dako) 
1 in 2000 
 
Goat α Rabbit HRP 
(Dako) 
1 in 2000 
 
Goat α Mouse (Green Fluorescence) 
(LI-COR) 
1 in 10000 
Donkey α Rabbit (Red Fluorescence) 
(LI-COR) 
1 in 10000  
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2.15.3 Sample Preparation 
Samples of total protein lysate were produced in a 4x master mix, this was to allow repetitions 
with antibodies if required. Typical a (4x) 40μl master stock would contain: 200μg total protein 
(Dystrophin screening), 50μg total protein (Cas9 screening). Samples were then prepared in a 
1.5ml screw top tube with: 4μl Reducing Agent, 10μl of Loading Sample Dye and the remaining 
volume is supplemented with ddH20. The samples alongside a positive control, either 
dystrophin extracted from muscle or from a previous positive transfection were denatured by 
heating to 70°C for 10 minutes. Samples were then cooled on ice. 
2.15.4 Gel Preparation and Electrophoresis 
A 3-8% Tris-Acetate precast gradient gel was used to resolve dystrophin and cas9 proteins. In 
preparation of the gel, the comb was removed and wells washed with ddH20. In addition, a 
white adhesive strip sealing the foot of the gel was removed. Gels were then placed in the X-
Cell Blot tanks vertically. Then a 10μl sample of the 4x master stock of each protein sample 
was loaded alongside, a pre-stained Hi-Mark ladder. The surrounding tank was filled 
approximately 1cm from the top with 1X Tris-Acetate buffer and 500μl of antioxidant was 
applied immediately prior to the initiation of electrophoresis. The gel was run for 
approximately 1 hour and 15 minutes at 150V, in accordance with the Nupage technical guide. 
The blue loading dye reaching the ‘foot’ of the gel and the ladder separation were parameters 
by which sufficient separation was assessed. During this time blotting pads were soaked in 1x 
transfer buffer supplemented with 10% methanol and 1ml antioxidant. Filter paper and 
0.45μM nitrocellulose membranes were cut to correct size for the transfer.  
2.15.5 Electro-transfer to Nitrocellulose Membrane. 
Upon suitable separation of the ladder and by extension the proteins, the Nupage Electro-
transfer cassette was prepared in accordance with the protocol: Diagram included below 
(Taken from NuPage Technical guide 2013): 
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Once pre-soaked blotting pads were applied to the bottom of the electro-transfer cassette, the 
3-8% Tris acetate gels cases were ‘cracked’ open to liberated the polyacrylamide gels. The top 
of the gel, above the top band of the Hi-Mark ladder was removed and disregarded. The 
remainder of the gel was then floated using the buffer to be situated above the filter paper, 
lifted out of the transfer buffer and transferred to the cassette. Once performed, the 0.45μm 
nitrocellulose membrane was submersed in buffer and placed on top. This was then rolled 
across the surface of the gel using a plastic roller to ensure tight contact throughout. A filter 
paper and a blotting pad placed on top. The whole cassette was kept wet during this time. If a 
second gel was the present then process was repeated. When completed this was placed in 
the X-Cell tank. The top of the electro-transfer cassette was refilled with buffer and the 
surrounding area filled with cold ddH20. The proteins were then transferred for 2 hours at 
30V.  
2.15.6 Post-Transfer Nitrocellulose Membrane Checks and Blocking  
Following the two hour transfer, the membrane is stained with 1X Ponceau. This stains all 
proteins across the lanes and is used to ensure that the transfer was complete and successful. 
The stain was then washed off with 0.1% PBS-T, washing at 5 minute intervals until no stain 
was visible.  
The nitrocellulose membrane was then blocked with 5% (w/v) Marvel milk in 0.1% (v/v) PBS-
Tween for 1 hour at room temperature, to prevent non-specific binding.  Once the membrane 
was blocked, the membrane was incubated at 4°C shaking overnight in a suitable dilution of 
primary antibody. 
2.15.7 Visualisation of the Nitrocellulose Membrane: The ECL Method 
The nitrocellulose membrane was then subject to 4 washes with 0.1% PBS-T for 5 minutes and 
incubated with a conjugated HRP antibody diluted to 1in 2000 in 5% milk, made with 0.1% 
PBS-T at room temperature for 1 hour, whilst gently shaking at 60 rpms. 
Post incubation the membrane was washed a further 4x for 5 minutes in 0.1% PBS-T. Once 
clean, 3mls of ECL solution 1 and 2 were mixed. Immediately on mixing the solution was 
applied to the nitrocellulose membrane. This was incubated for 1 minute at room 
temperature, blotted try and transferred to an X-ray cassette for development.  In order to 
visualise the blot, the film was placed into contact with the membrane for defined timed 
intervals, e.g. 30 seconds, 1 minute and then placed through the developer, until a blot was 
observed. Cas9 protein western blots were developed for 3 seconds. 
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2.15.8 Visualisation of the Nitrocellulose Membrane: The Odyssey Method 
This method also requires 4 washes for 5 minutes. In this instance however, the secondary 
antibody is conjugated to a fluorescent label that requires a 1 in 10,000 dilution prior to the 1 
hour incubation. This was then scanned at 700nm and 800nm channels respectively. 
Ordinarily, the protein of interest would be present within the 800nm channel, such as 
dystrophin and the loading control which is by nature more abundant within the 700nm, this 
being alpha tubulin.  
2.16 Quantification of Dystrophin 
2.16.1 Software 
 Image Studios Version 4 (Li-Cor) 
2.16.2 Methods 
The nitrocellulose membrane was then visualised with Image Studios Version 4. Bands were 
automatically identified using the software, and adjusted to be tight to the band in question in 
individual 800nm and 700nm channels. User defined noise values were subtracted away from 
the band in question and used to attain intensity values, for both dystrophin (800nm) and α-
tubulin (700nm). An image is included for reference below.  The values were normalised to 
tubulin: 
𝐷𝑦𝑠𝑡𝑟𝑜𝑝ℎ𝑖𝑛 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝛼 − 𝑇𝑢𝑏𝑢𝑙𝑖𝑛 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
= 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑉𝑎𝑙𝑢𝑒𝑠 
This was performed for each lane and the native and optimised dystrophin (n=5) and a mean 
value was attained. Once mean values were attained the Sequence optimised dys/tub ratio 
was normalised to the native dys/tub, to establish a fold difference in expression.  
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2.17  Polymerase Chain Reactions (PCR) 
A standard three stage polymerase chain reaction: Denaturation, Primer annealing and 
Extension, was undertaken throughout the course of this investigation. The general materials 
and methods are outlined here. Specific amplification reactions will be outlined in their 
respective sections. 
2.17.1 Materials 
 2X PCR Master mix (GeneSys Ltd) 
 GoTaq G2 Flex (Promega) 
 Hotstart Phusion Flex (NEB) 
 Thermocycler (VWR) 
 Primers (Eurofins MWG /IDT) 
 dNTP mix 100mM (Bioline) 
2.17.1.1 General Polymerase Chain Reaction Methodology: 
All primers were bought from Eurofins MWG and or IDT and diluted to 100pmol/μl and subject 
to a further 1 in 10 dilution to attain a stock [10μM], prior to being used in standard PCR 
reactions. All PCR amplification reactions were supplemented with 250ng genomic DNA or 
100ng of plasmid DNA. In addition, the annealing temperatures were determined 
experimentally for individual primer pairs using temperature gradients and the extension times 
were calculated in accordance with the polymerase manufacturer’s protocol.  
2.17.1.2 Colony PCR with the 2x PCR Mastermix (GeneSys Ltd) 
This master mix contains all necessary constituents for a PCR: Magnesium, free nucleotides, 
Taq polymerase, Red Buffer/loading dye. All constituents are in propriety amounts and require 
only a 2-fold dilution, to attain suitable concentrations for amplification. A standard PCR 
reaction comprises: 12.5μl master mix, 1μl of forward and reverse primer and 9.5μl of ddH20 
to attain a final volume of 25μl.  
2.17.1.3  Amplification Using GoTaq G2 Flex 
This polymerase had relatively low fidelity, and was used for general amplification procedures. 
The standard PCR reaction comprised:  1.5mM Magnesium Chloride, 0.2uM forward and 
reverse primers, 0.2mM dNTP mix, and 0.05 u/μl Gotaq G2 Flexi polymerase.  This equated to 
1.5ml Magnesium chloride, 0.5μl forward and reverse primers, 0.5μl dNTP mix and 0.25μl of 
GoTaq G2 flex in a 25μl reaction.  
2.17.1.4 Amplification Using HotStart Phusion Flex  
This polymerase has approximately 50x higher fidelity than Taq polymerase, thus it was used 
for amplification for mismatch detection assays. The 5x high fidelity buffer was already 
supplemented with 1.5mM Magnesium. Thus the PCR reaction comprised:  0.5μM of forward 
and reverse primers, 0.2mM free dNTPs and 0.02u/μl of Hotstart phusion polymerase. These 
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concentrations were often achieved in a 50μl total reaction volume, these reactions were 
produced in triplicate, allowing for purification and enrichment processes to be undertaken. 
2.18 Mismatch Detection Assays: 
Mismatch detection assays were used to analyse amplicons spanning the target site for the 
presence of small Insertions or Deletions (InDels). The presence of InDels indicates that the 
NHEJ DNA pathway has been active and thus can be used as a proxy for gene modification. As 
such DNA extracted from treated cell cultures, progress through 4 stages: 
 Asymmetric amplification of the genomic locus of interest. 
 Hybridisation of the resultant heterogeneous amplification, containing: homogeneous 
W.T amplicons – absence of InDels and heterogeneous modified amplicons – InDels 
are present – heteroduplexes are present. 
  Incubated with Surveyor / T7E1 enzymes to cleave heteroduplexes. 
 Resolve samples by agarose gel electrophoresis or Poly Acrylamide Gel 
Electrophoresis (PAGE) 
2.18.1 Materials 
 Surveyor Nuclease 100 reaction Kit (Transgenomics) 
 T7 Endonuclease I (NEB) 
2.18.2 Human Intron 1 High Fidelity PCR: 
2.18.2.1 Primers for Assessing Guides 1,2 and 4 
Primer Name Primer Sequence 5’-3’ Amplicon Size (Bp) 
hINT1 1960F 
hINT1 2471R 
CTTAACCATTTTGAGGGGTAAGTTT 
CTTGATCTTTGAATGAAGTTGGTCT 
512bps 
The Human Intron 1 amplification was performed in triplicate 50μl reactions with HotStart 
Phusion Flex (see section 15.1.4).  
The cycling conditions: Denaturation 98°C  30 s, 35 cycles – (98°C 10s, 63°C 30s, 72°C 24s), 
Final Extension 72°C 10 minutes and held at 4°C. 
2.18.2.2 Primers for Assessing Guide 3 
Primer Name Primer Sequence 5’-3’ Amplicon Size (Bp) 
hINT1 1960F 
hINT1 2541R 
CTTAACCATTTTGAGGGGTAAGTTT 
CTTTGTTGAGTACTGCACTTCCAGTC 
582bps 
 The cycling conditions: Denaturation 98°C  30 s, 35 cycles – (98°C 10s, 63°C 30s, 72°C 24s), 
Final Extension 72°C 10 minutes and held at 4°C. 
2.18.3 Mouse Intron 1 High Fidelity PCR: 
2.18.3.1 Primers for Assessing Mouse Guides 1 -5 
Primer Name Primer Sequence 5’-3’ Amplicon Size (Bp) 
hINT1 1950F 
hINT1 2775R 
CTTAACCATTTTGAGGGGTAAGTTT 
CTTGATCTTTGAATGAAGTTGGTCT 
556bps 
The cycling conditions: Denaturation 98°C  30 s, 35 cycles – (98°C 10s, 60°C 30s, 72°C 24s), 
Final Extension 72°C 10 minutes and held at 4°C. 
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2.18.4 Surveyor Assay 
Cell cultures were transiently transfected with U6-driven guides and Cas9 nuclease, and 
incubated for 48 hours prior to a DNA extraction. The DNA samples were amplified from both 
treated samples and cells incubated in the presence of transfection reagent alone, in a 50μl 
PCR reaction using primers asymmetric with regard to the target site. The PCR amplicons were 
then hybridised using the following transgenomic ‘surveyor hybridisation programme’ 
protocol: 
95 ºC for 10 min then 95 ºC to 85 ºC (-2.0 ºC/s)  
85 ºC for 1 min then 85 ºC to 75 ºC (-0.3 ºC/s)  
75 ºC for 1 min then 75 ºC to 65 ºC (-0.3 ºC/s)  
65 ºC for 1 min then 65 ºC to 55 ºC (-0.3 ºC/s)  
55 ºC for 1 min then 55 ºC to 45 ºC (-0.3 ºC/s)  
45 ºC for 1 min then 45 ºC to 35 ºC (-0.3 ºC/s)  
35 ºC for 1 min then 35 ºC to 25 ºC (-0.3 ºC/s)  
25 ºC for 1 min and finally hold at 4 ºC. 
Once hybridised 6μl, 12μl and 18μl aliquots of samples were pipetted into PCR tubes and 
supplemented with 1μl enhancer and 1 or 2μl of surveyor nuclease. These were then 
incubated at 42°C for 1 hour and stopped with 0.9, 1.5 and 2.2μl of the stop solution 
respectively.  
2.18.5 The T7 Endonuclease I 
Amplicons of transiently transfect samples as described in 1.16.2, were more routinely assayed 
with T7 Endonuclease I. This is an alternative to the Surveyor enzyme with the propensity to 
cleave heteroduplexes formed upon hybridisation. 
The human DMD intron 1 PCR was undertaken in triplicate and the three resultant 50μl 
reactions pooled. The total 150μl PCR volume was then subject to Qiaquick PCR purification, in 
accordance with the manufacturer’s protocol and eluted in 50μl of ddH20.  The resulting 
concentration of the amplicon was quantified with the use of the nanodrop.  
Once quantified a standard digestion in a PCR tube comprised: 2μl of NEB Buffer 2, 400ng of 
sample amplicon and ddH20 to attain a final volume of 19μl. Samples were then subject to the 
‘surveyor hybridisation’ programme.  
Upon completion of the hybridisation programme, 1μl of T7 Endonuclease I was added and the 
reaction was incubated at 37°C for 30 minutes. This was then stopped with 2.5μl of 1.5M 
EDTA.   
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2.19 Indel Quantification Approaches 
2.19.1 Gel Based Quantification Methods: 
2.19.1.1 Materials  
 10% TBE Polyacrylamide gels (ThermoFisher) 
 1x TBE buffer. 89 mM Trizma base, 89 mM boric acid, 2 mM EDTA pH 8.0. 
The total volume of digested sample (or 17μl volume remaining after the removal of 3μl for 
Agilent analysis) was either resolved by standard agarose gel electrophoresis (see section 
1.6.1.3), or by PAGE gel electrophoresis. 
 In the case of precast 10% TBE polyacrylamide gels; the gel was prepared, by removing the 
comb and washing wells with ddH20. In addition, a white adhesive strip sealing the foot of the 
gel was removed. This was then carefully loaded with T7E1 digested amplicons. The gel was 
then resolved at 200V until the loading dye reached the foot of the gel after 30- 45minutes.  
Once resolved the gel would be extracted from the pre-cast cassette and incubated with 1x 
TBE buffer supplemented with 0.02% SYBR Safe, in the dark for 1 hour. This was then rinsed 
with 1X TBE and visualised under U.V. If successful, the image captured would then be 
analysed with the use of Image J software. 
2.19.1.2 Image J analysis 
Gel images of samples resolved following analysis with the mismatch detection assay, were 
opened with Image J software. This software uses boxes positioned to identify bands, using the 
number of pixels to provide a histogram plot. To allow for a more accurate determination of 
gene modification boxes were drawn the full length of the lane.  The resultant histogram 
showed peaks for uncut amplicon, cleavage product 1 and 2, as well as for any residual noise.  
Lines were drawn under the base of each peak and gene modification was calculated using the 
following formula:  
% 𝐺𝑒𝑛𝑒 𝑀𝑜𝑑𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 = (1 − (1 − 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑐𝑙𝑒𝑎𝑣𝑒𝑑)0.5) ∗ 100 
Equation 1: An equation used to determine gene modification at a particular locus. 
 
Where the fraction cleaved is calculated by:  
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑐𝑙𝑒𝑎𝑣𝑒𝑑
=  
𝑇𝑜𝑡𝑎𝑙 𝐶𝑙𝑒𝑎𝑣𝑒𝑑 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠 (𝐼𝑛𝑑𝑖𝑐𝑎𝑡𝑖𝑛𝑔 𝐻𝑒𝑡𝑒𝑟𝑜𝑑𝑢𝑝𝑙𝑒𝑥 𝐷𝑒𝑛𝑠𝑖𝑡𝑦)
𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑠: 𝑇ℎ𝑒 𝑠𝑢𝑚 𝑜𝑓 𝑡ℎ𝑒 𝑢𝑛𝑒𝑑𝑖𝑡𝑒𝑑 𝑎𝑚𝑝𝑙𝑖𝑐𝑜𝑛 𝑎𝑛𝑑 𝑐𝑙𝑒𝑎𝑣𝑒𝑑 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠
 
Equation 2: An equation used to determine the fraction cleaved in order to determine the percentage of gene 
modification. 
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This calculation is performed to account for the fact that any in-situ hybridisation resulting in 
heteroduplex formation, comprised of one wild type strand and one mutated strand. The 
above system of quantification was previously presented by (Guschin et al. 2010), it is this 
method of quantification this study followed.  
2.19.2 Agilent Bioanalyser Analysis 
 Agilent Bioanalyser 
 DNA High Sensitivity Chips 
2.19.2.1 Preparation of DNA Dye-Gel Mixture 
To prepare Gel-Dye mix for the Agilent chip, the DNA dye concentrate and DNA gel matrix 
were allowed to equilibrate to room temperature for 30 minutes. The DNA dye was subject to 
a 10s pulse vortex at maximum speed using a bench-top microcentrifuge. A 25μl volume of the 
DNA dye mix was then aliquoted into the DNA gel matrix vial, and vortexed. This was then 
spin-filtered from 15 minutes at 6,000rpm. If this DNA Dye-gel mix was to be stored, it would 
be wrapped in foil to reduce light exposure and stored at 4°C.  
2.19.2.2 Loading the Agilent Chip 
If using pre-prepared DNA dye-gel mix, this was allowed to 
equilibrate at room temperature for 30 minutes. Once at room 
temperature, the high sensitivity DNA chip was placed in the 
priming station and 9μl of this mixture was then pipetted into the 
bottom –right well labelled with a white G encased in a black 
circle. A fresh syringe was placed in the priming station, which 
was set at the lowest priming position and 60 seconds was put on 
a timer. This was then depressed for 60 seconds, until it was held 
in place by the metal clip; allowing the DNA-gel mix to travel 
through the capillaries of the chip.  Once the 60 seconds had 
passed, the metal clip was released, and the plunger left for 5 
seconds before being pulled back to the 1ml position. 
The primer station was then opened and 9μl of the DNA Dye-gel 
mixture pipetted in the middle and top right wells labelled with black Gs . Following this 1μl of 
the yellow capped ladder was placed into the bottom right of the chip which has a ladder 
symbol. Then 5μl of DNA marker was pipetted into all remaining wells. Then 1μl T7 
Endonuclease I enzyme mismatch assayed samples were loaded into the wells. No wells were 
left empty, if there were insufficient samples the well was loaded with 1μl ddH20. The chip 
was then vortexed for 60 seconds at 2400rpm and read within 5 minutes. 
84 
 
2.19.2.3 Running Samples 
The chip was then removed carefully, from the vortex and placed in the Agilent receptacle. The 
lid was carefully closed, and a High Sensitivity DNA analysis was selected from the menu. The 
programme was started and progressed in an automated fashion. Once the analysis was 
complete electrodes were cleaned with 350μl of ddH20 in a designated chip and air dried for 
10 seconds. The results for each sample was shown in the form of a histogram; the area under 
each peak identified (uncut, cleaved product 1 and 2) being proportional to concentration of 
DNA fragment present.  The histograms were therefore analysed and exported alongside 
pseudo-gel images. 
2.19.3 Tracking of Indels by DEcomposition (TIDE) 
Finally, computational software was used to analyse the presence of InDels in an amplicon. 
This was reliant upon sequencing of amplicons using 2μl of hINT1 1960F primer (as described 
in section 1.7.4.2). The resultant ABI or SCF files from Eurofins MWG were downloaded for 
wild-type and treated samples. Multiple mock and treated sequence traces were aligned using 
the TIDE web tool, and the mean decomposition of the trace detected was used as a proxy for 
gene modification (Brinkman et al. 2014). 
This alignment was performed under default parameters of: Alignment window left boundary 
100bps upstream of break point and right -10 bps. Decomposition window left boundary max 
INDEL and 5bps downstream from breakpoint, right boundary 5bps upstream of shortest 
amplicon. InDel size range 10bps. p- Threshold value: p<0.001. 
2.20 In Vitro Transcription of mRNA guides 
In order to produce single chimeric RNA guides with the ability to associate with Cas9 and 
mediate DNA cleavage, the following primers were ordered from IDT, USA. 
Forward Extended DNA Primer Guide 1:  
GAAATTAATACGACTCACTATAGG (AGACTAAGAACCAGATGCTA) GTT TTA GAG CTA GAA ATA 
GCA AG  
Reverse Invariant Extended DNA Primer:  
AAAAAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTA GCCTTATTTTAA CTT GCT 
ATT TCT AGC TCT AAA AC  
Figure 1: Hybridisation of Extended DNA primers: 
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The forward extended DNA primer is guide specific, whereas the reverse is common to all RNA 
guide production; hence these were ordered as 4nM and 20nM customer ultramer primers 
with standard desalting. For subsequent reactions, they were re-suspended in DEPC treated 
water to a concentration 100pmol/μl, in 40 and 200μl respectively.  
The primers are subject to a standard 3 step PCR, where a 5’ region of the tracrRNA proximal 
to the cRNA (20nt guide without PAM) hybridises to one another. During the amplification 
process a linear double stranded PCR amplicon with a functional T7 promoter is produced, this 
is highlighted in blue. This amplicon can subsequently be processed for In vitro RNA 
transcription. 
2.20.1 PCR Amplification and Purification of Extended Guide 
Oligonucleotides: 
2.20.1.1 Materials 
 Hot Start Phusion Flex (NEB) 
 DEPC Treated Water 
 10mM dNTP (Bioline) 
 Forward and Reverse oligonucleotides (IDT) 
 Qiaquick PCR purification (Qiagen) 
In order to produce a double stranded DNA amplicon, the following 50μl reaction mixture was 
produced in triplicate: 36μl DEPC treated water, 5μl HotStart Phusion Buffer, 10mM dNTP 
2.5μl, 0.5μl of forward and reverse oligonucleotides at F 100pmol/μl, and 0.5μl HotStart 
Phusion Flex DNA polymerase. 
Denaturation 98°C  30s, 35 cycles – (98°C 10s, 54 °C 20s, 72°C 30s), Final Extension 72°C 5 
minutes and held at 4°C 
Post amplification the 50μl PCR products were pooled into an Eppendorf, giving a total volume 
of 150μl. This was then purified using a QiaQuick PCR purification kit, in line with 
manufacturer’s protocols. The final elution volume of 50μl DEPC water was then nanodropped 
and to ensure the concentration was in the range of 150 – 200ng/μl.  
2.21 In Vitro RNA Transcription of Guides and Clean-up: 
2.21.1.1 Materials 
 100mM free NTPs [ATP, CTP, GTP and UTP] (NEB, UK) 
 T7 RNA Polymerase (NEB) 
 Murine RNAse inhibitor (NEB) 
 DNAse (NEB or Quiagen) 
Once the PCR amplicon has been purified, the following reaction should be set up at room 
temperature: 18.5μl DEPC-treated water, 28μl 50mM MgCl2, 4μl of 100mM each NTP [ATP, 
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CTP, GTP and UTP], 10μl T7RNA buffer (NEB,UK), 10μl T7RNAP, 2.5μl RNAse Inhibitor, 15μl PCR 
amplicon [100ng/μl]. This would then be incubated at 37°C for 16 hours, prior to being 
maintained at 4°C until the sample can be processed. 
The RNA would then be DNAse treated with 10μl 10x DNAse Buffer and 1μl of DNAse (NEB, 
UK) at 37°C for 30 minutes.  
Optional isopropanol precipitation step: the reaction mixture was treated with 2.5x 
isopropanol absolute and incubate at -20°C and then centrifuge at 13,000 rpm for 10 minutes, 
aspirate the supernatant and allow to air dry. This was omitted in general production of mRNA. 
Then 500μl of PB Buffer was added, the RNA pellet was re-suspended and work progressed to 
the QIAquick PCR Purification Kit, in accordance with the manufacturer’s protocols. Once 
completed RNA was eluted in 30μl of DEPC-treated water and samples stored at -80°C. 
2.21.1.2 Functional Validation of RNA Guides: 
To assert that the chimeric mRNA guide produced is functional, 2.5μg of mRNA was transiently 
transfected into HEK293T.Cas9 cells via a 3:1 Lipofectamine Messenger Max reagent to DNA 
ratio (See section 1.10 and 1.10.4). Following a 48 hour incubation, DNA was harvested via the 
DNAeasy Blood and Tissue Kit, amplified and subjected to T7E1 mismatch detection assay 
(section 1.16.4).  
2.22 In Vitro Transcription of Cas9  
2.22.1 Materials  
 Qiaquick PCR purification 
 T7 Ribomax Large Scale RNA production system (Promega, UK) 
 RNAeasy  Mini-prep Kit (Qiagen) 
Cas9 mRNA was produced using a T7 Ribomax Large Scale RNA production system. In this 
instance 10ug of Endofree Maxi prepared HC-Cas9 plasmid was linearized in triplicate for 10 
hours at 37°C with SpeI-HF (NEB, UK).  
The digest reaction comprised: 7μl DEPC-treated water, 2μl Cutsmart buffer, 1μl of Enzyme 
SpeI-HF and 10μl of DNA [1ug/μl]. Subsequent to this the reaction was maintained at 4°C then 
purified using QiaQuick PCR Purification, in accordance with the manufacturer’s protocols. 
Once completed the digest was eluted in 50μl of DEPC-treated water.  
Post purification, 5μl of mixture loaded with 1μl 5x Loading Dye onto a 1 (w/v) % agarose gel 
and visualised via gel electrophoresis using SyBr safe. This was to ensure the plasmid had been 
linearized and that no non-specific star activity had occurred. If the digest was suitable, an RNA 
In Vitro transcription reaction was set up consisting of: 40μl of DEPC-treated water, 20μl of T7 
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Transcription 5x Buffer, 5μl each of individual NTPs [100mM ATP, CTP, GTP and UTP], 10μl 
Linear DNA template [1ug/μl], and 10μl of T7 Enzyme Mix This was incubated at 30°C for 3.5 – 
4 hours. 
Following the transcription incubation the reaction was treated with RQ1 RNase-Free DNase, 
which was added 1 unit per μg of template DNA; this was then incubated for 15 minutes at 
37°C. Following the removal of any residual DNA, the reaction mixture was then applied to an 
RNAeasy Mini Kit. The process was carried out in line with the manufacturer’s protocol. Finally, 
the RNA was obtained in two sequential elutions of 50μl of DEPC water.   
The quality of the RNA produced was examined by Gel Electrophoresis, by loading 2μl of RNA 
with 2μl of 5x loading dye (Bioline) onto a 2.5% Agarose gel as outlined by the Ribomax 
protocol run alongside hyperladder III. Provided there was no evidence of RNA degradation, 
the RNA was quantified via nanodrop and frozen at -80C in aliquots to prevent repeat freeze 
thawing cycles.  
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2.23 Cas9 Protein Production 
2.23.1 Materials (Work Undertaken in Paris): 
 All Salts were obtained from Sigma Aldrich 
 Protease Ultra 1x Inhibitor (Roche) 
 FPLC Akta Purifier (GE Healthcare) 
 Instant Blue Dye (Expedeon) 
 Tris (2-carbocyethyl)phosphine hydrochloride solution (ThermoFischer) 
 Acrylamide (Euromedex) 
 Protein Ultra 15 concentrator spin columns (Amicon) 
 TEV protease (Made in the lab) 
 HisTrap Column (GE Healthcare) 
 12-14kDa Dialysis Membrane (Spetropore) 
 Sp Sepharose (GE Healthcare) 
 Superdex 200 (GE Healthcare) 
 Centrifuge (Hettich rotanta 460R) 
 Ultracentrifuge (70TI Beckmann) 
Heat shock transformation of BL21 Rosetta 2 competent E.coli, with 10-100ng pET-Cas9 
protein encoding plasmid was undertaken by Dr. DeCian. The resultant suspension was plated 
onto an agar plate supplemented with 50μg/μl kanamycin and grown overnight at 37°C to 
obtain single colonies. Once obtained a few colonies were inoculated into a 200ml starter 
culture of 2XYT media, with 50μg/μl kanamycin and 2% glucose. This was incubated at 
30°Covernight, prior to the OD600 being taken, a more substantial 2L culture of the 2XYT 
medium was inoculated with the starter culture until an initial OD600 was obtained. This was 
then grown at 37°C until an OD of 0.7 was achieved, this culture was then cooled in the cold 
room for 20 minutes induced with IPTG to a concentration of 0.2mM prior to being incubated 
for 3 days at 16°C.        
The sequential processes of bacterial lysis and Cas9 protein purification were undertaken with 
the support of Dr. DeCian. After the 72hour incubation, the bacteria were spun down to 
produce a pellet of approximately 15g. The pellet was washed in 1x PBS and re-suspended in 
80ml of lysis buffer comprising: 25mM Tris-oxaloacetate pH 8,  NaCl 500mM, Imidazole 20mM, 
Protease Inhibitor, 1mM TCEP, filtered using a 0.22μM vacuum filter. This suspension was then 
sonicated for 15 minutes, using a 1s on, 1s off on ice, prior to spinning once more.  The 
resultant lysate was then loaded onto a pre-equilibrated HisCrude FF 5ml column, overnight 
with the use of the Akta, and a 100ml wash is undertaken after the full lysate is loaded. Post 
loading the his-tagged Cas9 protein would be immobilised by its affinity for nickel, present in 
the column and protein contaminants would have been washed through. To liberate the Cas9 
protein of interest an elution buffer with the same constituents of the lysate buffer but an 
increase in imidazole to 250mM was loaded to the column, the Imidazole out competes the 
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Cas9 for the nickel moieties thereby eluting the Cas9 protein. Normally elution occurs over 8 
column volumes, 40mls was used to elute the Cas9 protein in 3ml sequential fractions from 
the point of elution buffer entry into the column.  A 2μl aliquot of each of the fractions was 
visualised on 8% SDS-PAGE and visualized with instant blue.  This combined with absorption 
peaks at 260nm and 280nm, was used to ascertain which column fractions the Cas9 protein 
was present to be pooled and enriched  
The protein eluted from the crude HisTrap column was concentrated using 100kDa amicon 
inserts into a 50ml falcon spun at 4600rpm for 20 minutes. Anything 100kDa protein or smaller 
will pass through the filter into the flow through, whereas the 150kDa Cas9 protein will remain 
in the supernatant. In this manner the crude Cas9 protein was concentrated to 3ml. This was 
then subject to  MBP cleavage using the TEV protease and dialysed using a 12-14kDa 
membrane (spectrapore)  in 2L 1X dialysis buffer in a large burette.  This buffer comprised: 
20mM Hepes NaOH pH 7.5, 100mM KCl, 10% Glycerol and TCEP 1mM, one again all passed 
through a 0.22μm filter. The protein was then concentrated once again and then subject to 
ion-exchange chromatography using a 2ml SP sepharose column. This ion-exchange step is 
considered optional for many protein purification protocols, however, it is used to remove the 
MBP tag and free nucleotides DNA/RNA contamination perhaps pertinent when considering 
the Cas9 protein hybridises to RNA.  The positive cas9 protein binds to the negatively charged 
beads during the loading process. The Cas9 protein is then eluted by the addition of varying 
concentrations of Buffer B, this being the same as A with the addition of a 10 fold increase in 
KCl to the concentration of 1000mM.  Initially, there is a two column volume addition of 
elution gradient of 10-38%, 38-80% and finally 80-100%. As before 2μl aliquots of the eluate 
and the increase of the 260-280ratios was used to indicate the fractions Cas9 protein was 
eluted in  
The previous purification gave rise to two pools of Cas9 protein, pool 1 deemed slightly purer 
and pool 2 which likely is still pure but requires examination for contamination. In this manner 
the two pools of MBP-cleaved and enriched protein were further enriched using amicon filters 
as previously described, initially the 400μl of the purer sample was loaded in two tranches to 
the superdex size exclusion column equilibrated using 5% Buffer B. Notably, this column does 
not have a loading and elution process rather all protein loaded travels at different speeds 
through porous beads depended upon their size. Smaller contaminants and proteins are eluted 
sooner. This serves to provide a homogenous suspension of 150kDa Cas9 protein. Similarly to 
the previous purification processes, 2μl of protein eluted was visualised on an 8% SDS-PAGE 
gel, at this stage samples were deemed pure and adjusted to 30μM and 90μM concentrations 
for the purer preparation denoted P108 and the second pool denoted P109. At this stage the 
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Cas9 protein was considered pure and concentrated to achieve a desired concentration of 
4.7mg/ml, aliquoted to 20μl and snap frozen in liquid nitrogen.   
2.23.2 In Vitro Cleavage Assay using Cas9 protein and In Vitro Transcribed 
RNA: 
Ribonucleoprotein complexes were generated by mixing in vitro transcribed T2-GFP guide RNA 
and Cas9 protein. The resultant RNP was generated at 5, 15, 50 and 150nM concentrations. 
This was then incubated with a Vgej-AAV with XmnI linearised plasmid encoding a GFP target 
sequence at 5nM, for either 30 minutes or 1 hour at 37°C. The resultant reaction was stopped 
using: 40μl RNAse A (Invitrogen 20mg/ml), 50μl Sucrose 800μ/μl and 40μl Proteinase K (NEB). 
The cleavage products were then resolved on 0.8% agarose gel with ethidium bromide.    
2.24 Zeocin Selection Methods  
2.24.1 Materials 
 Zeocin 8 x 1.25ml (Invitrogen) 
2.24.2 Generation of a Zeocin Kill-Curve: 
Following passaging, cells were plated in duplicate at a density estimated to provide between 
25-35% 24 hours post seeding: HEK293T 1.7x 105 and patient myoblasts 8.3 x 104. In each 
instance, 24 hours post seeding growth media was removed and replaced with fresh media 
supplemented with incremental concentrations of zeocin.  The standard concentration range 
was: 0, 50, 100, 200, 400, 600, 800 and 1000μg/ml. In order to ensure the cells were under 
constant selection, 1ml of the growth media was removed from each well and replaced every 3 
days with 1ml of fresh growth media supplemented with an appropriate concentration of 
zeocin. 
 The seeding of cells in incremental concentrations of zeocin was denoted Day 0; microscopy 
images were subsequently taken at day 3, 7, 10, 14, and 21 respectively. This was to gradually 
examine morphological changes and any cellular de-attachment that may take place as a 
consequence of zeocin exposure over this time period and to assess whether cell cultures 
showed reduced viability in the presence of this antibiotic. 
2.25 Production of Polyclonal MD1 Cell lines 
HEK293T cells and Patient myoblasts were subject to a standard Viafect transient transfection 
of U6-Guide 1-CBh-Cas9-2A-GFP and hINT1-MD1-RT, at 2μg: 2μg or 4μg: 2μg. These were 
incubated at 37°C at 5% CO2 for 48 hours, and then the cultures were examined for the 
presence of green fluorescence. This was used as a visual indicator of Cas9 nuclease 
expression.   
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If Green fluorescence was present, cells were passaged. To achieve this media was aspirated, 
each well was washed with 500μl 1x sterile PBS, before the addition of 500μl of 1x Trypsin. 
Once trypsin was applied to the 6 well plates, they were incubated at 37°C for 2 minutes.  Post 
incubation the trypsin was neutralised with 2ml of appropriate growth media. The cell 
suspension was then transferred to a 15ml falcon tube, which was centrifuged at 1000rpm for 
5 minutes, before cells were re-suspended in 3mls and counted. Following this process treated 
HEK293T and patient myoblasts were seeded at cell densities of 1.7 x 105 and 8.4 x 104 
respectively.  HEK293T samples were seeded in duplicate across two plates; this was to reduce 
the risk of contamination and to allow the cells to be exposed to two antibiotic doses of 600μg 
and 800μg respectively. This process was repeated with patient myoblasts except with doses 
of 800μg and 1000μg.  
Seeding the cells in the presence of zeocin was classed at Day 0 of selection. To maintain 
selection 1ml of the growth media was removed from each well and replaced every 3 days 
with 1ml of fresh growth media supplemented with an appropriate concentration of zeocin. In 
addition cultures were the subject to microscopy imaging at 3, 7, 10, 14 and 18 days 
respectively.  This was performed to examine visual differences in growth between the wild-
type and treated cultures, in the presence of zeocin. Patient myoblasts were unable to survive 
this process. In contrast, selection continued for HEK293T. 
By day 20, wells showed evidence of ‘patchy’ confluence where localised plaques had formed 
within wells. The cells were therefore passaged and split 1 in 2, and grown under continued 
zeocin selection until confluency was attained being photographed at 24 and 27 days. Once 
confluent these plates were split 1 in 2 again.  The cells from 3 of the 4 x 6 well plates were 
harvested for DNA, RNA and Protein.  
The cells from the fourth plate were counted: a proportion was used to generate a monoclonal 
culture, the remainder were placed in cryovials in a Mr Freezie at -80°C overnight and 
transferred to liquid nitrogen for long term storage.  
2.26 Generation of HEK293T-MD1 Monoclonal Cultures 
2.26.1 Materials 
 Cloning Discs (Sigma; 50 discs/tube) 
 Crystal Violet Powder (Sigma): 0.1g crystal violet, 80ml of ddH20 and 20ml of absolute 
methanol. (0.1% solution) 
 Sterile Forceps  
 Media supplemented with zeocin 
 1 X Trypsin (Gibco) 
 1 x Sterile PBS (Gibco) 
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 10cm Tissue Culture Dishes (Corning) 
 24 well plate (Corning) 
 
2.26.2 Culturing Cells at Low Density to Attain Single Colonies: 
To attain monoclonal cultures, the cells counted from the fourth six well plates in polyclonal 
cultures were serially diluted to cell densities of 105 and 104 in 10mls of cell growth media. 
These were then seeded into 10cm petri dishes in the presence of the concentration of zeocin 
antibiotic, reflective of the enriched polyclonal condition 600μg or 800μg for HEK293T/ 800μg 
or 1000μg for Δ45-55 patient myoblasts. When examined at 24 hours post seeding individual 
cells could be seen as attached to the dish with ample distances between them due to high 
dilution. These were cultured until individual colonies became 1 -3mm in diameter and could 
be seen by eye.  At this stage, microscopy images were taken at 25x magnification.  
2.26.3 Identification and Picking of Individual Colonies 
The 10cm petri dishes were held overhead and examined for individual colonies with sufficient 
spacing for picking. Once colonies were identified, cloning discs were poured into a separate 
clean petri dish, with 500μl of trypsin pipetted to the opposing edge of the dish.  
Once the materials were organised, petri dishes harbouring single colonies were carefully 
tipped to allow the media to be carefully aspirated, and colonies washed with 2ml 1x sterile 
PBS. Following washing the cloning discs were picked up with sterile forceps, dipped into 1x 
Trypsin and then applied to the colony of interest identified. This was performed for four 
colonies for each petri dish and incubated for 2 minutes at 37°C.  
During this 2 minute incubation, a 24 well plate was prepared with 1ml of growth media 
supplemented with antibiotic per well (at concentrations consistent with enriched polyclonal 
conditions, as described in 1.24.2). Once the incubation was completed colonies were picked 
off of the plate (attached to the cloning disc) and transferred into a well in the 24 well plate.  
Once four colonies were picked the remaining colonies were stained by adding 1ml of 0.1% 
crystal violet stain. The petri dish was inverted to ensure the stain attained maximum 
coverage, and then excess stain was washed away carefully with water. Prior to the dish being 
inverted and left to air dry.   
These cells in the 24 well plate were cultured and expanded until 4x 6 well plates were 
attained for the purposes of freezing a stock and DNA, RNA and protein extractions. 
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2.27 Molecular Characterisation of Colonies 
2.27.1 Integration PCRs 
2.27.1.1 Primers 
Primer Name Primer Sequence 5’-3’ Amplicon Size (Bp) 
LAH Out F 
LAH Out R 
GGAATGTACCTTCCTAATGTGATCA 
AAGGTTTTCTTCTGCACGTCC 
1291bps 
LAH In F 
LAH In R 
TGAAGCACAGATTCTACTTTCAGAG 
GAAAGGCAAAGTGGATGTCAGTAAG 
1139bps 
RAH Out F 
RAH Out R 
GCATCACAAATTTCACAAATAAAGC 
TGCGGTTTATTGACATTAAAGACAT 
1277bps 
RAH In F 
RAH In R 
TTTCACTGCATTCTAGTTGTGGTTT 
AAATTTGCAGCATAATTGGAAGTGT 
1171bps 
 LAH – Left Arm of Homology, RAH – Right Arm of Homology 
DNA harvests from excess cells at the 48 hour time point, polyclonal and monoclonal cultures 
were examined for the integration of MD1, by using primers that span from the intron 1 
genome into the exogenous repair template.  
2.27.1.2 Nested PCR 
At the 48 hour time point it was necessary to nest the PCR with outer and inner primers 
spanning the intron 1 genome – exogenous repair template junction. Standard PCR reactions 
were set up using GoTaq G2 Flexi with the outer primer sets across left and right junctions (see 
section 1.15.1.3).  
Cycling conditions:  Denaturation 95°C  2minutes,  20 cycles – (95°C 30s, 57 °C 30s, 72°C 90s), 
Final Extension 72°C 10 minutes and held at 4°C 
Toward the end of the amplification cycle, an amplification using the inner intron 1 primers 
was prepared and supplemented with 1μl of amplification product from the first round.  
Cycling conditions: Denaturation 95°C 2minutes, 35 cycles – (95°C 30s, 57°C 30s, 72°C 80s), 
Final Extension 72°C 10 minutes and held at 4°C. 
2.27.1.3 Single Round PCR 
For the later more enriched polyclonal and monoclonal populations a single round GoTaq G2 
flexi PCR using only the outer PCR primer primers across the intron 1 genome-exogenous 
repair junction was performed.  
2.27.2 Reverse Transcriptase PCR 
Total mRNA was harvested from polyclonal and monoclonal cultures, to examine the splicing 
between the Dp427m and Exon 2 of the MD1 exogenous repair template. Reverse 
transcriptase, is the key enzyme of the RT PCR and used to generate complimentary DNA 
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(cDNA) from total RNA lysate. Once the cDNA has been synthesised, it is then used as template 
for exponential amplification of a specific target sequence. 
To begin with, 500 µg of the total RNA lysate from polyclonal and monoclonal culture were 
was added to a reaction comprising: 1μl of Oligo-p(dT)15 [50μM] (Roche) and 1μl random 
primers 10pmol/μl [10μM] made up to 10μl with DEPC treated H20. This was then heated to 
70°C for 5 minutes and held at 4°C for 5 minutes, to eliminate the any secondary structures 
that may be present.  
Subsequently 10μl of a master mix comprising: 4μl (5x GoScript reaction buffer), 2μl MgCl2, 
2μl dNTPs and 1μl reverse transcriptase and 1μl DEPC treated water. To attain final 
concentrations of 1x buffer, 2.5mM MgCl2, 0.5mM dNTPs and 8 units of enzyme respectively.  
The cycling conditions: 25°C for 5 mins, followed by 42°C for 1 hr, 70°C for 15 mins and then 
held at 4°C 
In the next step, 1 µl of the cDNA was used as a template for a PCR reaction using primers 
across the Dp427m-Exon 2 genome-repair template junction.  
Primer Name Primer Sequence 5’-3’ Amplicon Size (Bp) 
hINT1 SC F 
hINT1 SC R 
TAGAGGACTGTTACGAGCGC 
TCCACGTTGTTGTTCTGCAG 
250bps 
 
Cycling conditions: 95°C 2minutes, 35 cycles – (95°C 30s, 57°C 30s, 72°C 80s), Final Extension 
72°C 10 minutes and held at 4°C. 
2.27.3  MD1 Western Blotting 
Total protein lysate was also obtained from polyclonal and monoclonal cultures, to assess MD1 
expression. Protein was quantified and each sample was prepared at a 50μg concentration. In 
instances where the protein was too dilute to attain 50μg, such as in repair template only 
conditions the maximal volume of protein was used in the production of mastermix. This was 
then subject to western blotting using the Odyssey system as described in section 1.14. 
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Chapter 3 In Silico Analysis of the 5’-End of the DMD Gene and 
Design of Customisable Endonucleases: 
3.1 Introduction 
3.1.1 Human DMD Gene  
The genetic aetiology of Duchenne muscular dystrophy (DMD) has long been understood, with 
the identification of the DMD gene being one of the prominent successes of positional cloning 
in the 1980s (Koenig et al. 1987). However, the complexity of the DMD gene has made 
correction of disease pathology challenging. Firstly, the DMD gene is sizeable, being 
approximately 2.4Mb in length and constituting 0.01% of the human genome. Spanning this 
region are 79 exons that encode a 14kb mRNA transcript, which is eventually translated to a 
427kDa full-length dystrophin protein (Koenig et al. 1987; Bushby et al. 2010a). Secondly, 
although it was first anticipated that dystrophin was a muscle-specific protein, it has since 
been determined that the DMD gene encodes numerous full-length and truncated isoforms, 
expressed in either muscle or brain tissues (Nudel et al. 1989; Nudel 2005). This is mirrored 
clinically by one third of patients exhibiting a non-progressive cognitive impairment in addition 
to the dystrophic muscle pathology prominent in the disease (Bushby et al. 2010a; D’Angelo et 
al. 2011).   
The long rod-shaped  dystrophin protein encoded by the DMD gene comprises four main 
domains: 1) N-terminal F-actin binding domain, 2) central rod domain of 24 spectrin-like 
repeats, interrupted into 3 sub-regions by 4 proline-rich hinges, 3) cysteine-rich domain which 
binds  dystroglycan and the DAPC, and 4) C-terminal domain involved in syntrophin and 
dystrobrevin binding (Koenig et al. 1988; Banks et al. 2010). These domains are all important to 
the structural link dystrophin provides between intracellular cytoskeletal actin and 
extracellular matrix, pertinent to muscle integrity (Allen et al. 2016). However, it has since 
been determined that in addition to its structural role, spectrin-like repeats 16 and 17 of 
dystrophin protein interact with neuronal nitric oxide synthase (nNOS) and 6 and 7 with Par1b 
signalling proteins (Lai et al. 2009; Dumont et al. 2015). Studies suggest nNOS has a role in 
modulating muscle hemodynamics, and Par1b in microtubule dynamics and asymmetric 
division in satellite cells. These activities and others serve to extend the anticipated functions 
of the dystrophin protein (Dumont et al. 2015).    
Beyond these features, further challenges to the development of genetic treatments are posed 
by the wide spectrum of mutation types that give rise to DMD, that result in the destruction of 
the open reading frame.  These mutation subsets include: large deletions (68%), duplications 
involving one or more exons (12%) and small mutations (20%) (Bladen et al. 2015). Notably, 
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these mutations are not uniform throughout the DMD gene. Rather they are clustered around 
two mutation hot-spots between exons 2 -20, and between exons 45-55, situated near genetic 
recombination points (Aartsma-Rus et al. 2006; Jarmin et al. 2014). As a consequence of this, 
genetic therapeutic strategies have largely been mutation-specific, and focused upon 
restoration of the open reading frame and conversion of a DMD phenotype to the clinically 
milder BMD-like phenotype, with the outlook of stabilising and slowing disease progression.  In 
contrast to DMD, BMD mutations retain the reading-frame of the transcript, and give rise to 
truncated dystrophin protein products with internal deletions (England et al. 1990; Aartsma-
Rus et al. 2006; Taglia et al. 2015). One notable example of a mutation-specific genetic therapy 
is exon skipping in which antisense oligonucleotides are delivered to block splice enhancer 
sites within dystrophin pre-mRNA, promoting the exclusion of specific frame-shifting exons 
and restoration of the open reading frame (Aartsma-Rus et al. 2009; Cirak et al. 2011; Jarmin 
et al. 2014). In contrast , universal gene augmentation strategies are normally reliant upon the 
delivery of full-length or truncated dystrophin cDNAs, driven by either viral or muscle-specific 
promoters (Romero et al. 2004; Le Guiner et al. 2017). This often results in expression of 
dystrophin at lower levels than that observed physiologically, with the extent of muscle 
correction being dependent upon the route of administration. Moreover, these gene based 
therapies may require repeat administration and may carry adverse immunological risks. 
In addition to the complexity of the DMD gene architecture and diversity of mutation types, 
dystrophin protein has a complex spatial expression profile. Shortly after discovering the 
muscle isoform of dystrophin protein,  a full-length dystrophin transcript was also identified in 
the brain (Nudel et al. 1989; Nudel 2005). It was quickly determined to be a distinct isoform, 
differing at the initiating exon and converging from exon 2 onwards to the previously identified 
full length sequence. This was originally denoted as a brain isoform, but the nomenclature was 
later revised to cortical upon the elucidation of two further isoforms expressed in the cortical 
and cerebellar Purkinje regions of the brain (Górecki et al. 1992).  Thus the full-length isoforms 
were referred to as Dp427c, Dp427m and Dp427p1 and Dp427p2, denoting cortical, muscle 
and Purkinje expression respectively. In addition to these full length variants, shorter DMD 
gene transcripts deriving from internally located promoters and with non-muscle expression 
patterns were also identified. These shorter transcripts encoded shorter protein isoforms 
including Dp260, Dp140, Dp116 and Dp71, with the numbers indicating the size of the protein 
in kDa (Bar et al. 1990; Byers et al. 1993; Lidov et al. 1995; D’Souza et al. 1995; Austin et al. 
1995). It should be noted that most therapeutic strategies aim to ameliorate the prominent 
muscle pathology of DMD by correcting or reintroducing expression of the muscle isoform.  
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Notably, our understanding of the DMD gene continues to evolve. Recently an internal 
ribosomal entry site (IRES) within exon 5 has been identified, and it is speculated that the DMD 
mRNA can be translated from this point in the presence of some 5’ gene mutations (Wein et al. 
2014). This serves to explain why some 5’ mutation types that are predicted to result in the 
DMD gene being out-of-frame, actually give rise to a BMD phenotype. In addition, a further 
dystrophin isoform Dp412e has also been recently discovered which initiates from a promoter 
active in embryonic cells (Massouridès et al. 2015). Continued investigation of the DMD gene 
architecture and scrutiny of reported findings over coming years is still warranted, particularly 
as historically a fifth full length isoform Dp427l, was identified in lymphocytes and later 
discredited on the basis of inconsistent splicing evidence and low physiological significance 
(Nishio et al. 1994; Wheway & Roberts 2003; Nudel 2005). Ongoing advances in our 
understanding of the DMD gene through dystrophin protein structure and function studies 
thus continue to inform and refine the development of new translational therapeutic 
strategies. 
At the genomic level, the current series of studies aim to assess the relative positions of the 
full-length DMD promoters (Dp427c, Dp427m, Dp427p1 and p2), and identify a putative intron 
1 genome editing target sequence common to all. It is anticipated that targeting this common 
intron 1 sequence with a customised endonuclease and an exogenous repair template would 
enable the reconstitution of dystrophin cDNA under the control of all endogenous promoters. 
It is speculated that this would enable correct spatial expression in cortical, muscle and 
Purkinje cells consistent with physiological levels observed. The exploitation of this could 
provide clinical benefit in the context of both the degenerative muscle pathology and the non-
progressive cognitive impairment. 
3.1.2 Murine Dmd Gene: 
Interestingly, even prior to identification and cloning of the human DMD gene and cDNA, a 
naturally occurring mouse model of DMD was identified with relatively mild dystrophic muscle 
pathology, this being the mdx mouse (Bulfield et al. 1984). However, prior to becoming an 
established animal model of DMD, an examination of the genetic aetiology was required. This 
initially proved elusive until a point mutation within exon 23 was identified resulting in a 
premature stop codon (Sicinski et al. 1989). Moreover, research into the murine Dmd gene, 
indicated it had a similar genomic localisation and expression profile to the human orthologue 
(Heilig et al. 1987; E. K. Brown 1987; Chamberlain et al. 1987; Chamberlain et al. 1988). Thus it 
is perhaps unsurprising that when a range of novel putative promoters driving expression of 
full-length dystrophin were identified within the human genome, analysis revealed parallel 
sequences were found in the mouse genome (Koenig et al. 1987; Nudel et al. 1989; Górecki et 
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al. 1992). In combination, the dystrophic phenotype and the similar genomic organisation of 
the DMD gene served to establish the mouse as an attractive model of DMD in the context 
both basic and translational research. 
Generally, mice are among the most favoured animal models. Pertinent to this is the 
comparable nature of the murine and human genomes, with 99% of human genes having a 
murine orthologue as discovered by the Human Genome Project and Mouse Genome 
Sequencing Consortium (Waterston et al, 2002). In addition to the high number of 
orthologues, 90% of human and mouse gene show conserved synteny, this being a comparable 
gene organisation or structure resulting from inheritance from a common ancestor (Waterston 
et al, 2002). Aside from these genetic factors, logistically, the small size of mice, quick 
maturation times and relatively easy husbandry, all serve to make them beneficial models to 
scientific research (Larcher et al. 2014; Whitmore & Morgan 2014; Manning & O’Malley 2015). 
The mdx mouse model is no exception and has remained the most favoured experimental 
animal model of DMD. This stated, there has been growing demand for animal models that 
exhibit more clinically representative phenotypes (Larcher et al. 2014; Whitmore & Morgan 
2014). As a consequence therapeutics are often tested in mouse as a small animal model prior 
to progressing to larger models with more dystrophic muscle pathology such as the Golden 
Retriever Muscular Dystrophy (GRMD) model (Nakamura & Takeda 2011). Interest has also 
shifted to the use of rat models (Nakamura et al. 2014; Larcher et al. 2014).  Most recently a 
CRISPR-generated rat model of DMD has been described (Huchet et al. 2017). 
Importantly, DMD orthologues are present in a multitude of mammalian and non-mammalian 
species and exhibit a high level of sequence similarity both at the DNA and protein levels as 
summarised in table 1. This is crucial to the development of representative clinical models and 
the translation of therapeutic strategies demonstrated in in-vitro cell cultures into in-vivo 
models. This investigation will utilise the comparable DMD gene architecture across both 
human and mouse species, aiming to assess and compare the genomic sequence of the DMD 
gene at the 5’ end to identify common endonuclease target sites in both species. This would 
enable the development of dystrophin cDNA integration techniques in human cell culture, with 
the outlook for expedited clinical translation through the mdx mouse model. This is proposed 
by the means of corrected human myoblast engraftment into immunodeficient mdx mice 
(Vallese et al. 2013), or indeed via direct viral-mediated effector gene delivery. 
  
99 
 
 
 
 
 
 
 
 
Table 1 The percentage sequence similarity of the DMD gene and Dystrophin protein, in a range of species 
relative to the human DNA and protein sequences. (NCBI Homologene 2015). 
3.2 Chapter Aims: 
This investigation is concerned with the development of a genome editing strategy with near-
universal applicability to DMD patients. This is to be achieved by customised endonucleases 
and an exogenous repair template compatible with a variety of full length minidystrophin and 
microdystrophin cDNA configurations, targeted to the 5’ end of the DMD gene, preferably 
intron 1. Previous work by our lab demonstrated that a cDNA block containing exons 45-52 
flanked by synthetic splice acceptor and donor sequences could be correctly introduced into 
DMD patient myoblasts harbouring deletions of the same exons, thereby restoring the full 
dystrophin mRNA open reading frame (Popplewell et al. 2013). Thus it is speculated that exon 
1 pre-mRNA sequence transcribed from the main full length endogenous promoters would be 
able to splice to dystrophin cDNAs delivered in a promoter-less exogenous repair template 
format with a suitable 5’-splice acceptor site. If site-specific integration was to occur, the 
dystrophin cDNA within this template would be expressed at physiological levels and mirror 
the spatio-temporal expression profile observed endogenously. Such expression could 
ameliorate all clinical phenotypes of DMD. 
To facilitate attainment of these outcomes, this chapter identified the initiating exons of full-
length dystrophin isoforms. These were mapped for both human and mouse genes, relative to 
exon 2 where all full-length isoforms have been determined to converge. An intron 1 sequence 
common to all dystrophin isoforms for both species was then subjected to a rigorous pairwise 
sequence alignment to assess sequence similarity.  
The identified region of sequence similarity was then assessed for the presence of 
Streptococcus Pyrogenes CRISPR/Cas9 guides and TALEN target sites, being common to the 
human and mouse genome, it was speculated that this would permit facilitated translational 
development. Further analysis was also undertaken for the presence of species specific 
Comparison to H. 
Sapiens 
% Sequence similarity 
Species DNA Protein 
P.Troglodytes 88.7% 85.2% 
C. Lupus 92.9% 94.9% 
M. Musculus 90.4% 91.3% 
G. Gallus 78.4% 79.0% 
D. Melanogaster 48.2% 39.0% 
A. Gambiae 48.2% 39.0% 
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endonucleases. Once suitable gene-editing designs were resolved upon, CRISPR guide 
expression plasmids were generated and this was later used to identify a gene-editing reagent 
able to introduce a DSB in intron 1 of the DMD gene with high efficiency.   
3.3 Results: 
3.3.1 Mapping the 5’ End of the DMD Gene to Locate Full Length Dystrophin 
Promoters and Exon 1 Elements Relative to the Common Exon 2 Sequence: 
Promoter motifs and downstream initiating exon sequences for each of the four human full-
length dystrophin isoforms were accessed on NCBI:  Dp427c NM_000109.3, Dp427m 
NM_00406.2, Dp427p1 NM_004009.3 and Dp427p2 NM_004010.3. The exon 2 where all full-
length dystrophin isoforms converge and exon 3 sequences were obtained in a similar fashion 
from the Dp427m isoform. Once all of the sequences were identified and downloaded in a 
standard FASTA format, they were subject to a Basic Local Alignment Search Tool (BLAST) 
analysis against the full human X-chromosome sequence [Homo Sapiens Chromosome X, 
GRCh37.p13 Primary Assembly (Accession NC_000023.10)].  
The full-length dystrophin isoform promoters were shown to occur in the following order on 
the X chromosome, Dp427c, Dp427m, Dp427p1 and Dp427p2, consistent with literature 
(Nudel 2005). Moreover, this analysis provided co-ordinates for all of the exons in question 
and by extension the intron 1 sequence common to all isoforms between Dp427p2 and exon 2, 
shown schematically in (Figure 3-1). Notably, the co-ordinates were consistent with the human 
DMD gene being encoded on the reverse strand, running in a 3’ – 5’ direction, as anticipated in 
accordance with the European Bioinformatics Institute (EMBL/EBI). The sequence spanning 
Dp427c to exon 3, with an additional 1kb flanking sequence, was downloaded in reverse 
orientation between the co-ordinates c33357826-33037000 of the X-chromosome. This 
ensured the sequence was obtained in a 5’ – 3’ orientation which was later confirmed via the 
Ensembl genome browser (Ensembl 2017).  
This sequence retrieval and evaluation process identified two intron sequences at the 5’ end of 
the DMD gene common to all full-length isoforms that would be suitable for targeting with 
customised genome editing reagents. The first sequence referred to as “common intron 1” 
spanned 107kb located between Dp427p2 and exon 2. The second sequence referred to as 
“common intron 2” spanned 170kb between exons 2 and 3.  In terms of selecting a target site 
for genome editing the preferred candidate sequence in this instance is common intron 1 due 
to its close proximity to endogenous promoters which is anticipated to be beneficial for 
splicing and to potentially increase the breadth of DMD mutation applicability. 
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Once candidate target sequences were identified for the human genome attention was shifted 
to the murine Dmd gene. The high sequence similarity of human and mouse exons enabled the 
derived human sequences to be utilised in BLAST analysis against the full murine X-
chromosome sequence [Mus Musculus Strain C57BL/6J Chromosome X, GRCm38.p1 C57BL/6J 
Primary Assembly (Accession NC_000086.7)]. As anticipated, corresponding promoter and 
exon 1 sequences were identified across the mouse X-chromosome occurred in the same 
order as on the human X-chromosome One important distinction between human and mouse, 
however, is that the murine Dmd gene is encoded on the forward stand of the mouse X-
chromosome. Thus in contrast to the human genome, the mouse coordinates attained in a 5’ - 
3’ orientation and the same common sequence between mouse Dp427c and exon 3 was 
downloaded directly between co-ordinates of 82815000-83317000 of the mouse X-
chromosome.  
In the case of the murine genome, this analysis served to identify a common intron 1  spanning 
93kb between Dp427 and p2 and a common intron 2 spanning 209kb between exon 2 and 3 
respectively. This disparity in intron size across human and mouse genomes is not uncommon 
and is often attributable to alternative evolutionary patterns (Waterston et al. 2002). 
Importantly, the different sized human and mouse common intron sequences had implication 
for the type of sequence analysis that can be performed. The two main forms of alignment are 
global in which the 5’ end of two sequences are ‘anchored’ and the alignment of the 
nucleotides occurs sequentially or local alignment where regions of high sequence similarity 
are identified and aligned regardless of their position in the sequence (McWilliam et al. 2013).  
On account of the different sizes it was decided the latter would provide a more suitable form 
of assessment.  
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Figure 3-1 Schematic diagram illustrating the sequential occurrence of the dystrophin full length 
promoters, and the identification of exon 1 and common intron sequences. 
 (A) A schematic diagram showing full length and truncated dystrophin isoforms, with their locations 
indicated relative to the exons of the full length DMD gene. The 5’ end of the DMD gene is then enlarged 
to show the sequential appearance of full length dystrophin promoters and exon 1 elements relative to 
exon 2. The introns that could provide candidate endonuclease target sites and site of dystrophin 
transgene integration, common to all full length isoforms between Dp427p2 and exon 2, and exon 2 and 
3 are indicated by red lines. B) A 345 nucleotide sequence excerpt from the rigorous ‘EMBOSS Matcher’ 
local pairwise alignment of human and mouse common intron 1 sequences: top human, bottom mouse.  
The numbers flanking the sequence refer to the relative position within the common intron sequences 
identified, being 14kb and 10kb respectively. Finally, a 100 nucleotide stretch with high sequence 
similarity, bearing only four mismatches, within this region is highlighted in blue. This sequence became 
the focus of a multitude of endonuclease designs. 
A 
B 
Human  
Mouse  
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3.3.2 Rigorous Local Pairwise Sequence Alignment of Human and Mouse Intron 1 
Sequences: the Identification of a Region of Homology within DMD Intron 1.  
The common intron 1 sequence was selected as being 3kb downstream of the identified 
Dp427p2 promoter and upstream of the  common exon 2 sequence, prior to a rigorous 
pairwise local alignment being performed. These 3kb terminal sequences were excluded from 
analysis, to ensure modulatory signals and native splice sequences, necessary for transcription 
and RNA splicing were retained. This was deemed crucial as the native transcriptional 
machinery would be utilised to splice to the integrated dystrophin cDNA introduced by the 
exogenous repair template. It was predicted that once integrated the cDNA would then be 
driven by the endogenous promoter and give rise to physiological expression levels of 
dystrophin. This premise was the novel foundation of the therapeutic approach proposed by 
this work. These marginally shortened intron sequences were then subject to a pairwise local 
alignment using the EMBOSS matcher algorithm, provided by the EMBL EBI bioinformatics 
institute (https://www.ebi.ac.uk/Tools/psa/emboss_matcher/). Notably, this bioinformatics 
tool provides an optimal alignment with the exclusion of excessive adjacent sequence. As a 
consequence, the alignment of the adjusted 101kb and 87kb human and mouse common 
intron 1 sequences respectively identified a 12kb sequence as being optimally aligned. 
Interestingly, this 12kb alignment began7kb into the human sequence input spanning from 7-
19kb and 4kb into the mouse input sequence spanning 4 -15kb (with a sizeable central gap in 
the middle of the alignment identified).    
Importantly, the high level of sequence exclusion from the local alignment was anticipated on 
the basis that introns, or so-called ‘non-coding’ sequences, are identified as being less highly 
conserved across different species than exons. Interestingly however, the 12kb optimal 
alignment of human and mouse common intron 1 only exhibited 53.9% sequence similarity, 
with 15.8% gaps and dispersed mismatches throughout the sequences. This prompted a closer 
visual inspection of the sequence alignment, which in turn yielded a 345 nucleotide stretch 
with high sequence similarity (Figure 3-1).  
This 345 nucleotide region of homology was then identified in human and mouse sequences, 
and independently aligned, this alignment indicated 84.9% sequence similarity between the 
two sequences with 5.5% gaps. Moreover, within this sequence, a continuous 100 nucleotide 
stretch with only 4 mismatches could clearly be identified. These observations in turn 
established the 345 region and the 100 nucleotide stretch, as sequences of interest to assess 
and select putative target sites for custom endonucleases. The rationale being designing an 
endonuclease to this sequence with the avoidance of polymorphisms, would potentially 
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mediate DSBs in both human and mouse genomes. This common genome editing reagent 
could then be exploited for the purposes of facilitated translational development. 
The identification of these relatively short sequences prompted further assessment of the 
common intron 1 for more regions of high sequence similarity between human and mouse 
genomes. To this purpose, the human common intron 1 sequence was divided into 1kb 
fragments and aligned to the full mouse common intron 1.  This was undertaken on the 
premise that the larger sequence inputs may have produced an alignment that obscured 
shorter regions of high sequence similarity between human and mouse genomes. This stated, 
no homology in excess of the 345 nucleotides identified was observed for the first 20kb of 
human common intron 1 aligned in this manner (results not shown); the failure to identify 
further regions of sequence similarity resulted in this approach being halted. Finally, a rigorous 
local pairwise alignment was undertaken for human and mouse common intron 2 sequences. 
However, no regions of comparable sequence similarity to that identified for intron 1 were 
observed (results not shown). Overall in this alignment regions of sequence similarity were 
fewer and shorter than observed for intron 1, with the longest continuous stretch being 24 
nucleotides. Thus assessment for endonucleases progressed with the region of homology 
identified in the common intron 1 sequence alignment. 
3.3.3 Identification of TALEN Target Sites and CRISPR Guide Designs to the 5’ End 
of the DMD Gene:  
3.3.3.1 Main Design Strategy: Targeting the Region of Homology Identified 
between Human and Mouse Sequences. 
The recent development of the endogenous CRISPR/Cas9 system for the purpose of 
mammalian genome editing meant this system was untested in our lab. In addition, TALEN 
synthesis is relatively complex and expensive process. Finally, the desire for an expedited 
translation of this gene editing approach from in vitro cell culture to in vivo DMD mouse 
models was also among considerations which indicated that the design of a common 
endonuclease would be beneficial to this investigation. Thus the primary focus was to analyse 
the 100 nucleotide region of homology identified between the human and mouse common 
intron 1 for TALEN target sites and CRISPR guide sequences. Designs for both the established 
TALEN platform and novel Cas9 system, were undertaken in parallel enabling exploration of 
this new versatile genome editing system whilst also ensuring the best chance of successful 
outcomes for the project. 
TALEN target sites were identified with the use of the Cellectis TALEN hit software, with 
designs comprising of 17 nucleotide TALE left and right recognition units separated by a 
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variable 10-25 nucleotide spacer region  (Cellectis Bioresearch 2011). This analysis yielded 12 
TALEN pairs spanning 3 hit zones within the homologous region. Of these designs only 1 TALEN 
pair comprised of left and right TALE recognition arms targeting completely homologous 
sequences between both species (Figure 3-2). Notably, the design in question harboured two 
polymorphisms within the spacer region. However, this intervening sequence, serves to allow 
FokI nucleases tethered to the TALE arms to undergo obligatory dimerization thereby 
introducing a DSB. This is in contrast to the TALE arms which confer sequence specificity, 
enabling the endonuclease to bind to the desired genomic locus. In consideration of this, it was 
speculated that polymorphisms confined to the spacer region would have little bearing on 
TALEN specificity and efficacy. Based upon this assertion, this TALEN pair was firstly selected as 
a potential genome editing reagent common to both human and mouse intron 1 of the DMD 
gene.  
Following the successful identification of a TALEN target site, the same common sequence was 
analysed for CRISPR guide targets with the use of the CRISPR MIT software,  (Optimised CRISPR 
Design 2013). CRISPR guide RNA designs were produced in line with the requirements of the 
well characterised Streptococcus Pyrogenes Cas9, which is a 20 nucleotide sequence upstream 
of a protospacer adjacent motif (PAM). The PAM being a key recognition sequence either 5’-
NGG-3’ or 3’-NCC-5’, where N denotes any nucleotide. The Cas9 nuclease is directed to cleave 
target DNA at a position 3 nucleotides upstream from this PAM recognition sequence.  
Notably, the CRISPR MIT identifies CRISPR guides, and generates a list of potential off-targets 
by identifying similar sequences within a defined genomic build. As a consequence mouse and 
human sequences were analysed for CRISPR guide RNA designs individually against their 
genomic builds respectively. The results obtained from these two separate analyses were 
compared and compiled to assess for similar CRISPR guide designs. Overall, 10 CRISPR guides 
were identified: 4 human and 6 mouse (Figure 3-2). One guide, 5’-TATTTTGCTTCCTTAGCATC-
3’, was identified to target a sequence completely homologous between both species. This was 
noted as guide 2 for human and guide 5 for mouse on the basis of the numerical ranking 
system of the CRISPR MIT tool. Thus the Cas9 nuclease could be directed to cleave this 
sequence in both genomes.  
The CRISPR MIT tool ranks guides on the basis of their specificity, using a specificity score (1-
100) and a colour coding system to simplify the guide selection process; guides coloured green, 
amber or red have respective specificity scores of >50 (high specificity),  20-50 (moderate 
specificity)  or <20 (poor specificity). In accordance with this ranking system, all guides 
designed with the exception of mouse guide 6 were coded as amber or higher (Figure 3-2). 
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Interestingly, in contrast to the CRISPR MIT tool, the Cellectis TALEN design software provided 
no predicted specificity or efficacy profiles for the TALENs identified. Nonetheless provisional 
analysis of guides appeared promising and indicated that gene modification assessments were 
warranted to assess whether they functioned with high enough efficacy for inclusion in the 
investigation. Figure 3-3 provides a schematic of the TALEN and CRISPR guide and illustrates 
the designs locations across the 100 nucleotide region of high similarity between human and 
mouse sequences. 
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Figure 3-2 Design of TALEN and CRISPR/Cas9 Endonucleases to the region of high sequence similarity 
between human and mouse in common intron 1.  
A) The raw output schematic of the cellectis TALEN hit software: the input sequence is along the top, 
TALE recognition arms are illustrated in dark purple and intervening spacer in pale purple.  In this 
instance, 12 TALEN designs were apparent across three sub-regions, the position of sequence 
mismatches between the human and mouse genome  were highlighted by green rectangles Notably, a 
single TALEN design with TALE arms targeting completely homologous sequences between human and 
mouse, was identified as indicated by the blue arrow. B) The guide design outputs for human and mouse 
from CRISPR MIT: guides are ranked numerically in accordance with their specificity ‘score’ (1 -100). 
Furthermore, they are colour coded on the left hand side: green optimal, amber moderate off targets 
and red high off-target effects. Finally, the protospacer ‘guide’ sequence is denoted in black whilst the 
PAM recognition motif is shown alongside in green. Of these designs human guide 2 and mouse guide 5, 
target a common sequence without any mismatches. 
A 
Human  
Mouse  
B 
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Figure 3-3 A schematic outline of endonuclease designs and the occurrence of single nucleotide 
polymorphism for the highly homologous sequence input.  
The 100 nucleotide human sequence with high sequence similarity to the mouse genome can be seen at 
the top of the diagram and is denoted in black. Human and mouse endonuclease designs are indicated 
in blue and red respectively and sequence mismatches between the species are shown in green 
lettering. TALEN designs illustrate the two mismatches between the human and mouse sequence 
confined to the spacer region, whilst the TALE recognition arms are shown to be homologous.  Of the 
CRISPR guide designs identified, only the centrally located human guide 2 and mouse guide 5 are 
completely homologous. All other human guide designs harbour at least a single nucleotide mismatch 
relative to their murine counterpart.   
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3.3.3.2 Alternative Design Strategy 1: Targeting DMD Exons 1 -3 in Human 
and Mouse  
The low sequence similarity between human and mouse intron sequences common to the full-
length isoforms, served to limit endonuclease designs. This was not unexpected as ‘non-
coding’ intron sequences tend to be less conserved than exons across different species’ 
genomes. Thus in an effort to expand the repertoire of common genome editing reagents, 
rigorous pairwise local alignment of the first three exons of the Dp427m isoform was also 
undertaken.  
As predicted exon sequences showed a higher level of sequence similarity compared to the 
intron alignments shown above. The Dp427m exon 1 sequences showed 82.9% similarity with 
5.0% gaps. Exon 2 sequences had 98.4% similarity with 0.0% gaps. Exon 3 sequences had 
87.1% similarity with 0.0% gaps. Whilst higher homology exists between human and mouse 
exon sequences, the mismatches present were dispersed throughout the exon which served to 
limit identification of TALEN targets and CRISPR guides common to both species.  
The pairwise sequence alignment of Dp427m exon 1 (Figure 3-4) harboured five notable 
regions of continuous sequence similarity spanning  33 nucleotides (position 243-276), 22 
nucleotides (position 20-42) and 13 nucleotides (#1 at position 134-147, #2 at position 175-
188, #3 at position 222-235). The former more extensive runs of homology of 22 and 33 
nucleotides were situated at the 5’ and 3’ regions of the exon respectively. Thus whilst the 
homologous sequences would be large enough to permit the binding of left or right TALE 
recognition arms, the intervening sequence is too extensive and would not permit obligatory 
dimerization of the FokI nuclease.  Importantly, in the absence of FokI obligatory dimerization, 
the reagent will not orchestrate DNA cleavage at the genomic locus. Furthermore, the 
remaining regions of 13 nucleotide sequence similarity, whilst more closely positioned are of 
insufficient length to permit TALEN designs common to both species to be undertaken. Thus 
the profile of sequence similarity for Dp427m exon 1 indicates that a common TALEN design to 
this region was not feasible. 
The Dp427m exon 1 was also assessed for CRISPR guides. While 22 guides could be designed to 
the exon sequence, at least one sequence polymorphism between human and mouse was 
present in all cases. Similarly to the TALEN analysis, no common guide was present that would 
enable DSB induction in both species (Figure 3-4).  
Contrastingly, exon 2 pairwise sequence alignment showed only a single centrally located 
polymorphism, at position 42 out of 63 nucleotides. When analysed with Cellectis TALEN hit 
software 11 TALEN pairs across 3 hit zones were identified. Interestingly, in 8 of the 11 TALEN 
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designs, the single nucleotide polymorphism was constrained to the spacer region (Figure 3-5). 
Thus these designs represent potential genome editing reagents to induce DSBs in both the 
human and mouse genomes.  
The CRISPR guide designs to this exon 2 sequences were more limited, with only 2 human and 
1 mouse guide designs identified. The two guides from the human analysis were targeted to 
completely homologous sequences, between the two organisms. Interestingly however, only 
one of these guide sequences appeared when designs were made in the context of the mouse 
genome. Nonetheless, their low specificity scores, being 28 and 23 for human and 18 for 
mouse, contraindicated their development in this study. The limited identification of guide 
sequences targeting exon 2, was attributed to the A-T rich nature of this sequence, (71.4% 
being A or T) which reduces the occurrence of PAM sequences.   
Finally, exon 3 pairwise sequence alignment identified 3 regions of high sequence similarity. 
These regions spanned 17 nucleotides (position 22-37) and 15 nucleotides (#1 at position 52-
67 and #2 at positions 78-94) and they had insufficient length for TALEN or CRISPR guide 
designs to be undertaken (Figure 3-4).  
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Figure 3-4 Rigorous Pairwise alignment of human and murine Dp427m exon 1 -3 sequences, using the 
EMBOSS matcher tool.  
Dp427m: A) Exon 1, B) Exon 2, and C) Exon 3. Notably, the top sequence is human, the bottom is 
murine. Numbers alongside denote the position within the exon. Moreover, sequence mismatches are 
highlighted by green rectangles. Notably, exon 2 showed the highest sequence similarity with only a 
single centrally located mismatch. This appeared the most suitable to analysed for the presence of 
endonuclease sites.  
A 
B 
C 
Human  
Mouse 
Human  
Mouse 
Human  
Mouse 
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Figure 3-5 TALEN designs to Dp427m exon 2 using the Cellectis TALEN hit software 
A raw schematic output of the Cellectis TALEN hit software: the human exon 2 sequences is along the 
top, TALE recognition arms are illustrated in dark purple and intervening spacer in pale purple. The 
sequence mismatch between human and mouse genomes is indicated by a green rectangle.  In this 
instance, 11 TALEN designs were apparent across 3 sub-regions. Notably, there are 8 TALEN designs in 
which the TALE arms bind to sequences completely homologous between human and mouse. This 
would represent a series of endonuclease designs to develop, should guides designed to the common 
intron sequence show low efficacy.  
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3.3.3.3 Alternative Design Strategy 2: Species-Specific CRISPR Guide 
Designs. 
Thus far, theoretical genome editing reagents have been designed to target homologous 
sequences between the human and mouse at the 5’ end of the DMD gene. The ability to target 
a common site remains important as de novo synthesis of TALENs, remains expensive and thus 
it would not be possible to produce TALENs targeting multiple genomic sites. Thus it was 
speculated that a single reagent functioning in both organisms would be more cost effective 
and enable facilitated translational development. However, the re-purposed CRISPR/Cas9 
system does not warrant the same considerations. In contrast to TALENs, this genome-editing 
platform forms an RNA-DNA duplex rather than protein-DNA interaction. Thus rather than 
extensive protein engineering, which is required to produce a novel TALEN targeting a distinct 
genomic site, the Cas9 nuclease can be re-targeted by changing a 20 nucleotide  guide RNA 
sequence. This is achieved simply by self-annealing two primer sequences and sub-cloning 
them into a plasmid downstream of a U6 promoter. This ease of construction and versatility 
makes this an attractive genome editing platform but also enables multiple designs to a 
genomic locus to be undertaken and tested.  
In addition to the distinctions of these genome editing platforms, some limitations were 
identified with regard to designing common genome editing reagents to both human and 
mouse species. These included: the low availability of homologous sequences, the distinct 
genomic localisation of identified sequences e.g. 7-19kb human and 4 -14kb mouse and finally 
the recognition that even upon design of common genome editing reagents, distinct repair 
templates with species-specific arms of homology would be necessitated. These 
considerations, taken into combination, prompted the design of species-specific CRISPR guides 
with the intention of expanding potential target sites across the genomic locus of interest.   
In pursuit of designing species specific genome editing reagents targeting the intron 1 
sequence common to the full length dystrophin isoforms, human and mouse intron sequences 
were analysed independently for CRISPR guides.  A new guide design tool ‘CHOP’ became 
available and was used for this purpose. In contrast to the previous CRISPR MIT tool, which 
only screened 250 nucleotides per input, this tool was permissive to larger sequence inputs. 
Hence the use of this tool was deemed more suitable to analyse the full intron 1 sequences, 
which were divided into 1kb fragments that were screened sequentially. 
In addition to enabling increased sequence inputs, the ‘CHOP’ tool also utilised a ranking and 
colour coding system analogous to CRISPR MIT. In order to identify promising regions for gene 
targeting, the numbers of highly ranked guides were plotted for each 1kb fragment across the 
intron 1 sequence (Figure 3-6). 
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These one kilo base sequences were selected for further examination, if they contained 5 
‘highly ranked’ guide designs positioned within a 300 nucleotide stretch. It was decided that 5 
guide designs at each site would be desirable, to ensure at least one guide design functioned 
with high efficacy  (Ran et al. 2013). Furthermore, the close proximity of guide designs would 
permit the design of a single asymmetric PCR spanning the region identified that could be used 
in subsequent mismatch detection assays. 
This bioinformatics analysis identified 3 candidate sequences with sufficient CRISPR guide RNA 
designs for each of the human and mouse intron 1 sequences. Human sites were positioned at 
67, 83 and 88 kilobases (Figure 3-7) and mouse sites were positioned at 28, 29 and 41 
kilobases into the common intron 1 sequence identified (Figure 3-8). This served to expand the 
repertoire of intron 1 targeting options, ensuring that if high efficacy guides were not present 
targeting both mouse and human homologous sequences, then investigation would remain 
viable utilising alternative species-specific target sites. 
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Figure 3-6 A graph showing the number of highly ranked guide designs for human and mouse, 
common intron 1 sequences.   
The number of highly ranked guides with a specificity score of 50 or above was plotted for every 
kilobase of human and mouse intron 1 sequence: blue (human) and red (mouse). Furthermore, a 
threshold of 5 highly ranked guides was used as a criterion to select genomic sites of interest, on the 
basis that guide designs cleave the genome with variable efficacy. In this manner, species specific 
CRISPR/Cas9 guide designs were undertaken across the whole common intron sequence and positions 
of interest were short-listed. 
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Human 83kb  
Human 88kb  
A 
B 275 – 442 bps 
412 – 460 bps 
403 – 506 bps 
C 
 
Figure 3-7 Schematic diagrams showing the 
guide designs for three of the short-listed 
target sites within the human common 
intron 1 sequence performed using the 
CHOP CHOP guide design tool.  
A) Site 1 positioned 67kb into the common 
intron 1 sequence. B) Site 2, 83kb C) Site 3, 
88kb. Notably, the guides are colour-coded 
to indicate the predicted specificity ranking: 
green - optimal with few off target effects, 
amber- moderate off-target effects and red 
– extensive off-target effects. Importantly, 
the regions the 5 guides are localised to, is 
indicated by a blue horizontal bracket.  
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Figure 3-8 Schematic diagrams showing the 
guide designs for three of the short-listed 
target sites within the mouse common 
intron 1 sequence performed using the 
CHOP CHOP guide design tool.  
A) Site 1 positioned 28 kb into the common 
intron 1 sequence. B) Site 2, 29kb C) Site 3, 
41kb. Notably, the guides are colour-coded 
to indicate the predicted specificity ranking: 
green - optimal with few off target effects, 
amber- moderate off-target effects and red 
– extensive off-target effects. Importantly, 
the regions the 5 guides are localised to, is 
indicated by a blue horizontal brackets.
 
 
 
Mouse   28kb  
Mouse 29kb  
Mouse 41kb  
A 
B 
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512- 622 bps 
170 - 331 bps 
426 - 604 bps 
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3.3.4 Sub-Cloning of Guide Sequences  
3.3.4.1 U6 Plasmids: 
Due to the ease of construction and increased versatility of the CRISPR/Cas9 genome editing 
platform relative to TALENs, it was resolved that the former nuclease would be used 
throughout the investigation. This decision was made on the basis that if the system proved 
challenging to establish, the investigation could revert to targeting with TALENs, thereby 
increasing the potential for successful project outcomes. 
To facilitate the generation of an expression plasmid for the CRISPR guides, an empty U6 
plasmid was used kindly donated by the lab of Professor Jin-Soo Kim (Figure 3-9). This U6 
plasmid comprised of a 700bp spacer, flanked by asymmetric BsaI restriction sites, where self-
annealed oligonucleotides constituting the guide sequence should be cloned. In addition, U6-
plasmids encoding human guide designs 1 -4 were kindly cloned by Dr. Taeyoung Koo, to 
facilitate the development of mismatch detection assays.  For mouse guides, oligonucleotides 
containing the 20 nucleotide guide sequence in forward and reverse orientations were 
synthesised. These were flanked with guanine and cytosine residues on the 5’ forward and 3’ 
reverse primer termini, and suitable overhangs for the cloning site respectively. These 
sequence additions are necessary to ensure the cloning of the guide and transcription by RNA 
polymerase(Gagnon et al. 2014). 
To generate the mouse guide RNA expression plasmids, the U6 plasmid was digested with BsaI 
to obtain the plasmid backbone by gel purification (Figure 3-10), oligonucleotides self-
annealed and finally the two constituents were mixed in a ligation reaction.  These mixtures 
were used in the heat shock transformation of Top10 chemically competent E. coli, which once 
recovered were plated onto agar plates inoculated with ampicillin. Subsequent colonies were 
analysed for the presence of the correct guide sequences by colony PCR. In instances where 
the guide sequence had not been successful sub-cloned an 817bp band was anticipated in 
which the 700bp spacer was present and amplified. In contrast if successful guide sub-cloning 
had occurred a 140bp product was expected, in which the guide sequence was inserted in 
place of the spacer. This process was shown to occur with high efficiency as exemplified by the 
cloning of one of the mouse guides shown in Figure 3-10. In this instance of the 16 guides 
screened, 15 were positive for the presence of guide sequence and 1 was negative on the basis 
of colony PCR.  Following this primary indication, 2 colonies positive for the presence of the 
guide sequence were grown and plasmid DNA was isolated and sequenced. If sequencing 
provided findings consistent the colony PCR, the mouse guide plasmid was expanded and 
purified for use in transfection experiments. 
119 
 
3.3.4.2  U6-Guide-CBh-Cas9-2A-GFP Plasmids 
The methodology of cloning guide sequences into expression plasmids remains conserved 
across a range of differing plasmid types.  An analogous method was utilised with regard to the 
U6-guide-CBh-Cas9-2A-GFP plasmid, the only notable distinction being the U6 guide cloning 
site in this construct which harbours a single BbsI restriction site with no spacer region (Figure 
3-11). As a consequence of this, no preliminary screening was possible, rather a multitude of 
bacterial colonies were cultured, from which plasmid DNA was extracted and sequenced. This 
stated the efficiency appears comparable to that shown in the previous section. As high 
frequency success was obtained, only a few colonies needed to be expanded to identify the 
guide sequence anticipated. 
This plasmid was utilised for the dual expression of Cas9 and GFP, with GFP expression being 
used as a proxy for transfection efficiency. This made this plasmid extremely useful when 
extending methods into patient and mouse myoblast lines which relative to HEK293T are more 
challenging to transfect. 
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Figure 3-9 A schematic of the U6 plasmid, for the sub-cloning and transcription of CRISPR/Cas9 guides: 
This plasmid has a U6 RNA polymerase III promoter to transcribe guides, shown in red. Following this, 
two asymmetric BsaI restriction sites flank a ‘spacer region’ shown in dark green, this being a 677 
nucleotide fragment that allows for identification of accurate restriction digestion. Downstream of the 
3’ BsaI site, is the invariant tracrRNA sequence shown in orange, which is necessary for the 
reconstitution, correct functioning and activation of CRISPR/Cas9 guides. Finally, bacterial sequences of 
the plasmid backbone are denoted in light green. This plasmid was used for the sub-cloning of all guide 
sequences, which once cloned formed complete single guide RNA architecture. 
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Figure 3-10 Guide-Cloning and subsequent colony PCR screening with the U6 guide plasmid. 
 A) U6 plasmid restriction digests. On the left there are internal controls: (UC) Uncut, (NotI) Linearise and 
BsaI digest all performed with 1μg of U6 plasmid. On the right 2μg BsaI restriction digests performed in 
triplicate to resolve a 2464bp destination vector backbone, this band was subject to Quiagen Gel 
purification whereas the677bp spacer region was disregarded. Notably, there was some evidence of 
partial digest, where the spacer region had not been removed accounting for the faint 3141bp band of 
unmodified U6 plasmid, this produced some background post-cloning and transformation. All samples 
were loaded and resolved on a 1% agarose gel alongside hyper ladder I. B) The amplicons from a Colony 
PCR screen, with primers designed within the U6 plasmid and tracrRNA region. Amplicons positive for 
the sub-cloned guide sequence were 140bp, in contrast colonies negative for the guide sequence 
retained the spacer region and were 817bps in size. These were run alongside a positive control (+) a 
guide construct kindly generated by Dr. Taeyoung Koo and a negative (-) an empty U6 expression 
cassette and (H) water control. All samples were resolved on a 2% agarose alongside hyperladder IV.  
A 
B 
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Figure 3-11 Guide Cloning into the U6-Guide-CBh-Cas9-2A-GFP (Px458) plasmid. 
 A) A schematic plasmid map of U6-guide-CBh-Cas9-2A-GFP (Px458), this all-in-one plasmid has the U6 
RNA III polymerase U6 promoter upstream of two asymmetric BbsI restriction sites, separated by 22 
nucleotides that were used to clone in guide sequences. Downstream of the CBh promoter, a modified 
version of the CAG promoter drives high SpCas9 and GFP expression, interrupted by a 2A peptide linker 
cleavage site. In addition this plasmid contains the bacterial backbone sequence and ampicillin 
resistance. B) Restriction digests of the Px458 plasmid for sub-cloning guide sequences. On the left 
internal controls were present including (UC) Uncut, (NotI) Linearise and BbsI all of which were carried 
out on 1μg of plasmid. On the right four replicates of the BbsI digests were undertaken. In the absence 
of the spacer, there was little distinction between the UC and BbsI digested plasmid. As a consequence, 
the subsequent colonies were not screened by PCR but rather by sequencing. 
A 
B 
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3.3.5 Retrospective Bioinformatics Analysis of the Specificity of Guide RNA 
Sequences Directed to the Homologous Region in DMD Intron 1: 
To be established as a safe therapeutic strategy, genome editing techniques must be both 
precise and efficacious. Moreover, in approaches requiring the introduction of genetic 
material, the integration must occur with high fidelity. One concern relating to the use of 
endonucleases in the correction of disease causing genetic mutations is the potential for off-
target effects. This refers to genome editing reagents having the potential to non-specifically 
cleave sequences with similarity to the desired target locus, in large eukaryotic genomes. 
Numerous strategies for improving CRISPR/Cas9 specificity have been developed by the field 
throughout the course of this investigation. These include: improved computational models 
based upon specificity-governing rule-sets (Benchling 2015; Haeussler et al. 2016), improved 
In-silico prediction of potential off-targets (Hsu et al. 2013b; Fu et al. 2013; Mali et al. 2013), 
improved Cas9 nuclease architecture resulting from protein engineering and novel delivery 
strategies (Slaymaker et al. 2016; Kleinstiver et al. 2016).  
At the outset of this study, rule sets determining the tolerance of mismatches between RNA 
guide sequences and genomic DNA upon hybridisation were under investigation. Notably, a 
series of investigations were undertaken and specificity predicting computational tools were 
not yet developed  (Fu et al. 2013; Pattanayak et al. 2013; Mali et al. 2013; Hsu et al. 2013b; 
Carroll 2013). As a consequence, provisional scoring from CRISPR MIT, a first generation 
CRISPR/Cas9 guide design tool, was used as an indication that designs should be pursued 
(Figure 3-2). However, when more advanced tools were developed, these were used to 
analyse human guide designs identified by CRISPR MIT more thoroughly. In this study, the 
CRISPOR tool was selected for this purpose (Haeussler et al. 2016);  particularly as this tool 
gave more insight into potential off-target site positions within the human genomes, than its 
predecessor. Note this was performed for human guides as the investigation later only focused 
upon gene-editing in human in vitro cell based models (Table 2). The off-target sites identified 
by the CRISPOR tool were positioned either within exons, intergenic regions or introns. 
Furthermore, gene names were provided to facilitate more streamlined analysis of off-target 
loci. Finally, this tool also provided quantitative prediction of guide efficacy, which was not 
available at the time initial designs were undertaken.  
Notably, guide 1 remained the best ranked with the fewest off-target sites and had the best 
predicted efficacy of the guides identified, this remained the most favourable for further 
development. Guide 4 remained the least favourable with the most off-targets and least 
efficacy predicted. Finally, all guide designs had a specificity score of above 50, which CRISPOR 
sets as a threshold for guide development. 
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For each guide a graphical plot indicating the number of off-targets was produced, containing 
1 - 4 mismatches between the guide RNA and DNA predicted on- target site. These potential 
off targets were then further classified to their position in the genome (Figure 3-12 and Figure 
3-13).  As anticipated, as the number of mismatches increases the proportion of predicted off-
target sites also increases, which can be attributed to the increased number of sequence 
permutations that may arise within the genome. This in combination with the preceding 
CRISPR MIT analysis indicated that the identified guides remained suitable for further 
development. 
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Table 2: An output table from the CRISPOR tool, showing the specificity and efficacy analysis of the human guides previously identified: 
Analysis of the four guides identified with the CRISPR MIT tool. . Importantly, all of the guides have a specificity score of above 50, which is considered the threshold for inclusion in 
a scientific research project, using the algorithm developed by Hsu, et al 2013. Furthermore, their efficiency scores for two algorithms Doench, et al 2016 – largely used for U6 
guide targeting strategies and Moreono-Mateos, et al 2015 – largely for transcribed RNA guides are included. Finally, the numbers of off-targets categorised by the number of 
mismatches they contain are present on the right hand side. Not all of these parameters were available at the time of the initial guide RNA designs, but nonetheless would not 
have prevented the guides being further developed. 
Position/ 
Strand  
Guide Sequence + PAM 
+ Restriction Enzymes   
+ Variants   
 
Specificity 
Score  
Predicted Efficiency  Show all 
scores 
 
Doench              Mor. Mateos 
Out-of-Frame 
score   
 
Off-targets for  
0-1-2-3-4 
mismatches 
+ next to PAM  
Guide 
1  
AGACTAAGAACCAGATGCTA AGG  
.................... ... 
Enzymes: BstDEI, MwoI 
 
69 54 41 57 0 - 0 - 2 - 24 - 163  
0 - 0 - 0 - 4 - 5 
 
189 off-targets 
Guide 
2 
TATTTTGCTTCCTTAGCATC TGG  
.................... ... 
Enzymes: LweI 
 
57 39 34 54 0 - 2 - 3 - 42 - 278  
0 - 0 - 2 - 5 - 6 
 
325 off-targets 
Guide 
3 
GATGAAGCATGATATTATTT TGG  
......T............. ... 
Enzymes: Tru1I 
  
61 19 17 61 0 - 0 - 4 - 33 - 204  
0 - 0 - 2 - 3 - 13 
 
241 off-targets 
Guide 
4 
TCTGTCTAATTACATTATAA TGG  
...............C.... ... 
 
Enzymes: SmiMI, AanI 
  
57 36 13 56 0 - 1 - 5 - 26 - 212  
0 - 0 - 3 - 7 - 5 
 
244 off-targets 
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Figure 3-12 Graphical off-target profiles of Guide designs 1 and 2 divided into the location of their off-
targets, being within: exons, intergenic or intron sequences. 
(Top) Off-target profile of guide 1, the numeracy of mismatches (MM) is indicated along the bottom and 
their position in the genome being within the Exon (Red), Intergenic (Blue) or within an intron (Purple) is 
provided. No off-target sites with a single MM are identified and of the 26 off target sites with 3 MM or 
less, 22 are within intergenic or introns sequences and thus are not likely to affect the reading frame of 
genes.  (Bottom)  Off-target profile of guide 2. There are two off-targets with a single MM and 47 with 3 
MM or less, of which 44 are within intergenic or intron sequences. 
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Figure 3-13 Graphical off-target profiles of Guide designs 3 and 4 divided into the location of their off-
targets, being within: exons, intergenic or intron sequences.  
(Top) Off-target profile of guide 3, the numeracy of mismatches (MM) are indicated along the bottom 
and their position in the genome being within the Exon (Red), Intergenic (Blue) or within an intron 
(Purple) is provided No off-target sites with a single MM are identified and of the 37 off target sites with 
3 MM or less, 34 are within intergenic or intron sequences and thus are not likely to affect the reading 
frame of genes. (Bottom)  Off-target profile of guide 4. There is one off-target with a single MM and of 
the 34 off-targets with 3 MM or less, of which 33 are within intergenic or intron sequences 
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3.4 Discussion 
Intron sequences common to the full-length dystrophin isoforms for human and mouse were 
successfully identified and subjected to a pairwise sequence alignment. Due to the size 
distinction between the two intron sequences, a rigorous local alignment using the EMBOSS 
matcher tool from the EMBL/EBI suite was undertaken (McWilliam et al. 2013). In 
consideration of the extensive size of the DMD gene intron sequences, this alignment in 
isolation was far from exhaustive. The alignment produced may have obscured shorter 
stretches of high sequence similarity, which may have been of interest to this investigation. 
One way to address this could have been  to use the sequence similarity tract within the UCSC 
genome browser,  to examine the human DMD gene (Kent et al. 2002). 
In contrast to the pairwise alignment of the human and murine DMD gene sequences 
presented; the UCSC genome browser would produce a sequence alignment for multiple 
species. This could be used to identify similar sequences between the human DMD gene and 
multiple larger animal models with more representative clinical pathology; including the 
Golden Retriever and the newly developed DMD rat models (Larcher et al. 2014; Brinkmeyer-
Langford & Kornegay 2013). If candidate sequences with similarity between the human DMD 
gene and one or more animal models were identified; these could be subject to a rigorous 
multiple sequence alignment with the use of CLUSTRAL; in a similar fashion to the analysis 
described (McWilliam et al. 2013). If undertaken this analysis would serve to identify further 
sequences suitable to the design of common endonucleases, which would be particularly 
useful in the context of TALENs. Further to expanding the repertoire of genome editing 
reagents if such sites were identified for larger animal models this would extend the 
translational scope of the investigation. A demonstration of the proposed therapy outlined in 
this study in a larger animal model with more comparable dystrophic pathology to DMD 
patients, would provide a beneficial insight into potential clinical benefit to patient cohorts. 
The current alignment process however, was sufficient to identify a 345 nucleotide stretch of 
high sequence similarity between human and mouse, within the common intron 1 sequence.  
Importantly it was determined early in the investigation that endonucleases targeting the 
common intron 1 sequence, would be most beneficial to the therapeutic strategy proposed for 
three reasons. Firstly, intron sequences are deemed ‘non-coding’; hence modification within 
this region will not disrupt an open reading frame of a gene. Thus it was anticipated an intron 
target site would circumvent the risk of producing further deleterious DMD gene mutations. 
and reduce the risks associated with insertional mutagenesis (Howe et al. 2008). Secondly, it 
was anticipated that targeting the most 5’ non-coding intron of the DMD gene, would increase 
the applicability of this genome-editing approach to patients. The targeting of intron 1 
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described here, is estimated to have 95% applicability to patients, making this therapeutic 
strategy near-universal (Bladen et al. 2015).  Notably any mutations occurring upstream’ of this 
region,  particularly  those within the dystrophin promoters, which have a documented 
association with X-linked cardiomyopathy, will not be amenable to correction via this approach 
(Muntoni et al. 1993). Thirdly, it was speculated that targeting intron 1 would improve the 
potential of the endogenous promoter and exon 1 elements, to splice to the   dystrophin cDNA 
insertions, introduced by the exogenous repair template.  
A 100 nucleotide region of this candidate sequence was then analysed for potential TALEN 
target sites and CRISPR guide designs.  Endonuclease designs were found with the propensity 
to cleave genomic sequences common to both human and mouse species for both platforms, 
denoted as common gene editing reagents. Notably, the Cellectis TALEN hit software provided 
no information pertaining to the specificity or efficiency of the single common TALEN design 
identified (Cellectis Bioresearch 2011). However, if this construct was to be used a BLAST 
analysis could be undertaken to provide an insight into its potential off-target effects. In 
contrast, the CRISPR MIT software provided some information on guide specificity, with the list 
of predicted off-target sites derived from a BLAST analysis of the common guide  sequence 
against the species genome (Optimised CRISPR Design 2013). Whilst an improvement, this tool 
provided little information as to the location of predicted off-targets within the genome and 
were not based upon specificity governing rules, which were later derived experimentally from 
examination of large numbers of guide designs(Hsu et al. 2013b; Fu et al. 2013; Pattanayak et 
al. 2013; Mali et al. 2013).   
The limited information with regard to endonuclease specificity and efficacy, coupled with the 
versatility of targeting the CRISPR/Cas9 gene editing platform, prompted the examination of 
alternative endonuclease sites at the 5’ end of the DMD gene. Interestingly, the alignment of 
the first three exons of the Dp427m isoform highlighted high sequence similarity at exon 2 for 
both human and mouse sequences. Importantly, 8 TALEN designs identified had the propensity 
to cleave both sequences; this could represent an interesting and alternative genomic target 
site for development. Whilst the original concerns for targeting exon sequences were the 
production of further deleterious mutations within the genome, the risk of this could be 
outweighed by the potential benefit, particularly if corrected colonies were screened on an 
individual basis, clonally expanded and engrafted. Thereby following an ex vivo modification 
and subsequent engraftment strategy.  If the exon 2 sequence is conserved between multiple 
species, this could also provide the benefit of enabling the translation of this therapeutic 
approach to larger animal models. Furthermore, if the synthesis of TALENs was optimised all 8 
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TALEN pairs could be screened to identify the common gene-editing reagent with the highest 
efficacy.  
In addition, to the strategy of addressing sequences of high similarity between human and 
mouse genomes, the full common intron 1 was screened in a species specific manner. This was 
performed to further expand the repertoire of guide designs, particularly as variable efficacy of 
guides to direct Cas9 cleavage was anticipated and later confirmed by a variety of studies 
(Doench et al. 2014; Doench et al. 2016; Liu et al. 2016a; Moreno-Mateos et al. 2015). It was 
speculated that multiple high-ranked guide designs in close proximity would be beneficial to 
the targeting of the intron 1 sequence and thus this was the criteria adhered to.  Moreover, 
increased designs to the intron 1 sequence would maintain the proposed targeting strategy 
but also allow for higher efficacy guides to be identified. However, it has since been indicated 
by others that high numbers of PAM motifs in close proximity can be detrimental to guide 
efficacy (Malina et al. 2015). As a consequence whilst specific designs continue to hold merit, if 
this approach was to be developed further, additional bioinformatics analysis with newer in-
silico prediction tools would be required.   
Although further guide designs and target sequences were identified to ensure the most 
successful outcomes for the project, the four guides designed to the region of homology had 
provisional specificity profiles from the CRISPR MIT tool that made them favourable for further 
development and assessment. Hence these became the foundational designs utilised 
throughout this study. Importantly however, during the course of this investigation, other 
research groups extensively screened guide libraries to identify guides with high specificity and 
efficacy(Hsu et al. 2013b; Doench et al. 2014; Doench et al. 2016; Liu et al. 2016a). The 
subsequent findings identified guide RNA specificity and efficacy-governing rule sets that were 
used in the development of computer algorithms, to facilitate optimal guide selection. Once 
available the original four guide designs were re-assessed with the CRISPOR.org tool, which 
utilises these algorithms (Haeussler et al. 2016). Interestingly, their specificity profile still 
indicates that the development of these guides would be feasible in the context of this project. 
Furthermore, this tool provided more insight into the location and future screening of off-
target sites. 
If time had of permitted it, off-target analysis would have been undertaken in a biased manner 
for off-targets with up to three mismatches. In this instance, primers would have been 
designed to a predicted off-target site and the subsequent amplicons are analysed by a 
mismatch detection assay (Qiu et al. 2004; Vouillot et al. 2015; Tycko et al. 2016). A biased 
approach would be opted for due to its increased scalability. However, if the proposed 
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therapeutic strategy of this investigation was to be further developed a more robust and/or 
stringent  genome-wide assessment using a variety of newly developed methods would have 
to be undertaken, including: Targeted deep gene sequencing (Ran et al. 2013), Guide-seq (Tsai 
et al. 2014) or Digenome seq (Kim et al. 2015). This is particularly pertinent as it has been 
indicated that as much as up to 6 mismatches can be tolerated by the CRISPR/Cas9 system 
(Tsai et al. 2014).  
Nonetheless, the guides designed to this region were selected for further development, to 
improve the near-universal applicability of this approach. If successful it is speculated that the 
integration of the dystrophin transgene at the 5’ end of the DMD gene will ameliorate the 
pathology associated with a wide range of mutations. Notably however, internal dystrophin 
isoforms such as the Dp260, Dp140, Dp116 and Dp71, will not be reconstituted by this process. 
These isoforms are non-muscle expressing isoforms, implicated in the non-progressive 
cognitive impairment; in light of this some of the cognitive symptoms displayed by DMD 
patients may not be addressed by this therapeutic strategy. These constraints noted, the 
muscle pathology is the most debilitating aspect of the disease, which ultimately leads to 
premature death (Bushby et al. 2010a). Furthermore, by targeting the common intron 1 
region, it is speculated that in addition to the muscle isoform, the cortical, Purkinje 1 and 2 full 
length isoforms will also be reconstituted and expressed at physiological levels.  
Thus this near universal strategy could provide permanent correction of a range of dystrophin 
mutations and be therapeutically beneficial for a significant proportion of patients addressing 
a clear unmet medical need.  The few mutation types not encompassed by this near-universal 
strategy, could be addressed later by mutation-specific means in the future or by gene therapy 
approaches such as utrophin up-regulation or MD1 gene addition (Tinsley et al. 2011; Guiraud, 
Squire, et al. 2015; Le Guiner et al. 2017). 
3.5 Conclusion 
This chapter presents a series of pragmatic design strategies to identify suitable TALEN and 
CRISPR guides for the introduction of a DSB, at the 5’ end of the DMD gene. These designs 
focused upon areas of high sequence similarity between human and mouse genomes at both 
exon and intron sequences, but also upon species-specific designs across the common intron 1 
sequence. Notably, a series of designs were undertaken to increase the likelihood of the 
project having successful outcomes. This stated, it was resolved that targeting the intron 1 
sequence common to all full length isoforms, using CRISPR guides would facilitate the 
development of the therapeutic strategy proposed. However, in light of this CRISPR/Cas9 
bacterial immune system being newly re-purposed for mammalian genome editing, TALEN 
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designs were also undertaken, to permit the use of the established TALEN endonuclease 
platform if required. 
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Chapter 4 Establishing a Delivery System for the Cas9 Nuclease 
and Validation of Guide RNA Efficacy at the Human DMD Intron 
1 Site 
4.1  Introduction 
Successful gene editing is reliant upon the delivery of customisable nucleases into mammalian 
target cells and the subsequent ability of the endonuclease to introduce double stranded 
breaks (DSBs) at a specific genomic locus.  Notably, the occurrence of DSBs at the genomic 
locus dictate the extent to which NHEJ or HDR DNA repair pathways can be exploited to modify 
the mammalian genome and by extension address or compensate for disease-causing 
mutations (Ciccia & Elledge 2010; Liang et al. 1998; Jasin & Rothstein 2013). Thus in the 
context of this investigation which aims to utilise the low efficiency HDR DNA repair pathway 
(Mao et al. 2008; Heyer et al. 2010) to mediate an MD1 transgene integration, highly efficient 
delivery of gene-editing reagents and identification of guide RNAs that introduce DSBs with the 
high efficacy will be crucial to attaining successful outcomes. It is important to establish that 
throughout this investigation a single guide RNA (sgRNA) scaffold was used comprising of two 
part a 20 nucleotide cRNA and an invariant 83 nucleotide tracrRNA sequence. Notably, the 
crRNA associates with Cas9 nuclease and directs it to DNA via Watson-Crick complementary 
base pairing.  This 20 nucleotide sequence within the sgRNA is referred to as “guide” RNA 
sequence throughout the field. 
Interestingly, publications near the start of this investigation highlighted the inherent 
variability in the ability of CRISPR guide RNAs to direct the Cas9 nuclease in producing DSBs 
and the importance of screening multiple guide RNA designs targeting the genomic locus (Mali, 
Yang, et al. 2013; Ran et al. 2013). Established methods for assessing the efficacy of 
endonucleases use the low fidelity of the NHEJ repair pathway and the resultant small 
insertions or deletions (InDels) as a proxy for gene-modification at a locus (Ciccia & Elledge 
2010; Qiu et al. 2004). Numerous methods have been developed to assay the diverse resulting 
InDel spectrum including mismatch detection assays such as High Resolution Melt Curve 
Analysis (HRMCA) (Vossen et al. 2009), Surveyor (Qiu et al. 2004) and T7 Endonuclease I (T7E1) 
(de Massy et al. 1987; White et al. 1997) assays, sequencing assays including deep gene 
sequencing, tracking of InDels by decomposition (TIDE) (Brinkman et al. 2014) and restriction 
digest assays in the form of Restriction Fragment Length Polymorphism (RFLP) (Jeffreys 1979; 
Kim et al. 2014). These methods have differing inherent capacity to identify InDel types and 
quantify the frequency of InDel occurrence. Moreover, in many instances the DNA termini 
following the introduction of DSBs are often ligated perfectly, as a consequence these 
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methods provide an underestimate of the amount of DSB present in situ (Ciccia & Elledge 
2010).  
Importantly, the in-silico guide RNAs designed to DMD intron 1 will introduce DSBs and InDel 
modifications to varying degrees. This process has since been elucidated to be largely 
influenced by guide sequence determinants (Xu et al. 2015; Liu et al. 2016b; Doench et al. 
2014), local chromatin structure (Malina et al. 2015), the ability of the guide to form secondary 
structures once transcribed (Moreno-Mateos et al. 2015) and the format in which the guide 
RNA is delivered, whether it be encoded within plasmid vectors, or directly in an RNA (Doench 
et al. 2014; Moreno-Mateos et al. 2015; S. Kim et al. 2014).  Thus this chapter will be 
concerned with trialling alternative gene-editing reagent delivery strategies and the 
identification of the most efficacious in-silico guide RNA design. 
4.2 Chapter Aims:  
The primary aims of this chapter were to assert successful delivery and expression of gene-
editing reagents by transient transfection into HEK293T cells and to establish a functional 
gene-modification assay, to enable the detection of InDels. These methods were then 
employed to assess the efficacy of guide RNAs designed to target intron 1 of the DMD locus. 
Once the delivery, expression and efficacy of the gene-editing reagents were demonstrated in 
HEK293T, these approaches were then transitioned to Δ45-55 immortalised patient myoblasts. 
As a secondary aim, the Cas9 nuclease was also produced and delivered in mRNA and protein 
formats, as it was speculated this would improve the efficiency of the system and by extension 
the approach being trialled within the immortalised patient myoblasts.  
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4.3 Results: 
4.3.1 An Examination of Cas9 Nuclease Delivery and Expression using HEK293T 
Cells as a Model System: 
In an attempt to achieve successful delivery and subsequent expression of the Cas9 nuclease, 
two plasmids CBh-Cas9 and U6-Guide1-CBh-Cas9-2A-GFP (For plasmid maps see Figure 4-1), 
hitherto referred to as Px165 and Px458 respectively, were delivered to HEK293T by transient 
transfection. Notably Cas9 expression in both cases is driven by the chicken beta-actin hybrid 
promoter (CBh), reported to give robust expression in a range of mammalian cell lines (Gray et 
al. 2011). Furthermore the Px458 utilises a T2A self-cleaving peptide between Cas9 and a GFP 
transgene [for a review of 2A linkers, see (Liu et al. 2017). The outlook here was to optimise a 
western blotting protocol to assess the expression of Cas9 nuclease by harvesting total protein 
lysate 48 hours post transfection. Upon establishing a suitable and robust methodology, dose 
responses of the gene-editing reagents were undertaken to identify a dose that provides 
suitable expression and to assess the cell culture for potential toxicity. In the case of Px458, 
GFP could be used as a proxy for Cas9 expression with the proportion of GFP positive cells as 
assessed by FACS analysis indicating the number of cells where Cas9 gene delivery and 
expression has been successful.  
4.3.2 Establishing a Western Blotting Protocol for the Detection of Cas9 Protein. 
In an effort to establish a suitable western blotting procedure for Cas9 protein, 2μg of the 
Px165 plasmid was transiently transfected into HEK293T, using a lab established 5:1 Viafect 
transfection reagent (μl): DNA (μg) ratio. Protein was harvested 48 hours post transfection and 
50μg total protein lysate was subjected to Western blotting with the Diagenode Cas9 antibody. 
Initially, antibody dilutions ranging from 1:1000-1:5000 were trialled in the Western blotting 
procedure (Figure 4-2). This was performed with the aim of identifying Cas9 protein expression 
and obtaining a Western blot with low background. Importantly a protein of 150kDa 
corresponding to the anticipated size of Cas9 protein was present in each of the dilution series.  
This stated, the protein did not resolve as a sharp distinct band, but rather a smear, with 
marginal differences observed in the resolution and background in the dilution series trialled 
(Figure 4-2-A).  
The 1:5000 dilution of the Cas9 antibody was selected for further optimisation investigations. 
The next parameter to be altered related to the amount of total protein lysate loaded to the 3-
8% Tris-acetate gel during the Western blot procedure. To this end, 25μg and 12.5μg total 
protein lysate respectively were loaded and assessed for Cas9 expression (Figure 4-2-B). The 
12.5μg total protein lysate loading condition yielded a distinct band, albeit with a large surface 
area, after 3 seconds exposure using the HRP method.  This indicated that the Px165 plasmid 
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was expressing Cas9 protein. Furthermore, the results suggested that for future detection of 
Cas9 protein a 1:5000 dilution of the Diagenode Cas9 antibody and 12.5μg of total protein 
lysate should be utilised. 
4.3.3 Examination of Cas9 Protein Expression Following Transient Transfection in 
HEK293T Cells with Dose Escalation. 
A dose escalation study was performed for both Px165 and Px458 plasmids, to evaluate 4μg, 
2μg, 1μg and 0.5μg doses.  The transient transfection was undertaken in parallel for both 
plasmids, total protein harvested 48hours post-transfection, and 12.5μg of total protein lysate 
was subject to western blotting. In addition, microscopy imaging and FACS analysis for eGFP 
expression was undertaken in cells treated with Px458. 
As anticipated the western blots show both the Px165 and Px458 show a dose dependent 
expression profile (Figure 4-3). Importantly bands corresponding to the 150Kda Cas9 protein 
were in both transfection series. Notably doses between 1μg and 4μg produced strong bands, 
whereas at the 0.5μg dose bands are absent in the Px165 and only marginally detected in the 
case of Px458. Interestingly, additional bands were present in the dose ranges of both 
plasmids. In the case of P165, below the expected 150kDa band, two additional bands were 
present estimated to be 140 and 130kDa in size, which was more pronounced in 4μg and 2μg 
doses. In contrast in the case of Px458, two bands were present both above and below the 
band corresponding to Cas9 protein. The upper two were estimated to be 177kDa and 167kDa 
and the lower two of 140kDa and 130kDa respectively. The lower bands, consistent across 
both samples, were speculated to be degradation products. In contrast the larger bands 
observed for Px458 were anticipated to reflect Cas9 and GFP fusion proteins that have not 
undergone 2A peptide cleavage. 
The dose dependent expression of Cas9 nuclease was mirrored in fluorescence microscopy and 
FACs analysis of the Px458 samples, which were undertaken alongside a pCI-GFP positive 
control. This plasmid was selected as a positive control as it utilises a strong viral 
Cytomegalovirus (CMV) promoter to drive green fluorescent protein (GFP) expression (Figure 
4-4). The mean percentage of GFP+ cells for each condition were as follows: 0.5μg 6.50% ± 
0.04, 1.0μg 40.23%± 0.44 , 2.0μg 71.70% ±2.09 and 4.0μg, 92.67% ±3.00 (N=3: mean± SEM 
in all cases). A significant difference was detected between doses of 0.5 and 1μg (P>0.001), 1 
and 2μg (p=0.023) and 2 and 4μg (p=0.0143). Interestingly, there was no significant difference 
between the GFP+ population at 4μg dose of Px458 and 2μg dose of pCI-GFP both giving 
expression levels of almost 100%.  
  
137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 Schematic of Streptococcus Pyrogenes Cas9 expression plasmids used in transfection 
efficiency and gene-modification investigations; both of which were obtained from Addgene.  
The Px165 construct (Top) comprises: the Chicken Beta Actin (CBh) promoter, a modified CAG promoter 
with validated robust expression in a range of mammalian cells, immediately flanked by human 
sequence-optimised SpCas9, terminated by a Bovine Poly A signal. This construct requires dual 
transfection alongside a U6-guide plasmid to provide the guide expression necessary for mediate gene-
modification. The Px458 construct (Bottom) contains the same CBh promoter and Cas9 components as 
the Px165. However, it also contains a U6 promoter upstream with a sgRNA scaffold in place allowing for 
a guide sequence to be directly cloned with the use of BbsI, a type II restriction enzyme, circumventing 
the requirement for dual transfection. In addition, a GFP marker terminating on a Bovine Poly A signal is 
present downstream of the SpCas9 using a T2A promoter to aid assessment of transfection efficiency. 
Both plasmids harbour ampicillin resistance cassettes, to facilitate bacterial transformation and 
selection.  
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Figure 4-2 HRP Western Blotting undertaken to optimise the detection of Cas9 protein, using the 
Diagenode Cas9 antibody. 
A) Western blotting was performed on 50μg total protein lysate harvested from HEK293T cells 48hours 
post transfection of 2μg of Cbh-Cas9 (Px165) using 5:1 Viafect reagent (μl): DNA (μg) ratio, using serial 
dilution ranges of 1 in 1000- 1 in 5000 of the Diagenode Cas9 antibody raised to the N-terminal of Cas9 
in mouse. B) Western blotting of samples from A diluted to 25μg and 12.5μg total protein lysate, using a 
1 in 5000 dilution of the Diagenode antibody. Samples were resolved on a 3-8% Gradient Tris-Acetate 
gel, alongside NuPage HiMark ladder, prior to transfer to a 0.45μM nitrocellulose membrane. The 
samples were then incubated for an hour in the presence of a horse radish peroxidase (HRP) conjugated 
goat anti mouse secondary antibody, prior to the blot being developed by chemiluminescence for 1 
minute.  Film (GE healthcare) was then positioned over the blot and imaged after a3 second exposure 
time.  
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Figure 4-3  HRP Western blotting to detect Cas9 protein in HEK293T culture, subjected to a dose 
escalation of Px165 and Px458 Cas9 expression plasmids. 
Western blotting was performed on 12.5μg total protein lysate harvested from HEK293T cells 48hours 
post transfection of Cas9 expressing plasmids (A) Px165 and (B) Px458 at doses of 4μg, 2μg, 1μg or 0.5μg 
using 5:1 Viafect reagent  (μl): DNA (μg)  ratio. Protein samples were assessed for Cas9 expression using 
a 1 in 5000 dilution of the Diagenode Cas9 antibody. Loading control was assessed using of an alpha 
tubulin antibody (Abcam 40774) at a 1:2500 dilution. Cas9 protein at the 150kDa and Alpha tubulin at 
44kDa are indicated. Samples were resolved on a 3-8% Gradient Tris-Acetate gel, alongside NuPage 
HiMark ladder, prior to transfer to a 0.45μM nitrocellulose membrane. The samples were then 
incubated for an hour in the presence of a horse radish peroxidase (HRP) conjugated secondary 
antibody, goat anti mouse (Cas9) or a goat anti-rabbit (alpha-tubulin), prior to the blot being developed 
by chemiluminescence for 1 minute.  Film by GE healthcare was then positioned over the blot and 
imaged after a 3 second exposure time in both instances.  
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Figure 4-4 Microscopy Images of HEK293T Cells 
48 hours post transient transfection Px458 
plasmid at increasing doses, alongside a 2μg pCI-
GFP control. 
 (A) Representative Microscopy images of 
HEK293T transfected with the Px458 plasmid at 
doses of 4, 2, 1 and 0.5μg using 5:1 Viafect 
reagent (μl): DNA (μg) ratio, 48 hours post-
transfection. Transient transfections of Px458 
were undertaken alongside mock samples, in 
which cells were treated with 20μl of Viafect 
transfection reagent in isolation and 2μg of pCI-
GFP as a positive control. (B) A histogram overlay 
of FITC-positive cells determined by FACs analysis 
and produced by FlowJo software, for the 
transfected populations from A) harvested 48 
hours post transfection into 2% PFA FACs buffer. 
Samples: Red: Mock (1% gating), Dark green: 
0.5μg, Light blue: 1μg, Orange: 2μg and Light 
Green: 4μg respectively. C) A bar chart of mean 
percentage GFP positive cells, determined by 
FACs analysis for each of the transfected Px458 
doses, with error bars representing standard error 
of the mean. Differences between doses 
transiently transfected were deemed significant 
by means of an unpaired t-test: comparisons 
0.05μg-1μg P<0.0001, 1μg -2μg p=0.023 and 2μg- 
4μg p=0.0143. 
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4.4 Establishing the Surveyor and T7 Endonuclease (T7E1) Cleavage 
Assays for the Detection of Targeted Genome Modification. 
4.4.1 Efficient PCR Amplification of the Human DMD and Mouse Dmd Intron 1 
Locus 
In order to evaluate guide RNA efficacy in producing DSBs, this being how efficiently in silico 
guide designs identified can direct the Cas9 nuclease to introduce DSBs at the DMD intron 1 
locus, PCRs were designed and optimised spanning the region of homology. These PCRs used 
primers 1960F and 2741R or 1960F and 2541R for the human DMD intron 1 locus and 1950F 
and 2775R for mouse. In all instances a single amplicon band was obtained when 250ng of 
untreated HEK293T DNA was amplified using the high fidelity polymerase Hotstart phusion 
flex.  
Importantly, for Surveyor or T7E1 mismatch detection to be successful, PCR amplicons need to 
be asymmetric with regard to the predicted cleavage point of the guide RNA under 
examination. This is due to the inherent mechanism of mismatch detection assays which rely 
upon the hybridisation of wild-type and modified amplicon sequences, the latter harbouring 
InDels as a result of subsequent DNA cleavage and repair. Importantly, these sequences 
hybridise imperfectly as a result of the sequence modification and heteroduplex or ‘loop’ 
structures form that can be cleaved by enzymes such as Surveyor and T7E1 (Figure 4-5). For 
cleavage products to be successfully resolved via gel electrophoresis, the heteroduplex should 
be positioned nearer to one terminus of the amplicon. The two PCRs designed for the human 
intron 1 site are a case in point, with 1960F and 2741R having suitable asymmetry for guide 
designs 1, 2 and 4, and 1960F and 2541R for guide 3.  
Notably, the outlook was to trial all human and mouse guides and assess for efficacy. However, 
due to the considerable time taken to optimise the DMD intron 1 PCRs, and Surveyor and T7E1 
mismatch detection assays, the investigation was focused to human DMD intron 1 from this 
point onwards.  
4.4.2 Efficacy of Human Guides and Optimisation of the Surveyor and T7E1 
Enzyme Mismatch Detection Assays. 
4.4.2.1 Co-Transfection of U6 Guide and Cas9 Expressing Px165 Plasmids into 
HEK293T 
Once PCRs asymmetric to predicted guide RNA cleavage points were optimised (Figure 4-6), U6 
expression plasmids encoding human guide RNAs 1, 2, 3 or 4, kindly cloned by Dr Taeyoung 
Koo, were co- transfected alongside the Cas9 expressing Px165 plasmid into HEK293T cells. 
These plasmids were delivered at either a 1μg:1μg or a 2μg:2μg dose, using a 5:1 Viafect 
volume: DNA mass transfection ratio in a 6 well plate. DNA was harvested 48 hours post 
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transfection and 250ng of DNA amplified with primers 1960F and 2741R for guides 1, 2 and 4, 
or primers 1960F and 2541R for guide 3, alongside mock and Cas9 alone controls.  
These samples were then subject to Surveyor and T7E1 mismatch detection assays and 
resolved on 2% agarose alongside hyperladder IV. Importantly, varying volumes of amplicon 
6μl, 9μl and 12μl were utilised in the Surveyor assay, whereas the latter T7EI was trialled with 
200ng of PCR purified amplicon (Figure 4-7). Importantly, faint products consistent with the 
sizes of the anticipated cleavage fragments were observed (see Table 3) on the agarose gels 
for the 1μg:1μg and 2μg:2μg conditions in both Surveyor and T7E1 mismatch detection assays. 
This intensity of cleavage products was however a lot more prominent in the higher 2μg: 2μg 
dose for both assays, suggesting a dose dependent response of gene modification. Finally, the 
cleavage products did not appear to differ across the varying amplicon volumes utilised in the 
Surveyor assay. 
 
 
 
 
 
Table 3 Anticipated bands of the uncut amplicon and cleavage products should InDels be present at the location 
of the cleavage site of the guide RNA designs.   
*Notice that guides 1, 2 and 4 sizes corresponding to the amplicon resulting from the PCR primer pairs 1960F and 
2571R and guide 3 sizes corresponding to 1960F and 2541R 
4.4.2.2 Quantification of Gene Modification Efficiency and Polyacrylamide Gel 
Electrophoresis 
The intensity of both uncut amplicons and cleavage products from agarose gels in Figure 4-7 
was estimated using Image J analysis. The resultant values were used to attain estimates of the 
frequency of gene modification in accordance with published equations and methods (Guschin 
et al. 2010). This method was used throughout this chapter to provide gene modification 
frequency estimates. In accordance with these calculations, guide RNAs 1, 2 and 4 were 
estimated to give respectively, 11%, 5% and 12% gene modification frequency in 2μg:2μg 
conditions. Unfortunately band resolution using an agarose gel was insufficient to attain gene 
modification percentage in the 1μg:1μg condition. Finally, these co-transfections were 
performed as single treatments only to establish the functionality of the surveyor and T7E1 
Guides  Anticipated Band Fragments 
1 512 (uncut), 288 and 224 (Cut) 
2 512 (Uncut), 289 and 223 (Cut) 
3 582 (Uncut), 332 and 250 (Cut) 
4 512 (Uncut), 319 and 193 (Cut) 
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mismatch detection assays, thus a mean and standard error of the mean could not be 
calculated in this instance.  
In an effort to enhance the signal from the T7E1 mismatch detection assays, 400ng of amplicon  
was subject to the T7E1 cleavage and resolved on a 10% TBE polyacrylamide electrophoresis 
gel and visualised by 1 hour incubation in a 1/5,000 dilution of SYBRsafe in 1x TBE buffer 
(Figure 4-8).  This type of gel electrophoresis was selected to improve the resolution and 
quantification of cleavage fragments. In this system the percentage of gene modification for 
guide RNAs 1, 2 and 4 was determined to be 7%, 3% and undetectable at the 1μg:1μg and 27%, 
7% and 25% at the 2μg:2μg treatments respectively.  
In consideration of the findings thus far, the assessment of guide RNA 3 was undertaken with 
primer set 1960F-2541R using 400ng of amplicon and resolved on a 10% TBE gel (Figure 4-8).  
The gene modification under the 2 transfection conditions was estimated to be 5.5% and 9.2%. 
However, the accuracy of this estimation was likely influenced by the close proximity of non-
specific bands present on the gel. 
The efficacy of guides RNAs estimated under a range of transfection conditions in the T7E1 
assay on both 2% agarose and 10% TBE polyacrylamide gels are tabulated in Table 4, and 
presented graphically in Figure 4-9. Notably, gene modification for 1μg: 1μg samples were only 
quantifiable on the 10% TBE polyacrylamide gels. Furthermore, the estimates of gene 
modification of the 2μg:2μg samples were higher when resolved on the 10% TBE 
polyacrylamide gel. The guide RNAs 1, 2 and 4 gave estimates on agarose gels of 11%, 5% and 
12%, in contrast to 27%, 7% and 24% by 10% polyacrylamide gels.  
These results indicate that the use of high resolution polyacrylamide gels to identify T7E1 
cleavage products is probably the best system but are more complicated and costly, and it was 
decided that agarose gels would continue to be used routinely for initial indications of the 
occurrence of InDels by T7E1 assay. Furthermore, these attempts to establish a mismatch 
detection assay highlighted that the T7E1 assay was easier to optimise, perform and reproduce 
than the Surveyor assay. Thus the T7E1 system was selected and utilised from this point 
onwards in the investigation. Finally, the trend in the data suggests that guide RNA 1 
introduces DSBs with the highest efficacy out of the various in-silico designs.  
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 Agarose 1:1 10% TBE 1: 1 Agarose 2: 2 10% TBE 2: 2 
Guide 1 NQ 7.20 11.1 27.1 
Guide 2 NQ 3.00 5.30 6.6 
Guide 3 N/A 5.50 N/A 9.2 
Guide 4 NQ NQ 12.30 24.9 
 
Table 4 A table to show the gene-modification estimates attained for conditions of 1μg:1μg and 2μg:2μg of U6-
Guide and Px165 co-transfected, subject to the T7EI and subsequently resolved on agarose and 10% TBE 
acrylamide gels. NQ – Not quantifiable and N/A not applicable. 
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Figure 4-5 A schematic illustrating the underlying mechanism of the T7E1 mismatch detection assay. 
A) A diagram showing the underlying mechanism of the T7E1 mismatch detection assay, an asymmetric PCR is 
performed across the genomic region the guide RNAs have affinity to. Post treatment with the CRISPR/Cas9 system, 
the DSB introduced by the guides will be repaired by an NHEJ mechanism, causing the local introduction of INDELs. 
The resultant amplicons are heterogeneous, with a mixed population of amplicons with INDEL mutations (MT) and 
amplicons without INDEL mutations (WT). The amplicons in this population are denatured to resultant single 
stranded DNA, INDEL mutations are denoted by the green line on the DNA. The resultant ssDNA are hybridised, WT 
sequences anneal without secondary structures in the DNA. Whereas when a WT and MT single strands anneal 
there is the formation of a heteroduplex structure in the DNA (loop in the diagram). The T7E1 nuclease (blue 
scissors) can cleave these secondary structures in the DNA, and thus the mixed amplicon indicating the presence of 
INDELs. B) A schematic diagram of the Intron 1 PCRs used for the T7E1 assay, the amplicon (blue line) is produced by 
either by 1960F and 2471R (green half arrows 512bps amplicon: Guides 1,2 and 4) or 1960F and 2541R (green 
forward and blue reverse arrows 582bp amplicon: Guide 3). The position of guides is indicated by the orange lines 
and the position of DNA cleavage and local INDEL introduction is indicated by orange triangles touching the 
amplicon. Below a table and “predicted” agarose gel image show the anticipated uncut and cut amplicon fragments 
following digestion with the T7E1 nuclease.    
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Figure 4-6 Gel electrophoresis of amplicon products from human DMD and mouse Dmd intron 1 PCRs.  
A) Gel electrophoresis of a PCR amplicon, amplified from 250ng wild-type genomic HEK293T DNA. The 
product was amplified using 1960F and 2471R primers in a 35 cycle reaction using HotStart Phusion Flex 
(NEB). Once amplified a 10μl aliquot of the sample denoted DMD amplicon was resolved on a 2% 
agarose gel. The size is consistent with the 512bp amplicon anticipated and is asymmetric with regard to 
guide RNA 1, 2 and 4 putative cleavage sites. B) Gel electrophoresis of a PCR amplicon, amplified from 
250ng of wild-type genomic HEK293T DNA. The product was amplified using 1960F and 2541R primers in 
a 35 cycle reaction using HotStart Phusion Flex (NEB). Once amplified a 10μl aliquot of the sample 
denoted DMD amplicon was resolved on a 2% agarose gel. The size is consistent with the 582bp 
amplicon anticipated and is asymmetric with regard to the guide RNA 3 putative cleavage site.  C) Gel 
electrophoresis of a PCR amplicon, amplified from 250ng H2kb mdx genomic DNA. The product was 
amplified using 1950F and 2775R primers in a 35 cycle reaction using HotStart Phusion Flex (NEB). Once 
amplified a 10μl aliquot of the sample denoted Dmd amplicon in the figure was resolved on a 2% 
agarose gel. The size is consistent with the 556bp amplicon anticipated and is asymmetric with regard to 
mouse guide RNA 1, 2, 3, 4 and 5 putative cleavage sites. All samples were resolved alongside a suitable 
non-template water control (H) and hyperladder IV. 
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Figure 4-7 Surveyor and T7E1 mismatch cleavage digests, spanning the human DMD intron 1 Cas9 
target site resolved on 2% Agarose gel. 
A) Gel electrophoresis of Surveyor Nuclease digests for the purposes of mismatch detection, undertaken 
on amplicons from HEK293T genomic DNA following a range of treatments. Including: Mock (M) - 
addition of 20μl of Viafect transfection reagent to cells, Cas9 Alone (C) -  1μg Cas9 expressing Px165 
plasmid alone and co- transfection of 1μg U6- Guide 1, 2 or 4 alongside 1μg Px165 at a 1:1 ratio,  
labelled G1, G2 and G4 respectively. Once amplified using 1960F and 2741R primers, varying volumes of 
6µl, 12µl and 18μl of each PCR condition (loaded left to right in order of ascension), were annealed and 
subject to a 2μl of the Surveyor nuclease. B) The same process as described in A except for 2μg G1, G2 
and G4 and 2μg Px165 Cas9 expressing plasmid in dual transfections. C) T7E1 nuclease digest 
undertaken on 200ng PCR purified hybridised amplicon for all treatments of the 1μg U6-guide :1μg 
Px165 condition described in A. D) T7E1 nuclease digest undertaken on 200ng PCR purified hybridised 
amplicon for all treatments of the 2μg Guide :2μg Px165 Cas9 condition. Notably cleavage products are 
present for Guide RNA 1: 288bps and 224bps, Guide RNA 2: 289bps and 223bps and Guide RNA 4: 
319bps and 193bp, for both conditions when subject to the Surveyor and the T7E1 assay, this stated the 
presence of bands is much clearer with the 2μg:2μg conditions. Band present are indicated by white 
triangles for the surveyor gel images and arrows for the T7E1 gel images. All samples were resolved on 
2% agarose alongside hyperladder IV using 1X TAE buffer and inversion of the image was performed to 
enhance the appearance of cleavage products. 
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Figure 4-8 T7E1 Digest products of HEK293T hybridised treated amplicons resolved on a 10% TBE 
polyacrylamide gel. 
A) T7E1 digests for mismatch detection were undertaken on 400ng of purified PCR amplicons, 
performed on 250ng of HEK293T genomic DNA following a range of treatments. PCR amplifications were 
performed using 1960F and 2741R primers and resolved on 10% TBE polyacrylamide gel. Treatments 
included: Mock (M) addition of 20μl of Viafect transfection reagent to cells, Cas9 Alone (C) 1μg Cas9 
expressing Px165 plasmid alone and co-transfection of U6- Guides 1, 2 or 4 alongside Px165 at a 1:1 
ratio, at 1μg: 1μg or 2μg:2μg doses labelled as G1, 2 and 4 in both conditions respectively. B) T7E1 
digests for mismatch detection on the same treatment conditions, using the U6-guide3 expression 
plasmid and associated 1960F- 2541R primer pair as previously described. All gels were run at 200V for 
45 minutes in line with the Thermofischer (Invitrogen) protocols in 1X TBE buffer. This was subsequently 
stained with SYBRSafe diluted 1 in 5000 in 1xTBE, which was incubated at room temperature  for 1 hour 
to visualise bands. Sizes of cleavage bands are indicated, note guide RNA 2 gives 289bp and 223bp 
cleavage products due to the marginal 1 nucleotide difference relative to guide RNA 1, this is not directly 
labelled.  
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Figure 4-9 Graphical summary of percentage gene modification produced by 1:1ug and 2:2μg co- 
transfection of HEK293T cells with U6 and Px165 plasmids as estimated by the T7E1 assay, when 
resolved on either a 2% agarose or 10% TBE polyacrylamide gel. 
Graphical summary of the general trends observed on optimising the surveyor and T7E1 mismatch 
detection assays. Note that 1μg:1μg samples could not be accurately quantified using 1% agarose due to 
low resolution of cleavage products and thus are not included. Furthermore findings suggest that 10% 
TBE gels give superior resolution of cleavage products and more accurate gene-modification estimates 
relative to 2% agarose. As a consequence of this, guide RNA 3 quantification was only taken on a 10% 
TBE gel. Notably, findings indicate that guide RNA 1 appears the most efficacious of the in silico guide 
designs however; more repetitions are required for assertion of this finding.  
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4.4.2.3 Continued Assessment of Guide RNA Efficacy Employing the HEK293T.Cas9 
Cell Line. 
In parallel with the optimisation of the gene-modification assays described above, U6-guide 
plasmid transfection dose escalation studies were undertaken in HEK293T.Cas9 cells. This cell 
line, from Genocopeia, harbours the stable integration of the bi-cistronic CBh-Cas9-Ef1a-eGFP 
cassette at the AAVSI safe-harbour locus (Figure 4-10). Thus only the transient transfection of 
U6-Guide RNA encoding plasmids is required to provide the necessary constituents for Cas9 
mediated DNA cleavage. The constitutive expression of integrated Cas9 within this cell line 
makes it a useful guide RNA screening tool removing variations in Cas9 expression that could 
occur as result during the co-transfection of U6 Guide RNA and Cas9 expressing Px165 
plasmids. 
In this instance, HEK293T.Cas9 cells were transiently transfected with 1μg, 2μg and 4μg doses 
of U6-gRNA plasmids using Viafect. Consistent with previously described methodologies 
samples were harvested at 48 hours and amplified in triplicate and pooled prior to 400ng of 
purified amplicon being hybridised and subjected to T7E1 cleavage.  
The resultant cleavage products for each of these treatments were resolved on a 2% agarose 
gel (Figure 4-10). For guide RNA 1 the mean percentage gene modification were estimated to 
be 10.45% ±0.32, 12.90% ± 0.72 and 11.63%±1.61 at doses of 4, 2 and 1μg (mean± SEM; 
N=3) respectively. In addition, guide RNA 4 percentage gene modification was estimated at 4.1 
±0.94 SEM (N=3).  For all other guide RNAs the determination of mean percentage gene 
modification was estimated at 2% or less. The increase in guide RNA 1 activity was deemed 
statistically signification relative to all other in silico guide designs at the 95% confidence 
interval using a one way ANOVA. A summary of percentage gene modification estimates 
obtained for all guide RNAs is presented graphically (Figure 4-11). The in-silico analyses 
undertaken previously indicated that guide 1 had the fewest off-targets, and taken in 
combination with the gene modification estimates presented this suggested that guide 1 was 
the most suitable candidate to progress to co-transfection studies exogenous microdystrophin 
repair template, in the pursuit of achieving integration at the DMD intron 1 site.  
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Figure 4-10 Screening guide RNA efficacy with the use of HEK293T.Cas9 cells  
A) Constitutive GFP expression of HEK293T.Cas9 cells imaged at 100X magnification, using 1400ms 
exposure in the GFP channel 48 hours post seeding to a six well plate. B) A schematic of the Cas9 
expression cassette integrated into the AAVSI locus of the HEK293T cells. The human optimised 
Streptococcus pyrogenes Cas9 protein expression in these cells is driven by the CBh promoter, whilst the 
GFP and hygromycin transfection selection markers are under the control of the Ef1a promoter. This 
indicates that GFP expression is not necessarily reflective of the level of Cas9 protein in the culture. C) 
T7E1 digests undertaken on purified PCR amplicons, amplified from HEK23T.Cas9 genomic DNA 
following a range of treatments. Treatments included: Mock (M) HEK293T.Cas9 cells were treated with 
transfection reagent alone, or doses of 4μg, 2μg or 1μg of U6 expression cassettes encoding guide RNAs 
1 -4. Cleavage products consistent with gene-modification were present for each of the guide RNAs, 
with guide 1 providing the most robust gene editing. All samples were resolved on a 2% agarose gel 
alongside hyperladder IV. 
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Figure 4-11 Graphical summary of the efficacy of In Silico guide designs, following transient 
transfection of 1μg, 2μg and 4μg U6 guide plasmids encoding guide RNAs 1, 2, 3 or 4 into 
HEK293T.Cas9. 
Graphical summary of the mean gene modification estimated from the T7E1 treatment of 400ng of 
1960F and 2741R amplicon. Each of the samples were amplified from 250ng HEK293T.Cas9 DNA, 
following transient transfection of U6-guide plasmids containing guide RNAs 1, 2, 3 or 4 at 1μg, 2μg and 
4μg respectively. Notably, the mean gene modification was higher in samples treated with guide RNA 1 
relative to all other in silico guide designs. This effect was deemed statistically significant to the 95% 
confidence interval by a 2-way ANOVA. Finally, the effect of U6-guide 1 dose did not significantly change 
the amount of mean gene modification identified.  
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4.5 Assessing Non-Viral Delivery Strategies for Cas9 Nuclease into 
Immortalised Δ45-52 Patient Myoblasts. 
4.5.1 Transient Transfection of Px458 to Immortalised Patient Myoblasts 
Harbouring Deletions of Exon 45 -52 
Functional mismatch detection assays were established and guide RNA 1 was identified as the 
most efficacious of the in silico guide designs. To transition gene-editing approaches to a more 
therapeutically representative in-vitro dystrophic model, studies were undertaken in the Δ45-
52 immortalised DMD patient myoblasts. To facilitate this transition the empty Px458 plasmid 
construct was used to assess and optimise transfection efficiency (Ran et al. 2013). 
4.5.1.1 Lipofectamine3000 Transient Transfections of Immortalised Patient 
Myoblasts 
Transient transfection of Px458 was trialled initially with Lipofectamine3000, a reagent with a 
propensity to deliver DNA with high efficiency to difficult-to-transfect cells. The transfection 
was performed in accordance with the manufacturer’s protocol using a transfection reagent 
(μl) to DNA (μg) ratios of 1.5:1 or 3:1 with 2.5μg of Px458 or pCI-GFP positive control. In both 
ratios trialled, the delivery of pCI-GFP was successful, as determined by microscopy imaging 
and cytometric analysis of the proportion of GFP positive cells (Figure 4-12). In the 1.5:1 and 
3:1 ratios with pCI-GFP, mean percentage fluorescence was established to be 10.3% ± 1.29 
and 18.5%± 0.647 respectively (Mean ± SEM, N=3) which was deemed statistically significantly 
different at the 95% confidence interval by 2-way ANOVA. Whereas, in the case of Px458, 
transfection efficiency was diminished and mean percentage GFP was established to be much 
lower at 0.297% ±0.083 and 0.327% ±0.061 in both conditions yielding a non-significant 
difference. Finally, a statistical difference at the 95% confidence level was also observed 
between the number of GFP positive cells yielded from pCI-GFP and Px458 transient 
transfections.  
It was noted that the disparity in plasmid sizes used in the investigation (pCI-GFP is 4709bp, 
and Px458 is 9289bp) would result in more plasmid copies of pCI-GFP being present relative to 
Px458 in the 2.5μg DNA mass added to the transfection mixture.  It was speculated that this 
could in turn influence the transfection efficiency observed. To address this a dose escalation 
was required in which a 3:1 ratio of transfection reagent, asserted in the case of pCI-GFP to 
facilitate higher delivery, was used to deliver 2.5μg, 5μg and 7.5μg of Px458 (Figure 4-13).  
At these doses, mean percentage of GFP positive cells was established to be 2.39%±0.118, 
4.15% ±0.265 and 1.65% ±0.186 SEM respectively, with N =3 in all conditions. The difference 
observed was determined to be significant between the 2.5μg and 5μg doses, at the 95% 
confidence interval by 2-way ANOVA, but the difference between 2.5μg and 7μg was identified 
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as non-significant.  Notably, the baseline transfection of 2.5μg showed improved transfection 
efficiency relative to preceding experiment. However, the highest mean percentage of GFP 
positive cells observed in this experiment was ~5% achieved with the 5μg dose. This would 
provide a very small pool of cells to undergo gene modification and subsequent HDR, thus this 
method of DNA delivery was deemed insufficient for the requirements of the investigation. 
4.5.1.2 Viafect Transient Transfections of Immortalised Δ45-52 Patient Myoblasts 
Due to the unexpectedly low efficiency of Lipofectamine3000, a second transfection reagent, 
Viafect, was trialled in the delivery of Px458 plasmid to immortalised Δ45-52 patient 
myoblasts. Once more, transient transfections was performed in accordance with the 
manufacturer’s protocol In this instance three ratios of Viafect, 3:1, 4:1 and 5:1, were used to 
deliver 2μg of Px458 or pCI-GFP (Figure 4-14). At 48 hours post transfection there was a 
striking proportion of GFP positive cells, in both PCI-GFP and Px458 conditions. The mean 
percentage of GFP positive cells at ratios of 3.1, 4.1 and 5.1 for pCI-GFP was established as to 
be 75.33% ± 0.81, 75.93% ± 0.38 and 74.10% ± 1.40 SEM respectively and for Px458 to be 
31.25% ± 1.86, 20.56% ± 1.33 and 29.33% ± 2.53 SEM. A statistically significant 2-3 fold 
decrease in transfection efficacy was observed when delivering Px458 compared to pCI-GFP 
(95% confidence interval by 2-way ANOVA). 
The different ratios trialled showed comparable transfection efficiency, but toxicity and cell 
death occurred at higher transfection reagent to DNA ratios, as evidenced by phase contrast 
images of the 4:1 ratio of transfected patient myoblasts relative to the 3.1 ratio and mock 
conditions. In this instance the number of GFP positive cells at the 3.1 relative to the 4.1 ratio, 
was deemed significantly higher (p<0.05). This stated the difference observed between 3.1 and 
5.1 ratios was deemed non-significant. In light of the comparable transfection efficiency and 
visual indications of toxicity it was resolved that the lowest transfection reagent to DNA ratio 
of 3:1 would be adhered to from this point onwards.  
Using a 3.1 transfection reagent ratio, dose escalation delivering 2μg, 4μg and 6μg of Px458 
was then undertaken (Figure 4-15) yielding GFP positive cells of 38.92% ± 1.55, 42.89% ± 0.67 
and 38.5% ± 0.817 respectively (Mean +/- SEM;  N=3). No significant differences between the 
doses were observed. 
Whilst, the Lipofectamine3000 and Viafect transient transfections of Px458 were undertaken 
using slightly differing conditions as dictated by their associated protocols, comparison of the 
two transfection reagents highlights that Viafect achieves greater transfection efficiency than 
Lipofectamine3000. As noted by the maximal transfection efficiency achieved of >40% GFP 
positive cells following Viafect transfection of 4μg of Px458 relative to <5% following 
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transfection of 5μg of Px458 by with Lipofectamine3000.  Thus the Viafect transfection reagent 
was selected for ongoing assessments of gene editing.   
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Figure 4-12 Transient Transfection of PCI-GFP and Px458 into Δ45-52 Immortalised DMD patient 
myoblasts using lipofectamine3000. 
A) Phase Contrast (PC) and fluorescent microscopy images were taken of Immortalised Δ45-52 patient 
myoblasts in the FITC (GFP) channel. The cells were transiently transfected with 2.5μg PCI-GFP or Px458 
plasmids at 1.5:1 and 3:1 Lipofectamine3000 reagent μl: DNA μg ratios. All images were taken with the 
Zeiss microscope 48 hours post transfection, using 100x magnification. Phase contrast images were 
taken at 30ms exposure and GFP Images at 800ms exposure. The image displayed is representative of 5 
images taken per well. B) A bar chart showing the mean percentage of GFP positive cells, determined 
using flow cytometric analysis of cells fixed in 2% PFA-FACs buffer 48 hours post transient transfection. 
The transfection efficiencies of GFP and Px458 at the two ratios of lipofectamine3000 reagent, were 
compared by two-way ANOVA, it is indicated in the graph where differences are statistically significant.  
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Figure 4-13 A dose escalation of Px458 transfected into immortalised Δ45-52 DMD patient myoblasts.   
A) Phase Contrast (PC) and fluorescent microscopy images were taken of Immortalised Δ45-52 patient 
myoblasts in the FITC (GFP) channel. The cells imaged were transiently transfected with doses of 2.5μg, 
5.0μg and 7.5μg Px458 at a 3:1 Lipofectamine3000 reagent μl: DNA μg ratio. All images were taken with 
the Zeiss microscope 48 hours post-transfection at 100x magnification. Phase contrast images were 
taken at 30ms exposure and GFP Images at 800ms exposure. The image displayed is representative of 5 
images taken per well B) A bar chart showing the mean percentage of GFP-positive cells, determined 
using flow cytometric analysis of cells fixed in 2% PFA-FACs buffer 48 hours post transient transfection. A 
twofold difference between the 2.5μg and 5.0μg conditions was observed and deemed statistically 
significant by two way ANOVA. However the total transfection efficiency observed is a little under 5%, 
which is unlikely to enable sufficient DNA cleavage for dystrophin cDNA integration at the DMD intron 1 
site.  
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Figure 4-14 Transient transfection of PCI-GFP and Px458 into immortalised Δ45-52 DMD patient 
myoblasts using Viafect. 
Phase Contrast (PC) and fluorescent microscopy images were taken of Immortalised Δ45-52 patient 
myoblasts in the FITC (GFP) channel. The cells were transiently transfected with 2.0μg of PCI-GFP and 
Px458 plasmids at 3:1, 4:1 and 5:1 Viafect reagent μl: DNA μg ratios. Transient transfections of Px458- 
were undertaken alongside mock samples, in which cells were treated with 20μl of Viafect transfection 
reagent in isolation. All images were taken 48 hours post-transfection at 200x magnification on the Zeiss 
microscope. Phase contrast images were taken at 30ms exposure and GFP images at 800ms exposure. 
The image displayed is representative of 5 images taken per well. B) A bar chart showing the mean 
percentage of GFP-positive cells determined using flow cytometric analysis of cells fixed in 2% PFA-FACs 
buffer 48 hours post transient transfection, with differing ratios of Viafect reagent to pCI-GFP and Px458 
respectively. The transfection efficiencies of GFP and Px458 at the two ratios of Viafect reagent, were 
compared by two-way ANOVA, it is indicated in the graph where differences are statistically significant. 
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Figure 4-15 Transfected dose escalation of Px458 in immortalised Δ45-52 DMD patient myoblasts 
using Viafect transfection reagent. 
A) Phase Contrast (PC) and fluorescent microscopy images were taken of Immortalised Δ45-52 patient 
myoblasts in the FITC (GFP) channel. Cells were transiently transfected with the Px458 plasmid at doses 
of 2.0μg, 4.0μg and 6.0μg using 3:1 Viafect transfection reagent μl: DNA μg ratio. Transient transfection 
of the Px458 plasmid was undertaken alongside mock samples, in which cells were treated with 18μl of 
Viafect transfection reagent in isolation. The GFP expression was imaged with the Zeiss microscope 48 
hours post-transfection at 100x magnification, with phase contrast images taken at an exposure of 30ms 
and GFP images at an exposure of 800ms. B) A bar chart showing the mean percentage of GFP-positive 
cells, determined using flow cytometric analysis of cells fixed in 2% PFA-FACs buffer 48 hours post 
transient transfection, with differing doses of Px458 cas9 expressing plasmid. 
  
160 
 
4.5.1.3 Examination of Transfection Using the All-In-One Px458- Guide 1 Plasmid in 
Gene-Editing Experiments: 
After being used to establish transfection protocols, it was sought to use the all-in-one Px458 
plasmid for the purpose of gene editing. This was achieved by sub-cloning annealed oligos 
encoding guide 1, previously determined to be the most efficacious of in silico guide designs, 
into this plasmid backbone. In this manner GFP expression was used as a proxy to indicate the 
successful delivery of all constituents necessary for the CRISPR/Cas9 system to introduce DSBs 
at the DMD intron 1 locus.  
Transient transfection of Px458-Guide 1 was undertaken at both 2μg and 4μg doses in both 
HEK293T cells and immortalised Δ45-55 patient myoblasts. Microscopy images were taken 48 
hours post transfection, and GFP expression was use to visually assess the delivery of the 
Px458-Guide 1. The GFP expression was deemed comparable on gross estimation to previous 
transfections of the respective cell lines with the empty Px458 plasmid (Figure 4-16 and Figure 
4-19). 
Genomic DNA was harvested from both cell lines 48 hours post transient transfection of 
Px458-Guide 1, amplified using HotStart phusion polymerase and numerous methods were 
undertaken to estimate gene modification occurring at the DMD intron 1 locus.  The resultant 
amplicons were hybridised subjected to the standard T7E1 assay and subsequent cleavage 
products were then resolved and quantified using either a 10% TBE polyacrylamide gel or a 
high sensitivity DNA chip on the Agilent Bioanalyzer. The Agilent Bioanalyser uses 
electrophoretic microchips to determine nucleic acid size and concentration with high 
sensitivity, and it was speculated that this method could accurately identify the low levels of 
DNA cleavage product anticipated upon treatment of patient myoblast cultures. In addition to 
this, samples were also subject to tracking of InDels by decomposition (TIDE) analysis 
(Brinkman et al. 2014). This relatively novel TIDE method analyses sequence traces of wild type 
and treated amplicon products using a decomposition algorithm to assess for the presence of 
sequence modifications. TIDE was trialled due to the method in question being less expensive 
and labour intensive than mismatch detection assays. Furthermore, TIDE provides a greater 
level of insight into the resulting InDel spectrum at a DNA breakpoint. Collectively, these 
methods were used to provide robust quantification and insight into the gene editing 
occurring at the DMD intron 1 locus. 
Estimates of gene modification estimated varied in accordance with the method used. In the 
first instance a 20μl T7E1 digest was undertaken on 400ng of PCR purified amplicon, and a 17μl 
aliquot of the digest was resolved on a 10% TBE polyacrylamide gel (Figure 4-16-B). Gene 
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modification was quantified using Image J. For HEK293T cells treated with 2μg and 4μg of 
Px458-Guide 1 plasmid, this was estimated to be 4.00% ± 0.29 and 7.40% ± 1.14 respectively 
(Mean+/-SEM; N=3). The remaining 3μl digest sample was stored and 1μl was analysed using 
the Agilent Bioanalyser which produces a pseudo gel image and electrophoretogram for all 
samples (Figure 4-17). In this Bioanalyser method, cleavage products are presented as a 
percentage of the total sample and this fraction was used to provide mean percentage gene 
modification of 2.41% ± 0.37 and 4.86% ± 0.83 (Mean+/-SEM; N=3). Notably, a general non-
significant trend for the Bioanalyser to yield lower estimates of gene modification relative to 
samples resolved by polyacrylamide was observed. 
Finally sequencing was undertaken on 75ng of the same PCR purified amplicons. The resultant 
sequencing trace was subject to analysis using the TIDE algorithm web tool (https://tide-
calculator.nki.nl/) and a percentage estimate of InDels, proportional to gene modification was 
ascertained (Figure 4-18). The mean percentage of InDels was determined to be 10.93% ± 1.33 
SEM (N=2) and 10.31% ± 0.40 SEM (N=3), for 2μg and 4μg conditions respectively. Notably the 
difference between mean gene modification estimates obtained from 10% TBE polyacrylamide 
gel or Agilent bioanalyser relative to TIDE was generally denoted as statistically significant in 
most cases. 
The above was all achieved in HEK293T cells in the first instance, but the same analysis was 
undertaken in parallel for the immortalised patient myoblast samples which in the context of a 
10% TBE gel gave mean percentage gene modification values of 1.14% ± 0.39 and 5.24% 
±0.40 SEM (N=3), respectively, for the 2μg and 4μg transfection conditions (Figure 4-19).  In 
comparison the Agilent bioanalyzer determined a mean percentage of gene modification of 
1.08% ± 0.33 SEM (N=2) and 4.45% ± 0.71 SEM (N=3) (Figure 4-20). The difference in these 
two estimates of gene modification was once again deemed non-significant. In the context of 
TIDE the percentage of InDels present was deemed to be 6.85% ± 0.43 SEM (N=3) at 2μg and 
12.33% ± 1.88 SEM (N=3) (Figure 4-21). Once more the difference between mean gene 
modification estimates obtained from 10% TBE polyacrylamide gel or Agilent bioanalyser 
relative to TIDE was denoted as statistically significant in all cases at the 95% level. Finally, a 
graphical comparison of the methods undertaken to analyse the two transfection doses, for 
both cell lines can be seen in Figure 4-22.  
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Figure 4-16 Examination of Px458 Guide-1 Transfection efficiency and determination of gene-
modification in HEK293T cells.  
A) Phase Contrast (PC) and fluorescent microscopy images were taken of HEK293T cells in the FITC (GFP) 
channel Cells were transiently transfected with 2.0μg and 4.0μg doses of Px458-Guide 1 at a 5:1 Viafect 
reagent (μl): DNA (μg) ratio. Transient transfections of Px458-Guide 1 were undertaken alongside mock 
(M) samples, in which cells were treated with 20μl of Viafect transfection reagent in isolation. All images 
were taken with the Zeiss microscope 48 hours post transfection at 100x magnification, phase contrast 
images were taken at 30ms exposure and GFP images taken at 800ms exposure. (B) A T7E1 Assay 
performed on 400ng of DNA amplicon; amplified from genomic DNA harvested 48 hours post 
transfection using 1960F and 2471R, with the proofreading Hotstart Phusion polymerase (NEB). Samples 
were resolved on a 10% Tris-Borate-EDTA polyacrylamide gel run in 1X Tris-Borate-EDTA buffer 
alongside hyperladder IV (Bioline). Notably, across all Px458-Guide 1 treatments gene-modification is 
present, as indicated by the presence of cleavage products.  
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Figure 4-17 Agilent analysis of gene-modification in HEK293T treated with Px458-Guide 1 dual guide 
and Cas9 expressing plasmid. 
A) An example electrophoretogram, showing the analysis of a 1μl aliquot of a T7E1 digest, undertaken 
on hybridised amplicons and resolved on a high sensitivity DNA chip, alongside 1μl of high sensitivity 
DNA ladder. Samples were amplified from 250ng genomic DNA harvested 48 hours post transfection 
from HEK293T cells using 1960F and 2741R primers. Transiently transfected samples included: Mock in 
which cells were treated with 20μl of Viafect alone and either 2μg or 4μg of Px458-Guide 1. Peaks at 
15bps and 1500bps indicate higher and lower markers for the agilent, whilst peaks apparent at 512bps, 
288bps and 224bps are indicative of uncut and two cleavage products respectively. The area underneath 
the peaks was used to calculate levels of gene-modification. Notice in this instance the upper band 
appears to have a shoulder indicating the occurrence of a doublet. B) A composite gel, generated by the 
Agilent programme to simulate the amplicon resolution that would be apparent on gel electrophoresis. 
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Figure 4-18 Tide analysis of gene-modification in HEK293T cells mediated by Px458-Guide 1 dual guide 
and Cas9 expressing plasmid. 
A) A bar chart generated by TIDE analysis software (https://tide-calculator.nki.nl/), to indicate the 
percentage occurrence of InDels present in amplicons sequenced from a 4μg Px458-Guide 1 treatment. 
To achieve this, 250ng of HEK293T genomic DNA harvested from Mock and Px458 treatments 48 hours 
post transfection were amplified with 1960F and 2741R primers.  The resultant amplicons were purified 
and an aliquot corresponding to 75ng supplemented with 2μl 1960F at 10μM, was sent for sequencing 
by Eurofins MWG. Sequence traces obtained for mock and Px458 conditions were then compared by the 
TIDE software for the presence of decomposition at the guide 1 target site and the occurrence and type 
of InDels was estimated computationally. Note mock in this case was HEK293T cells incubated in the 
presence of 20μl of Viafect transfection reagent alone. B) A decomposition trace for the sample 
described in part A. Dark green indicates comparable reads, light green indicates trace decomposition. 
The gene modification of this sample is approximately 8% however this sample appears to have a 
relatively high background. 
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Figure 4-19 Examination of Px458 Guide-1 Transfection efficiency and determination of gene-
modification in immortalised Δ45-52 DMD patient myoblasts.  
(A) Phase Contrast (PC) and fluorescent microscopy images were taken of Immortalised Δ45-52 patient 
myoblasts in the FITC (GFP) channel. Cells were transiently transfected. Cells were transiently 
transfected with 2.0μg and 4.0μg doses of Px458-Guide 1 at a 3:1 Viafect reagent (μl): DNA (μg) ratio. 
Transient transfections of Px458-Guide 1 were undertaken alongside mock (M) samples, in which cells 
were treated with 20μl of Viafect transfection reagent in isolation. All images were taken with the Zeiss 
microscope 48 hours post transfection at 100x magnification, phase contrast images were taken at 30ms 
exposure and GFP images taken at 800ms exposure. (B) A T7E1 Assay performed on 400ng of DNA 
amplicon; amplified from 250ng of Immortalised Δ45-52 Patient myoblast genomic DNA, harvested 48 
hours post transfection using 1960F and 2471R, with the proofreading Hotstart Phusion polymerase . 
Samples were resolved on a 10% Tris-Borate-EDTA polyacrylamide gel run in 1X Tris-Borate-EDTA buffer 
alongside hyperladder IV (Bioline). Notably, across all Px458-Guide 1 treatments gene-modification is 
present, as indicated by the presence of cleavage products.  
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Figure 4-20 Agilent analysis of gene-modification in Δ45-52 Immortalised Patient Myoblasts mediated 
by Px458-Guide 1 dual guide and Cas9 expressing plasmid. 
A) An example electrophoretogram, showing the analysis of a 1μl aliquot of a T7E1 digest, undertaken 
on hybridised amplicons and resolved on a high sensitivity DNA chip, alongside 1μl of high sensitivity 
DNA ladder. Samples were amplified from 250ng genomic DNA harvested 48 hours post transfection 
from Immortalised Δ45-52 patient myoblasts using 1960F and 2741R primers. Peaks at 15bps and 
1500bps indicate higher and lower markers for the agilent, whilst peaks apparent at 512bps, 288bps and 
224bps are indicative of uncut and cleavage products respectively; the area underneath which was used 
for a calculation of gene-modification. Notice in this instance the upper band appears to be a single 
defined band. B) A composite gel, generated by the Agilent programme to simulate the amplicon 
resolution that would be apparent on gel electrophoresis. 
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Figure 4-21 Tide analysis of gene-modification in Immortalised Δ45-52 patient myoblasts mediated by 
Px458-Guide 1 dual guide and Cas9 expressing plasmid. 
A) A bar chart generated by TIDE analysis software (https://tide-calculator.nki.nl/), to indicate the 
percentage occurrence of InDels present in amplicons sequenced from a 4μg Px458-Guide 1 treatment. 
To achieve this, 250ng of Immortalised Δ45-52 patient myoblast genomic DNA harvested from Mock and 
Px458 treatments 48 hours post transfection were amplified with 1960F and 2741R primers.  The 
resultant amplicons were purified and an aliquot corresponding to 75ng supplemented with 2μl 1960F 
at 10μM, was sent for sequencing by Eurofins MWG. Sequence traces obtained for mock and Px458 
conditions were then compared by the TIDE software for the presence of decomposition at the guide 1 
target site and the occurrence and type of InDels was estimated computationally. Note mock in this case 
was immortalised Δ45-52 patient myoblasts incubated in the presence of 12μl of Viafect transfection 
reagent alone. B) A decomposition trace for the sample described in part A. Dark green indicates 
comparable reads, light green indicates trace decomposition. The gene modification of this sample is 
approximately 14% however this sample appears to have a relatively high background.  
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Figure 4-22 A graphical comparison of mean percentage gene modification estimated by the T7E1 
assay quantified in two independent ways and by TIDE analysis.  
A graphical summary of gene modification estimates attained from transient transfection of Px458-
Guide 1 at 2μg or 4μg into two cell lines. Estimates were obtained by resolution of T7EI cleavage 
products with either the use of 10% TBE polyacrylamide gels or the Agilent bioanalyser. Moreover, a 
final method, TIDE analysis was also used to assess the occurrence of InDels. Notably, the mean 
percentage gene modification estimated from the methods trialled followed the same trends across 
both cell lines, with TIDE giving the highest estimates and agilent the lowest.  All samples N=3 and the 
error bars represent the standard error of the mean. Samples in exception to this are except N=2 in 
HEK293T 2μg TIDE analysis and Immortalised Δ45-52 patient myoblast agilent analysis.    
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4.6 Establishing In-Vitro Transcription of guide RNAs and Delivery 
Approaches in the Context of Gene-Editing. 
Due to the moderate Px458 plasmid transfection efficiency observed in the immortalised Δ45-
52 patient myoblasts, the ability to produce and deliver CRISPR gene-editing reagents in an 
RNA format was assessed. It was speculated that this alternative delivery format could 
improve upon the low to moderate efficiency of plasmid-based approaches and increase the 
chance of the investigation attaining successful outcomes.   
4.6.1.1 Transient Transfection of GFP mRNA to HEK293T and Patient Myoblasts 
Harbouring Deletions of Exon 45 -52: 
Initially, assessment of RNA delivery to HEK293T and immortalised Δ45-52 patient myoblasts 
was undertaken using Lipofectamine Messenger Max and commercially produced GFP mRNA 
(Trilink). This was trialled using transfection reagent (μl): RNA (μg) ratios of 1.5:1 or 3:1, to 
deliver 2.5μg GFP mRNA in accordance with the manufacturer’s protocol. HEK293T and 
immortalised Δ45-52 patient myoblasts were seeded at 5x105 and 8.3 x 104 per well 
respectively and transfected when culture had attained 70% confluency in a 6-well plate.  
Transfection efficiency was then evaluated using fluorescence microscopy imaging and FACS 
analysis.  In HEK293T this resulted in a mean percentage of GFP positive cells of 58.48% ± 2.24 
and 88.83% ± 1.45 SEM (N=3) at the 1.5:1 and 3:1 ratios respectively (Figure 4-23). This was 
deemed a statistically significant difference by an unpaired t-test (p=0.0003). In immortalised 
Δ45-52 patient myoblasts this resulted in a mean percentage of GFP cells, of 59.12% ± 1.17 
and 63.89 ± 1.32 SEM at 1.5:1 and 3:1 ratios respectively (Figure 4-24).  Notably, the 
transfection efficiency of GFP mRNA into patient myoblasts at both 1.5:1 and 3:1 transfection 
reagent: mRNA ratios were comparable to transfection efficiencies observed at the lower 1.5:1 
ratio in HEK293T cells.  
4.6.2 Production and Genome Editing Efficiency of In-Vitro Transcribed Guide 
RNAs:   
Following demonstration of successful GFP mRNA delivery to the cell lines of interest, Guide 
RNA 1 was in vitro transcribed. Conventional methods of in-vitro RNA production depend on 
linearization and purification of plasmid DNA, prior to proceeding with an in vitro transcription 
process. However the short length of chimeric single guide RNAs utilised by the Cas9 system 
renders them amenable to a ‘one pot’ PCR method described by Liang (X. Liang et al. 2015).  
Briefly, this process anneals a customised forward primer and an invariant reverse primer to 
provide a short stretch of double stranded DNA encoding a single guide RNA that can be in-
vitro transcribed. The 67bp forward primer comprises a T7 RNA polymerase promoter directly 
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upstream of a GX20 guide sequence. The GX20 guide sequence functions as the ‘cRNA’ in this 
system conferring specificity to the genomic locus of interest. This sequence is contiguous with 
23bps of tracrRNA.  Importantly, the invariant reverse primer initiates on 23 nucleotides 
complementary to the 23 nucleotide tracrRNA sequence encoded by the forward primer. 
Beyond this sequence the reverse primer comprised 60 nucleotides that serve to complete the 
tracrRNA and encode a polyA sequence. 
A customised extended forward oligo was designed and synthesised to enable the production 
of guide 1 RNA. This was combined with an invariant extended reverse primer in a HotStart 
phusion PCR reaction to produce a double stranded DNA amplicon encoding single guide RNA 
1, downstream of a T7 promoter. This amplicon was then purified using the Qiagen PCR 
Purification kit and 1.5μg of this amplicon was then subject to an overnight in-vitro 
transcription reaction. The resultant transcribed RNA was then DNAse treated and purified 
again by a Qiagen PCR column system, with or without prior isopropanol precipitation and 
resolved on a 2% agarose gel to assess purity (Figure 4-25).  The isopropanol precipitation of 
transcribed RNA was investigated as it was observed that RNA was inaccurately and more toxic 
upon delivery to cells if the isopropanol precipitation was included in the method. 
Then 2.5μg of in vitro transcribed guide RNA from both purification streams was transfected 
into HEK293T.Cas9 cells at 70% confluency using a 3:1 ratio of Lipofectamine Messenger Max 
(μl): mRNA (μg). HEK293T.Cas9 culture genomic DNA was harvested 48 hours later, PCR 
amplified with 1960F and 2741R primers and 400ng of amplicon subject to the T7E1 assay and 
resolved on a 2% agarose gel (Figure 4-25). Notably, both guide purification methods produced 
comparable percentage gene-modification estimates of 5.50% ± 0.36 and 5.28% ± 0.82 SEM 
(N=3) with and without isopropanol precipitation respectively.  This indicated transcribed 
guide 1 RNA was functional and able to direct Cas9 nuclease cleavage. 
4.6.3 Production of In-Vitro Transcribed Cas9 mRNA and Genome Editing Efficacy 
in Immortalised Δ45-52 Patient Myoblasts: 
To facilitate the extension of an RNA-based CRISPR/Cas delivery platform to cell lines that do 
not have a stable integration of Cas9, production of Cas9 mRNA was examined. In pursuit of 
this 10μg digests of HC-Cas9 plasmid (Figure 4-26) containing a T7 RNA polymerase promoter 
upstream of sequence optimised Cas9 was linearised with the SpeI restriction enzyme (Figure 
4-27). The digest was subjected to Qiagen PCR purification, and used for in vitro transcription 
at 30°C for 4 hours with the T7 Ribomax Large Scale mRNA production kit (Promega, UK). The 
resulting transcripts were resolved on 3% gel to determine RNA purity and yield (Figure 4-25).  
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Cas9 mRNA and transcribed guide 1 RNA were then transfected into immortalised Δ45-52 
DMD patient myoblasts in two dose conditions: (i) 200ng guide 1 RNA with 1μg Cas9 RNA, or 
(ii) 400ng guide 1 RNA with 2μg Cas9 RNA. Harvested genomic DNA from the transfected 
myoblast cultures were PCR amplified, subjected to the T7E1 assay, and cleavage products 
resolved on 2% agarose electrophoresis gels (Figure 4-28). Striking gene modification was 
observed with estimates for the lower transfection dose being 17.4%, and the higher being 
10.4%.    
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Figure 4-23 Transient transfection of HEK293T with 2.5μg of GFP mRNA as a proxy for transfection 
efficiency. 
(A) Phase Contrast (PC) and fluorescent microscopy images were taken of HEK293T cells in the FITC 
(GFP) channel. Cells were transiently transfected Cells were transiently transfected with 2.5μg GFP 
mRNA at both 1.5:1 and 3:1 Lipofectamine Messenger Max reagent μl to RNA μg ratios. Transient 
transfections of 2.5μg GFP mRNA were undertaken alongside mock (M) samples, in which cells were 
treated with lipofectamine Messenger max reagent with: 3.75μl in 1.5:1 mock and 7.5μl in 3:1 mock 
respectively. All images were taken with the Zeiss microscope 48 hours post transfection at 100x 
magnification, phase contrast images were taken at 30ms exposure and GFP images taken at 800ms 
exposure.  B) A bar chart showing the mean percentage of GFP positive cells as assessed using flow 
cytometric analysis of treated cells fixed in 2% PFA-FACs buffer 48hours post transient transfection, with 
differing ratios of Messenger Max reagent to GFP mRNA.  The resultant GFP positive population was 
determined to be significantly different between the 1.5:1 ration and 3:1 ratio by unpaired t-test (p= 
0.0003). 
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Figure 4-24 RNA Transient Transfection of Immortalised Δ45-52 patient myoblasts, using GFP mRNA 
expression as a proxy for transfection efficiency 
A) Phase Contrast (PC) and fluorescent microscopy images were taken of the Δ45-55 patient myoblasts 
in the FITC (GFP) channel. Cells were transiently transfected, with 2.5μg GFP mRNA at both 1.5:1 and 3:1 
Lipofectamine Messenger Max reagent μl to RNA μg ratios. Transient transfections of 2.5μg GFP mRNA 
were undertaken alongside mock (M) samples, in which cells were treated with lipofectamine 
Messenger max reagent with: 3.75μl in 1.5:1 mock and 7.5μl in 3:1 mock respectively. All images were 
taken with the Zeiss microscope 48 hours post transfection at 100x magnification, phase contrast 
images were taken at 30ms exposure and GFP images taken at 800ms exposure.  B) A bar chart showing 
the mean percentage of GFP positive cells, determined using flow cytometric analysis of treated cells 
fixed in 2% PFA-FACs buffer 48hours post transient transfection, with differing ratios of messenger max 
reagent to GFP mRNA. There was no significant difference was found between the two transiently 
transfected populations. 
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Figure 4-25 Production of in vitro transcribed guide 1 and subsequent T7E1 assay: 
A) A T7E1 Assay performed on 400ng of DNA amplicon; amplified from 250ng of HEK293T.Cas9 genomic 
DNA, harvested 48 hours post transfection using 1960F and 2471R, with the proofreading Hotstart 
Phusion polymerase. Treatments included Mock (M) with 7.5μl of Lipofectamine Messenger Max alone 
and 2.5μg transcribed guide 1 RNA (purified with and without an isopropanol precipitation step. All 
samples were resolved on a 2% agarose gel, alongside hyperladder IV. Note all transfections were 
carried out using a 3:1 Lipofectamine messenger max transfection reagent: mRNA ratio. B) A 1μg aliquot 
of In Vitro transcribed Guide 1 RNA loaded onto a 2% agarose, alongside hyperladder IV. C) A graphical 
summary of gene modification estimates obtained through Image J analysis of the gel image shown in A. 
The difference between the gene modification estimates was deemed non-significant by an unpaired t-
test (N=3). 
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Figure 4-26 Ps3-Cas9-NLS-HA, A Cas9 Expression Cassette with an upstream T7 promoter amenable to 
In vitro transcription processes.   
This contains human sequence optimised Streptococcus Pyrogenes Cas9 downstream of 
cytomegalovirus (CMV) and a T7 RNA polymerase promoter (T7). Finally, the 3’ end of Cas9 has a HA tag 
and nuclear localisation signal (NLS), prior to terminating in a bovine growth hormone polyA. This 
plasmid was used for the T7 RNA polymerase and was used for Cas9 in vitro transcription experiments. 
In addition it harbours an ampicillin resistance cassette, used during bacterial heat shock transformation 
and to select for plasmid in starter and maxi cultures.  The plasmid was kindly gifted by Dr. Taeyoung 
Koo, from Professor Jin Soo Kim’s lab. 
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Figure 4-27 Images of agarose gels showing linearised HC-Cas9 and resultant mRNA production from 
in vitro transcription processes 
A) Gel electrophoresis of Linearised Human sequence optimised Cas9 plasmid (HC-Cas9), digested with 
the SpeI restriction endonuclease in triplicate as denoted by 1, 2 and 3, alongside Uncut (UC) controls 
resolved on a 1% agarose gel alongside hyperladder I in 1X TAE buffer.  This enzyme was selected as the 
restriction site upstream of the T7 promoter site. B) A 2μl aliquot of Cas9 mRNA, from the triplicate 
reactions undertaken, resolved on a 2.5% agarose gel alongside hyperladder III. Note all gels were 
resolved in 1x TAE buffer. 
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Figure 4-28 Examination of DNA cleavage following a dual transient transfection of in vitro transcribed 
guide 1 RNA and Cas9 mRNA, into Δ45-52 immortalised DMD patient myoblasts.  
A) A T7E1 Assay performed on 400ng of DNA amplicon; amplified from 250ng of Immortalised Δ45-52 
genomic DNA, harvested 48 hours post transfection using 1960F and 2471R, with the proofreading 
Hotstart Phusion polymerase. Dual transient transfection of transcribed guide 1 and Cas9 mRNA were 
undertaken at two conditions. Condition 1: 200ng transcribed guide 1 RNA and 1μg Cas9 mRNA and 
Condition 2: 400ng transcribed guide 1 RNA and 2μg Cas9 mRNA, with both Commercial Cas9 mRNA 
(CM) (using Cas9 mRNA from Trilink) and in-house in vitro transcribed Cas9 mRNA (IVT), the cleavage 
products following the T7E1 Assay were resolved on a 2% agarose gel alongside hyperladder IV in 1x TAE 
buffer. B) A graphical summary of gene modification estimated for the transient transfection of in house 
in vitro transcribed RNA using Image J analysis of condition 1 and 2 depicted on the gel image shown in 
part A.  Unfortunately, the co-transfection of guide 1 RNA alongside commercial cas9 mRNA did not 
produce quantifiable gene modification. 
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4.6.4 Production and Assessment of Cas9 Protein 
Finally, Cas9 protein was produced with the outlook to generate ribonucleoprotein (RNP) 
complexes by hybridising the protein to transcribed guide RNA, as first described by Kim et al 
(2014). This form of Cas9 delivery is becoming increasingly favoured in the gene-editing field 
owing to its ability to be introduced to hard-to-transfect cells lines ( Kim et al. 2014), low 
toxicity profiles ( Kim et al. 2014; Zuris et al. 2014; Yu et al. 2016) and finally transient 
expression profile ( Kim et al. 2014) which reduces the propensity for off-target effects ( Kim et 
al. 2014; Zuris et al. 2014; Tycko et al. 2016; Cho et al. 2014). These parameters could prove 
pertinent to the successful implementation of a gene editing strategy in the context of DMD 
patient myoblasts.  
4.6.4.1 Production, Concentration and Purification Processes for Cas9 Protein. 
The production of Cas9 protein was undertaken in Paris with the support and technical 
expertise of Dr. Anne DeCian in the lab of Dr. Jean-Paul Concordet, following the protocol of 
(Jinek et al. 2012). A pET-based expression plasmid encoding Cas9 protein (residues 1 -1368)  
was modified from the variant described in Jinek et al (2012), to include two further Nuclear 
Localisation Signals (NLS) this was to improve the shuttling of Cas9 protein to the nucleus of 
the cell, and subsequently enhance DNA modification achieved by the nuclease. The modified 
plasmid was used to produce Cas9 protein (Figure 4-29).  This plasmid encodes a fusion protein 
with N- and C- terminal hexahistidine (His) tags, and an N-terminal maltose binding protein 
(MBP) tags. The MBP tag functions to improve the solubility of recombinant Cas9 in E. coli and 
is separated from Cas9 by a tobacco etch virus protease cleavage site (TEV).  
Briefly, the pET-plasmid expressing Cas9 was introduced to chemically competent Rosetta 2 
BL21 E.Coli derivatives and the expression of Cas9 protein was induced with 0.2mM IPTG a 
mimic of the allolactose that triggers the lac operon. The bacterial culture was pelleted, re-
suspended in lysis buffer and sonicated. This crude lysate was loaded and immobilised on a 
HisTrapCrude FF 5ml affinity column prior to being competitively eluted in 3ml fractions with 
increasing concentrations of imidazole. A 2μl aliquot of each of the fractions was visualised on 
8% SDS-PAGE and visualized with Instant Blue staining.  This SDS-PAGE combined with 
absorption peaks at 260nm and 280nm was used to ascertain which column fractions 
contained Cas9 protein for subsequent enrichment processes (Figure 4-30).  
Following Histrap enrichment the Cas9 was concentrated, liberated from the MBP tag, and 
further purified using an SP sepharose ion exchange and size exclusion column 
chromatography. In each case 2μl aliquots of elutes and 260:280 ratios were used to assess 
Cas9 protein containing fractions (Figure 4-31 and Figure 4-32).  
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At this stage fractions identified as containing pure Cas9 were concentrated to 30μM and 
90μM and are denoted P108 and the P109. The P108 fraction of Cas9 protein at 30μM or 
4.7mg/ml concentration was pipetted into 20μl aliquots and snap-frozen in liquid nitrogen. 
This P108 aliquot is used in throughout this investigation.    
4.6.4.2 Validation of Cas9 Nuclease Activity via an In-Vitro Cleavage Assay: 
Once Cas9 protein was produced and purified an assessment of its activity to introduce DSBs 
was undertaken. Cas9 protein was complexed with  an in vitro transcribed test guide RNA 
‘GFP-T2’ which targets a GFP gene sequence (Mali, Yang, et al. 2013) and the RNP complex 
incubated with an Xmn1-linearised Vgej-AAV plasmid which contains a target GFP sequence 
(Figure 4-33-A). Using this assay the Cas9 nuclease was shown to be functional (Figure 4-33-B) 
by the emergence of the expected cleavage products of 3245bps and 2637bps. 
4.6.4.3 Delivery of Cas9 Protein to HEK293T Cells:  
Once the Cas9 protein was produced and validated by the in-vitro cleavage assay, the next 
milestone for the development of this system as a suitable gene editing strategy was the 
delivery of the Cas9 RNP to a mammalian cell culture. To facilitate this, Dr. DeCian kindly 
provided GFP- fused Cas9 protein which was transfected into HEK293T cells with the use of a 
3:1 Lipofectamine messenger max (μl) : protein (μg) using doses of 2.5, 5, 10 and 20μg Cas9-
GFP protein (Figure 4-34). These doses were selected due to the wide range of doses used 
throughout literature (S. Kim et al. 2014; Lin et al. 2014; X. Liang et al. 2015; Yu et al. 2016). 
Fluorescence microscopy images of the cells 3 hours after treatment showed GFP positive cells 
were present at all doses of Cas9-GFP protein with the signal dissipated by the 12 hours.  
4.6.4.4 Assessment of Gene Editing in HEK293T Cells Mediated by Cas9 RNP 
complexes:  
Once successful delivery had been demonstrated, RNP complexes were produced, comprised 
of Cas9 protein and transcribed guide 1 RNA. RNPs were formed by heating the guide 1 RNA to 
98°C for two minutes, cooling on ice, and then incubation at room temperature for 10 minutes 
with Cas9 protein at  4:1 and 2:1 ratios (ug: ug), comprising of 2.5μg:0.625μg and 2.5μg:1.25μg 
mixtures respectively. The RNP complexes were introduced into HEK293T cells using 
Lipofectamine CRISPRMax (Yu et al. 2016). The human DMD intron 1 site was assessed for 
gene modification using genomic DNA harvested 24 hours post treatment using PCR with 
1960F and 2741R primers, and the standard T7E1 assay.  The T7E1 assay with the 2:1 and 4:1 
ratio RNPs gave mean percentage gene modification values of 10.21% ±2.81 and 7.85% ± 0.10 
SEM respectively (Figure 4-35). In addition RNP-treated and control amplicons from the mock 
conditions were sequenced and assessed by TIDE which yielded mean percentage InDels of 
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31.5% ± 2.36 and 25.7% ± 3.71 SEM at 2:1 and 4:1 ratios respectively (Figure 4-35). This 
provides a demonstration of high efficiency gene-editing in mammalian cells using Cas9 RNPs 
as the delivery format.  
  
181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-29 A schematic map of the custom Pet plasmid expressing SpCas9 protein used in protein 
production processes. 
Custom Pet plasmid used to transform Rosetta BL2 and induced to produce Cas9 protein, with an N 
terminal hexahistidine-maltose binding protein (His-MBP) separated from Cas9 protein by a tobacco 
etch virus protease cleavage site. In addition, at the 3’ terminal of the Cas9, the plasmid harbours 6 x 
histidine tags for the process of purification using a nickel column. Note, this plasmid was modified from 
the PMJ806 plasmid from Addgene, which was used in the original production of Cas9 protein (Jinek et 
al. 2012), by cloning additional nuclear localisation signals in the 5’ and 3’ ends of the protein. Finally, 
the plasmid harbours a kanamycin resistance cassette, used during bacterial heat shock transformation 
and to select for plasmid in starter and maxi cultures.   
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Figure 4-30 Purification of MBP-Cas9 protein, by loading washing and eluting the samples from a crude lysate histrap column: 
A) A schematic of histrap crude FF 5ml column purification of Cas9 protein. The left column illustrates the loading process of Rosetta BL2 crude lysate post transformation with a 
custom Pet-plasmid encoding Cas9 protein and induction with 0.2mM IPTG. The hexahistidine tags on the C and N terminals of the Cas9 protein have affinity to and are 
immobilised by nickel present in the column.  The column on the right illustrates the elution process in which Cas9 protein – nickel binding is out competed using a buffer with a 
high concentration of Imidazole, which has a higher affinity for nickel. B) A 4-8% SDS PAGE gradient gel loaded with 2μl of flow through and sequential elution aliquots, these 
aliquots were selected on the basis of the Akter 260:280 absorption traces (Not shown). The samples were run alongside Page Ruler Plus prestained protein ladder and visualised 
with instant blue. 
183 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-31 Purification of Cas9 protein, liberated from the MBP tag, on an ion-exchange Sepharose Column 
A) A schematic of Sepharose column purification of Cas9 protein. The left column illustrates the loading process of concentrated TEV cleaved Cas9 protein post-HisTrap purification 
and dialysis. The positive charge of the Cas9 protein means it will have affinity to the negatively charged beads within this column and thus will be immobilised.  The right column 
demonstrates the elution process which was undertaken by using a high concentration of 1M KCL; the ions dissociate and out compete Cas9 protein for the negatively charged 
beads. B) A 4-8% SDS PAGE gradient gel loaded with 2μl of the initial (I) protein, flow through (FT) and sequential elution aliquots for pool 1, which was kept separate to ascertain 
purity based upon indication from the Akter 260:280 traces. C) The same as B, except for pool 2, which was implicated to be slightly purer than the former. The samples were run 
alongside Page Ruler Plus prestained protein ladder (L) and visualised with Instant Blue.  
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Figure 4-32 Purification of Cas9 protein using a Superdex 
size-exclusion column: 
A) A schematic of Superdex Size exclusion of Cas9 protein. 
The larger 150kDa Cas9 protein will be excluded from the 
porous beads and thus eluted in the void volume. In contrast 
smaller contaminants will be able to permeate the beads and 
thus will be eluted later. B) A 4-8% SDS PAGE gradient gel 
loaded with 2μl of the Sepharose purified initial (I) products 
and sequential elution aliquots for pool 1, based upon 
indication from the Akter 260:280 traces. C) The same as B 
except for pool 2. The samples were run alongside Page Ruler 
Plus prestained protein ladder and visualised with Instant 
Blue. Notably Pool 1 became P109 and Pool 2 P108, in 
accordance with the production numbers of Dr. Anne DeCian. 
Both samples in this process had similar purification.   
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Figure 4-33 In Vitro Cleavage Assay to 
determine Cas9 protein functionality.  
A) A schematic of pBIGT- VGEJ-AAV plasmid 
used in the in vitro cleavage process, linearized 
at the XmnI restriction site denoted by *. 
Importantly, this plasmid also has the site 
required for sgRNA GFP T2, a control guide 
RNA sequence (Mali et al. 2013). B) An assay of 
Cas9 protein activity of P108 and P109, 
alongside P102 a previously characterised Cas9 
control resolved on a 0.75% agarose gel, cast in 
ethidium bromide and resolved in 0.5X TBE 
buffer. Varying nM concentrations of 
ribonucleoprotein complexes (RNPs) 
comprised of Cas9 protein and guide RNA were 
used in this investigation including 5, 10, 50 
and 150nM. RNPs were made by using Cas9: 
sgRNA at a 2:1 ratio respectively. In addition 
5nM of a XmnI linearized pBIGT-vGEJ-AAV 
plasmid (200ng), which contained a suitable 
guide  target site within the eGFP was digested 
with the resultant RNP for 30 minutes at 37°C, 
prior to being halted with proteases and 
subjected to electrophoresis. The image was 
inverted to improve resolution of cleavage 
products.    
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Figure 4-34  Introduction of GFP-fused Cas9 protein in HEK293T using Lipofectamine CRISPRMax 
reagent.  
HEK293T cells were seeded at 3 x105 in a six well plate and transfected with a variety of Cas9-GFP 
protein doses 24 hours later when they reached at a confluency of approximately 50%, consistent with 
the 30-70% indicated in the protocol. Doses of the Cas9 protein included: 2.5μg, 5μg, 10μg and 20μg. 
These were transfected at a 3:1 transfection reagent μl: Cas9 protein μg ratio. In consideration of high 
Cas9 protein turnover, cells were imaged at 3, 6 and 12 hour time points. Images were taken at 100x 
magnification; phase contrast exposure of 30ms and GFP exposure of 4s was used. Cells appeared green 
consistent with the uptake of the Cas9-GFP protein, the cells exhibited low mean fluorescence, with a 
FITC signal observed most prominent with the 2.5µg dose at the 3 hour time point. Interestingly, over 
time cells are more challenging to discern likely in accordance with the degradation of the low level 
fluorescence. Moreover, a high background makes the determination of cells challenging; this could be 
due to Cas9-GFP protein being present in the media. Finally, the morphology of the cells at the higher 
transfection amount in the mock sample and the 20μg treated sample appears to change over the time 
course suggesting the reagent is associated with some toxicity.   
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Figure 4-35 Gene- modification determined for Cas9 protein HEK293T treated samples using TIDE. 
A) A T7E1 assay performed on 400ng of purified amplicons produced by PCR of genomic DNA harvested 
from HEK293T transfected with 2:1 and 4:1 Cas9 protein: guide RNA RNP mixtures  24 hours post 
treatment. Treatments comprised of 2.5μg of Cas9:1.25μg guide 1 RNA and 2.5μg Cas9: 0.625μg Guide 1 
RNA. Amplifications were performed using 1960F and 2741R primers with the proofreading Hotstart 
Phusion polymerase, hybridised and digested with T7E1, prior to being resolved on a 2% agarose gel in 
1X TAE buffer alongside Hyperladder IV. Notably, gene-modification is absent across mock conditions, in 
which cells were treated with 7.5μl Lipofectamine CRISPR Max and in Cas9 alone samples (C) in which 
2.5µg of Cas9 protein was transiently transfected in the absence of in vitro transcribed RNA.. Mean 
gene-modification was determined to be 10.2% =/- SD and 7.8%+/-SD from 2.1 and 4.1 conditions. B) An 
example bar chart generated by TIDE analysis software to indicate the INDEL spectrum present in an 
amplicon from a 2:1 RNP transiently transfected HEK293T genomic sample from decomposition 
determined relative to a mock baseline. C) A decomposition trace for the sample described in B. Dark 
green indicates comparable reads, light green indicates trace decomposition. The gene modification 
estimated for this sample is approximately 30.1%.  
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4.7 Discussion  
The repurposed CRISPR/Cas9 system was originally transiently transfected in a plasmid format 
to achieve gene-modification in mammalian cells (Mali, Yang, et al. 2013; Jinek et al. 2013; 
Cong et al. 2013; Fu et al. 2014). Since these early experiments the Cas9 plasmid constructs 
have been further developed, a chimeric single guide RNA has been generated to replace the 
dual crRNA and tracrRNA (sgRNA where the two components crRNA and TracrRNA are fused 
by a GAAA tetraloop), the Cas9 cDNA has been subject to sequence optimisation and finally 
the tethering of Cas9 to GFP (Jinek et al. 2013; Ran et al. 2013). The established protocols for 
the transient transfection of gene-editing plasmids and the aforementioned advances, that 
have served to simplify delivery, improve Cas9 protein expression and simplify the assessment 
of transient transfection efficacy made this delivery strategy attractive for this investigation. As 
such, plasmid based gene-editing techniques were initially trialled with HEK293T cells and 
immortalised Δ45-55 patient myoblasts.  
4.7.1 Establishing Mismatch Detection Assays 
Once western blotting confirmed that both Px165 and Px458 plasmids express Cas9 protein 
following transient transfection into HEK293T cells, an examination of the efficacy of in silico 
guide designs was warranted. In pursuit of this co-transfection of U6 guide plasmids encoding 
guides 1-4 alongside the Cas9 expressing Px165 plasmid was first trialled at doses of 1μg:1μg 
or 2μg:2μg. DNA was harvested at analysed with established mismatch detection assays, this 
being either the Surveyor (Qiu et al. 2004; Guschin et al. 2010) or T7E1 (de Massy et al. 1987; 
White et al. 1997) assay.  
Initially cleavage products from these assessments were resolved on agarose and proved 
challenging to visualise and quantify. When agarose was used to resolve cleavage products, 
quantifiable gene modification could not be quantified across either 1μg Guide: 1μg Px165 for 
either the Surveyor or T7E1 assay. In contrast 2μg of guide 1, 2 or 4 co-transfected with 2μg of 
Px165 could not be quantified in the surveyor assay, but mean gene modification estimates of 
11, 5 and 12% were estimated in the T7E1 assay respectively.  This finding could be due to 
differing resolution of the Surveyor and T7E1 agarose gels. However, a recent study by Vouillot 
et al 2015, comparing the Surveyor and T7E1 mismatch detection systems highlighted that the 
T7E1 enzyme was sensitive relative to the Surveyor nuclease (Vouillot et al. 2015). In line with 
study, current estimates suggests that the T7E1 assay can detect in the range of 0.5- 5% InDels 
(Zhu et al. 2015) relative to the 3 -5% detected by the Surveyor assay (Qiu et al. 2004; Fu et al. 
2013). This was pertinent to the decision to use T7E1 for future gene modification estimates.  
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Strikingly, when the same  1μg: 1μg and 2μg: 2μg  were treated with T7E1 and resolved on a 
10% TBE polyacrylamide gel, there was an apparent increase in gene-modification estimates. 
Guide RNAs 1 and 2 gave gene modification estimates in the 1μg:1μg conditions of 4 and 7% 
respectively. Furthermore, at in the 2μg:2μg condition an apparent increase in gene 
modification was observed for all guide RNAs, with a striking 2 fold difference in the case of 
guides 1 and 4 giving estimates of 27.1 and 24.9%. An important implication of this is that 
whilst mismatch detection cleavage products are resolved both on agarose (Qiu et al. 2004) 
and polyacrylamide gels (Guschin et al. 2010) and either is recommended in the 
manufacturer’s protocol (Transgenomic 2010), the estimates of gene editing will differ in 
accordance with the medium used to resolve the T7E1 cleavage products. This stated, the cost 
effectiveness of agarose meant this was used in provisional screens of guide RNA efficacy.   
4.7.2 Assessing the Efficacy of In Silico Guide Designs  
Continued examination of guide efficacy was undertaken in HEK293T.Cas9, in which 4μg, 2μg 
and 1μg doses of U6 plasmids encoding guide RNA 1, 2, 3 or 4 were transiently transfected.  
This cell-line constitutively expresses Cas9, thereby removing any variations in Cas9 expression 
that could occur on transient transfection of Px165.  Notably, this investigation demonstrated 
that guide1 produced higher mean gene-modification relative to all other in silico guide 
designs; this was deemed statistically significant at the 95% confidence interval by a two way 
ANOVA. This could also be seen visually on inspection of the gel images where mean gene 
modification in the range of 10-14% was observed for guide 1, 1-4% for guide 4 and 2% or less 
for guides 2 and 3.  
The finding that guide1 produces the best gene-modification is consistent with in silico 
predictions produced by CRISPOR (Haeussler et al. 2016). Notably, scores assigned to this 
guide based upon specificity (Hsu et al. 2013b) and efficacy (Doench et al. 2014) algorithms, 
which were developed after the initial guide designs of this study, were determined to be 69 
and 54 respectively. These scores are both above the threshold score of 50, which is used to 
assess whether a guide is favourable for development.  In addition, the increase in efficacy 
associated with this guide could be due it harbouring sequence determinant deemed 
beneficial to introduce DSBs at a locus, including: centrally positioned adenine nucleotides, a 
cytosine in position 20 and an adenine in position 1 (Doench et al. 2014). Note all numbering is 
PAM distal to proximal. 
4.7.3 Px458-Guide 1 Efficacy 
Guide 1 was selected for future experiments based on its higher efficacy relative to other in 
silico guide designs and examined using an all in one px458 plasmid backbone. Transient 
transfection of Px458- guide 1, demonstrated that gene-editing could be achieved in both 
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HEK293T and Δ45-52 immortalised DMD patient myoblasts using an all-in-one plasmid based 
approach.   
Importantly, Ran et al 2013 highlighted that the GFP tethered to the Cas9 does not affect the 
propensity of the Cas9 nuclease to cleave DNA. In consideration of this it is likely that the 
mean gene modification estimated at 4.0% and 7.4% in 2μg and 4μg transient transfections of 
Px458-guide 1 transfected HEK293T, is likely under reported. This is based upon the 
observation that co-transfection of 2μg U6-guide 1 and Px165 to HEK293T culture produced 
estimated gene modification of 27.1 % when resolved on 10% TBE polyacrylamide gel. Notably, 
this was a single reading established usingT7E1 assay; nonetheless this disparity in estimation 
was unanticipated. Further examination of gene modification resulting from U6-guide 1 and 
Px165 and Px458-guide 1 transfections would be beneficial to assess the most robust system 
for introducing DSBs at the DMD intron 1 locus.  
In exploration of determining robust estimates of gene modification, three methods were used 
to assess amplicons from the Px458 transient transfections in HEK293T and Immortalised Δ45-
52 Patient myoblasts. These included: T7E1 digest products resolved either on a 10% TBE 
polyacrylamide gel, or the Agilent bioanalyser and sequencing analysis of treated amplicons 
using TIDE analysis. Interestingly, the gene modification estimated by the 3 methods showed 
similar trends across the two cell lines. In both instances, the Agilent bioanalyzer showed an 
apparent but non-significant reduction in gene-modification estimates relative to that 
observed with 10% TBE polyacrylamide gels as established by 2 way ANOVA. Notably, in the 
case of HEK293T this resulted in almost a 2 fold reduction of estimates from 4% - 2.3% and 
from 7.4% - 4.8%. In contrast the reduction was subtle in the case of patient myoblasts from 
1.1% – 1% and 5.2%– 4.4%.  
Finally, both samples illustrated an increase in apparent gene-modification estimated by TIDE 
analysis. In the instance of HEK293T the mean gene modification was increased more than 2 
fold in the 2μg sample from 4% to 10.9%n deemed statistically significant and a more subtle 
difference in the 4μg sample from 7.4% to 10.3% deemed non-significant at the 95% 
confidence interval by two way ANOVA was observed.  In the case of patient myoblasts the 
effect was more striking with an increase from 1.1 to 6.8% and 5.2% to 12.3% in 2μg and 4μg 
treated samples, both of which were deemed statistically significant by two way ANOVA at the 
95% confidence level respectively.  
The results obtained serve to highlight that the methods used to determined gene-
modification can influence the estimates obtained from a single sample. TIDE analysis may 
have illustrated an apparent increase in gene modification on the basis that a multitude of 
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INDEL types are detected, including SNPs, which may not be susceptible to cleavage on the 
T7E1 assay (Brinkman et al. 2014; Vouillot et al. 2015). 
 An important implication of this finding is that where possible multiple methods to screen 
guide RNA efficacy should be undertaken.  This is suggested on the basis of increasing evidence 
that InDel patterns following gene-modification is a non-random process.  As evidenced by an 
extensive study that assessed 223 CRISPR guide RNAs and noted from sequencing that InDel 
patterns were maintained across multiple biological replicates (van Overbeek et al. 2016). Thus 
high efficacy guides that produce a high proportion of single nucleotide polymorphisms, could 
be excluded from further assessment if gene modification is only estimated by T7E1, which is 
unable to detect such subtle sequence alterations (Vouillot et al. 2015).   
Interestingly, a recent review by Tycko et al highlighted the requirement to standardise InDel 
detection methods at off-target sites by using stringent Next generation sequencing, a method 
with  high sensitivity estimated to detect 0.1% of InDels (Tycko et al. 2016; Kleinstiver et al. 
2016). Arguably, such a standardisation of gene-modification detection methods would also be 
helpful to characterise on-target gene modifications. In this manner, guide RNAs short-listed 
for development could be assessed using the existing accessible platforms, prior to being 
subject to defined delivery conditions standardised next-generation sequencing. This would 
provide a system by which guide RNAs between studies could potentially be bench-marked for 
activity.  
4.7.4 Alternative Cas9 Delivery Approaches 
In an attempt to improve upon the plasmid transient transfection delivery strategy in the 
context of patient myoblasts, alternative formats of Cas9 nuclease were examined, particularly 
as a transition in the field away from plasmid based gene-editing has become apparent (Zuris 
et al. 2014; Lin et al. 2014; S. Kim et al. 2014; X. Liang et al. 2015; Yu et al. 2016). Functional 
assessment of guide 1 RNA, produced by in vitro transcription, delivered to HEK293T.Cas9 cells 
in a six well plate highlighted the presence of DSB. Interestingly the quantification of mean 
gene modification in this instance asserted to be 5.5% was half the activity observed with DNA. 
Strikingly, however, when guide 1 RNA and Cas9 mRNA were co-delivered to patient cells in a 
12 well plate the gene-modification estimates attained were 17.4 and 10.4% for a lower and 
higher doses of mRNA delivered. This modification estimate is 3 times that achieved on 10% 
TBE gels with a plasmid based transient transfection. One reason for this disparity could be 
that the guide RNA and Cas9 mRNA was delivered in a six well plate in one instance and a 12 
well plate in another. This could serve to validate a recent argument that toxicity allowing, 
gene-editing reagents should be delivered to fewer cells at a 40-70% confluency (Yu et al. 
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2016). The premise being that this increases the amount of reagent relative to the pool of cells 
and functions much like a dose escalation. 
Unfortunately reproducing this result has proved challenging, which is likely indicative of 
variability within the mRNA quality. This serves to highlight the requirement for more stringent 
assessment of RNA quality; this could be achieved by resolving the RNA on a 3% agarose gel or 
on an Agilent Bioanalyser RNA microchip. Furthermore recent work in the field of gene editing 
has highlighted that extension of the polyA tail serves to increase mRNA stability (Yoshimi et al. 
2016). Moreover, in the course of this work a Cas9 GFP-tethered mRNA was produced (Yoshimi 
et al. 2016). These constructs could definitely facilitate the development of more robust RNA 
based gene-editing strategies in the context of the patient cells.  
The ribonucleotide protein format of the nuclease delivery was the last to be investigated. 
Initially, Cas9-GFP kindly provided by Dr. DeCian and Dr. Concordet, was delivered alone to 
assert identify a range of Cas9 protein doses that could be delivered to HEK293T cell culture 
with observable expression. This was an important milestone as a range of doses of Cas9 
protein from 1.5μg - 45μg were reported in literature, to be delivered alongside guide RNA (X. 
Liang et al. 2015; S. Kim et al. 2014; Lin et al. 2014). Using Lipofectamine mRNA messenger 
max 2.5μg and 5.0μg Cas9 protein appeared to be well tolerated in HEK293T cells. Whereas in 
comparison with untreated controls (not shown), the amount of transfection reagent required 
for the delivery of 10μg and 20μg Cas9 protein appeared to cause toxicity. The reason for this 
toxicity being observed in this instance but not reported in other investigations could be due 
to the route of delivery. Cas9 protein has been largely delivered by electroporation in gene 
editing studies (S. Kim et al. 2014; Lin et al. 2014; X. Liang et al. 2015). 
Notably, the field of cationic protein delivery continues to evolve, thus when a newer delivery 
reagent with reduced toxicity Lipofectamine CRISPR Max was released, this was used to trial 
lower doses of Cas9 protein with in vitro transcribed guide 1 RNA (Yu et al. 2016; Zuris et al. 
2014). When 2:1 and 4:1, doses of Cas9 protein: transcribed guide RNA were trialled mean 
gene modification was estimated to be 10.2% and 7.8% at the two ratio’s trialled when 
resolved on an agarose gel. The highest estimate is comparable to estimates obtained for 
guide 1 plasmid delivered into HEK293T.Cas9 cells and dual transfection of 2μg U6 guide 1 and 
2μg Px165 experiments, which provided gene modification estimates of 11.1% and 12.9% 
respectively. Furthermore, when the resultant intron 1 amplicon was subjected to TIDE 
analysis this showed nearly threefold increase in gene modification estimates, with 31.5% and 
25.7% being estimated, relative to 11% estimated for Px458-guide 1. Once again the different 
gene modification estimates serve to reinforce findings that multiple gene-editing assays 
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should be used to estimate mean gene-modification. Intriguingly, the InDel spectrum, this 
being the number of insertions and deletions at a DSB point differed between the Px458-guide 
1 and RNP analysis. This was unexpected as CRISPR guides are indicated to cause reproducible 
InDel patterns at a DSB point (van Overbeek et al. 2016). Interestingly, the increased number 
of larger deletions 3+ nucleotides observed with the Cas9 protein, could be attributed to either 
the Cas9 protein being more efficacious or due to the platform of delivery. This being protein 
as opposed to plasmid, further investigation is warranted. 
The work undertaken serves to expand the gene-editing repertoire of the lab and may prove 
beneficial to achieving a homology directed repair outcome in the lab. One constraint of this 
methodology however, is that is relies on efficient delivery of the MD1 repair template.  
However, recent work has demonstrated that Cas9 protein can be delivered alongside an 
Adenoviral Associated Viral vector. This virus with the packaging capacity of 4.5kb could be 
used to deliver the repair template whilst the Cas9 protein is able to introduce DSBs in cell 
culture. Furthermore, a dual strategy of this nature may also be supported by an alternative 
approach to introduce a transgene relating to NHEJ-mediated knock-in (Suzuki et al. 2016).    
4.7.5 Strategies to Enhance Gene-modification: 
In addition to the in-silico analysis for improved guide design (Chapter 3) and alternative 
delivery format of Cas9 nuclease, gene-modification at the human DMD intron 1 locus could be 
enhanced via a number of strategies, including: i) Improved single guide RNA architecture and 
composition to make it resilient to RNAse attack and subsequent degradation ii) Modified 
culturing conditions relating to the temperature the nuclease is incubated and iii) Examination 
of alternative delivery strategies, with electroporation appearing in literature to be the most 
efficient format.  
The original study fusing the crRNA and tracrRNA performed by Jinek et al. (2012), served to 
identify the minimum sequence architecture required to mediate a DSB. This was deemed to 
be 42nucletodies in length significantly shorter than the native dual RNA guide, comprised of 
cRNA and tracrRNA observed in the endogenous CRISPR-Cas9 system. However, since this 
numerous alterations to the single guide RNA architecture have been undertaken; 
predominantly these have served to examine the importance of duplex length and of the 
contiguous poly T stretch immediately downstream of the crRNA region, which serves 
endogenously to modulate the RNA III polymerase activity (Nielsen et al. 2013). Interestingly, a 
longer duplex than that used  by Jinek et al. (2012) was deemed optimal for mediating gene 
modification (Hsu et al. 2013b). Thus an sgRNA of approximately 85 nucleotides became the 
mainstay in the gene editing field, with extension beyond this deemed detrimental by Hsu et 
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al. (2013). In addition to this visualisation of telomeres undertaken using a dCas9, a Cas9 with 
ablated catalytic activity and an extended single guide RNA architecture harbouring mutations 
in the poly T region demonstrated increased target binding relative to the wild-type (Chen et 
al. 2013). Further assessment of these parameters in the context of knock-out generation, 
demonstrated that an increase of 5nt and the mutation of the 4th thymine to a cytosine 
adjacent to the cRNA, resulting in improved gene-editing outcome. Specifically, an increase 
guide efficacy when tested alone that was significant in a third of cases and an 10 fold increase 
when combined in knock-out  generation with a multiplex NHEJ-mediated deletion strategy 
(Dang et al. 2015). These sequence modifications have subsequently been adhered to in the 
gene-editing field. An implication of these investigations is that alternative single guide RNA 
scaffolds have varying propensity to introduce DSBs, further investigation and optimisation of 
the structure could serve to improve guide efficacy and subsequently the exploitation of NHEJ 
and HDR DNA repair pathways.  
In addition to an modified architecture of a single guide RNA, recent work has highlighted that 
modification of the encoding RNA could render it more resilient to RNAse activity (using a 
phosphorothiorate backbone)  and facilitate it attaining a conformation more favourable to 
RNA-DNA Watson Crick binding (the addition of 2’ O-Methyl or 2-Fluoro groups) (Rahdar et al. 
2015). Whilst investigations thus far indicate that the gene-editing achieved is sub-optimal 
relative to the single guide RNA in a plasmid delivery format, this may be attributable to the 
expression profile of the RNA delivered relative to plasmid. Furthermore, the increasing use of 
Cas9 nuclease highlights the requirement for more work in this area to be undertaken. 
It has been demonstrated previously that gene-editing with customisable nucleases, may be 
influenced by the temperature. Both ZFNs and TALENs have been demonstrated to show a 
higher level of efficacy in orchestrating a DSB, when cell cultures are placed under transiently 
hypothermic 30°C conditions (Doyon et al. 2010; Miller et al. 2011), an effect also 
demonstrated to extend to in vivo modification of the porcine and rat genes, upon TALEN 
mRNA injection into zygotes (Carlson et al. 2012; Remy et al. 2014).  Interestingly however, a 
recent paper has demonstrated that the Cas9 nuclease responds to temperature in a distinct 
manner from its predecessors, with increased gene editing efficacy at hyperthermic (39°C) as 
opposed to hypothermic (30°C) conditions (Xiang et al. 2017). This stated the effect was 
deemed to be subtle and not significant in many cell lines; nonetheless it may warrant 
investigation to improve gene modification. Finally, it was theorised that the increased gene 
editing observed was attributable to an increase in the expression of the guide RNA delivered 
and the activity of the Cas9 nuclease. In light of this it could be speculated that increasing the 
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amount of guide delivered, in addition to an increase in the temperature may serve to improve 
gene-editing outcomes.  
4.8 Conclusion: 
In conclusion this chapter assessed the efficacy of in silico guide designs targeted to the DMD 
intron 1 locus; it was found that guide1 produced DSBs with the highest efficacy. Thus this 
guide RNA will be used in future experiments to affect HDR-mediated integration of the 
MD1ΔEx1 transgene downstream of the full length dystrophin isoform promoters.  
In addition, plasmid based systems were explored in the introduction of DSBs to the DMD 
Intron 1 locus, including U6-guide plasmid alone in HEK293T.Cas9 cells and the U6-guide and 
Px165 Cas9 protein expressing plasmid co-transfection system or the Px458 all-in-one plasmid 
in HEK293T. The Px458 represents a particularly attractive for system for development as the 
GFP linked to Cas9 by 2A, can also be used to provide estimates of transfection efficiency.    
Finally, alternative systems of in vitro transcribed guide and Cas9 delivery and RNP formats 
were explored. These systems were also shown to have the propensity to introduce DSBs at 
the DMD intron 1 locus. Further research is required to establish these systems further. 
Nonetheless this represents an expansion to the gene-editing repertoire. 
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Chapter 5 Dystrophin Transgene Sequence Optimisation and 
Putative Design of cDNA-based Repair Templates: 
5.1 Introduction: 
As described previously, a CRISPR guide RNA, denoted as guide 1 was identified that directed 
high levels of DSB introduction at the selected human DMD Intron 1 site. Focus of the research 
then shifted to the design of a suitable exogenous repair template which would potentially 
allow insertion of recombinant cDNA sequences by HDR to mediate expression of dystrophin 
or microdystrophin. The exogenous repair template designed, will function as a cDNA donor 
during G2 and S phases of the cell cycle (Heyer et al. 2010). In the context of the therapeutic 
strategy under investigation, this repair template will serve to deliver a cDNA transgene 
encoding dystrophin variants from exon 2 onwards, utilising the full length endogenous 
promoters and DMD exon 1 to reconstitute the 5’ end of the dystrophin cDNA and, by 
extension the resultant protein. The primary emphasis will be to introduce microdystrophin 
cDNA, a functional albeit truncated dystrophin transgene, bearing deletion of dystrophin 
protein domains from spectrin-like repeat 4-23 and truncation of the C-terminal (MD1: ΔR4-
23-ΔCT)(Foster et al. 2008; Athanasopoulos et al. 2011). This strategy could also be applied 
with other dystrophin cDNAs but the MD1-based approach was initially investigated since its 
smaller size was deemed more favourable to integration via the HDR pathway. However, 
repair template plasmid design was developed with the intention to utilise this strategy, time 
permitting, to introduce the more extended dystrophin variants which may have functional 
advantages. These extended dystrophins variants included minidystrophin bearing an internal 
deletion of exons 45-55, a variant identified to result in mild Becker muscular dystrophy 
(BMD), which could be used to slow disease progression (Taglia et al. 2015) and full length 
dystrophin (Romero et al. 2004). Hence, the exogenous repair template was constructed to 
enable cloning and potentially the delivery of each of the dystrophin transgenes. Upon 
successful integration into intron 1, it is hypothesised that the endogenous full length 
promoters will transcribe exon 1 appropriately and this will splice to exon 2 of the MD1 cDNA 
and drive functional dystrophin protein expression, with spatial and temporal patterns 
consistent with that observed physiologically.  
5.1.1 Minidystrophin and Microdystrophin Transgenes 
Dystrophin has a modular architecture, comprising a N-terminal domain binding to 
cytoskeletal F-actin, a centrally located rod domain comprised of 24 coiled-coil spectrin-like 
repeats, interrupted by 4 proline rich hinges into 3 sub-regions, prior to a cysteine-rich region 
and C-terminal domains which associate with dystroglycan, syntrophin and dystrobrevin, and 
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other crucial components for the formation of the DAPC(Harper et al. 2002; Allen et al. 2016). 
In addition, it should also be noted that large in-frame deletions spanning the central rod 
region of dystrophin protein have been reported to result in mild symptoms.  As exemplified 
by the identification of BMD patient who patient lived into his 60s, despite of having a large 
deletion of central rod domain, equating to 46% of the dystrophin gene (England et al. 1990). A 
further recent example is provided by BMD deletions spanning exons 45-55 of the DMD gene 
(Taglia et al. 2015; Ousterout et al. 2015), which gives rise to a relatively benign BMD 
phenotype. These observations in combination prompted the development of shorter 
transgenes encoding the minimal components of dystrophin protein necessary to enable 
structural linkage between the intercellular cytoskeleton and the extracellular matrix. These 
smaller transgenes have the advantage that they can be delivered through packaging into 
lentiviral and AAV vectors, whose capacity is exceeded in the case of the native full-length 
dystrophin cDNA.  
Microdystrophins represent a compromise between the requirements to shorten the 
dystrophin cDNA, whilst retaining dystrophin protein functionality. It has been demonstrated 
at a biochemical level that microdystrophins enable the restoration of the DAPC (Bostick et al. 
2008; Koo et al. 2011), and at a physiological level they serve to reduce dystrophic pathology in 
both mouse and canine models of DMD (Koo et al. 2011; Le Guiner et al. 2017). Numerous 
microdystrophins have been designed by multiple groups (Wang et al. 2000; Harper et al. 
2002; Foster et al. 2008; Banks et al. 2010; Athanasopoulos et al. 2011; Reza et al. 2016). One 
well characterised microdystrophin is the ΔR4-23-ΔCT variant in which spectrin-like repeats 4 -
23 and the C-terminal region are removed. It has been demonstrated the removal of the C-
terminal of dystrophin is not detrimental to its structural function on the basis that 
syntrophins and dystrobrevins associate with the cysteine rich region of dystrophin protein 
(Yue et al. 2006). DNA constructs corresponding to microdystrophin (MD1, ΔR4-23-ΔCT), a 
minidystrophin harbouring deletion of exons 45-55 (minidystrophin Δ45-55), and the full 
length dystrophin itself were all considered as transgenes of interest for integration 
experiments of this investigation (Figure 5-1). Continued research has highlighted that several 
signalling molecules associate with the spectrin-like repeats of the dystrophin protein 
contributing to its function. Neuronal NOS associates with repeats 16-17 and is implicated in 
modulating the blood flow to muscles (Lai et al. 2009; Meng et al. 2016), and Par1b associates 
with repeats 6 and 7 and plays a role asymmetric division of satellite cells (Dumont et al. 2015). 
This has led to additional configurations of microdystrophin being designed and tested (Reza et 
al. 2016). However, in the current study we have focussed in particular on the sequence-
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optimised microdystrophin ΔR4-23-ΔCT transgene termed MD1 (Foster et al. 2008; Le Guiner 
et al. 2017) which has been shown to be highly functional in mouse and dog models of DMD.  
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Figure 5-1 Schematic of the full length, Quasi Δ45-55 Dystrophin and Micrdystrophin (R4-23 ΔCT) protein structure.  
N-terminal shown in pink,  proline rich hinge regions (H1-H4) shown as dark green squares, 24 spectrin-like repeats orange ovals (R1-R24), Cysteine rich region (CRD) light green 
rectangle  and the C-terminal orange rectangle. In addition to the dystrophin protein structure, signalling proteins that associate with dystrophin are also shown including actin 
(red oval), nitric oxide synthase (pink oval) and syntrophin (Syn) and dystroglycan (DTN) (dark blue and light blue ovals respectively).  These are the resultant protein structures 
that will be formed from the potential exogenous repair templates.  
Full Length Dystrophin Protein 427kDA 
Δ45-55 Dystrophin Protein 382kDA 
MD1Protein 137kDA 
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5.1.2 Sequence Optimisation of Dystrophin Transgenes 
Sequence optimisation broadly refers to the direct modification of a native DNA sequence, 
addressing parameters such as codon usage, DNA motifs, GC content and sequence 
repetitions, to increase resultant mRNA levels and stability and protein translation. This by 
extension serves to increase protein expression (Raab et al. 2010).   This first became of 
interest in molecular science as generation of native and recombinant human proteins was 
limiting to both basic research and therapeutic development. Early attempts to increase the 
production of human  proteins focused upon expression in E.Coli, thereby using the bacterial 
transcriptional machinery and quick doubling time to improve protein yield (Makrides 1996). 
Whilst the fast growth and easy culturing of this bacterium proved favourable to protein 
production and accessibility, the resultant protein exhibited some fundamental differences 
from the anticipated native protein. Notably, this included: aberrant folding of proteins, a lack 
of post translational modifications and evidence of protein aggregation. Furthermore, some 
constructs could not be expressed in E.Coli likely due to toxicity and/or size limitations (Fath et 
al. 2011). The alternative approach of autologous expression of the protein, this being 
expression in the native host cell culture, provided the expected protein but at sub-optimal 
levels (Fath et al. 2011).  
To overcome these limitations, sequence optimisation of DNA aimed to increase gene 
expression without the introduction of detrimental alterations to the downstream products 
was performed.  Several strategies were employed in pursuit of this goal and it should be 
noted that sequence optimisation is an on-going area of research that is still evolving. Two 
early strategies employed were focused upon DNA-motifs and back-translation. The first 
strategy was founded on the premise that certain DNA motifs regulate gene expression, some 
pertinent examples include: UpA critical for mRNA stability, CpG content correlated to de novo 
transcription and  AU rich elements related to mRNA stability (Fath et al. 2011). Once this was 
understood conventional genetic engineering approaches were employed to increase the 
occurrence of these motifs.  In parallel, it was shown that codon composition,  namely the use 
of codons favoured from a degenerate pool by the particular organism, could increase protein 
production by an order of magnitude  (Graf et al. 2000; Graf et al. 2004).  Hence the latter 
approach of back-translation was soon employed, causing a shift from genetic engineering to 
more de novo synthesis (Raab et al. 2010).  The former being modification of the nature of the 
genetic sequence and the latter being the commercial synthesis of an optimised product. 
The back-translation strategy is based upon the degeneracy of the genetic code. Degeneracy 
refers to the fact that a singular amino acid can be coded for by more than one codon.  The 
multiple codon combinations that could code for a singular amino acid are called synonymous 
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codons. However, the frequency of codon usage varies in accordance with organism and even 
tissue type (Plotkin et al. 2004). The central doctrine of back translation is to start the 
optimisation with an amino acid sequence and construct a DNA sequence comprised of codons 
most frequently used by the organism in which expression is desired. This underlying codon 
preference is posited to be due to variable tRNA pools within the given organism and/or tissue 
type, with larger pools of tRNA correlating to greater levels of translation (Cannarozzi et al. 
2010; Fath et al. 2011).   Although superficially this would appear to provide an optimal 
solution for expression, there are potential drawbacks that for this approach. Including the 
inadvertent introduction of undesired features such as restriction sites, splice sites and 
repetitive sequences (Raab et al. 2010). 
Thus  the ‘optimal sequence’ for a particular transcript is not obtained by using the back-
translation approach in isolation, but rather by compromising between optimal expression and 
the exclusion of certain undesirable sequence elements (Raab et al. 2010). Upon this 
realisation algorithms were employed to provide the optimal sequence solution by addressing 
these multiple parameters. Whilst it was universally recognised that the gold-standard to this 
approach would be to generate all of the possible combinations and test them, this is simply 
not a viable option as a great many combinations are possible. Raab uses the case in point that 
a 100 amino acid protein would have 1047 possible combinations (Raab et al. 2010). Thus 
‘optimal’ sequence results currently can only be calculated within the remit of the parameters 
of a given algorithm.  The Monte Carlo and GeneOptimizer Sliding window algorithms are two  
prominent algorithms (Gallagher et al. 1991; Raab et al. 2010). Although, the mathematical 
formulae, assertions and derivations are beyond the remit of this investigation, the conceptual 
elements of the algorithms harbour importance to sequence optimisation and thus will be 
briefly examined. 
The Monte Carlo algorithm uses a short sequence window and performs an exhaustive screen 
across a limited number of codons. The findings within this local region are then applied to the 
whole gene (Gallagher et al. 1991). This has been found in many instances to provide a protein 
where the local region within the window appears optimised, but globally a sub-optimal result 
is achieved.  The current gold-standard in sequence optimisation is the GeneOptimizer 
algorithm. Since an analysis of all the possible combinations is unachievable, this algorithm 
reduces the sequence space to a “variation window” of a few codons. An exhaustive search is 
performed in which all iterations of the sequence are trialled and analysed against desired 
parameters. If one of the iterations increases the overall quality of the protein optimisation 
then it is retained if not, it is disregarded. In this manner a candidate sequence is built. Upon 
achieving an optimal solution within the “variation window” the sequence is fixed and the 
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window shifts to the next region of the sequence in a unilateral manner, analogous to how it is 
transcribed in the cell (Raab et al. 2010). This continues along the entire length of the gene and 
until an optimal solution is achieved.  A singular multi-gene trial has been used to examine the 
GeneOptimizer algorithm extending to 50 genes (Fath et al. 2011), the results of which were 
striking with 96% of the sequence optimised constructs performing equal to or better than 
native counterparts. Moreover, 86% of the genes expressing in this subgroup showed a two-
fold or greater increase in expression relative to the native counterpart (Fath et al. 2011).  
In terms of this investigation, the sequence optimised transgenes that are being characterised, 
include full-length dystrophin, Δ45-55 minidystrophin and MD1 microdystrophin which have 
previously been optimised using GeneOptimizer algorithm, the MD1 construct referring to (R4-
23 ΔCT ) as previously described in the literature (Foster et al. 2008; Le Guiner et al. 2017). The 
sequence optimisation was undertaken using input parameters to optimise human codon 
usage and avoid detrimental cis-acting motifs including internal TATA boxes, chi-sites and 
ribosomal entry, AT- or GC-rich sequence stretches, RNA instability motifs, repeat sequences 
and RNA secondary structures, and cryptic splice donor and acceptor sites in higher 
eukaryotes. This sequence optimisation and de novo synthesis was undertaken by GeneArt 
prior to the initiation of this project. These constructs were subsequently examined to assess 
whether sequence optimisation increased expression levels of the corresponding recombinant 
protein. Optimised dystrophin variants hitherto will be referred to as Opt-HuDys (SO), Opt-
Δ45-55HuDys (SO) and Opt-HuMD1 (SO).  As described the GeneOptimizer algorithm uses a 
sliding window and accounts for optimisation in both a local and global manner. Thus owing to 
the varying lengths of all three constructs, subtle differences in sequence optimisation may be 
present.  
5.1.3 Chapter Aims: 
This chapter aimed to assess the expression of recombinant dystrophin protein resulting from 
both native and sequence optimised cDNA encoding microdystrophin, Δ45-55 minidystrophin 
and full length dystrophin. Subsequently, the design and molecular cloning of a generic 
exogenous repair template backbone was undertaken. This generic exogenous repair template 
was designed to unique endonuclease restriction sites to enable the sub-cloning and 
subsequent delivery of the 3 dystrophin cDNA variants. Finally, the microdystrophin variant 
was sub-cloned into the generic repair template plasmid.  
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5.2 Results: 
5.2.1 Assessment of Dystrophin Expression from Native and Optimised Fused 
Dystrophin-eGFP Expression Constructs. 
Initially, a microscopic indication of whether sequence optimisation improves transcription and 
subsequently synthesis of recombinant dystrophin protein was sought. Plasmids containing 
native and optimised Δ45-55 or full length dystrophin cDNAs directly fused to eGFP were 
transiently transfected into HEK293T cells. Expression was driven by the cytomegalovirus 
(CMV) promoter, a strong viral promoter to ensure adequate levels of protein expression. The 
fusion of eGFP to dystrophin enables fluorescence microscopy to be used as an indicator of 
dystrophin expression, particularly as the stoichiometry of eGFP to dystrophin is equivalent in 
the resultant fusion protein.  
Full length native and optimised dystrophin-eGFP fusion plasmids, Nat-hDys-eGFP and Opt-
HuDys-eGFP respectively, were transfected at a 4μg dose to HEK293T cells using a 5:1 ratio of 
Viafect transfection reagent (μl): DNA (μg). Cultures were then subject to microscopy imaging 
at 24, 48 and 72 hours post transfection. There was a dramatic difference in eGFP expression 
observed between cultures transfected with native and optimised plasmids across all time 
points examined. GFP positive cells were observed in all cultures indicating successful 
transfection with both native and optimised constructs, and in all samples the intensity of GFP 
fluorescence increased from 24-72 hours irrespective of optimisation, likely attributable to the 
accumulation of dystrophin-eGFP transcript and protein (Figure 5-2). The dramatic difference 
observed in eGFP expression between native and optimised constructs is speculated to be due 
to the sequence optimisation of the plasmid. The proposed implication being that the 
optimised construct enhances mRNA levels and/ or translational efficiency, and subsequently 
dystrophin-eGFP protein synthesis.  
 Native and optimised Δ45-55 minidystrophin-eGFP fusion constructs, Nat-Δ45-55hDys-eGFP 
and Opt-Δ45-55HuDys-eGFP (SO) were next examined in a similar way. The optimised Δ45-55 
minidystrophin-eGFP fusion construct also showed a dramatic increase in eGFP expression 
relative to the native construct (Figure 5-3). Thus the overall trend was retained across both 
studies.  
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Figure 5-2 Visual demonstration that sequence optimisation of cDNA improves recombinant protein 
expression as demonstrated by using constructs encoding native and optimised, full-length dystrophin 
fused to eGFP: 
HEK293T cells transfected with native and sequence optimised full length dystrophin-eGFP constructs, 
Nat-hDys-eGFP and Opt-HuDys-eGFP (SO) respectively. Transient transfections were undertaken at 4μg 
with a 5:1 viafect reagent: DNA ratio. Subsequent eGFP expression was imaged at sequential time points 
of 24, 48 and 72 hours with the Zeiss microscope at 100x magnification. Phase contrast (PC) images 
were undertaken at 30ms exposure and GFP images at 800ms exposure. A noticeable accumulation of 
eGFP expression can be seen in sequential time points for both constructs; in addition a difference in 
fluorescence intensity is seen between native and optimised dystrophin encoding constructs.  
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Figure 5-3 Visual demonstration that sequence optimisation of cDNA improves recombinant protein 
expression as demonstrated by using constructs encoding native and optimised Quasi Δ45-55 
dystrophin fused to eGFP 
HEK293T cells transfected with native and sequence optimised quasi Δ45-55 dystrophin-eGFP 
constructs, Nat-Δ45-55hDys-eGFP and Opt-Δ45-55HuDys-eGFP (SO) respectively. Transient transfections 
were undertaken at 4μg with a 5:1 viafect reagent: DNA ratio. Subsequent GFP expression was imaged 
at sequential time points of 24, 48 and 72 hours with the Zeiss microscope at 100x magnification. Phase 
contrast (PC) images were undertaken at 30ms exposure and GFP images at 800ms exposure. A 
noticeable accumulation of eGFP can be seen in sequential time points for both constructs; in addition a 
different in fluorescence intensity is seen between native and optimised dystrophin encoding 
constructs.  
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5.2.2 Quantification of the Difference in Expression of Native and Optimised 
Dystrophin Constructs Driven by a CMV Promoter: 
The increased fluorescent intensity observed prompted direct assessments by Western blot of 
dystrophin protein expression for both CMV-driven Nat-hDys and Opt-HuDys (SO) constructs. 
In this case constructs without the eGFP fusion were used. Transient transfections of plasmids 
were repeated in HEK293T as previously described; cultures were incubated for 72 hours and 
total protein lysate harvested for Western blot analysis. The protein samples were 
subsequently quantified and 50μg was examined with two dystrophin antibodies: the 6C5 
antibody, which binds to the C-terminus of the dystrophin, and the MannEx1011c, which binds 
to a dystrophin epitope encoded by exons 10 and 11. Blots were subsequently scanned and 
dystrophin expression was quantified and normalised against an alpha-tubulin loading control, 
using the Odyssey Licor system, as described in the Materials and Methods. 
Both the Nat-hDys and Opt-HuDys (SO) constructs expressed a 427kDa protein as determined 
by a HiMark Nupage Ladder, consistent with full length dystrophin. This was detected with 
both the 6C5 and the MannEx1011c antibodies. Congruent with the previous microscopic 
evaluations of eGFP fusions, the sequence optimised construct yielded a larger area band with 
increased intensity relative to the native construct. This trend was retained across 5 samples 
that were transiently transfected (Figure 5-4 and Figure 5-5). 
For the purposes of protein detection secondary-antibodies labelled with near-infrared (NIR) 
fluorescent dyes, with emission peaks detected within the 800nm and 700nm channels were 
used for dystrophin and alpha-tubulin respectively. This enabled the normalisation of 
dystrophin expression to alpha tubulin, to provide dystrophin / alpha tubulin expression ratios 
for both native and optimised dystrophin constructs. The mean ratio for optimised dystrophin 
was then divided the mean ratio of native dystrophin to provide a fold difference in 
expression. This form of analysis indicated a striking 57-fold difference with 6C5 antibody and 
a 22-fold difference with the MannEx101c antibody. This was deemed statistically significant in 
both cases giving a p=<0.001 by a two tailed unpaired t-test. 
Additionally, it should be emphasised that on examination of the western blot an alternative 
banding pattern between the two antibodies was observed. The 6C5 antibody appeared to 
produce a characteristic laddering pattern with the Opt-HuDys (S0) construct that was not 
observed in the case of the Nat-hDys construct. The additional banding seen had moderate 
intensity comparable to the full length band (Figure 5-1). In contrast the Mannex1011c 
antibody resulted in a singular sharp band for both Nat-hDys and Opt-HuDys (SO) constructs, 
with few additional bands at low intensity. In the case of the latter, this is likely result of 
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increasing the brightness to visualise the Nat-hDys bands. This could indicate that the 6C6, C-
terminal antibody detects further dystrophin splice variants or indeed degradation products. 
A parallel western blot series was extended to the Nat-Δ45-55hDys and Opt-Δ45-55HuDys (SO) 
constructs. These constructs yielded a 380kDa protein as determined by HiMark Nupage 
Ladder, consistent with the internal deletion of exons 45-55 present in this minidystrophin. 
Promisingly, this yielded similar results with an apparent increase in the area and intensity of 
the protein bands resolved in the sequence optimised condition (Figure 5-6 and Figure 5-7). In 
this experiment, no attempt was made to quantify the difference in expression resulting from 
native and sequence optimised constructs. This was not undertaken as the native Δ45-55 
Dystrophin band was barely visible relative to the optimised conditions, whilst the loading 
controls detected with alpha tubulin remained consistent. This suggested that the difference 
observed was significant, likely greater than that observed with full length dystrophin and 
would be over-estimated during quantification processes. 
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Figure 5-4 Optimisation of cDNA sequence increases recombinant dystrophin expression. 
Plasmids expressing native (Nat-hDys) and sequence-optimised dystrophin (Opt-HuDys-SO) cDNAs from 
the CMV promoter were transfected into HEK293T cells (n=5). After 72h protein were harvested using 
RIPA buffer and processed for Western Blotting (A) 50μg total protein lysate was analysed with 
antibodies to dystrophin (6C5) and alpha-tubulin. Dystrophin bands were then quantified relative to the 
alpha-tubulin loading controls and mean intensity ratios plotted (B: mean±SEM: ***8 p<0.001 
(unpaired t-test). Sequence optimisation produced a 57-fold increase in expression. Note that full length 
dystrophin corresponds to a 427kDa protein.  
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Figure 5-5 Optimisation of cDNA sequence increases recombinant dystrophin expression. 
Plasmids expressing native (Nat-hDys) and sequence-optimised dystrophin (Opt-HuDys-SO) cDNAs from 
the CMV promoter were transfected into HEK293T cells (n=5). After 72h cultures were harvested and 
processed for Western Blotting (A) 50μg total protein lysate was analysed with antibodies to dystrophin 
(ManEx1011c) and alpha-tubulin. Dystrophin bands were then quantified relative to the alpha-tubulin 
loading controls and mean intensity ratios plotted (B: mean±SEM: *** p<0.001 (unpaired t-test). 
Sequence optimisation produced a 22-fold increase in expression. Note that full length dystrophin 
corresponds to a 427kDa protein. 
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Figure 5-6 Optimisation of cDNA sequence increases recombinant Δ45-55 minidystrophin expression. 
Plasmids expressing native (Nat-Δ45-55hDys) and sequence-optimised dystrophin (Opt-Δ45-55HuDys-
SO) cDNAs from the CMV promoter were transfected into HEK293T cells (n=5). After 72h cultures were 
harvested and processed for Western Blotting (A) 50μg total protein lysate was analysed with antibodies 
to dystrophin (6C5) and alpha-tubulin. In this instance the samples could not be accurately quantified as 
the native quasi dystrophin had sub-optimal visualisation; banding in addition to the full-length band 
appeared apparent in the Opt-Δ45-55HuDys-SO lanes. Note Δ45-55 minidystrophin corresponds to a 
380kDa protein.  
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Figure 5-7 Optimisation of cDNA sequence increases recombinant Δ45-55 minidystrophin expression. 
Plasmids expressing native (Nat-Δ45-55hDys) and sequence-optimised dystrophin (Opt-Δ45-55HuDys-
SO) cDNAs from the CMV promoter were transfected into HEK293T cells (n=5). After 72h cultures were 
harvested and processed for Western Blotting (A) 50μg total protein lysate was analysed with antibodies 
to dystrophin (MannEx1011c) and alpha-tubulin. In this instance the samples could not be accurately 
quantified as the native quasi dystrophin had sub-optimal visualisation; banding in addition to the full-
length band appeared apparent in the Opt-Δ45-55HuDys-SO lanes. Note Δ45-55 minidystrophin 
corresponds to a 380kDa protein. 
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5.2.3 Quantifying the Difference in Expression of Native and Optimised Dystrophin 
Constructs Driven by a Spc512 Promoter: 
CMV driven constructs were used in the series of investigations described above. However, in 
the context of translational application a muscle specific promoter would be advantageous in 
providing expression restricted to muscle (Meng et al. 2016).  Nat-hDys and Opt-HuDys-SO 
constructs driven by the muscle specific Spc512 promoter (Li et al. 1999) were thus developed. 
In pursuit of this, 4μg of the constructs were transfected into HEK293T cells and total protein 
harvested at 72 hours for Western blot analysis. Protein samples were prepared, subjected to 
western blot and quantified in a manner consistent with the CMV based experiments. It should 
be noted that while HEK293T cells are not muscle derived, they do unexpectedly express 
constructs using the spc512 promoter  
The Opt-HuDys-SO construct once again resulted in a protein band of a greater area and 
fluorescent intensity, relative to Nat-hDys with both the 6C5 and ManEx1011c antibodies with 
15-fold and 17-fold increases respectively (Figure 5-8 and Figure 5-9). The laddering effect 
previously observed with the 6C5 antibody is retained even with the use of an alternative 
promoter.  
5.2.4 An Examination of Native and Optimised Microdystrophin Constructs Driven 
by the Spc512 Promoter: 
The ΔR4-23-ΔCT microdystrophin (MD1) is the shortest dystrophin variant in this investigation 
with a cDNA size of ~3.6Kb. Owing to its small size it was speculated that this transgene would 
be most likely to successfully integrate at the human DMD intron 1 site in a genome editing 
context. A sequence optimised variant of this dystrophin transgene was previously synthesised 
by the Dickson lab and placed downstream of the a Spc512 muscle specific promoter 
(Athanasopoulos et al. 2011). It was synthesised on the basis that this would be most 
favourable for translational gene augmentation studies, however direct comparison with 
native non-optimised forms had not been performed. The previous examination of Spc512 
driven constructs encoding full length dystrophin cDNA, highlighted that sequence 
optimisation improved protein expression, even in HEK293T cell culture. This finding indicated 
that differences in MD1 protein expression of native and optimised cDNA under the control of 
the Spc512 promoter could be examined in the same manner.  
 A native microdystrophin sequence counter-part of MD1 was synthesised, characterised and 
sequenced by Dr Susan Jarmin. This construct was kindly provided to enable a comparison in 
protein expression resulting from native and optimised MD1 cDNA driven by the Spc512 
promoter. As the small size of the MD1 cDNA prompted this to become the primary dystrophin 
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variant utilised during genome editing and HDR integration experiments, this arguably made 
an assessment of protein expression of these construct more pertinent. 
Importantly, both Nat-hMD1 and Opt-HuMD1 (SO) expressed a 137kDa protein upon Western 
Blotting with the MannEx101c antibody consistent with the size anticipated. Once more the 
sequence optimised condition, produced a band with a greater area and much increased 
intensity relative to the native construct (Figure 5-10). The subsequent analysis indicated a 23-
fold difference, which was asserted to be statistically significant by unpaired T-Test p=0.0001.  
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Figure 5-8 Optimisation of cDNA sequence increases recombinant dystrophin expression. 
Plasmids expressing native (Nat-hDys) and sequence-optimised dystrophin (Opt-HuDys-SO) cDNAs from 
the Spc512 promoter were transfected into HEK293T cells (n=5). After 72h cultures were harvested and 
processed for Western Blotting (A) 50μg total protein lysate was analysed with antibodies to dystrophin 
(6C5) and alpha-tubulin. Dystrophin bands were then quantified relative to the alpha-tubulin loading 
controls and mean intensity ratios plotted (B: mean±SEM: ***8 p<0.001 (unpaired t-test). Sequence 
optimisation produced a 15-fold increase in expression. Note that full length dystrophin corresponds to 
a 427kDa protein.  
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Figure 5-9 Optimisation of cDNA sequence increases recombinant dystrophin expression. 
Plasmids expressing native (Nat-hDys) and sequence-optimised dystrophin (HuDys-CO) cDNAs from the 
Spc512 promoter were transfected into HEK293T cells (n=5). After 72h cultures were harvested and 
processed for Western Blotting (A) 50μg total protein lysate was analysed with antibodies to dystrophin 
(ManEx1011c) and alpha-tubulin. Dystrophin bands were then quantified relative to the alpha-tubulin 
loading controls, and mean intensity ratios plotted (B: mean±SEM: **** p<0.0001 (unpaired t-test). 
Sequence optimisation produced a 17-fold increase in expression. Note that full length dystrophin 
corresponds to a 427kDa protein.  
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Figure 5-10 Optimisation of cDNA sequence increases recombinant microdystrophin expression. 
Plasmids expressing native (Nat-MD1) and sequence-optimised dystrophin (Opt-MD1-SO) cDNAs from 
the Spc512 promoter were transfected into HEK293T cells (n=5). After 72h cultures were harvested and 
processed for Western Blotting (A) 50μg total protein lysate was analysed with antibodies to 
microdystrophin (ManEx1011c) and alpha-tubulin. Microdystrophin bands were then quantified relative 
to the alpha-tubulin loading controls, and mean intensity ratios plotted (B: mean±SEM: *** p<0.0001 
(unpaired t-test). Sequence optimisation produced a 23-fold increase in expression. Note the 
microdystrophin construct refers to a 137kDa protein. 
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5.2.5 Design of an Exogenous Repair Template Plasmid Backbone Compatible with 
multiple dystrophin cDNA Variants: 
The exogenous repair template was designed with numerous features to make it optimal for 
this investigation. Firstly, it included a backbone sequence amenable to the cloning of multiple 
dystrophin cDNA variants including full-length, Δ45-55 and MD1, all SO on the basis of 
expression studies performed above. Secondly, a splice acceptor was appended at the 5’ end, 
in place of a promoter. The presence of the splice acceptor would enable the endogenous 
dystrophin full-length promoters Dp427c, Dp427m, Dp427p1, Dp427p2 and unique exon 1 
elements to splice to the exogenous repair template cDNA. As a consequence, the resultant 
protein will have the correct spatial and temporal expression patterns. It is hypothesised that 
this will ameliorate a range of pathogenic disease causing mutations across the DMD gene, and 
has near universal applicability to DMD patients. 
To attain a backbone sequence amenable to the cloning of a variety of dystrophin cDNA 
transgenes all unique restriction endonuclease sites were identified across full length Opt-
HuDys (SO), Opt-Δ45-55HuDys (SO) and Opt-HuMD1 (SO). This served to identify two unique 
restriction sites which were present and consistent across all of the above dystrophin 
plasmids. At the 5’ end this was FseI, present 30 nucleotides into exon 6 and at the 3’ end NotI 
situated at the terminus of exon 79. Thus a sequence was constructed with the following 
features: 
- DMD cDNA of exons 2-6 upstream of an FseI site 
- Intervening cyan fluorescent marker sequence 
- 3’-located NotI site.  
It was determined that this backbone construction would enable directional cloning of all 
sequence optimised dystrophin variants outlined previously, and this was the central premise 
around which the exogenous repair template was developed. 
In construction of an Exon 2-6 DMD cDNA block, consensus sequences of exons 1-6 of the 
Dp427m isoform were aligned against full length sequence optimised dystrophin cDNA 
(Sequence unpublished, Dickson Lab). In this manner, exons 1-6 of sequence optimised 
dystrophin cDNA was identified, and exon 1 determined as the first 31 nucleotides of the 
sequence removed.  It was anticipated that these nucleotides would be reconstituted by the 
endogenous Dp427m promoter-exon 1 sequence, upstream of the intron 1 DMD target site on 
successful RNA splicing, to integrated dystrophin transgenes. To this purpose, exon 2 was 
flanked at the 5’ end with a human β-globin synthetic splice acceptor and other regulatory 
sequences to facilitate splicing, including a polypyrimidine tract and synthetic branch points 
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(Seth et al. 2008; Popplewell et al. 2013). This splice acceptor was selected to facilitate the 
splicing of the endogenous promoter to the integrated dystrophin transgene, on the basis of 
being ranked as a strong splice acceptor site by Human Splice finder (Desmet et al. 2009) and  
previously being  used successfully by our lab (Popplewell et al. 2013).  To provide the repair 
template with more flexibility, this sequence was modified to include a silent mutation, to 
generate a HpaI restriction site.  This would enable the β-globin synthetic splice acceptor to be 
replaced with a splice sequence native to the DMD gene with ease should this be required. 
The 3’ end of this cDNA block, downstream of the NotI site, was also flanked by a sequence 
indicated to improve transcription in lentiviral vectors, a mutated woodchuck hepatitis virus 
post-transcriptional regulatory element (mWPRE) fused to a polyadenylation site polyA 
(Ranzani et al. 2013). This mutated WPRE and polyA tail sequence was kindly provided by Prof. 
Rafael Yanez.  
Between these FseI and NotI sites, a cyan fluorescent protein (CFP) was encoded. The 
sequence was gifted by Michael Davidson, (Addgene plasmid #54595, unpublished) and 
modified to remove the initiating methionine and append the first two nucleotides of DMD 
exon 2. This was undertaken to retain the open reading frame of partial Dys-CFP fusion protein 
and reduce background fluorescence that may arise from aberrant firing of the methionine. 
This was anticipated to provide the benefit of a visual blue-fluorescent output, which could be 
used to indicate Dys-CFP transgene integration and track subsequent enrichment processes. It 
was anticipated that this would streamline the development of integration methods in 
HEK293T cells and DMD patient myoblasts. The presence of a 491bp band removed upon FseI 
and NotI double digest could be used to indicate successful cleavage of the repair template 
and facilitate sub-cloning of dystrophin cDNA variants.  
Due to the HDR DNA pathway utilised in gene-editing, occurring with relatively low efficiency, 
an antibiotic selection cassette, SV40-Zeocin-PolyA, was placed downstream of the WPRE and 
PolyA sequences (Heyer et al. 2010). This encodes the She Ble protein, which when expressed 
renders the zeocin antibiotic inactive. This sequence was gifted by Rudolf Jaenisch (Addgene 
Plasmid #20725) and modified to include a silent point mutation to remove a FseI site present. 
This ensured the unique core FseI and NotI sites required for directional sub-cloning of 
dystrophin variants was retained.  
The decision to use a zeocin selection cassette was made because during the immortalisation 
process of DMD patient myoblasts harbouring  the deletion of exons 45-52 (Δ45-52), 
resistance to puromycin and neomycin antibiotics was introduced (Mamchaoui et al. 2011). 
Importantly, the zeocin cassette was floxed with LoxP sites that can conditionally remove 
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intermediate sequences in the presence of Cre-recombinase.  Continued expression of the She 
Ble protein is undesirable in any future clinical context (Marie et al. 2010) and Cre-mediated 
excision can provide a solution.  
Once the sequences of all constituents were assembled, they were flanked with 1kb arms of 
homology. These were derived from human DMD Intron 1 consensus sequence from NCBI. The 
two 1kb arms initiated either 6 nucleotides upstream of guide 3 or 6 nucleotides downstream 
of guide 4, these being the most upstream and downstream of the CRISPR guides identified. 
Consequently, none of the selected guide RNA target sequences were encoded within the 
exogenous repair template. This feature circumvents the risk that the repair template plasmid 
DNA may be cleaved by the Cas9 system in situ, or indeed that dystrophin cDNA variants might 
re-targeted following integration into the genome.  
Once the full sequence of the human DMD intron 1 repair template was compiled, it was 
assessed in parallel with dystrophin variants and the ISceit-Lentiviral vector for the absence of 
common restriction endonucleases. The list of common non-cutter restriction endonucleases 
was examined for compatibility in a double digest setting and used to flank all components of 
the exogenous repair template. This was sequence was then submitted to GenScript, 
synthesised and sequenced in a pUC57 backbone (Figure 5-11). Finally, the sequence was 
inserted in reverse orientation into the ISciet lentiviral backbone, to maintain the viral mRNA 
structure and prevent aberrant splicing or termination occurring (Figure 5-12).  
 
220 
 
Figure 5-11 A linear schematic of the pUC57- human DMD intron 1 plasmid repair template, synthesised by GenSys. 
A linear schematic of pUC57-hINT1-RT empty vector. The FseI and NotI sites flanking the Cyan fluorescent marker, serve as the directional cloning sites for all otpimised dystrophin 
variants: MD1, Quasi-Dystrophin and Full length dystrophin. Upstream of this cloning site is a 1kb left arm of homology, synthetic beta globin splice acceptor and Exons 2-6 of 
optimised DMD cDNA.  Downstream of this cloning sequence  is the WPRE and polyA to enhance expression followed thereafter by a floxed zeocin cassette to facilitated selection 
and a 1kb right arm of homology. Where possible this constituents are flanked by unique restriction sites that are annotated, ensuring that the repair template is not only common 
to all optimised forms of dystrophin but also amenable to changing constituents if required. 
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Figure 5-12 A schematic of the Lentiviral human DMD intron 1 plasmid repair template: 
A lentiviral vector encoding the human DMD Intron 1 repair template; notably, the constituents of the 
human DMD intron 1 plasmid run in reverse orientation to the transcription of the lentiviral plasmid; 
this is to prevent aberrant splicing from occurring that may be detrimental to viral mRNA transcription 
and subsequently viral production. This includes the FseI and NotI cloning sites downstream of 
optimised DMD cDNA exons 2-6, CFP protein and Woodchuck hepatitis virus regulatory element 
(WPRE). In addition the upstream and downstream 1kb arms of homology isogenic to the genomic 
sequence adjacent to the guide sites in intron 1 and the floxed zeocin cassette are also present. 
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5.2.6 Sub-cloning MD1 into the pUC57 Intron 1 Exogenous Repair Template: 
Following the synthesis of the Intron 1 exogenous repair template, focus was shifted to the 
sub-cloning of the MD1 from exon 6 to exon 79 between the FseI and NotI endonuclease 
restriction sites. To this purpose MD1 was subject to a series of diagnostic digests to assert the 
identity of the construct (Figure 5-13). Once assured the construct digested in a manner 
consistent with that anticipated, both the destination vector pUC57-hINT1-RT and MD1 
plasmids were subject to double digest with FseI and NotI restriction endonucleases. In the 
case of the destination vector the double digest served to remove the CFP marker and leave a 
6638bps backbone, whereas in the case of the MD1 it enabled the cDNA insert of interest to 
be liberated resulting in a 3213bp band (Figure 5-14).  Samples were resolved by 
electrophoresis and gel purification, prior to being subjected to overnight ligation. 
Subsequent ligation mixtures of insert and destination vector and controls were then subject 
to standard heat shock transformation in Top-10 cells. The E.coli suspension was allowed to 
recover and plated onto ampicillin plates for an overnight incubation at 30°C. The vector 
control yielded no colonies, indicating that no self-ligation had occurred, likely attributable to 
the incompatible DNA termini resulting from the double digest. In contrast, the ligation 
mixtures yielded a high number of single colonies that could be picked and characterised. 
These results taken together serve to indicate that the MD1 fragment from exon 6-79 was 
likely to have ligated correctly into the destination vector backbone.  
To assess whether ligation was successful a colony PCR was undertaken. The primer pairs were 
designed for the colony PCR so that the forward primer was present within the Exon 2-6 region 
of the pUC57-hINT1-RT backbone upstream of the FseI cleavage site, whereas the reverse 
primer with the MD1 transgene, would only be present if the MD1 insert was ligated (Figure 
5-15). Thus the 221bp resultant amplicon was only anticipated to occur in instances where the 
MD1 transgene had been successfully inserted into the pUC57-hINT1-RT destination vector in 
the correct orientation. Amplification of the Spc512-HuMD1 (SO) plasmid was used as a 
positive control, and the pUC57-hINT1-RT destination vector pre-digest and ligation served as a 
negative control.  Strikingly, all of the 32 colonies screened were positive for the presence of a 
221bp amplicon. This indicated that the MD1 transgene was successfully inserted into the 
pUC57-hINT1-RT destination backbone in all colonies screened.  
The first 4 colonies from the colony PCR series were selected and grown as a starter culture, 
the resulting plasmid isolated and subject to restriction digest confirm presence and identity of 
the MD1 transgene insert. Initially, FseI and NotI double digestion was performed on putative 
pUC57-hINT1-MD1-RT clones alongside the parental pSpc512-HuMD1-SO plasmid, which 
provided the insert. If ligation was successful a 3213bp fragment would be liberated from the 
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pUC57-hINT1-RT backbone as opposed to the former 491bps CFP fragment. All four colonies 
gave the anticipated digest profile (Figure 5-16A). 
Additionally, a diagnostic digest using the ScaI restriction endonuclease was undertaken. This 
produces distinct banding patterns for the parental Spc512-HuMD1 (SO) and the pUC57-hINT-
MD1-RT, resolving as two bands (5569bp, 2664bp) and three bands (5422bp, 2517bp, 1912bp) 
respectively. Once again the four colonies gave the anticipated digest profiles, consistent with 
MD1 being inserted into the pUC57-hINT-RT. The above screens indicate a repair template 
carrying MD1 exons 2-79 and an independent selection cassette, all flanked by arms of 
homology had been successfully produced (Figure 5-16B).  
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Figure 5-13 Digest profile of Spc512-MD1 plasmid, prior to cloning into the pUC57-hINT1-RT 
destination vector: 
A series of standard 20μl digests were undertaken for 3 hours at 37°C on 1μg of Spc512-MD1 plasmid, 
alongside an uncut (UC) control. A 10μl aliquot of these digests was resolved on a 1% TAE agarose gel 
alongside bioline hyperladder I. Notably, the fainter smaller size bands are indicated by a star *.  B) A 
table of the anticipated DNA profiles, showing all of the anticipated fragments for each of the restriction 
digests undertaken on the Spc512-MD1 plasmid. All of the bands were present and consistent with 
those anticipated enabling the sub-cloning of exon 6-79 to proceed as planned.  
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Figure 5-14 Parallel double digest of the pUC57- hINT1-RT and Spc512-MD1 plasmids for directional 
cloning of MD1 to reconstitute the MD1 transgene spanning exon2-79 in an exogenous repair 
template.   
A) A schematic of the pUC57-hINT1-RT, post FseI and NotI double digest, removing the Cyan Fluorescent 
protein, thereby serving as a destination vector enabling the insertion of MD1 exon 6-79.  B) A 
schematic of the MD1 exon 6-79 insert, liberated with FseI and NotI double digest. In both instances the 
FseI cleavage site is denoted in blue and the NotI cleavage site is denoted in red. C) A digest series of 
pUC57-hINT1-RT digests included: Uncut plasmid (UC), Linearised control (L) –single digest undertaken 
with SpeI, FseI single digest (F), NotI single digest (N) and FseI and NotI double digest. All single and 
double digests were undertaken on 1μg and 2μg of plasmid at 37°C for 2 hours respectively.  D) The 
same digest series described in C undertaken on the Spc512-MD1 plasmid. All digests were resolved on 
a 1% agarose, in 1X TAE buffer; alongside bioline hyperladder I. Sizes of digest fragments are indicated. 
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Figure 5-15 Complete pUC57-hINT1-MD1ΔEx1 plasmid, characterised by colony PCR.  
A) A schematic plasmid map of the pUC57-hINT1-MD1ΔEx1-RT, notice that in this instance the MD1 
exon 6-79 region has been sub-cloned directionally into the plasmid. B) A schematic of the colony PCR 
designed: the left indicates the outcome if the MD1 exons 6-79 insert is absent, the right indicates the 
outcome if the MD1 insert is correctly ligated. Notably, the forward primer binds upstream of the FseI 
site regardless of whether MD1 transgene insertion has occurred; in contrast the reverse primer only 
binds in the presence of the MD1 insert. Thus amplification will only be successful in the presence of the 
MD1 exon 6-79 insert. C) A 10μl aliquot of PCRs of1μl DNA from lysed bacterial colonies 1-32, Spc512-
MD1 (+), empty pUC57-hINT1-RT (-) and finally a water control (H). All samples were run on a 1% 
agarose gel in 1XTAE buffer alongside bioline hyperladder I. Sizes of PCR products are indicated.  
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Figure 5-16 Digest profiles of four pUC57-hINT1-MD1-RT colonies: 
A) A standard FseI and NotI double digest undertaken at 37°C for 3 hours on an empty pUC57-hINT1-RT 
(RT), four pUC57-hINT1-MD1-RT colonies and on Spc512-MD1 (MD1). Notably, the backbone of the 
empty RT and the four colonies is consistent at 6638bps; furthermore the MD1 insert size was 
consistent for the MD1 and the four colonies being 3213bps. B) A standard ScaI digest undertaken on 
the four Puc57-hINT1-MD1-RT colonies and on the Spc512-MD1 plasmid (MD1) alone. Interestingly, a 
distinct DNA profile of 3 digests of 5422bps, 2517bps and 1912bps, was apparent in pUC57-hINT1-MD1-
RT colonies consistent with expectations. This differed from the digest profile of the Spc512-MD1 
plasmid, which only produces the first two larger bands. A 10μl aliquot of all digests were resolved on a 
1% agarose gel and run in 1xTAE buffer alongside Bioline hyperladder I. Sizes of digest fragments are 
indicated. 
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5.3 Discussion  
5.3.1 Sequence Optimised Dystrophin cDNAs: 
Sequence optimisation of full length and Δ45-55 dystrophin cDNAs was shown to greatly 
enhance protein expression relative to native controls. This was established by microscopy 
imaging and Western Blotting. Both studies utilised plasmid constructs under the control of a 
CMV promoter, with the first investigation using dystrophin variants fused direct to eGFP. 
Importantly, in the case of full length dystrophin, up to a 57-fold difference in protein 
expression was observed between native and optimised constructs by Western Blotting.  
Whilst, such a difference could not be accurately determined for the Δ45-55 dystrophin 
constructs, the large increase in protein expression from optimised cDNA from both 
experiments was striking. 
The investigation was then extended to include full-length dystrophin cDNA under the control 
of the Spc512 muscle restrictive promoter (Li et al. 1999; Athanasopoulos et al. 2011). This was 
performed to examine whether the expression of Spc512 driven constructs could be compared 
in HEK293T cell culture. Furthermore, it was performed with the outlook of comparing Spc512-
Nat-hMD1 and Spc512-Opt-HuMD1 (SO). This cell culture model was used on the basis of more 
amenable transient transfection profiles relative to the immortalised Δ45-55 patient 
myoblasts.  Importantly, the Spc512 promoter enabled full-length dystrophin expression in 
HEK293T cell culture; this is speculated to be due to this cell-line facilitating leaky expression of 
this promoter. Interestingly, native and optimised full length dystrophin cDNA produced a 
varying fold difference in protein expression, when constructs were driven by the CMV and 
Spc512; being 22 fold and 15-17 fold respectively. This effect is attributed to two main 
parameters, the first being the relative strengths of the viral CMV and the muscle restrictive 
Spc512 promoters, and secondly, the expression of the full-length dystrophin cDNA with the 
Spc512 promote may be reduced in HEK293T cells due to its restrictive expression pattern. 
This trend of sequence optimisation enhancing protein expression extended to the Spc512 
native and optimised MD1 plasmids, which showed a 23-fold increase in expression. Notably 
this difference is greater than the highest 17 fold increase determined for full length native 
and optimised dystrophin cDNA driven by the Spc512 promoter. This is speculated to be due to 
the smaller size of the transgene. The MD1 cDNA is transcribed in a shorter time period 
relative to the full length dystrophin counterpart. During the 72 hour incubation period prior 
to protein harvest, it is speculated that this would enable a greater accumulation of MD1 
transcript and an increased overall protein synthesis.  To confirm this speculation, a further 
investigation comparing mRNA levels of native and optimised constructs using quantitative 
PCR is warranted. Interestingly, the difference between native and optimised Δ45-55 
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dystrophin, although not quantified visually appeared to be greater relative to full-length 
constructs, as indicated by the striking increase protein band area and fluorescent intensity in 
optimised conditions. This warrants further investigation, but could validate the suggestion 
that shorter optimised transgenes result in greater fold difference in protein expression.  
More accurate determination of the protein fold difference of the native and optimised Δ45-55 
and indeed other dystrophin variants could be achieved with refinement of quantification 
strategies employed. For example in the comparison of CMV-driven full length and Δ45-55 
dystrophin variants fused to eGFP, the exact difference in fluorescence intensity across native 
and optimised conditions was difficult to ascertain. This was due to occurrence of cell 
aggregation, which served to limit the quantification that could be achieved by FACs analysis. 
This cell adhesion is could result from overexpression of dystrophin transgenes, which in turn 
may have exhausted transcriptional machinery and lead to cell lysis.  Now that an overall trend 
of increased protein expression from optimised cDNA has been identified, future experiments 
would aim to employ a dose range and include a Live/Dead FACs stain to identify and/or 
compensate for reductions in cell viability.  
Furthermore, in the context of Western Blotting studies the accurate determination of fold 
differences in protein expression resulting from native and optimised Δ45-55 dystrophin cDNA 
was challenging. In this investigation, dystrophin intensity was normalised to alpha tubulin 
intensity for both conditions, and subsequent the ratios used to assert a fold difference. 
However, the large difference in Δ45-55 dystrophin intensity between native and optimised 
constructs made this method challenging to employ. If this normalisation strategy is to be 
continued, serial dilutions of the total protein from optimised conditions, may allow fold 
differences in protein expression to be determined. It is speculated that a 2-fold or a 4-fold, 
dilution of total protein harvested from optimised conditions, would allow visualisation of 
dystrophin band in both series. Particularly bands whilst have a determined value are 
displayed relative to the most intense band detected, in the associated channel using the 
Odyssey LI-COR. This would allow calculations of fold differences to be undertaken with the 
use of a dilution factor.  
In contrast, alternative normalisation strategies could be employed, which normalise 
dystrophin protein to total protein within the lane. This could be facilitated by the 
commercially available REVERT stain which functions much like Ponceau Red, staining all 
protein and emitting  within the 700nm channel (Blot & Handbook 2017). This normalisation 
strategy would circumvent possible limitations which could lead to overestimation of 
differences in protein expression, one example being the potential saturation of the 
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nitrocellulose membrane with the alpha tubulin protein.  This saturation of the nitrocellulose 
membrane with alpha-tubulin protein during the transfer process can occur when high 
concentrations of total protein are used (Blot & Handbook 2017)  such as the 50μg loading 
required to visualise dystrophin protein resulting from native cDNA. Interestingly, 
quantification proved more difficult with cDNA constructs driven by the CMV promoter where 
differences are suggested to be larger. Notably, in the case of native and optimised full length 
dystrophin it is speculated that overestimation of a 57-fold difference was achieved with 
Western Blotting using the 6C5 antibody. This is opposed to 22-fold difference determined 
with the MannEx1011c. Arguably, this could also be attributable to additional banding present 
in close proximity to the full length dystrophin in optimised conditions. The exact identity of 
these smaller dystrophin protein bands are currently unknown, one explanation is that the 
smaller dystrophin proteins result from the firing of downstream in frame methionine residues 
encoded by the full length dystrophin variant. The use of alternative translational initiation 
codons has been observed and confirmed clinically in patients harbouring mutations at the 5’ 
end of the DMD gene, focused to exons 1 and 2 (Gurvich et al. 2009). Interestingly in these 
instances, whilst patients should be anticipated to have a Duchenne muscular dystrophy 
phenotype based on non-sense mutation present, the translation from downstream in frame 
initiating codons situated in exons 6 and 8 results in a shortened dystrophin protein being 
translated and a Becker muscular dystrophy phenotype. A second explanation that is plausible 
is proteolytic degradation products, that may be more produced due to the increased 
expression of dystrophin protein.  Nonetheless, the observations from both CMV and Spc512 
studies together could hold important implications for clinical translation. Numerous studies 
have provided an insight into the amount of dystrophin protein expression required relative to 
wild-type endogenous levels to ameliorate dystrophic pathology. Variable estimates have 
arisen, likely attributable to the nature of investigation from which estimates were derived and 
how dystrophin levels were quantified.  Dystrophin expression of 30% in BMD patients (Neri et 
al. 2007; Anthony et al. 2011), 15% following antisense therapy in mice (Godfrey et al. 2015) 
and finally 20% in transgenic mice (Chamberlain 1997) were all shown to confer therapeutic 
benefit.  Whilst estimates of the minimum dystrophin expression levels required to be 
therapeutic vary between 15-30% among these investigations, the studies agree that a 
uniform dystrophin expression across the majority of myofibres as opposed to a sporadic 
distribution provides greater functional improvement. In addition, they indicate that the level 
of dystrophin correction required to be therapeutic will be influenced by the specific muscle 
pathology and disease progression of the patient seeking treatment. The striking increase in 
protein expression observed here with the use of sequence optimised cDNAs encoding a range 
of dystrophin variants could facilitate the attainment of such expression thresholds. By 
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extension of this it is speculated they could greatly improve clinical outcomes and functional 
improvements observed in clinical trials.  
The striking fold differences in protein expression observed between native and optimised 
constructs necessitate the examination of the potential effects of supra-physiological levels of 
dystrophin proteins. Importantly, others have demonstrated that overexpression of full length 
dystrophin up to 50 fold higher than endogenous levels was well tolerated (Chamberlain 
1997). This level was shown to ameliorate dystrophic pathology with the absence of any 
detrimental effects. This finding was supported and extended by Yue et al who produced 
similar overexpression of the mini-dystrophin (ΔH2-R19) in transgenic mdx mice in skeletal and 
cardiac tissues. Detrimental effects, particularly cardiotoxicity, only became apparent when 
dystrophin expression of 100 fold greater than physiological levels was attained (Yue et al. 
2016). Notably, this mini-dystrophin has an alternative architecture to MD1 (R4-23 ΔCT). 
Similarly, however, the sequence optimised MD1 has been delivered in many studies to assess 
its safety and efficacy profile (Koo et al. 2011; Le Guiner et al. 2017; Wang et al. 2000). The 
most recent study, administered a canine optimised rAAV-MD1, loco-regionally to muscle or 
intravenously to the GRMD DMD model. The findings from this indicated that not only was 
MD1 safe and efficacious in vivo, but it also showed sustained expression for over two years, 
with an associated reduction in dystrophic pathology (Le Guiner et al. 2017). The supra-
physiological and MD1 in-vivo studies taken together highlight that sequence optimised 
microdystrophin provides enhanced protein expression that is unlikely to have deleterious 
effects if used clinically. It should be noted that in-vivo trials of the Δ45-55 Minidystrophin and 
full-length optimised dystrophin are warranted to independently assess their safety and 
efficacy. This has not yet been undertaken as suitable delivery systems need to be developed.  
5.3.2 Design and Construction of Exogenous Repair Template Directed to DMD 
Intron 1: 
The improved protein expression resulting from sequence optimised MD1, Δ45-55 and full 
length dystrophin cDNA, served to influence exogenous repair template design. This prompted 
the generation of a backbone that would enable the directional sub-cloning of each of the 
aforementioned dystrophin variants, allowing the exogenous repair template to be easily 
adapted for each to be trialled in integration experiments.  
It could be envisaged that future microdystrophin constructions, like the one employed in this 
study, may include additional spectrin repeats with the outlook to restore the correct 
localisation of dystrophin associated signalling molecules. This is exemplified by a recent study 
in which a 5 spectrin repeat microdystrophin generated by Hakim et al, during the production 
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of this manuscript that promoted the restoration of the nNOS (Hakim et al. 2017). 
Alternatively, constructions with differing hinge compositions may also be generated, 
particularly as studies have also served to highlight the influence of hinge regions on MD1 
function. Interestingly, it was shown that the inclusion of hinge 3 instead of hinge 2 was found 
to increase the structural flexibility of MD1 and in mdx mice resulted in slightly larger 
myofibres and reduced evidence of Achilles myotendinous disruption and  aberrant 
neuromuscular junctions (Banks et al. 2010).  
As a consequence of these findings a range of different microdystrophin configurations 
continue to be developed and, the exogenous repair template described here would be able to 
accommodate such new emerging microdystrophins, thus providing a useful tool in future 
integration experiments with a repertoire of microdystrophin cDNAs. 
It should be noted that the exogenous repair template presented thus far has retained a 
human focus. Interestingly, the FseI and NotI sites are conserved within mouse sequence 
optimised dystrophin cDNA constructs. Thus with alteration of the 1kb arms of homology to 
contain sequences isogenic to the mouse genome, and in conjunction with a murine 
dystrophin cDNA spanning exons 2-6, this exogenous repair template could be utilised in the 
same manner. Thus the common structure could be used to target both human and mouse cell 
lines during integration studies (Byrne et al. 2015; Song & Stieger 2017). 
The exogenous repair template was designed to facilitate an HDR-mediated genome editing 
outcome at the human DMD intron 1 locus. It was designed with 1kb arms of homology 
isogenic to the human genome directly upstream and downstream of the CRISPR targeted 
region of homology identified. This length of arms of homology of isogenic sequence is 
deemed adequate for successful exploitation of HDR pathways. Extension of homology arms 
beyond this size only result in marginal increases of transgene integration (Byrne et al. 2015; 
Zhang et al. 2017).In addition, the repair template also  includes a floxed zeocin cassette to 
facilitate positive selection of gene edited cells (Mulsant et al. 1988; Seth et al. 2008). Zeocin-
mediated enrichment of corrected cells is important due to the low efficiency of the HDR 
process. 
Importantly, as scientists’ understanding of the DNA damage response (DDR) continues to 
evolve so too does the manner in which DNA repair pathways are exploited to facilitate the 
integration of genetic material.  Recent investigations have used NHEJ DNA repair pathways to 
introduce genetic material (Maresca et al. 2013; Suzuki et al. 2016). This strategy is reliant 
upon genomic target sites of the endonuclease TALEN or CRISPR being encoded in reverse 
orientation directly adjacent to the transgene for which integration is desirable. The resultant 
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in-situ cleavage of genome and exogenous repair template, facilitates the integration of the 
transgene independently of the HDR pathway (Suzuki et al. 2016). Importantly, the exogenous 
repair template developed here in our investigations was designed so components were 
flanked with endonuclease restriction sites. Thus it could be easily customised to facilitate 
exploration of such strategies with dystrophin cDNA.  
Finally, Opt-HuMD1 (SO) was successful cloned into the pUC57-hINT1 repair template to 
enable HDR investigations to be undertaken in HEK293T and DMD patient myoblasts. This 
became the primary transgene of interest owing to its small size which was anticipated to 
provide the most successful outcomes. This stated the exogenous repair template in this 
investigation was designed to enable the sub-cloning and subsequent delivery of the 3 
dystrophin cDNA variants discussed and potentially have compatibility to emerging constructs. 
5.4 Conclusions 
A novel exogenous repair template was designed with restriction sites enabling the sub-cloning 
of MD1, Δ45-55 and full length sequence optimised dystrophin cDNA exonic constructions. The 
design was founded upon the demonstration that sequence optimisation enhanced 
recombinant dystrophin protein expression. The repair template was designed with 1Kb arms 
of homology isogenic to sequences upstream and downstream of the CRISPR MIT guide RNA 
targets identified within human DMD intron 1. Furthermore, the repair template incorporates 
a floxed zeocin expression cassette to facilitate positive selection of gene edited cell 
populations during HDR investigations. The Opt-MD1 (SO) exon 6-79 sequence was 
successfully cloned into the exogenous repair template. The resultant pUC57-hINT1-MD1-RT 
plasmid affords an exogenous repair template for HDR-mediated integration studies with the 
use of CRISPR/Cas9; enabling the feasibility of the gene editing therapeutic strategy presented 
to be assessed.  
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Chapter 6 An Examination of CRISPR-mediated Microdystrophin 
Knock-in Downstream of Full-length Endogenous DMD 
Promoters. 
6.1 Introduction: 
Current treatment of DMD relies upon the use of corticosteroids, which are inadequate. 
treating only the palliative symptoms of the disease rather than the underlying genetic 
aetiology (Bushby et al. 2010a; Mercuri & Muntoni 2013; NICE 2016). Furthermore, some 
therapeutic strategies under development addressing the genetic causation are largely 
mutation specific. These aim to convert an out-of-frame deletion to an in-frame deletion, or 
induce a stop codon read-through, thereby transitioning DMD to a BMD genotype (Monaco et 
al. 1988). Such therapeutic approaches aim to slow disease progression rather than provide 
complete amelioration. This is exemplified by antisense oligonucleotide (AON) exon skipping 
(Aartsma-Rus et al. 2017) and nonsense mutation read-through platforms such as Ataluren 
(McDonald et al. 2017). Mutation specific strategies for the treatment of DMD remain broadly 
challenging to translate, with EU medical approval requiring safety and efficacy testing of the 
individual compounds used for the treatment of specific mutation types; e.g. AON therapies 
for 45, 51 and 53 would all require individual approval (Aartsma-Rus et al. 2017). Moreover, 
even with all AON avenues maximally developed, including multi-exon skipping this approach 
would be applicable for 90% of patients, leaving 10% without treatment (Verhaart & Aartsma-
Rus 2012).  
Although universal strategies are under development such as microdystrophin 1 (MD1) gene 
augmentation (Mendell et al. 2010; Le Guiner et al. 2017), utrophin upregulation (Ricotti et al. 
2016) and myostatin inhibition (Bhattacharya et al. 2017); the main limitation of these 
approaches is the transience of their expression and the requirement of repeated 
administration. In the case of AAV-MD1 delivery, this carries the inherent risk of an adverse 
immunogenic response to the AAV capsid (Mendell et al. 2010). In contrast, SMTC1100 
(Ezutromid) and myostatin antibodies although well tolerated, have variable serum 
concentrations on administration and limited efficacy (Ricotti et al. 2016; Wagner et al. 2008), 
challenges which are currently being addressed with improved formulations (Summit 
Therapeutics Plc 2016; Bhattacharya et al. 2017). Nonetheless, even if successful, such 
therapies would likely require life-long adherence.  
Gene editing offers an attractive alternative strategy, providing the permanent correction of a 
range of DMD mutations, and preventing the requirement for repeated administration. A 
plethora of studies have been undertaken using NHEJ-mediated deletions to promote for 
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example the excision of exon 51 (Ousterout et al. 2015) and exons 45-55 (Kabadi et al. 2014; 
Maggio et al. 2016). The studies described in the current thesis chapter aim to introduce a 
microdystrophin cDNA exon MD1 downstream of the full-length endogenous dystrophin 
promoters and exon1 elements, an approach that if successful would have applicability to 95% 
of DMD patients.    
6.2 Chapter Aims: 
Using both the highly efficacious guide 1 targeted to intron 1 of the DMD gene and the 
exogenous pUC57- hINT1- MD1 repair template (MD1 RT) constructed to encode MD1ΔEx1 
cDNA and a downstream zeocin selection cassette; this chapter aimed to assess the feasibility 
of a HDR-mediated MD1ΔEx1 integration at the 5’ end of the DMD gene, in both HEK293T and 
Δ45-55 immortalised patient myoblast cells. Initially, the susceptibility of HEK293T and Δ45-55 
immortalised patient myoblasts to zeocin was analysed by the generation of a kill-curve in 
which cells were exposed to a defined concentration gradient of zeocin for up to 3 weeks.  
Concentrations of zeocin identified to cause cell death in untreated cultures will then be 
applied to cells 48 hours following co-transfection of guide 1 and the MD1 RT at 1:1 and 2:1 
ratios.  
Cultures co-transfected with guide 1 and the MD1 repair template were assessed initially at 48 
hours post transient transfection for DNA integration. Polyclonal cultures generated following 
exposure to zeocin were then assessed for DNA integration, mRNA and protein expression of 
microdystrophin, driven by the endogenous Dp427m promoter. Individual clones were then 
isolated and expanded. The resultant monoclonal cultures were then subject to the same 
characterisation. It was speculated an in vitro correction of this nature would showcase the 
near universal therapeutic potential of this approach, highlighting the use of MD1 in gene 
editing to ameliorate the effects of a diverse range of DMD mutations types. Furthermore, the 
template has been customised to enable the exploration of Δ45-55 and full length dystrophin 
transgenes, enabling expansion if this approach proved successful.  
6.3 Results  
6.3.1 Determination of Zeocin Sensitivity of HEK293T and Immortalised DMD 
Patient Myoblasts  
As HDR is considered to occur with low efficiency (Heyer et al. 2010), it was speculated that 
positive selection would be crucial to the identification of genetically modified cells and the 
subsequent success of this study. Zeocin antibiotic was resolved upon as a positive selection 
reagent, as puromycin and neomycin resistance cassettes were integrated into patient 
myoblasts as a by-product of the immortalisation process (Mamchaoui et al. 2011). Thus 
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zeocin antibiotic would be suitable for use in integration experiments undertaken in both 
HEK293T and immortalised Δ45-52 patient myoblasts. 
In order to determine whether HEK293T and Δ45-52 Immortalised patient myoblasts were 
sensitive to zeocin toxicity, they were subjected to a 50-1000μg/ml dose range of the 
antibiotic. HEK293T cells were seeded at a density of 1.7 x105 cells in a 6 well plate estimated 
to provide an estimated 25% confluency in 24 hours, as recommended by the manufacturer’s 
protocols (Invitrogen 2017). In contrast, 8.3 x 104 immortalised patient myoblasts were seeded 
in a 6 well plate, a cell number estimated to provide 35% confluency in 24 hours. It was 
decided to seed patient myoblasts at standard cell number due to their poor viability in sparse 
culturing conditions. Importantly, cells were seeded in growth media supplemented with 
incremental doses of zeocin. Notably, this dose escalation was performed in duplicate for both 
cell lines. Furthermore to maintain selection, 1ml of growth media was removed and 
substituted with 1ml of fresh growth media supplemented with the appropriate volume of 
zeocin antibiotic every 72 hours.  
Once zeocin selection was commenced, phase contrast images were taken of each dose at 3, 7, 
10, 14 and 21 day time points. Interestingly, on exposure to zeocin, dying cells do not only 
detach but exhibit irregular morphologies, including: thin spindle-like projections or 
appendages, cellular elongation and a thin squamous appearance (Invitrogen 2017). 
Microscopy imaging allowed visual assessment of these morphological changes and cell 
viability in HEK293T (Figure 6-1) and Δ45-55 Immortalised Patient Myoblasts (Figure 6-2). 
In HEK293T cultures, there was an estimated 60-70% reduction in viable cells by day 3, 
apparent in 50μg - 600μg/ml doses of zeocin antibiotic relative to the untreated control. This 
affect was heighted at higher doses of 800μg 
/ml and 1000μg/ml where the reduction was closer to 80-90%. By days 7 and 10, >95% cell 
death was observed across all doses, with few cell clusters present at doses below 400μg. 
Strikingly, by day 7 localised patches of cell growth formation was apparent and cellular 
detachment started to occur in the mock condition likely attributable to the over-confluency 
and continued proliferation of the cells, serving to emphasise the result observed. Imaging was 
halted by day 14, as >95% cell death continued to be present across all zeocin doses. 
In contrast, at day 3 there was 20-30% subtle decline in cell viability between 50μg-600ug/ml 
in patient myoblasts relative to the untreated mock. Again this affect was heighted in 
800μg/ml and 1000μg/ml doses, following a similar trend to HEK293T, with an estimated 50-
60% reduction. By day 7, the untreated patient myoblasts started to undergo differentiation, 
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due to continued proliferation and myoblasts forming contacts with one another. Interestingly, 
the number of cells across 50μg-600μg/ml doses at days 7 and 10 appeared visually 
comparable to the number observed at day 3, which due to the increase of growth in the 
untreated sample gave an apparent 50-60% reduction in cell viability, at this stage.  In contrast 
a more marked decline in cell viability was apparent in 800μg/ml and 1000μg/ml conditions, 
with an estimated 70-80% reduction at day 7 and a 90% reduction at day 10.  By day 14, 
noticeable cell death was apparent across all doses: with cell viability reduced by 70% in 50μg-
100μg/ml, 80% in 200μg-600μg/ml and 90% in 800μg/ml and 1000μg/ml doses. This trend 
continued on day 21 with viability reduced by 80% in 50μg-100μg/ml, 90% in 200μg- 600μg/ml 
and >95% in 800μg/ml and 1000μg/ml doses.  
Of note, an MTT cell viability assessment would have been desirable to provide more accurate 
quantification of cell death; however, the requirement to continuously expose cells to zeocin 
for up to 3 weeks during selection precluded the use of this assay. Thus visual examinations 
were used to determine cell death. Nonetheless, this investigation demonstrated that both 
HEK293T and Δ45-55 Immortalised patient myoblasts show susceptibility to zeocin antibiotic; 
promoting the use of this positive selection reagent in the identification of stably transfected 
cell lines.  
On the basis of this assessment minimal zeocin doses of 600μg/ml and 800μg/ml were 
selected for use with HEK293T cell lines, as by day 7 the lowest dose where no cell clusters 
were observed was 600μg/ml of zeocin antibiotic. In contrast, minimal zeocin doses of 
800μg/ml and 1000μg/ml will be used for Δ45-55 patient myoblast, as these doses are 
required to promote almost complete cell death following 21 days of exposure.  These doses 
will be used, following transient transfection to select for cells with stable integration of the 
exogenous repair template. 
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Figure 6-1 Determination of non-transfected HEK293T cells viability when cultured in varying concentrations of Zeocin antibiotic:  
Following passage, HEK293T cells were diluted in standard 10% DMEM growth media to provide a cell count of 1.7 x 105 per 2ml, providing the approximate 25% confluency 24 
hours post seeding in a six well plate recommended by the zeocin selection protocol. On seeding, the 2ml of cell suspension was supplemented with varying volumes of zeocin 
(stock concentration 100μg/μl), to provide the defined antibiotic concentrations recommended in production of a kill curve. The concentration of zeocin was replenished every 
72hours, by replacing 1ml of the existing 10% DMEM growth media with a fresh 1ml aliquot, supplemented with the necessary volume of zeocin. Abnormal cell morphology and 
cell death was then captured by phase contrast microscopy imaging at day 3, 7, 10 and 14 at 100x magnifications using the Zeiss Microscope. The zeocin was demonstrated to be 
effective, with estimates of cell death in excess of 90% observed for all doses following 3 days of exposure.   
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Figure 6-2 Determination of immortalised Δ45-52 DMD myoblast cells viability when cultured in varying concentrations of Zeocin antibiotic:   
Following passage immortalised Δ45-52 patient myoblasts were diluted in standard myoblast growth media to provide a cell count of 8.4 x 104 per 2ml, providing the approximate 
35% confluency 24 hours post seeding in a six well plate, a little in excess of that recommended by the zeocin selection protocol. On seeding, the 2ml of cell suspension was 
supplemented with varying volumes of zeocin (stock concentration 100μg/μl, to provide the defined antibiotic concentrations recommended in production of a kill curve. The 
concentration of zeocin was replenished every 72hours, by replacing 1ml of the existing myoblast growth media with a fresh 1ml aliquot, supplemented with the necessary volume 
of zeocin. Abnormal cell morphology and cell death was then captured by phase contrast microscopy imaging at day 3, 7, 10 and 14 at 100x magnifications using the Zeiss 
Microscope. The zeocin was demonstrated to be effective at the higher doses, with estimates of cell death in excess of 90% observed at 21 days.  
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6.3.2 Transient Transfection of HEK293T Cells with Cas9, Guide RNA and Repair 
Template Plasmids and Polyclonal Enrichment using Zeocin Selection:  
6.3.3 Dual Transfection Experimental Design 
The demonstration that the CBh promoter within the all-in-one Px458 plasmid could drive 
both Cas9 and GFP expression prompted a dual transfection experimental design to be 
explored in the attainment of HDR-mediated integration of MD1ΔEx1. Utilising Px458-Guide 1 
(Px458-G1, in figures) to introduce a double stranded break (DSB) and pUC57- hINT1- MD1 
repair template constructed to encode MD1ΔEx1 cDNA and a downstream zeocin selection 
cassette, hitherto referred to as MD1 repair template (MD1 RT), to enable HDR repair. 
Notably, the use of the all-in-one Px458 plasmid had two inherent advantages:  it enabled the 
use of GFP fluorescence as a proxy of transient transfection efficiency providing a visual 
indication of the delivery of gene-editing reagents and the assurance that both constituents of 
the Cas9 system, the guide and Cas9 nuclease encoding components, were co-delivered to 
each fluorescent cell. 
To maximise the chance of attaining the successful integration of MD1ΔEx1 into DMD intron 1, 
two co- transfection conditions were employed, using a 1:1 and 2:1 ratio of Px458-Guide 1: 
MD1 RT plasmids, equating to 4μg and 6μg of total DNA per transfection respectively. These 
co-transfections were performed in triplicate alongside controls, including: a Viafect 
transfection reagent only mock, Px458-Guide 1 alone and MD1 RT alone to assert that any 
downstream observations were attributed to the co-delivery of the gene-editing and repair 
template plasmids.  Notably, when delivered alone Px458-Guide 1 was delivered at either 2μg 
in the 1:1 or 4μg in the 2:1 conditions respectively. Whereas the MD1 repair template alone 
was routinely delivered at 2μg in both conditions.  
6.3.3.1 Visual Assessment of Transient Transfection Efficiency:   
Phase contrast and fluorescent microscopy images in the FITC channel were taken of HEK293T 
48 hours post transfection. As anticipated Px458-Guide 1 and MD1 RT co-transfected, and 
Px458-Guide 1 alone samples, at both doses showed high levels of GFP expression (Figure 6-3). 
This is consistent with previous findings that transfection of 2μg and 4μg of Px458-Guide 1 
resulted in 71.4% ± 4.0 (N=3) and 92.7% ±3.0 (N=3) of GFP positive HEK293T cells 
respectively. Whilst promising, GFP fluorescence only provides transfection efficiency for the 
gene-editing Px458 plasmid in isolation; it does not provide information pertaining to the 
delivery of the exogenous repair template or indeed the co-localisation of the two constructs. 
However, given the similar sizes of the Px458 and MD1 repair plasmid of approximately 9.3kb 
and 9.9kb, the inference is transfection efficiency of the two plasmids would have been 
comparable and co-localisation would likely occur in a high proportion of cells. 
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Following this visual indication of successful transient transfection at 48 hours the treated 
HEK293T cells from the two transfection conditions were passaged and seeded at cell number 
of 1.7x105 cells per well into two six well plates. The media was supplemented on seeding with 
a volume of zeocin antibiotic in line with either a 600μg/ml or 800μg/ml dose; consistent with 
the conditions outlined by the zeocin sensitivity assay. This gave rise to a total of 4 conditions, 
in which both the 4μg transfection using a 1:1 ratio of Px458-Guide 1: MD1 RT and the 6μg 
using a 2:1 ratio of Px458-Guide 1: MD1 RT were exposed to 600μg/ml and 800μg/ml of 
zeocin. Conditions will be referred to throughout this chapter as 4μg 600μg, 4μg 800μg, 6μg 
600μg and 6μg 800μg respectively. This coding system was selected to highlight the amount of 
plasmid (μg) transfected and the amount of zeocin per ml used for each condition. 
6.3.3.2 DNA Extraction and PCR Amplification to Identify Successful Exogenous 
Repair Template Integration at DMD Intron 1 Site: 
HEK293T cells in excess of the 1.7 x 105 cell count required for zeocin selection, attained from 
Mock, Px458-Guide1 and MD1 RT controls and co-transfected Px458-Guide 1 and MD1 RT 
samples were subject to Qiagen DNA extraction. This was undertaken for both 4μg 1:1 and 6μg 
2:1 transfection conditions. 
The resultant genomic DNA harvested was quantified and 250ng was amplified to assess for 
integration of the exogenous repair template. This was performed using a single-round 35-
cycle PCR using either ‘Outer LAH’ or ‘Outer RAH’ primers, or a nested PCR in which 20 cycles 
of amplification were performed using outer primers and 1μl of resultant product was applied 
to a second PCR using ‘Inner LAH’ or ‘ Inner RAH’ primers. The resultant products were 
resolved on 1% agarose by gel electrophoresis. Both amplification processes utilised forward 
and reverse primers that spanned the genome-repair template junction, amplifying across the 
arms of homology included in the exogenous repair template respectively. This was performed 
for the left arm of homology, in which the forward primer was in the HEK293T genome and the 
reverse primer was within the repair template and the right arm of homology, in which the 
forward primer was in the repair template and the reverse was situated in the HEK293T 
genome; hitherto referred to as LAH and RAH PCRs respectively.  
Following single round amplification of 250ng of DNA harvested from both 4μg and 6μg Px458-
Guide 1 and MD1 RT co-transfected samples; a low intensity amplicon of 1291bps was 
resolved for the LAH PCR. This was consistent with the size anticipated. However 
unexpectedly, no amplicons were resolved for the RAH PCR in these samples. Finally, as 
anticipated, no amplicons were resolved for LAH or RAH PCRs in the Mock, Px458-Guide 1 or 
MD1 RT control conditions (Figure 6-4A and Figure 6-5A). Taken in isolation these results may 
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indicate that the LAH and RAH PCRs occur with varying efficiencies or that partial integration of 
the exogenous repair template has occurred. 
To further assess the samples for low levels of exogenous repair template integration, nested 
LAH and RAH PCRs were undertaken with the outlook to increase the yield of resulting 
amplicons. In contrast to the single round amplification, nested  LAH and RAH PCRs showed 
evidence for integration in Px458-Guide 1 and MD1 RT co-transfected samples, with 1139bp 
and 1171bp amplicons being resolved from inner PCRs respectively. All of these bands 
occurred with high intensity. An additional amplicon was also observed on resolution of nested 
LAH amplicons, estimated to be 1500bps in size; this is speculated to be due to mis-priming of 
the primers.  As anticipated, no amplicons were resolved for LAH or RAH PCRs in Mock and 
Px458- Guide 1 alone samples. However, counter-intuitively a faint amplicon corresponding to 
the LAH PCR 1139bp amplicon was present in MD1 RT alone sample on the 6μg gel;  
furthermore faint amplicons corresponding to1171bp RAH PCR amplicon were present in MD1 
RT alone samples, in both 4μg and 6μg gels (Figure 6-4B and Figure 6-5B). Taken in 
combination these results indicate that 48 hours post transient transfection, low levels of 
exogenous repair template integration has occurred in all triplicate repeats of Px458-Guide 1 
and MD1 RT co-transfections with both 4μg and 6μg conditions. Additionally, unexpectedly 
low levels of random integration may also have occurred following transient transfection of 
2μg MD1 RT in isolation. This form of nuclease independent integration has previously been 
reported for the albumin safe-harbour locus, thus it was speculated that intron 1 of the DMD 
gene may have an open chromatin structure permitting this form of integration (Barzel et al. 
2014).  
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Figure 6-3 Microscopy Images of HEK293T 
Cells 48 hours post Co-transfection of 
Px458-Guide 1 at a 2μg or 4μg dose, with 
2μg MD1 repair template, alongside 
Untreated, Px458-Guide 1 or MD1 RT 
alone. 
(A) Phase contrast (PC) and fluorescent 
images in the FITC channel (GFP) of HEK293T 
transfected with 2μgof gene editing GFP-
plasmid. Mock (M) = 25μl of Viafect 
transfection reagent alone; Px458-Guide 1 = 
2μg of Px458alone; MD1-RT= 2μg of MD1-RT 
alone; Px458-Guide 1 + MD1 RT = co-
delivery of 2μg Px458-Guide 1 and MD1 RT 
in a 1:1 ratio across three technical 
replicates (Rep 1-3). (B) Phase contrast (PC) 
and fluorescent images in the FITC channel 
(GFP) of HEK293T transfected with 4μg of 
gene editing GFP-plasmid., same as (A) 
except 4μg of Px458-Guide 1 was used in 
delivery alone and co-delivery alongside 2μg 
MD1 RT constituting a 2:1 ratio. 
PC 
GFP 
PC 
GFP 
 
 
A 
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Figure 6-4 An examination of repair template integration into DMD intron 1, using PCR amplification; 
spanning from the endogenous genomic sequence, across the left or right arms of homology into the 
repair template. Performed for the 4μg (Px458-Guide 1 1:1 MD1-RT) condition. 
A) Gel electrophoresis to resolve PCR products resulting from a single round of amplification performed 
on genomic DNA harvested from the 4μg (Px458-Guide 1 1:1 MD1-RT) condition, 48 hours post transient 
transfection. PCRs were performed and resolved spanning either the left arm of homology (LAH) or the 
right arm of homology (RAH). Samples included: Mock (M) – cells incubated with Viafect transfection 
reagent alone, Px458-Guide 1 (G) - 2μg of Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT 
transfected alone and triplicate co-transfection of 2μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3 
and a no-template water control (H). In all single round conditions, 250ng of genomic DNA was 
subjected to a 30 cycle GoTaq G2 Flexi PCR, prior to being resolved on a 1% agarose gel alongside 
hyperladder I. B) A Nested PCR performed on the same samples as A) except 1μl of a single 20 cycle 
outer PCR performed on 250ng of genomic DNA, was added to a second 30 cycle PCR to improve, the 
amplicon yield.  
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Figure 6-5 An examination of repair template integration into DMD intron 1, using PCR amplification; 
spanning from the endogenous genomic sequence, across the left or right arms of homology into the 
repair template. Performed for the 6μg (Px458-Guide 1 2:1 MD1-RT) condition. 
A) Gel electrophoresis to resolve PCR products resulting from a single round of amplification performed 
on genomic DNA harvested from the 6μg (Px458-Guide 1 2:1 MD1-RT) condition, 48 hours post transient 
transfection. PCRs were performed and resolved spanning either the left arm of homology (LAH) or the 
right arm of homology (RAH). Samples included: Mock (M) – cells incubated with Viafect transfection 
reagent alone, Px458-Guide 1 (G) - 4μg of Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT 
transfected alone and triplicate co-transfection of 4μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3 
and a no-template water control (H). In all single round conditions, 250ng of genomic DNA was 
subjected to a 35 cycle GoTaq G2 Flexi PCR, prior to being resolved on a 1% agarose gel alongside 
hyperladder I. B) A Nested PCR performed on the same samples as A) except 1μl of a single 20 cycle 
outer PCR performed on 250ng of genomic DNA, was added to a second 30 cycle PCR to improve, the 
amplicon yield. 
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6.3.4 Positive Selection:  The Enrichment of Stably Transfected HEK293T-MD1 
Cells 
The indication that exogenous repair template integration may have occurred at low levels, 
producing a heterogeneous HEK293T culture, prompted continued zeocin selection of 
HEK293T treated cells. In an analogous fashion to the zeocin sensitivity assay, 1ml of media 
was removed every 72 hours and replenished with 1ml fresh media supplemented with either 
600μg/ml or 800μg/ml of zeocin. Furthermore, phase contrast and fluorescent microscopy 
imaging undertaken in the FITC (GFP) Channel were taken at 3, 7, 14, 18, 24 and 27 day time 
points to examine the selection process and cell viability.  This was undertaken for all 4 
conditions previously outlined, including: The 4μg 1:1 Px458-Guide 1 and MD1 RT conditions: 
4μg 600μg (Figure 6-6) and 4μg 800μg (Figure 6-7) and the 6μg 2:1 Px458 Guide 1 and MD1 RT 
conditions: 6μg 600μg (Figure 6-8) and 6μg 800μg (Figure 6-9) respectively.  The general trends 
of this positive selection process, rather than individual conditions will be described for the 
purposes of clarity. 
Initial phase contrast images captured at day 3, showed low cell number across all of the 
conditions with viable cells estimated to constitute 10-30% confluency for all treatment 
conditions: Mock, Px458-Guide 1, MD1 RT alone and co-transfected Px458-Guide 1 and MD1 
RT triplicates in the 4μg conditions. Notably, cell viability was reduced in the 6μg conditions 
relative to the 4μg conditions at this stage, with 10% confluency estimated in 6μg 600μg/ml 
conditions and 5-10% for 6μg 800μg/ml generally observed across treatments. This could be 
attributable to cells being exposed to higher DNA and transfection reagent concentrations. 
This stated, clusters of cells were present in some Px458-Guide 1 and MD1 RT co-transfected 
replicates in the 6μg condition, as exemplified by 6μg 600μg/ml repetition 1 and 2 and 6μg 
800μg/ml repetition 2 images. Furthermore, fluorescent images taken at this time point 
indicated a higher proportion of GFP positive cells on visual assessment in 6μg relative to 4μg 
conditions. This suggests higher transfection efficiency in 6μg conditions and potentially a 
greater chance for MD1 integration to occur. 
By Day 7, Mock and Px458-Guide 1 alone treatments showed extensive cell death across all 4 
conditions, comparable to the >95% death observed in the zeocin sensitivity assay.  In contrast 
samples transfected with MD1 repair template alone or co-transfected with Px458-Guide 1 
and MD1 repair template, showed an increase in cell number.  This observation was more 
pronounced in 4μg and 6μg conditions under 600μg/ml zeocin selection, where cell number 
was visually estimated to double relative to day 3. Notably, 4μg and 6μg samples placed under 
800μg/ml still showed evidence of surviving cell clusters but the numbers of cells surviving 
appeared more variable. This is apparent in Px458-Guide 1 and MD1 RT co-transfection 
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repetition 1 in the 4μg 800μg/ml condition whereby cell number had a marked increase 
relative to the MD1 RT alone and other co-transfected repetitions. Further evidence of 
variability also apparent in Px458-Guide 1 and MD1 RT co-transfected repetition 2 of the 6μg 
800μg/ml condition, where the cell number was reduced relative to repetitions 1 and 3 and 
MD1 repair template alone treatments. In addition, the number of GFP-positive cells at this 
stage appeared markedly reduced across all conditions when visually compared to the Day 3 
time point. This is likely attributable to the effects of clonal dilution, and the subsequent 
expression of the Px458 plasmid being dissipated. 
 At day 14 and 18 cells appeared rounded and detached in mock and Px458-Guide 1 alone 
samples across all conditions. This indicated complete cell death had occurred and these 
treatments were not imaged after these time points. In contrast, in Px458-Guide 1 and MD1 RT 
co-transfected samples, clusters of cells examined had continued to proliferate and were able 
to fill a field of capture as observed in 4μg 600μg/ml, 6μg 600μg/ml and 6μg 800μg/ml 
conditions.   The 4μg 800μg/ml condition appeared as a notable exception to this observation, 
with few small cell clusters being observed at day 14 and only co-transfected repetitions 1 and 
3 appearing to fill approximately 60-70% of the field of capture at day 18. This was attributed 
to a combinatorial effect of lower anticipated exogenous repair template integration and the 
higher dose of zeocin selection. Interestingly, the MD1 repair template alone treatments were 
not anticipated to survive zeocin selection. This stated, the number of cells in MD1 RT alone 
treatment in the 4μg conditions, were visually estimated to be comparable to the Px458-guide 
1 and MD1 RT co-transfected samples at day 14 and 18 time points. Moreover, evidence of cell 
growth in MD1 RT alone samples was present among the 6μg conditions, although a reduction 
in cell number relative to co-transfected repetitions was observed. Finally, by day 14, GFP 
expression was almost completely absent and thus images in the FITC channel were no longer 
captured. 
By day 20 visible localised areas of cell growth had occurred in MD1 RT alone and co-
transfected Px458-Guide 1 and MD1 RT samples across all conditions (not shown).  Thus the 
cells within these treatments were passaged and seeded back into a 6 well plate under 
continued zeocin selection to avoid detachment and promote healthy monolayer growth. 
Mock and Px458-guide 1 alone samples were discarded at this time. 
Post passage, all cells were then imaged at two further time points, days 24 and 27. At the day 
24, the number of surviving cells in 4μg conditions appeared reduced across MD1 RT alone and 
co-transfected treatments relative to the 6μg conditions.  In addition, it should be noted that 
one sample, the MD1 RT alone treatment in the 4μg 800μg/ml condition did not survive the 
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passage process.  Finally, by day 27, all MD1 RT alone and co-transfected Px458-Guide 1 and 
MD1 treatments, with the exception of the single condition noted above attained over 70% 
confluency in a 6 well plate and appeared to be proliferating in a manner comparable to that 
expected of untreated HEK293T.  
In summary, in Mock and Px458-guide 1 alone treatments, cells exhibited a rounded 
morphology and detachment from the plate after 14 days of selection consistent with cell 
death. Unexpectedly, HEK293T cells subject to MD1 RT alone treatments, with the exception of 
one sample in the 4μg 800μg/ml condition, appeared to survive the zeocin selection process. 
Finally, all Px458-Guide 1 and MD1 RT co-transfected triplicates, survived the zeocin selection 
process across all conditions, achieving greater than 70% confluency by the latest 27 day time 
point. 
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Figure 6-6 Microscopy images of HEK293T post 4μg (Px458-Guide 1 1:1 MD1-RT) co- transfection, 
alongside controls during the process of zeocin selection. At 48 hours post transfection, HEK293T cells 
were passaged and seeded at 1.7 x 105 cells per well and exposed to 600μg/ml of zeocin. 
 Samples included: Mock (M) – cells incubated with Viafect transfection reagent alone, Px458-Guide 1 
(G) - 2μg of Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT transfected alone and 
triplicate co-transfection of 2μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3. A 1ml growth media 
aliquot was removed, and substituted with 1ml fresh growth media supplemented with 600μg/ml of 
Zeocin every 3 days to maintain selection. Cell death initially ensued, however by day 20, confluent 
HEK293T localised patches of cell growth were present and the cells were passaged and placed into a 
fresh six well plate. Phase Contrast and fluorescent images in the FITC channel (GFP) were taken at time 
points of 3, 7 and 14 days. Phase contrast microscopy was continued to 18, 24 and 27 days after the GFP 
expression had diminished. 
PC 
GFP 
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Figure 6-7 Microscopy images of HEK293T post 4μg (Px458-Guide 1 1:1 MD1-RT) co- transfection, 
alongside controls during the process of zeocin selection. At 48 hours post transfection, HEK293T cells 
were passaged and seeded at 1.7 x 105 cells per well and exposed to 800μg/ml of zeocin. 
 Samples included: Mock (M) – cells incubated with Viafect transfection reagent alone, Px458-Guide 1 
(G) - 2μg of Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT transfected alone and 
triplicate co-transfection of 2μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3. A 1ml growth media 
aliquot was removed, and substituted with 1ml fresh growth media supplemented with 800μg/ml of 
Zeocin every 3 days to maintain selection. Cell death initially ensued, however by day 20, confluent 
HEK293T localised patches of cell growth were present and the cells were passaged and placed into a 
fresh six well plate. Phase Contrast and fluorescent images in the FITC channel (GFP) were taken at time 
points of: 3, 7 and 14 days; phase contrast was continued to 18, 24 and 27 days after the GFP expression 
had diminished. 
PC 
GFP 
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Figure 6-8 Microscopy images of HEK293T post 6μg (Px458-Guide 1 2:1 MD1-RT) co- transfection, 
alongside controls during the process of zeocin selection. At 48 hours post transfection, HEK293T cells 
were passaged and seeded at 1.7 x 105 cells and exposed to 600μg/ml of zeocin. 
 Samples included: Mock (M) – cells incubated with Viafect transfection reagent alone, Px458-Guide 1 
(G) - 4μg of Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT transfected alone and 
triplicate co-transfection of 4μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3. A 1ml growth media 
aliquot was removed, and substituted with 1ml fresh growth media supplemented with 600μg/ml of 
Zeocin every 3 days to maintain selection. Cell death initially ensued, however by day 20, confluent 
HEK293T localised patches of cell growth were present and the cells were passaged and placed into a 
fresh six well plate. Phase Contrast and fluorescent images in the FITC channel (GFP) were taken at time 
points of: 3, 7 and 14 days; phase contrast was continued to 18, 24 and 27 days after the GFP expression 
had diminished.  
PC 
GFP 
PC 
GFP 
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Figure 6-9 Microscopy images of HEK293T post 6μg (Px458-Guide 1 2:1 MD1-RT) co- transfection, 
alongside controls during the process of zeocin selection. At 48 hours post transfection, HEK293T cells 
were passaged and seeded at 1.7 x 105 cells and exposed to 800μg/ml of zeocin. 
 Samples included: Mock (M) – cells incubated with Viafect transfection reagent alone, Px458-Guide 1 
(G) - 4μg of Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT transfected alone and 
triplicate co-transfection of 4μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3. A 1ml growth media 
aliquot was removed, and substituted with 1ml fresh growth media supplemented with 800μg/ml of 
Zeocin every 3 days to maintain selection. Cell death initially ensued, however by day 20, confluent 
HEK293T localised patches of cell growth were present and the cells were passaged and placed into a 
fresh six well plate. Phase Contrast and fluorescent images in the FITC channel (GFP) were taken at time 
points of: 3, 7 and 14 days; phase contrast was continued to 18, 24 and 27 days after the GFP expression 
had diminished. 
PC 
GFP 
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6.3.5 Molecular Characterisation of Zeocin-Enriched Polyclonal Cultures and 
Establishing Single Colonies Allowing for Clonal Expansion:  
Once polyclonal cultures of zeocin selected HEK393T cells were established, they were 
expanded; where the contents of a single well were split into two wells, through two 
sequential passages, for each individual treatment. This culminated in four 6 well plates: 
comprising of MD1 RT alone and triplicate Px458-Guide 1 and MD1 RT co-transfections for 
each of the four conditions (4μg 600μg, 4μg 800μg, 6μg 600μg and 6μg 800μg).  
For each condition, this expansion provided 3 plates for DNA, RNA and protein harvests 
respectively. This was to permit molecular characterisation of the polyclonal cultures, 
assessing endogenous repair template integration and MD1 transgene expression from the full 
length Dp427m dystrophin promoter. Additionally the cells seeded on the final plate were 
passaged and serially diluted to attain individual colonies for each condition.  
6.3.5.1 Examination of Exogenous Repair Template Integration at DMD intron 1: 
It was speculated that zeocin selection would enrich HEK293T populations where integration 
of the exogenous repair template had occurred. On this basis DNA was harvested from the 
expanded polyclonal culture and 250ng was amplified to assess for integration of the 
exogenous repair. This was performed using a single round PCR across the genome-repair 
template junction for both the LAH and RAH and products were resolved by gel 
electrophoresis, as described in section 6.3.3.2.  
This was performed for all MD1 RT alone and co-transfected Px458-Guide 1 and MD1 
treatments across the 4 conditions. Strikingly, for all Px458-Guide 1 and MD1 RT co-transfected 
samples, amplicons of 1291bp and 1277bps were resolved by gel electrophoresis for the LAH 
and RAH PCRs respectively. These amplicons are in line with the sizes anticipated, and 
consistent with the results obtained from the nested PCR undertaken at the 48 hour time 
point, indicate that integration of the exogenous repair template has occurred (Figure 6-10). 
Notably, as previously observed a single larger amplicon estimated to be 1500bps in size was 
apparent following resolution of LAH PCRs, likely attributable to mis-priming of the primers. 
Interestingly, no amplicons were resolved for MD1 RT alone treatments, subject to single 
round LAH or RAH PCRs. This finding in combination with the observation that MD1 RT alone 
transfected HEK293T cells survived zeocin selection, indicates either low level targeted 
integration at the DMD intron 1 locus or random integration of the MD1 RT has occurred. 
Importantly, the resolution of LAH and RAH amplicons following a single round of amplification 
as opposed to the nested PCR required to enhance the amplicon signal at the transient 48 hour 
time point, suggests that the zeocin positive selection was successful. This indicates that the 
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HEK293T culture has been enriched for cells in which the specific integration of the exogenous 
repair template is present. 
6.3.5.2 Examination of MD1 Transcription from the Endogenous Dp427m DMD 
Promoter: 
Once evidence was attained that indicated the exogenous repair template had been 
successfully integrated into DMD intron 1, focus was then shifted to examine whether 
expression of the MD1ΔEx1 transgene was driven by the endogenous Dp427m full-length 
dystrophin promoter. To assess this, expanded polyclonal cultures were harvested for total 
RNA and a reverse transcription PCR was undertaken on 500ng on purified RNA using random 
primers to produce cDNA.  
 The cDNA was then assessed for Dp427m- MD1 exon 2 splicing using a forward primer 
designed to span the Dp427m- MD1 exon-exon 2 junction and a reverse primer within exon 5. 
In this design an ~250bp amplicon would only be visualised following amplification and 
resolution by gel electrophoresis if correct splicing had occurred. Furthermore, due to the 
sequence optimisation of the MD1, primers design would detect Dp427m –MD1 exon1-exon 2 
splicing, distinctly from any native dystrophin splicing that may occur, in the culture. 
Interestingly, in all MD1 RT alone and co-transfected Px458-Guide 1 and MD1 RT treatments, a 
250bp amplicon was resolved by gel electrophoresis of amplified products across all conditions 
(Figure 6-11). Indicating Dp427m-MD1 exon 2 splicing is occurring across all conditions. When 
considered in combination with the survival of MD1 RT alone transfected HEK293T cultures, 
following zeocin selection, it could suggest low levels of targeted integration of the repair 
template alone occurred in this treatment. 
6.3.5.3 Examination of MD1 Protein Expression:  
Provisional indication of mRNA expression prompted an examination of MD1 protein 
expression. In this instance 50μg total protein lysate, was subject to western blotting with the 
ManEx10-11c antibody. Crucially this would highlight that the MD1 mRNA transcribed by the 
endogenous promoter is functional, enabling MD1 protein synthesis.   
The MD1 construct, encodes a 137kDa protein that can be visualised by western blotting (see 
Chapter 5). However in both MD1 RT alone and co-transfected Px458-Guide 1 and MD1 RT 
treatments, a truncated protein product, estimated to be 117kDa in size, was identified across 
all conditions (Figure 6-12A and Figure 6-13A). Notably, this band was not present in untreated 
HEK293T cell lysate, indicating this protein expression is likely a result of the treatment 
performed (Figure 6-12B and Figure 6-13B). 
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The resolution of truncated MD1 protein product was unexpected. It could be speculated to 
arise due to aberrant splicing being favoured over the Dp427m splicing observed, or an 
internal deletion within the integrated MD1 cDNA. 
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Figure 6-10 An examination of repair template integration into DMD intron 1, following polyclonal 
enrichment. This was performed by PCR amplification that spanned from the endogenous genomic 
sequence, across the left or right arms of homology into the repair template. 
Gel electrophoresis to resolve PCR products resulting from a single round of amplification, performed on 
genomic DNA harvested from both 4μg (Px458-Guide 1 1:1 MD1-RT) Top and 6μg (Px458-Guide 1 2:1 
MD1-RT) Bottom conditions, exposed to either 600μg/ml or 800μg/ml of zeocin for 28 days.  PCRs were 
performed and resolved spanning either the left arm of homology (LAH) or the right arm of homology 
(RAH). Samples included: MD1 RT (R) - 2μg of MD1-RT transfected alone and triplicate co-transfection of 
either 2μg Px458-Guide 1 and 2μg of MD1 RT or 4μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3 
and a no-template water control (H). In all single round conditions, 250ng of genomic DNA was 
subjected to a 35 cycle GoTaq G2 Flexi PCR, prior to being resolved on a 1% agarose gel alongside 
hyperladder I. The findings indicate evidence for a positive integration of the MD1 exogenous repair 
template in DMD intron 1 in co-transfected Px458-Guide1 and MD1 RT at this stage.  
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Figure 6-11 An examination of endogenous Dp427m promoter and exon 1 element splicing to exon 2 
of MD1, undertaken on RNA harvested from polyclonal HEK293T cultures. 
Gel electrophoresis to resolve PCR products resulting from a single round of amplification of cDNA. 
Importantly, cDNA was produced from 500ng of total mRNA lysate, and amplified with isoform specific 
primers, in which the forward primer targeted the Dp427m Exon 1 and MD1 Exon 2 splice junction. This 
was performed for both 4μg (Px458-Guide 1 1:1 MD1-RT) top and 6μg (Px458-Guide 1 2:1 MD1-RT) 
bottom conditions, for the MD1 RT (R)-2μg of MD1-RT transfected alone and triplicate co-transfection of 
either 2μg Px458-Guide 1 and 2μg of MD1 RT or 4μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3 
and a no-template water control (H).The presence of a band indicates splicing between the endogenous 
full length Dp427m and the modified MD1 transgene integrated into the genome. 
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Figure 6-12 Western blotting for MD1 expression in HEK293T 4μg (Px458-Guide 1 1:1 MD1-RT) 
condition after polyclonal zeocin selection. 
The four samples surviving either 600μg/ml or 800μg/ml zeocin selection: MD1 RT (R)-2μg of MD1-RT 
transfected alone and triplicate co-transfected 2μg Px458-Guide 1 and 2μg of MD1 RT samples, denoted 
as 1-3; were harvested for total protein lysate. A 50μg sample was subject to western blotting using the 
MannEx10-11c antibody to examine, for MD1 protein expression and Ab70774 (AbCam) for the 44kDA 
protein alpha tubulin as a loading control. This was performed alongside a positive control of MD1 
transfected HEK293T protein lysate (Top) and untreated HEK293T protein lysate negative control 
(Bottom). Noticeably, the wild type MD1 protein is 137kDa and a truncated protein estimated to be 
117kDa was expressed across all samples.  
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Figure 6-13 Western blotting for MD1 expression in HEK293T 6μg (Px458-Guide 1 2:1 MD1-RT) 
condition after polyclonal zeocin selection. 
The four samples surviving either 600μg/ml or 800μg/ml zeocin selection: MD1 RT (R)-2μg of MD1-RT 
transfected alone and triplicate co-transfected 4μg Px458-Guide 1 and 2μg of MD1 RT samples, denoted 
as 1-3; were harvested for total protein lysate. A 50μg sample was subject to western blotting using the 
MannEx10-11c antibody to examine, for MD1 protein expression and Ab70774 (AbCam) for the 44kDA 
protein alpha tubulin as a loading control. This was performed alongside a positive control of MD1 
transfected HEK293T protein lysate (Top) and untreated HEK293T protein lysate negative control 
(Bottom). Noticeably, the MD1 protein is 137kDa and a truncated protein estimated to be 117kDa was 
expressed across all samples.  
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6.3.6 Establishing Single Colonies: Further Enrichment and Molecular 
Characterisation: 
The final plate of polyclonal HEK293T cells was used to establish single colonies for MD1 RT 
alone and triplicate co-transfected Px458-Guide1 and MD1 RT treatments for each of the four 
conditions. In pursuit of this, cells were passaged counted and seeded at serial dilutions of 105 
or 104 cells into 10 cm cell culture dishes, in 10mls of media supplemented with zeocin. 
Notably, the zeocin concentration applied to the 10cm cell culture dish was kept consistent 
with the condition from which the treatment was derived at the polyclonal level. Treatments 
derived from the 4μg 600μg/ml and 6μg 600μg/ml conditions were placed in media 
supplemented with 600μg/ml of zeocin and those from 4μg 800μg/ml and 6μg 800μg/ml were 
placed in media supplemented with 800μg/ml of zeocin respectively.  The premise for this 
being that this would allow for individual cells to attach to the dish, with a suitable radius of 
space to enable continued proliferation until a single colony achieving a diameter of 2 -3mm 
across is formed, without coming into contact with other cells.  
6.3.6.1 Single Colony Visualisation and Expansion: 
After culturing, colonies between 2-3mm in diameter forming an opaque circular region of 
cells could be clearly visually identified in all 10cm dishes. This stated, 10 cm dishes seeded at 
the lower 104 cell count yielded fewer colonies with greater intervening distances, which was 
deemed beneficial for ensuring clonality and thus these dishes were used to pick colonies. To 
identify colonies expanded from a single cell with a suitable radius to enable picking, plates 
were examined by phase contrast microscopy (Figure 6-14). This highlighted that some 
colonies were not suitable for selection as the colonies had intersected and may therefore be 
considered polyclonal in nature. However, in many instances colonies in isolation were 
identified, and circled for identification. 
Once identified, colonies were removed from the 10cm dish using filter discs dipped in 1x 
trypsin and transferred to a 24 well plate. The cells attached to these discs were then cultured 
until 60-70% confluency was attained, and then the cells were passaged and transferred to a 6-
well plate. These cultures were then subjected to continued expansion in a manner analogous 
to the polyclonal population. 
Subsequently, four 6 well plates were produced that enabled harvesting of DNA, RNA and 
protein as before, and a final plate for stock cells to be frozen. Importantly, all the cells that 
are expanded in this instance were derived from a single cell and thus are monoclonal in 
nature for the genetic modification that has occurred. 
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6.3.6.2 Crystal Violet Staining of Individual Colonies: 
Once picked and transferred to a 24 well plate, the colonies remaining attached to the 10 cm 
dishes were stained with 0.001% crystal violet solution. This served to highlight a general trend 
that the number of colonies present on the MD1 RT alone dish were reduced relative the 
replicates of Px458-Guide 1 and MD1 RT co-transfection, as exemplified by colonies obtained 
from the 6μg 600μg/ml condition (Figure 6-15). Unfortunately, this could not be directly 
quantified as the application of trypsin coated filter discs to the 10cm plate resulted in leaching 
of the trypsin into the nearby proximity in some instances. Thus whilst the filter disc was 
removed taking the colony of interest in isolation, nearby colonies were disrupted upon the 
application of crystal violet stain and subsequently detached. 
6.3.6.3 Examination of Monoclonal Cultures for Exogenous Repair Template 
Integration: 
Once monoclonal cultures were expanded, genotyping was undertaken using a single round 
PCR as previously described. For all monoclonal cultures expanded from Px458-Guide 1 and 
MD1 RT co-transfected clones, amplicons of 1291bps and 1277bps were resolved for LAH and 
RAH PCRs respectively. This is consistent with the polyclonal analysis and indicates that 
integration of the exogenous repair template has occurred at the DMD intron 1 site. One 
distinction from the polyclonal analysis identified, was that 1291bp and 1277bp amplicons 
corresponding to LAH and RAH PCRs were also present in monoclonal cultures expanded from 
MD1 RT alone clones (Figure 6-16 and Figure 6-17). This provides an indication that some 
targeted integration, has occurred in HEK293T exposed to the MD1 RT in isolation.  
6.3.6.4 Examination of RNA harvested from Clonal Cultures:  
The same examination pertaining to transcription of the MD1ΔEx1 transgene performed on 
the polyclonal populations was repeated at the monoclonal stage of enrichment. As 
anticipated, this yielded results consistent with the polyclonal analysis. The anticipated RT-PCR 
250bp amplicon spanning from the Dp427m promoter to exon 5 of the MD1ΔEx1 transgene 
was present across both MD1 RT alone and Co-transfected Px458-Guide 1 and MD1 
treatments (Figure 6-18). Sequencing of the PCR products at both the polyclonal and 
monoclonal stages revealed the sequence anticipated for correct Dp427m – MD1 Exon 2 
splicing (not shown). 
6.3.6.5 Examination of Protein Harvested from Clonal Cultures: 
Western blotting performed on 50μg of total protein at the monoclonal stage with MannEx10-
11c as described previously was also congruent with results obtained from polyclonal 
populations. In all MD1 RT alone and co-transfected Px458-Guide 1 and MD1 RT treatments, a 
117kDa MD1 truncated protein was present (Figure 6-19 and Figure 6-20). Interestingly, 
however, when western blots were over-exposed at this stage a low level of full length 137kDa 
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MD1 protein could visualised in addition to the 117kDa truncated MD1 protein (Figure 6-21). 
This indicates some full-length MD1 can be transcribed and successfully synthesised as a 
protein. The presence of truncated protein is therefore likely due to the occurrence of 
aberrant splicing. This is speculated as if the truncated protein appeared as a result of internal 
deletion it would not be possible to synthesis the full length MD1 protein.  
6.3.6.6 Re-examination of Computational Splicing in the Context of the MD1 Repair 
Template: 
The presence of low level full length 137kDA and high levels of truncated 117 kDa MD1 
protein, prompted a re-examination by bioinformatics of potential cryptic splice sites within  
the MD1 exogenous repair template (Figure 6-22). Interestingly, whilst the artificial beta globin 
splice acceptor appeared strongest at position 181 nucleotides in accordance with Human 
Splice Finder bioinformatics analysis, there were low levels of upstream splicing enhancers. 
Furthermore, downstream of this splice acceptor was both a cluster of relatively strong splice 
acceptors and enhancers around 201nts. It is thus plausible that this cluster could work 
antagonistically, competing for Dp427m promoter and exon 1 element splicing. 
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Figure 6-14  Phase contrast microscopy images and visual analysis of single colonies on a 10 cm dish 
using crystal violet. 
(A) Phase contrast microscopy image of multiple colonies in close proximity with one another, these are 
unsuitable for passaging due to likelihood they have intercepted and may be polyclonal in nature. (B) 
Phase Contrast microscopy image of a single colony with ample diameter 2-3 mm, with suitable distance 
from other colonies to assert that this population arose from a single cell. Both microscopy images were 
taken at 200x magnification. (C) Crystal violet stains of the 10 cm dish these colonies were imaged from. 
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Figure 6-15 Crystal Violet Stains performed on the single colonies from the MD1 repair template alone 
and triplicate 4μg Px458-Guide 1 and 2μg of MD1 RT co-transfected samples, following 600μg/ml 
zeocin selection. 
A schematic showing the relative frequencies of colonies observed post crystal violet staining, for MD1 
RT Alone condtion and invidual repetition of 4μg Px458-Guide 1 and 2μg of MD1 RT co-transfected 
samples. B) Crystal violet stains of the MD1 RT alone (Top) and three repetitions of Px458-Guide 1 and 
MD1 co-transfection. Notice the trend that colonies appear to be increase in the latter relative to the 
former.  
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Figure 6-16 An examination of repair template integration into the DMD intron 1, undertaken on DNA 
harvested from three individual clones from the 4µg 600µg and 800µg conditions. This was performed 
by a single round PCR amplification that spanned from the endogenous genomic sequence, across the 
left or right arms of homology into the repair template. 
Gel electrophoresis to resolve PCR products resulting from a single round of amplification. Performed on 
genomic DNA harvested from both 4μg (Px458-Guide 1 1:1 MD1-RT) exposed to either 600μg/ml or 
800μg/ml of zeocin.  PCRs were performed and resolved spanning either the left arm of homology (LAH) 
or the right arm of homology (RAH). Samples included: MD1 RT (R) - 2μg of MD1-RT transfected alone 
and triplicate co-transfection of either 2μg Px458-Guide 1 and 2μg of MD1 RT denoted by 1-3 and a no-
template water control (H). A single round of amplification was performed in which 250ng of genomic 
DNA was subjected to a 35 cycle GoTaq G2 Flexi PCR, prior to being resolved on a 1% agarose gel 
alongside hyperladder I. The findings indicate evidence for a positive integration of the MD1 exogenous 
repair template in both repair template alone samples and co-transfected samples.  
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Figure 6-17  An examination of repair template integration into the DMD intron 1, undertaken on DNA 
harvested from three individual clones from the 6µg 600µg and 800µg conditions of HEK293T cells. 
This was performed by a single round PCR amplification that spanned from the endogenous genomic 
sequence, across the left or right arms of homology into the repair template. 
Gel electrophoresis to resolve PCR products resulting from a single round of amplification. Performed on 
genomic DNA harvested from both 6μg (Px458-Guide 1 2:1 MD1-RT) exposed to either 600μg/ml or 
800μg/ml of zeocin.  PCRs were performed and resolved spanning either the left arm of homology (LAH) 
or the right arm of homology (RAH). Samples included: MD1 RT (R) - 2μg of MD1-RT transfected alone 
and triplicate co-transfection of either 2μg Px458-Guide 1 and 2μg of MD1 RT denoted by 1-3 and a no-
template water control (H). A single round of amplification was performed in which 250ng of genomic 
DNA was subjected to a 35 cycle GoTaq G2 Flexi PCR, prior to being resolved on a 1% agarose gel 
alongside hyperladder I. The findings indicate evidence for a positive integration of the MD1 exogenous 
repair template in both repair template alone samples and co-transfected samples.  
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Figure 6-18 An examination of the endogenous Dp427m promoter and exon 1 splicing to MD1 exon 2, 
using an RT-PCR across the exon 1-exon 2 junction, undertaken on RNA harvested from monoclonal 
HEK293T cultures. 
Gel electrophoresis to resolve PCR products resulting from a single round of amplification of cDNA. 
Importantly, cDNA was produced from 500ng of total mRNA lysate, and amplified with isoform specific 
primers, in which the forward primer targeted the Dp427m Exon 1 and MD1 Exon 2 splice junction. This 
was performed for both 4μg (Px458-Guide 1 1:1 MD1-RT) top and 6μg (Px458-Guide 1 2:1 MD1-RT) 
bottom conditions, for the MD1 RT (R)-2μg of MD1-RT transfected alone and triplicate co-transfection of 
either 2μg Px458-Guide 1 and 2μg of MD1 RT or 4μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3 
and a no-template water control (H).The presence of a band indicates splicing between the endogenous 
full length Dp427m and the modified MD1 transgene integrated into the genome. 
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Figure 6-19 Western blotting for MD1 expression in monoclonal samples from the HEK293T 4μg 
(Px458-Guide 1 1:1 MD1-RT) condition. 
Individual colonies expanded for the four conditions: MD1 RT (R)-2μg of MD1-RT transfected alone and 
triplicate 2μg Px458-Guide 1 and 2μg of MD1 RT co-transfected samples, denoted as 1-3 subject to 
600μg/ml or 800μg/ml zeocin selection; were harvested for total protein lysate. A 50μg sample was 
subject to western blotting using the MannEx10-11c antibody to examine MD1 protein expression and 
Ab70774 (AbCam) for the 44kDA protein alpha tubulin, used as a loading control. This was performed 
alongside a positive control of MD1 transfected HEK293T protein lysate (Top) and untreated HEK293T 
protein lysate negative control (Bottom). Noticeably, the MD1 protein is 137kDa and a truncated protein 
estimated to be 117kDa was expressed across all samples.  
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Figure 6-20 Western blotting for MD1 expression in monoclonal samples from the HEK293T 6μg 
(Px458-Guide 1 2:1 MD1-RT) condition. 
Individual colonies expanded for the four conditions: MD1 RT (R)-2μg of MD1-RT transfected alone and 
triplicate 4μg Px458-Guide 1 and 2μg of MD1 RT co-transfected samples, denoted as 1-3 subject to 
600μg/ml or 800μg/ml zeocin selection; were harvested for total protein lysate. A 50μg sample was 
subject to western blotting using the MannEx10-11c antibody to examine MD1 protein expression and 
Ab70774 (AbCam) for the 44kDA protein alpha tubulin, used as a loading control. This was performed 
alongside a positive control of MD1 transfected HEK293T protein lysate (Top) and untreated HEK293T 
protein lysate negative control (Bottom). Noticeably, the MD1 protein is 137kDa and a truncated protein 
estimated to be 117kDa was expressed across all samples.  
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Figure 6-21 Overexposure of Western blots of monoclonal samples from 4μg (Px458-Guide 1 1:1 MD1-
RT) and 6μg (Px458-Guide 1 2:1 MD1-RT) conditions; examination for full length MD1 expression. 
Individual colonies expanded for the four conditions: MD1 RT (R)-2μg of MD1-RT transfected alone and 
triplicate 2μg or 4μg Px458-Guide 1 and 2μg of MD1 RT co-transfected samples, denoted as 1-3 subject 
to 600μg/ml or 800μg/ml zeocin selection; were harvested for total protein lysate. A 50μg sample was 
subject to western blotting using the MannEx10-11c antibody to examine MD1 protein expression and 
Ab70774 (AbCam) for the 44kDA protein alpha tubulin, used as a loading control. This was performed 
alongside a positive control of MD1 transfected HEK293T protein. Noticeably, the MD1 protein is 
137kDa and a truncated protein estimated to be 117kDa was expressed across all samples, however on 
overexposure a faint band indicating full length MD1 is apparent as indicated by the red arrow.  
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Figure 6-22 Post Hoc bioinformatics analysis of the 5’ region of the MD1 exogenous repair template, 
using Human Splice Finder, to predict the presence of splicing acceptors and enhancers. 
(A) Identification of splice acceptors (blue squares) and splice donors (purple circles) across the MD1 
exogenous repair template with the artificial beta globin splice acceptor indicated by a blue star. Notice 
this is the strongest splice acceptor sequence present; however there is a downstream cluster around 
the 201 nucleotide region downstream. (B) Identification of splicing enhancers (pink/red rectangles) and 
splicing silencers (blue/green) rectangles, across the sequence. Interestingly few enhancers are 
upstream of the splice acceptor however; there is a cluster downstream around 201 nucleotides; this is 
indicated by the red star. 
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6.3.7 Patient Myoblasts: A Parallel CRISPR Cas9- HDR Mediated Knock-in of the 
MD1 Transgene: 
The gene-editing approach was then expanded to immortalised DMD patient myoblasts 
carrying a deletion of exons 45 to 52. As this muscle cell line harbours an out-of-frame 
dystrophin mutation, it was deemed a more appropriate cell lineage to test MD1ΔEx1 knock-in 
downstream of the exogenous Dp427m full length dystrophin promoter and exon 1 sequence.   
6.3.8 Assessment of Transient Transfection Efficiency:  
The same 1:1 and 2:1 co-transfections of Px458-Guide 1: MD1 RT was undertaken alongside 
controls as previously described for the HEK293T integration study.  Phase contrast and 
fluorescence microscopy images in the FITC channel, were taken on immortalised Δ45-55 
patient myoblasts 48 hours post transfection (Figure 6-23). Notably, the transient transfection 
was successful but the GFP expression level visually appeared slightly lower than levels 
observed upon 2μg and 4μg transient transfections of Px458 to this cell line previously, being 
38.92% ± 1.55 and 42.89% ± 0.67 respectively.  
Following this visual indication of successful transient transfection at 48 hours, the treated 
immortalised patient myoblasts were passaged and seeded at cell count of 8.3x104 into two six 
well plates. The media was supplemented on seeding with a volume of zeocin antibiotic in line 
with either a 800μg/ml or 1000μg/ml dose, consistent with the conditions outlined by the 
zeocin sensitivity assay. 
6.3.8.1 DNA Extraction and PCR Amplification Processes to Identify Successful 
Integration: 
Immortalised Δ45-52 patient myoblasts in excess of the 8.3 x 104 cell count required for zeocin 
selection, attained from Mock, Px458-Guide1 and MD1 RT controls and co-transfected Px458-
Guide 1 + MD1 RT samples were subject to Qiagen DNA extraction. This was undertaken for 
both the 4μg 1:1 and 6μg 2:1 conditions.  
Due to the lower transient transfection, 250ng of harvested DNA was amplified only by nested 
PCR to assess for the integration of the exogenous repair template. Notably, a low intensity 
amplicon of 1139bps was present in the 6μg, 2:1 Px458-Guide 1 and MD1 RT co-transfected 
samples. Although far from a stringent and robust result, this was indicative that a low level of 
transgene integration could have occurred, a prospect that warranted further investigation 
(Figure 6-24). 
6.3.8.2 Zeocin Selection of Immortalised Patient Myoblast Polyclonal Populations: 
In consideration of the positive PCR across the left genome-repair template junction, it was 
deemed pertinent to continue the positive selection process, for the 6μg transfection. Phase 
contrast and fluorescent microscopy imaging undertaken in the FITC (GFP) channel were taken 
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at 3, 7, 14, 18, 21 and 24 day time points to examine the selection process and cell viability for 
both 6ug 800μg/ml (Figure 6-25) and 6μg 1000μg/ml (Figure 6-26) zeocin streams. 
At day 3, phase contrast images showed some cell survival was apparent in both of the 
conditions. Notably, cells were estimated to be at approximately 10-15% confluent in the 6μg 
800μg/ml condition across all treatments, whereas slightly higher cell numbers were observed 
in the 6μg 1000μg/ml condition. With Px458-Guide 1 alone and MD1 RT alone showing 
approximately 10% confluency, but Mock and co-transfected Px458-Guide 1 and MD1 RT 
samples showing estimated confluency of 50%. This could be attributed to a slightly higher cell 
number being seeded at 48 hours.  In addition, few GFP expressing cells were observed at this 
time and a high level of auto-fluorescence of the patient myoblast culture made it difficult to 
delineate cells undergoing cell death from those positively transfected. As a consequence 
fluorescent imaging was halted at this stage. 
By day 7, the cell number appeared to increase an estimated 2 fold relative to day 3, in the 6μg 
800μg/ml condition. This stated cell number appears to remain comparable in the 6μg 
100μg/ml condition. This was observed across all treatments.  
At day 14, 6μg 800μg/ml showed a reduction in cell number, becoming comparable once more 
with the cell number observed at day 3. In contrast in the 6μg 1000μg/ml, a marked reduction 
in cell viability was observed in mock, Px458- Guide 1 alone and MD-1 alone treatments. 
Interestingly, however, cell number only exhibited subtle decrease in Px458-Guide 1 and MD1 
RT transfected samples.  
The final time-points of day 18-24 showed continued cell decline and death in both conditions, 
across all treatments. Interestingly, a few cells were still present in the 6μg 1000μg/ml 
condition. This stated no proliferation or expansion of this cell population appeared to occur. 
This resulted in the discontinuation of this experiment. 
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Figure 6-23 Images of Immortalised 
Δ45-52 Patient Myoblasts 48 hours post 
Co-transfection of Px458-Guide 1  at a 
2μg or 4μg dose, with 2μg MD1 repair 
template, alongside Untreated, Px458-
Guide 1 or MD1 RT alone. 
(A) Phase Contrast (PC) and fluorescent 
images in the FITC channel (GFP) of 
Immortalised Δ45-52 patient myoblasts 
transfected with 2μg of gene editing 
GFP-plasmid. Mock (M) = 25μl of Viafect 
transfection reagent alone; Px458-Guide 
1 in which 2μg Px458alone; MD1-RT= 
2μg of MD1 RT alone; Px458-Guide 1 + 
MD1 RT represents co-delivery of 2μg 
Px458-Guide 1 and MD1 RT in a 1:1 ratio 
across three technical replicates (Rep 1-
3). (B) Phase Contrast (PC) and 
fluorescent images in the FITC channel 
(GFP) of Immortalised Patient Myoblasts 
transfected with 4μg of gene editing 
GFP-plasmid., same as (A) except 4μg of 
Px458-Guide 1 was used in delivery 
alone and co-delivery alongside 2μg 
MD1-RT constituting a 2:1 ratio. 
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Figure 6-24 An examination of repair template integration into DMD intron 1, using PCR amplification; 
spanning from the endogenous genomic sequence, across the left or right arms of homology into the 
repair template. Performed for the 6μg (Px458-Guide 1 2:1 MD1-RT) condition. 
A) Gel electrophoresis to resolve PCR products resulting from a Nested PCR amplification performed on 
genomic DNA harvested from the 6μg (Px458-Guide 1 2:1 MD1-RT) condition, 48 hours post transient 
transfection. In which 1μl of a single outer PCR comprised of 20 cycles performed on 250ng of genomic 
DNA, was added to a second 30 cycle PCR to improve the amplicon yield. PCRs were performed and 
resolved spanning either the left arm of homology (LAH) or the right arm of homology (RAH). Samples 
included: Mock (M) – cells incubated with Viafect transfection reagent alone, Px458-Guide 1 (G) - 2μg of 
Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT transfected alone and triplicate co-
transfection of 2μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3 and a no-template water control 
(H).  
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Figure 6-25 Microscopy images of Immortalised Δ45-55 patient myoblasts post 6μg (Px458-Guide 1 2:1 
MD1-RT) co- transfection, alongside controls during the process of zeocin selection. At 48 hours post 
transfection, Patient myoblasts were passaged and seeded at 8.3 x 104 cells per well and exposed to 
800μg/ml of zeocin. 
 Samples included: Mock (M) – cells incubated with Viafect transfection reagent alone, Px458-Guide 1 
(G) - 4μg of Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT transfected alone and 
triplicate co-transfection of 4μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3. A 1ml growth media 
aliquot was removed, and substituted with 1ml fresh growth media supplemented with 800μg/ml of 
Zeocin every 3 days to maintain selection. Phase Contrast and fluorescent images in the FITC channel 
(GFP) were taken at time points of: 3 days; phase contrast was continued to 7, 14, 18, 21 and, 24 days 
after the GFP expression had diminished. 
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Figure 6-26 Microscopy images of Immortalised Δ45-55 patient myoblasts post 6μg (Px458-Guide 1 2:1 
MD1-RT) co- transfection, alongside controls during the process of zeocin selection. At 48 hours post 
transfection, Patient myoblasts were passaged and seeded at 8.3 x 104 cells per well and exposed to 
1000μg/ml of zeocin. 
 Samples included: Mock (M) – cells incubated with Viafect transfection reagent alone, Px458-Guide 1 
(G) - 4μg of Px458-Guide 1 transfected alone, MD1 RT (R) - 2μg of MD1-RT transfected alone and 
triplicate co-transfection of 4μg Px458-Guide 1 and 2μg MD1-RT, denoted by1-3. A 1ml growth media 
aliquot was removed, and substituted with 1ml fresh growth media supplemented with 1000μg/ml of 
Zeocin every 3 days to maintain selection. Phase Contrast and fluorescent images in the FITC channel 
(GFP) were taken at time points of: 3 days; phase contrast was continued to 7, 14, 18, 21 and, 24 days 
after the GFP expression had diminished  
PC 
GFP 
278 
 
6.4 Discussion  
6.4.1 HEK293T, HDR-mediated MD1 Transgene Integration: 
6.4.1.1 Transient Transfection of HEK293T: 
The transfection efficiency of HEK293T was striking when using the all-in-one gene-editing 
plasmid Px458 (U6-Guide-CBh-Cas9-2A-GFP) in which green fluorescence was used as a proxy 
for plasmid uptake. In both the 4μg and 6μg transient transfection, 80-90% of cells were 
estimated to exhibit green fluorescence. This served to highlight that the transfection 
efficiency of gene-editing reagents was not the limiting factor in this investigation.  
Interestingly, the same successful integration of the MD1 transgene was not extended to the 
three component system trialled comprising of: Px165 (CBh-Cas9), U6-Guide, and the MD1-RT 
(data not shown). A likely explanation of this can be afforded in the first instance by a lower 
efficiency of delivery. Transient transfection is fundamentally reliant upon electrostatic 
interaction between cationic lipids and anionic nucleotides to facilitate the introduction of 
DNA into cells (Zuris et al. 2014). The general rule of thumb being the larger the piece of DNA 
or the greater the number of components sought to be introduced into the cell, the lower the 
overall transfection efficiency.  This arguably was the main justification for the development of  
a chimeric guide comprising crRNA-Hairpin loop- tracrRNA coined single guide RNA (sgRNA), 
the conventional scaffold used throughout this investigation. This single scaffold, enables the 
delivery of cRNA and tracrRNA together as one component able to initiate gene editing in 
mammalian cell culture as opposed to the two separate constituents observed in the 
endogenous system (Jinek et al. 2012). In addition to the introduction of the three 
components, their co-expression may also be a limiting factor. However, it should be noted 
that the three-component gene editing system described had no fluorescent marker to 
indicate successful DNA introduction to the HEK293T cells. Thus a methodological error 
pertaining to the transfection mixture constitution cannot be excluded. Future investigations 
should aim to fluorescently tag all components required for gene-modification to enable 
suitable tracking throughout in-vitro development.  
6.4.1.2 Integration of the MD1 Transgene at the Genomic and Transcriptomic levels: 
Importantly the PCR amplification extending from the genome-repair template and repair 
template – genome on the left across the left and right arms of homology respectively yielded 
an amplicon indicative of integration across all stages examined. The stages examined included 
48 hours post transfection, polyclonal HEK293T-MD1 and monoclonal HEK293T-MD1. In the 
former stage a nested PCR was required to detect the desired amplicon, whereas in the latter 
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two stages a single round of amplification was sufficient; this is consistent with a zeocin-
mediated enrichment of genetically-corrected cells. 
The survival of HEK293T cells treated with the MD1 RT alone yielded no amplicon associated 
with integration at the 48 hour post transfection stage. Initially, the absence of an amplicon 
led to speculation that random or non-targeted integration of the transgene and zeocin 
cassette had occurred. Notably, there was an overall trend that this treatment yielded a lower 
proportion of viable cells, relative to conditions in which the repair template was co-
transfected with gene-editing reagents. The combinations of these two observations added 
weight to this hypothesis. However, at the single colony stage the PCR amplicon was positive 
for site-specific integration of the repair template when used alone, a finding that was 
substantiated by the later determination of the occurrence of Dp427m promoter and exon 1  
element and MD1 exon 2 splicing in the MD1 RT alone treatment. In light of these findings, a 
new postulation of low level targeted integration became favoured. This being founded upon 
the basis that low levels of HDR can occur in the absence of a DSB, albeit with much less 
efficiency (Jasin & Berg 1988; Jasin & Rothstein 2013); this coupled to the finding that some 
genomic loci are more susceptible to  DNA integration events, two well-documented examples 
being the AAVSI and Albumin Loci (Kotin et al. 1990; Barzel et al. 2014).  Admittedly, these 
studies have a viral based integration focus; however, the genomic locus being predisposed to 
integration may be postulated to facilitate plasmid based integration as well. The target site 
within intron 1 for this investigation appears highly conserved; the possibility of a regulatory 
function and the associated open chromatin structure cannot be overlooked. 
Both of these theories demand further investigation, although all of the colonies yielded a 
positive PCR, indicating MD1 integration at monoclonal stage and there was no evidence of 
random integration. The process of Southern Blotting may elucidate whether copies of the 
MD1 transgene were integrated at a site distinct from that targeted by nucleases. If present 
this undesirable effect could be reduced with the use of negative selection utilising the Herpes 
Simplex Virus thymine kinase (HSVtk), which when integrated into a region outside of the arms 
of homology sensitises cells to ganciclovir (Schwartz et al. 1991).  This could also be achieved 
by utilising the analogous strategy using Diphtheria Toxin A fragment (Araki et al. 2006). In 
contrast, the potential of the region of homology identified having a favourable chromatin 
structure or indeed an associated regulatory function could be investigated by its subsequent 
destruction or use with an up-regulatory Cas9 system. 
It should be noted that additional bands appear to occur upon the left integration PCR at 
around 1500bps in addition to the 1291bps, both upon nested conditions and in the final 
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polyclonal and monoclonal amplifications. Initially, this was anticipated to be outer PCR 
product at the 48 post transfection condition. However, its continued presence in single round 
amplification processes renders this argument inadequate. Thus this is largely thought to be 
considered to be a mis- priming artefact of the PCR, potentially highlighting that this PCR could 
be further optimised. This stated, the artefact arguably only appears in integration positive 
samples as seen by its absence in Mock, Px458-Guide 1 and MD1 RT alone samples 48 hours 
post transfection stage. As a consequence, this amplicon could likely be removed by the 
optimisation of the PCR but is largely considered inconsequential particularly when presented 
in combination with the right arm of homology PCR. 
Once DNA integration had been asserted, the next parameter that warranted investigation was 
transcription which was undertaken at the polyclonal and monoclonal stages of HEK293T-MD1. 
Initially, it was anticipated that splicing would only occur in instances where gene-editing 
reagents were co-delivered with exogenous MD1 repair template, particularly at the polyclonal 
stage. However, the reverse transcription and subsequent PCR, yielded amplicon sizes 
congruent with Dp427m promoter and exon 2 splicing across all conditions at this stage 
including repair template alone and instances of co-delivery of gene-editing reagents. This 
adds additional weight to the theory of nuclease independent integration at the target locus. 
This likely indicates that nested amplification of the repair template alone DNA at the 
polyclonal stage, would likely yield an amplicon consistent with integration. The positive 
transcription result of the exogenous MD1 repair template alone is further validated by the 
MD1 protein expression at both the polyclonal and monoclonal HEK293T-MD1.   
A major implication of this result is that the endogenous Dp427m promoter can be spliced to 
exon 2, potentially yielding MD1 transgene expression with the same temporal and spatial 
expression of dystrophin. This finding could be particularly pertinent to the field of DMD 
research if the ability to splice to the β-globin splice acceptor is retained across the other full-
length dystrophin isoforms Dp427c, Dp427p1 and p2. This is especially important as 
permanent integration could enable prolonged dystrophin expression, as opposed to gene 
augmentation approaches.   
6.4.1.3 MD1 Protein Expression within Enriched Polyclonal Populations and 
Monoclonal Populations: 
An interesting albeit unanticipated finding was the presence of truncated microdystrophin at 
the polyclonal and monoclonal stages of this investigation (Full length MD1 137kDA, detected 
MD1 approximately 117kDa). It should be stated this truncated MD1 was the prominent 
protein expressed alongside low levels of full-length MD1 at the monoclonal stage of the 
investigation. The truncated MD1 was shown to result from the treatment of HEK293T cells 
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with the promoter-less MD1 endogenous repair template, as no protein of corresponding size 
was detected in HEK293T only cell lysate. Moreover, the presence of this protein product was 
not only limited to conditions where gene-editing reagents were co-expressed. Initially, this 
was thought to be attributable to some aberrant initiation of transcription from a downstream 
methionine constitutively expressed within the MD1-RT. However, the RT PCR data highlights 
that splicing is occurring between the full length Dp427m promoter and the MD1 Exon2 within 
the repair template in all conditions that survived to the clonal stage. Equally, all conditions 
showed evidence of integration at the target locus whether co-expressed with the Cas9 
nuclease or expressed in isolation with absence of Cas9.  
The evidence accrued indicates that this protein product is a positive dystrophin variant, due 
to the use of the MannEx10-11c antibody, which recognises an epitope between the exon 10-
11 boundaries respectively. However, the use of MannEx10-11c in detection means that 
currently the exact nature and position of the truncation cannot be empirically asserted. This 
stated, the MD1 cloned from Exon 6 onwards into the Puc57 backbone, contains only the 
terminating stop codon downstream from Exon10 and 11c, making it likely that any truncation 
would likely be a resulting from the 5’ end of the DMD gene. Due to time constraints, it was 
not possible to investigate this further. However, such investigations would include the use of 
a panel of antibodies screening the C-terminal and N-terminal of MD1 protein. Based upon this 
assumption a post-hoc bioinformatics analysis was performed in an attempt to ascertain the 
putative identity of this protein.  Using the correct in-frame microdystrophin, protein 
predictions were produced using the downstream in-frame methionine residues.  This 
pertained to 3 initiating ATGs, including 2 ATGs within exon 3, which would yield a 129kDa 
protein and a final ATG within Exon 6, which would yield a 117kDa protein.  Interestingly, this 
may be  consistent with the Internal Ribosome Entry Site (IRES) being used within Exon 5 to 
enable translational initiation from Exon 6 (Wein et al. 2014). The preferential utilisation of the 
IRES could be attributable to either the absence of a regulatory region perhaps destroyed as a 
process of the gene-editing undertaken that would modulate expression from exon 1, or 
indeed the potential for a sequence alteration that disrupt the reading frame.   The latter 
would be particularly consistent as this mechanism was used to describe N-terminal 
truncations that were exceptions to the Monaco rule, yielding milder BMD phenotypes with an 
out-of-frame deletion (Monaco 1989). 
In this study describing IRES functionality, the IRES was assessed by sequential deletions of 
dystrophin exons 1-6, which were fused to a downstream fluorescent reporter. Although the 
IRES activity was not strong enough to induce fluorescence expression in the HEK293T cell 
lineage, in the study undertaken (Wein et al. 2014); many parameters are different in this 
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research including: use of optimised MD1,  introduced into the intron 1 site. The former is of 
particular importance as the sequence optimisation enhancing the level of subsequent 
transcription, could be postulated to promote the IRES to activity (Raab et al. 2010).  For a 
further assertion of this IRES theory, prospects of aberrant splicing and the potential of cryptic 
splice sites would also have to be excluded via thorough investigation.  A second post-hoc 
bioinformatics analysis was undertaken using Human Splice Finder to identify other putative 
splice sites (Desmet et al. 2009). This served to highlight that whilst the artificial beta-globin 
acceptor previously utilised successfully by our lab was the strongest splice acceptor, there are  
a multitude of splice enhancers present downstream around 201nts, which could influence 
aberrant splicing in the MD1 (Popplewell et al. 2013). This would enable splicing of the third 
exon which in turn could be speculated to bias the IRES translation. Thus it is plausible that 
more enhancers need to be appended to the 5’ end of the MD1-RT, to facilitate the expression 
of the full length MD1 product.  
In summary, evidence for Dp427m promoter exon 1 to exon 2 successful splicing as 
determined by PCR and sequencing and the presence of a full lengthMD1 transgene appear 
consistent with in-frame reading of the MD1 transgene. However, the presence of truncated 
MD1 necessitates further examination as to how this truncated protein form came into 
production in the context of IRES, Aberrant / Cryptic Splice sites and / or subtle sequence 
alterations. These investigations would need to be extended to both the repair template itself 
and the subsequent integration to find the source of any such mutation that may have 
occurred. In addition current examinations indicate that the integrated MD1 is being 
expressed from the endogenous Dp427m promoter. Further investigation examining the 
function of the resultant transgene is necessitated although this would likely require the use of 
an animal model such as the mdx mouse and an alternative delivery system.  
6.4.2  Stability of HDR-mediated MD1 Transgene Integration in Δ45-52 Patient 
Myoblasts, 
Stable integration of the MD1 transgene could not be established in the Δ45-52 patient 
myoblast culture. The numerous parameters of this investigation namely transfection 
efficiency, transgene Integration and cell survival on exposure to zeocin, could all be improved 
upon to enhance the chance of successful MD1 knock-in and subsequent expression. 
6.4.3 Transfection Efficiency of Immortalised Δ45-55 Patient Myoblasts:  
The immortalised Δ45-52 patient myoblasts utilised in this study appear relatively refractory to 
transient transfection, like many other primary-like cell lines. Introduction of tethered Cas9-
2A-GFP constructs indicated notable successful transfection efficiencies in the range of 20 and 
40%. However, considering the decreasing proportion of cells associated with each stage of 
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genome-engineering i.e. number of cells transfected, transfected cells that undergo gene-
modification and finally, of interest genetically modified cells that has undergone HDR, the 
parameter of transfection efficiency could still be drastically improved in attainment of the 
final HDR-outcome, particularly as the PCR amplification across the left arm of homology, 
could indicate a low level of integration. Interestingly, the integration PCR is only detectable 
across a single junction. This is likely attributable to PCR efficiency with the right junction PCR 
occurring with less efficiency than the left. Delivery of gene-editing reagents remains a 
fundamental limiting step in the development of therapeutic approaches to numerous cells 
lines of physiological interest. However, much advancement has been made in the field at 
large that could be utilised to improve upon the current transfection efficiency. 
In the context of a non-viral delivery strategy, multiple transfection reagents have been trialled 
in this investigation and a series of optimisations were undertaken to try and improve plasmid 
delivery to patient myoblasts (Chapter 4).  Further improvements in transfection efficiency 
with plasmids would likely necessitate the examination of further transfection reagents and 
culture conditions. An alternative strategy for the delivery of plasmids too hard to transfect 
cell lines is electroporation whereby an electrical current is applied to cells to facilitate the 
uptake of plasmids. In the context of guide and Cas9 plasmids, this has shown comparable or 
improved efficiency across a range of mammalian cell lines relative to  cationic lipid transient 
transfection based delivery systems (X. Liang et al. 2015). The reason such an approach 
remained unutilised in this investigation is that the optimisation process is relatively costly and 
time consuming. Furthermore, if not optimised correctly, cell viability is greatly diminished. 
In addition to alternative delivery strategies consideration should be given to alternative 
delivery platforms for the Cas9 namely, mRNA and protein. Plasmid delivery platforms have a 
number of inherent limitations such as risk of random integration, higher associated toxicities 
and/ or off-target effects and lower gene modification across a number of cell lines, which are 
largely overcome by mRNA and protein gene-editing reagents (X. Liang et al. 2015; Yu et al. 
2016; S. Kim et al. 2014; Zuris et al. 2014). It should be noted that transfection, is a 
multifactorial process related to the dose of reagents administered, the cell number seeded 
and finally any toxicity (Yu et al. 2016). In this instance, some toxicity was observed in the 
microscopy images of transfected patient myoblasts relative to the mock samples. If toxicity 
can be circumvented by the delivery of Cas9 protein as opposed to plasmid based platforms in 
a manner analogous to that observed in multiple cell lines, then the extent of gene editing can 
be increased. Moreover, an instance where there is less toxicity lower cell densities could be 
exploited, thereby enhancing the amount of reagent per cell available for gene editing (Yu et 
al. 2016). By extension of this, lower doses of reagents would be required and the proportion 
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of gene modification occurring would be heightened. This could represent a beneficial 
prospect with patient myoblast where the cell seeding of 8.3 x 104is relatively low. In 
conventional transfections this is left for 48 hours prior to delivery, but the optimisation of a 
protein based system may allow protein transfection to be attempted at 24 hours post 
seeding.  These types of approaches have been provisionally developed (Chapter 4) with the 
outlook to apply them in the context of patient myoblasts. 
Finally, viral vectors should be considered as a potential delivery mechanism of gene-editing 
reagents. Notable examples of viral vectors established in the field of CRISPR/Cas9 include 
Adenoviral, Lentiviral and Adeno-Associated Viral vectors.  Adeno and Lentiviral vectors, 
arguably are more suitable vectors owing to their large capacities and ability to transduce 
proliferating and non-proliferating cells (Maggio et al. 2014; Maggio et al. 2016; Ousterout et 
al. 2015; Ran et al. 2015). The former has been used in the context of multiplexing and the 
latter has shown promise orchestrating NHEJ-mediated deletions, across the DMD gene in 
myoblasts. Lentiviral vectors were under development in this thesis for utilisation in such a 
manner but time restrictions precluded exploitation. Perhaps the most promising candidate is 
however the adenoviral vector as a dual transfection would enable the delivery of larger 
transgene cDNA repair template, thereby enabling the introduction of the full range of 
dystrophin variants highlighted in Chapter 5.  
6.4.3.1 Enhancing the HDR DNA Repair Pathway: 
The presence of a PCR amplicon across the left genome-repair template junction provides an 
indication that low levels of HDR had occurred within the heterogeneous Δ45-52 patient 
myoblast culture. In addition to enhancing gene-editing reagents delivery, numerous strategies 
could be employed that have been shown to successfully bias the DNA repair pathway utilised 
in genome repair.  In reference to the DSB resolution, NHEJ and HDR pathways occur 
concurrently and competitively. The NHEJ pathway is the predominant repair mechanism used 
throughout the mammalian cell cycle, thereby limiting the extent scientists can exploit the 
high fidelity repair afforded by HDR. However, it is suppressed  by HDR during late G2 and S 
phases where a sister chromatid becomes available as a template for HDR (Maruyama et al. 
2016; Velic et al. 2015; Heyer et al. 2010). Thus to enhance precise genome repair and 
subsequent transgene integration, two strategies may be employed: upregulation of the HDR 
repair pathway or suppression of the NHEJ repair pathway  
In consideration of HDR being constrained to the late G2 / S phase, this could be addressed by 
the modulation of cell cycle. By  transiently locking the cells into certain phases of the cell 
cycle, this can result in an increase in HDR efficiency, from the conventional values cited in 
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literature of 10-17% to a level reported in HEK293T of 36% (Lin et al. 2014; S. Kim et al. 2014; 
Zuris et al. 2014). However, manipulation of the cell cycle has largely been explored with 
ssODN exogenous donors and further work utilising larger transgene donors is warranted in 
the case of CRISPR-mediate gene knock-in. interestingly, an alternative approach has been 
trialled in studies, in which the Cas9 protein is synchronised to G2 and S phases. This provides 
an alternative complementary approach to cell synchronisation and was achieved by tethering 
the N-terminal 110 amino acids of geminin to Cas9 protein. This post translational modification 
rendered the endonuclease susceptible to proteolysis via endogenous ubiquination, a process 
that geminin would ordinarily partake. The expression of geminin oscillates becoming lowered 
during the M and G1 phases of the cell cycle and higher at S and G2 phases. This process was 
used to successfully limit, an engineered Cas9 protein expression to phases in the cell cycle 
where HDR is elevated (Gutschner et al. 2016). The combination of both approaches can be 
utilised to achieve desirable HDR outcomes. 
Further promising research relates to fusion of yeast Rad52 protein to Cas9 protein, and such 
an approach has been utilised in chicken cell backgrounds (Wang et al. 2017). The premise 
here is that the expression of this Rad52 fusion intermediate will improve Rad51 filament 
formation and enhance the rate of strand invasion and subsequent HDR by extension. In 
isolation the overexpression of Rad52 protein increased HDR by up to 37 fold in HeLa cells, a 
striking result which was improved upon to 50 fold when combined with nucleus localising HIV 
Tat11 protein (Di Primio et al. 2005; Kalvala et al. 2010). Whilst the Cas9-Rad52 fusion protein 
has only to date been trialled in a chicken background, further work aiming to develop this 
fusion construct to enhance HDR correction in mammalian cells, could prove promising to the 
field at large. 
The second strategy employs use of NHEJ-inhibitors which aims to suppress the NHEJ pathway 
in favour of HDR, enabling HDR to be exploited in the context of genome engineering. The 
transient downregulation of the NHEJ pathway could enhance the MD1 transgene integration 
observed within Δ45-52 patient myoblasts. In consideration that a low level of transgene 
integration was found by PCR, this should be explored. Fortunately, the plethora of mediators 
used in the NHEJ DNA repair pathway to resolve a DSB yields a number of candidates that 
could be modulated. As such, four classifications of biomolecules have become apparent: 
Ku70/80 inhibitors, Nucleotide DNA-Phosphokinase (DNA-PK) inhibitors, small molecule DNA- 
PK inhibitors  and finally DNA IV Ligase inhibitors (Velic et al. 2015).  This list of drug targets is 
extensive and non-exhaustive, thus for simplicity, discussion will only pertain to DNA-PK 
inhibitors and DNA IV ligase inhibitors. 
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In brief, during the c-NHEJ, a DNA DSB is stabilised by Ku70/Ku80 dyad molecules; these in turn 
recruit DNA-PKs which undergo auto-phosphorylation potentiating a phosphorylation cascade, 
ultimately promoting DNA end processing and ligation by DNA IV ligase.  A range of 
morpholino-containing molecules with the propensity to inhibit DNA-PKs have been identified: 
including vanillin, NU7026 and NU7441 (Durant & Karran 2003; Leahy et al. 2004; Calabrese et 
al. 2004). These all represent potential candidates to suppress the NHEJ pathways and 
enhance the HDR, improving the MD1 integration occurring in patient myoblasts.  
This could prove particularly promising when utilising an ex-vivo gene correction strategy, 
during which cells could be transiently exposed. However, some inherent concerns to the 
therapeutic use of these reagents relate to drug target specificity since DNA-PK is a member of 
and thereby similar to Phosphatidylinositol-3-kinases, potential toxicity and ability to sensitise 
the cells to DNA damage (Velic et al. 2015). These parameters require further examination 
prior to being used to supplement a translational approach. 
Interestingly, a recent investigation utilised Sc7, a ligase IV inhibitor alongside Cas9 in both 
mammalian cell culture and murine zygotes. This was shown to potentiate HDR mediated 
insertion, increasing HDR to a striking 19 fold in the case of mammalian cell culture (Maruyama 
et al. 2016). However, this study highlighted some major considerations that would need to be 
met prior to employing such a strategy for MD1 integration in patient myoblasts. Initially, Sc7 
exhibits a cell dependent response with one mammalian epithelial cell used in the study A549, 
showing only a moderate 3 fold increase at a low dose of 0.01μM and attenuation of HDR at 
higher doses, attributed to toxicity. This is in contrast to the 19 fold increase of HDR show-
cased in at a high dose 1μM with MuJullSO, a melanoma cell line. Moreover, the transgenes 
inserted were considerably shorter than MD1 with inserts of 200-800bps being inserted 
flanked by arms of homology. These are considerable shorter than the MD1 transgene and 
zeocin selection cassette, which is in the range of 5.1kb. In addition, only in the murine zygotes 
were gene-editing and HDR reagents delivered alongside the Sc7; all mammalian cell lines 
were engineering to have doxycycline inducible sgRNA and Cas9 expression. In short, whilst 
none of the conventional contraindications were shown with this study e.g. DNA IV ligase-
associated apoptosis in culture conditions or failure of lymphocyte maturation and a shift 
towards alt-NHEJ at the murine zygote level, the applicability of such an approach may prove 
challenging in the context of patient myoblasts.  
Another more broad study with the use of a Traffic Light Reporter (TLR), this being a system 
that indicates whether a DSB has been resolved by NHEJ or HDR by alternative fluorescent 
reporter, cited a more modest 4-5 fold increase of HDR with Sc7 (Chu et al. 2015). The 
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disparity in fold increase in HDR reported is likely attributable to the fact that reagents were 
delivered by transient transfection as opposed to being constitutively expressed. Thus this is 
more likely representative of the HDR increases likely to be observed with transient 
transfection into patient myoblast if employed. In addition to small molecule therapy with Sc7, 
this investigation also highlighted a 5 and 8 fold increase in HDR upon gene silencing of Ku70 
and DNA ligase IV co expression of Cas9 with Adenovirus 4 E1B55k and E4orf6 proteins (using a 
tethered protein) respectively.  This coupled to another NHEJ inhibitor study undertaken in 
Cryptococcus neoformans, admittedly a fungal background, highlights the requirement to 
screen multiple drug candidates and formats in order to attain the most efficient NHEJ 
pathway suppression (Arras & Fraser 2016).   
To conclude, there are a variety of potential drug targets that could interrupt the NHEJ or 
indeed enhance the HDR pathway improving the successful integration of the MD1 transgene. 
However, such an approach could prove challenging to implement and could prove 
detrimental to cell cultures. Nonetheless, this represents a potential manner to improve upon 
the current outcomes.  
6.4.3.2 Further Refinement of Zeocin Doses  
A final revision to this investigation may be to reduce the zeocin concentration applied during 
the selection process. Whilst higher doses of zeocin were required to cause cell death to 
untreated patient myoblasts, this represented a somewhat artificial situation that does not 
account for the effects of transfection related toxicity and sparse seeding of muscle cells. 
Moreover, from the microscopy imaging undertaken, in some instances an increased myoblast 
number is present in some of the treated conditions relative to mock samples. This may be 
attributable to inaccurate seeding of cells in the presence of zeocin, particularly as high cell 
number has been indicated to reduce the efficacy of the drug (Invitrogen 2017). The 
alternative explanation being the cells have retained the resistance cassette but the dose of 
zeocin surmounts the protective effect of the cassette.    
6.5 Conclusion 
In conclusion this chapter has demonstrated that the human DMD intron 1 locus, a region 
common to transcription of all full-length dystrophin RNA isoforms, can undergo Cas9-
mediated HDR integration of the MD1ΔEx1 transgene. In HEK293T cells, integration of the 
MD1ΔEx1 transgene was not only detected upon PCR at 48 hours post transfection and also at 
two sequential stages of DNA harvest following long-term zeocin enrichment. Interestingly, the 
Dp427m exon 1 was demonstrated by RT PCR and sequencing to splice to the inserted 
MD1ΔEx1 transgene. However, a smaller than predicted MD1 protein was detected and was 
the predominate product, alongside low levels of full length MD1 by western blot of zeocin-
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enriched cells. It is theorised that this may be as a result of either aberrant splicing or 
increased utilisation of the IRES site on exon 5. None-the-less this provides valuable evidence 
relating to a novel near universal strategy of splicing a dystrophin transgene to the Dp427m 
promoter.  
Further refinement is required to achieve successful integration in patient myoblasts, although 
initial evidence of a positive single junction PCR appears promising.  Furthermore, additional 
research is warranted to assess the functionality of the resultant truncated MD1 protein. This 
stated, with some refinement, the near-universal therapeutic strategy presented could achieve 
the endogenous spatial and temporal expression of dystrophin transgenes and hold promise 
for nearly all patient cohorts. 
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Chapter 7 General Discussion  
This investigation aimed to and provided the first proof of principle, in vitro demonstration of 
MD1ΔEx1 integration downstream of full length endogenous dystrophin promoters and exon 1 
elements. This near universal permanent gene-correction approach could provide a clinical 
strategy distinctive from gene augmentation. It is distinctive as it would not require repeated 
administration, serving to reduce the risk of adverse immunogenic events in patients. 
Secondly, being integrated downstream of and driven by full-length endogenous dystrophin 
promoters, it speculated that this approach is unique relative to other gene-editing strategies 
on the basis of its high patient applicability. In addition, by targeting downstream of 
endogenous promoters and exon 1 elements this approach is likely to provide spatial 
expression profiles of MD1 consist with dystrophin in vivo. Furthermore, the improved 
transcription associated with sequence optimisation predicts that microdystrophin protein 
expression levels would likely be equal to or higher than those observed for dystrophin 
physiologically. The latter sequence optimisation, examined for MD1, Δ45-55 and full-length 
dystrophin will undoubtedly make achieving a therapeutic threshold of dystrophin in patients 
easier.  
These findings could hold therapeutic promise for the field of DMD, particularly if a successful 
demonstration of this strategy’s ability to ameliorate disease phenotype could be achieved in 
an animal model. As a consequence the discussion will be divided into considerations of the 
current research, enhancement of transgene integration approaches and translation of 
research into therapeutic setting; the outlook for each of the sections will be to examine the 
work undertaken in the context of the current gene-therapy field. 
7.1 Current Research Considerations: 
7.1.1 Identify and Resolve the Source of the MD1 Truncation 
Molecular characterisation of polyclonal and monoclonal HEK293T-MD1 cells indicated that 
splicing between the Dp427m exon 1 and exon 2 of the integrated MD1 transgene was 
successful, as confirmed by an RT-PCR across the exon junctions performed on mRNA lysate. 
However, when total protein was subject to analysis by western blotting with MannEx10-11c, 
only a faint band of full-length MD1 was observed in monoclonal cultures, being absent or 
below detection in preceding polyclonal cultures. Whilst, this served to validate that splicing 
between Dp427m Exon 1 and MD1 Exon 2 was occurring, the full-length MD1 protein was 
largely overshadowed by a high intensity band corresponding to a truncated MD1 protein 
estimated to be 117kDa in size.  
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It is speculated that the source of this truncation is attributable to aberrant splicing between 
the Dp427m exon 1 and MD1 transgene or an internal deletion of MD1 cDNA. In light of this, In 
silico predictions of splice sites strength using human splice finder, were re-examined (Desmet 
et al. 2009). Notably, whilst the artificial β-globin splice acceptor used for the repair template 
was ranked as the strongest splice acceptor ,relative the native exon 2 splice acceptor, overall; 
a cluster of splicing enhancers were observed downstream of this, surrounding moderately 
ranked splice acceptors. Consequently, it is predicted that this could provide a favourable 
environment for splicing and a source for competition for the β-globin splice acceptor. 
Empirical evidence of this could be attained by undertaking RT-PCRs spanning the sequence 
between Dp427m exon 1 and predicted downstream splice acceptor candidates. If aberrant 
splicing was found to be the cause of truncation, the inclusion of native dystrophin exon 61 or 
64 splice acceptors in place of the β-globin, may overcome this problem particularly as these 
were observed to the strongest in triple-transplicing experiments (Lai et al. 2005). To eliminate 
the alternative possibility of internal deletions within the integrated MD1 cDNA, PCRs tiling the 
whole MD1 transgene should also be undertaken. In addition, RT PCRs could also be 
undertaken to assess the mRNA and findings could be further validated with the use of 
antibodies across the MD1, if a specific deletion is suspected.  
Identifying the source of the truncation is of paramount importance to the investigation, as the 
nature of the 5’ deletion may / may not influence the functionality of the MD1 construct 
(Banks et al. 2007; Wein et al. 2014). If the functionality, is in anyway impaired it could 
undermine the strategy proposed and thus requires resolution.  
7.1.2 Assess the Region of Homology Identified between Human and Mouse Intron 
1 for Potential Functionality: 
The genomic region targeted at the 5’ end of the DMD gene in this study showed high levels of 
sequence similarity between human and mouse. This, in combination with the unanticipated 
truncation of the integrated MD1 transgene, prompted further sequence analysis. It was 
speculated that the target site could represent a non-coding sequence with function. 
Interestingly, studies have indicated that only 1 -2% of the human genome codes for proteins, 
yet studies estimate that approximately 10% of the genome conserved (Lander et al. 2001; 
Wright & Sanjana 2016; Canver et al. 2017). Thus a potential expanse of non-coding DNA 
retains functions beyond the conventional mRNA and protein synthesis. 
To investigate further, the human 345 nucleotide region of homology with 100 nucleotides of 
adjacent flanking sequence was subject to pairwise sequence analysis against the genomes of 
the following species: Canis Lupis Familaris, Macaque Fasicularis, Rattus Norvegicus and Sus 
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Scrofa (Figure 7-1, Figure 7-2). Intriguingly, all species showed 82% or higher sequence 
similarity relative to human, with alignments ranging from 311 -351 in length (see Table 7-1). 
Further scrutiny of the sequence highlighted that the single nucleotide polymorphisms (SNPs) 
present within the nucleases designed appeared to be conserved. This is particularly 
exemplified for Guide 1 and 4, where respective 12T-C and 9A-G SNPs, were conserved across 
3 of the 4 species examined; the one exception being the Macaque Fasicularis. Furthermore, 
the rule is partially retained for guide 3 where Mouse and Rat harbour the same 9T-C, 20C-A 
polymorphisms. All SNPs noted followed a PAM proximal to distal nomenclature.  
In light of this evidence, the sequences were examined using the UCSC browser for DNAse I 
Hypersensitivity and histone acetylation/methylation; the presence of which are considered to 
be biochemical hallmarks of functional non-coding regions (Kent et al. 2002; Wright & Sanjana 
2016).  Despite Encylopedia of DNA Elements (ENCODE) providing a high level of genome-scale 
annotation (Dunham et al. 2012), which UCSC utilises, no sequence annotation was present for 
the site of interest (Figure 7-3).  This stated, the tool confirmed the high conservation of the 
sequence among the species in question. In addition short stretches of sequence to the left 
and right of the region examined, were indicated to have patents pending, due to predicted 
regulatory function. Although, there was no genomic annotation, this does not necessary 
disprove the presence of a functioning non-coding element. A recent study that produced 
Nanog, Rpp25, Tdgf1 and Zfp42 GFP fusions, in mouse embryonic stem cell lines, identified 
several regulatory elements that were not indicated by  annotation of biochemical hallmarks 
(Rajagopal et al. 2016). 
Collectively, these findings indicate experimental assessment of the sequence to delineate 
potential function and suitability of this site for gene-editing is warranted. Loss of function 
studies, either by the destruction of the local sequence or steric hindrance of transcriptional 
machinery, would likely aid in this process (Canver et al. 2017). Wild-type myoblasts and those 
treated for NHEJ-mediated removal of the region of homology could be differentiated in 
parallel. If a disparity in dystrophin expression is observed between the two groups it would 
suggest this sequence retains a regulatory function. The exact motif within this region could 
then be ascertained by tiling sgRNAs across the site and causing defined sequence 
modification with micro-insertions and deletions.   Alternatively, tethering a fluorescent 
marker to the 3’ end of the DMD gene would allow for an examination of transcriptional 
activity, with catalytically inactivated dead Cas9 (dCas9) tethered to transcriptional activators 
or repressors (Gilbert et al. 2013; Chen et al. 2013). The level of fluorescence and fluorescence 
intensity would serves as parameters to assess whether the site functions to modulate 
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transcription of the DMD gene.  Finally, of note a novel isoform Dp412e was recently 
elucidated downstream from the region of homology; on this basis one further speculation 
could be that this site could function as a promoter to the DMD gene (Massouridès et al. 
2015). 
Species  Sequence Similarity to 
Human  
Gaps Length of 
Alignment 
Common Nucleases (Guide 
and TALEN) 
Mouse 84.9% 5.5% 311 2 and TALEN 
Dog 82.0% 1.9% 322 2(X19) and TALEN 
Macaque 98.0% 3.1% 351 1, 2, 3 and TALEN 
Rat 83.9% 6.4%  311 2 and TALEN 
Pig 82.0% 4.0% 350 2(X19), 3 and TALEN 
 
Table 7-1 : A table showing the sequence similarity attained by rigorous local alignment of the human region of 
homology sequence, identified in DMD intron 1, against a multitude of species. 
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Figure 7-1 The human region of homology identified within the DMD common intron 1 aligned against 
consensus DMD sequences of Canis Lupis Familiaris and Macaque Fasicularis, using a rigorous local 
alignment tool ‘Emboss Matcher’. 
The top local alignment is between human and Canis Lupis Familaris, the bottom is between human and 
Macaque Fasicularis. Notice the region deemed to be highly homologous between mouse and human is 
highlighted in blue for both of the sequences retain high similarity. 
Human  
Dog 
Human  
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Figure 7-2 The human region of homology identified within the DMD common intron 1 aligned against 
consensus DMD sequences of Rattus Norvegicus and Sus Scrofa, using a rigorous local alignment tool 
‘Emboss Matcher’. 
The top local alignment is between human and Rattus Norvegicus, the bottom is between human and 
Sus Scrofa. Notice the region deemed to be highly homologous between mouse and human is 
highlighted in blue for both of the sequences retain high similarity. 
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Figure 7-3 An examination of genomic annotation at the region of homology identified in DMD intron 1 using the UCSC genome browser. 
Notably, this sequence has no histone acetylation tracts and DNAI hypersensitivity annotation (All tracts labelled on the left hand-side), which are regarded as biochemical markers 
of accessibility for functional non-coding DNA sequences. In addition high levels of conservation are notes for rhesus, macaque, rat and dog sequences; as evidenced by the green 
multiz alignment and vertebrate conservation. Finally, sequences within the blue semi-circle have been patented as sequences with regulatory function. 
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7.2 Enhancement of Transgene Integration Approaches 
7.2.1 Advances in CRISPR Guide Design: A Prospect for Improved CRISPR guides 
At the initiation of this project in 2013 the prokaryotic adaptive immune system CRISPR/Cas9 
had just been repurposed for mammalian gene editing (Jinek et al. 2013; Mali, Yang, et al. 
2013; Cong et al. 2013). This simple gene-editing platform appeared attractive over 
predecessors being an RNA rather than protein guided customisable endonuclease (Mali, 
Esvelt, et al. 2013). One major limitation to the use of this system, at the start of the 
investigation, was the lack of specificity and efficacy-governing rules to guide design. The 
variable efficacy of guides and lack of understanding thereof, was certainly a hindrance to the 
computational design of gene-editing reagents. This was  exemplified by Liu et al’s study, 
which demonstrated that 41% of the 218 guides tested failed to show detectable on-target 
mutagenesis in Neuro-2A-cells, with mismatch detection assays(Liu et al. 2016a). Interestingly, 
studies indicated that guides targeted to the same genomic locus, showed variable efficacy. 
One example of this was Mali et al’s paper, which demonstrated two guides targeting the 
AAVS1, separated by 19 nucleotides, showed an approximate two-fold difference in gene-
modification frequencies (Mali, Yang, et al. 2013).  
These findings lead to speculation that the nucleotide composition of a guide could influence 
the overall efficacy of the Cas9 system. This prompted a plethora of investigations to identify 
sequence determinants that govern guide efficacy; one milestone study screened 1841 guides 
targeted to 6 cell surface markers. The knock-out of markers was examined by Fluorescence 
Activated Cell Sorting (FACs), with the use of antibodies; the extent of knock-out was used as a 
proxy for guide efficacy. This study amongst many others confirmed that nucleotide 
composition had an influential role on on-target mutagenesis; this lead to the derivation of 
sequence rule-sets, which served to inform computational prediction tools. 
The sequence parameters deemed beneficial to a high efficacy guide included: i) The presence 
of guanine in position 1 of guide, ii) The presence of guanine in position 20, iii) Adenine 
residues positioned to the middle of the guide, iv) A cytosine in position 17 at the RNA-DNA 
cleavage junction and v) A poly GGGG runs in In-vitro transcribed guides. Those deemed 
detrimental included: i) A cytosine in position 3 of the guide and ii) A poly TTTT run.  
Interestingly, numerous studies indicated that the presence of a guanine nucleotide in position 
1 of guide designs was related to higher efficacy (Doench et al. 2014; Moreno-Mateos et al. 
2015; Xu et al. 2015; Chari et al. 2015b; Liu et al. 2016a). This was attributed to two reasons, 
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guanine being a pre-requisite for correct transcription from U6 RNA III polymerase promoters 
and the 5’ nucleotide enabling a stronger RNA: DNA hybridisation between guide and genome 
(T. Zhang et al. 2017; Moreno-Mateos et al. 2015). The requirement of the guide to have a 
certain 5’ composition to enable efficient transcription was also expanded to  in-vitro 
transcription studies in zebrafish using T7 and Spc6 promoters, the former was observed to 
have a bias to a 5’ ‘GG’ and the latter showed comparable activity between guides with a 5’ 
‘GG’ or ‘GA’ sequence (Gagnon et al. 2014).  The ability to transcribe an expanded repertoire of 
guides, served to indicate that the Sp6 was a superior promoter. As not all guide sequences 
identified computationally begin with a guanine residue, Cho et al examined the effect of 
appending guanine residues to guide sequences. The findings of the study suggest that the 
substitution of the first nucleotide of the guide to form GX19  was superior to simply 
appending ‘GG’ at the 5’ end (Cho et al. 2014b).  
In contrast to the guanine at position 1, indicated to be beneficial to transcription, the 
presence of a poly TTTT sequence is inhibitory to RNA III polymerase activity.  It is speculated 
that this poly TTTT run promotes the premature termination of mRNA transcription. 
Interestingly, the first generation chimeric single guide RNA, used a TTTT motif to connect the 
crRNA-tracrRNA; this was later modified to a GAAA- tetraloop by Chen and Dang et al to 
serving to enhance on-target mutagenesis (Jinek et al. 2013; Dang et al. 2015; Chen et al. 
2013). As a consequence guide sequences should avoid the inclusion of this motif as 
transcription of the guide may be variable or indeed unsuccessful.   
Remaining sequence determinants are thought to influence secondary structures formed via 
intermolecular interaction upon hybridisation of the guide and genome/ RNA: DNA, or 
intramolecular interactions within the guide itself. In the case of intermolecular interaction, it 
is speculated that the guanine at position 20 of the CRISPR guide, facilitates the unwinding of 
genomic DNA and the formation of an R-loop structure between RNA and DNA. This R-loop 
formation is indicated to stabilise the RNA-DNA duplex, thereby facilitating more efficient 
genomic modification (Anders et al. 2014; Malina et al. 2015; Liu et al. 2016a). Further general 
trends indicated to improve RNA: DNA duplex interactions or enable greater DNA cleavage 
include: the avoidance of cytosine in position 3 (Doench et al. 2014; Moreno-Mateos et al. 
2015), adenine nucleotides positioned to the middle of the guide (Doench et al. 2014; Moreno-
Mateos et al. 2015; Xu et al. 2015) and the presence of cytosine in position 17 (Xu et al. 2015).  
 The relationship between the presence of a poly GGGG sequence and guide efficacy proved 
more difficult to determine. Wong et al indicated that the presence of a poly GGGG sequence, 
not only reduced the oligo yield upon synthesis, but also formed an unfavourable G-quad 
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secondary structure, hindering the formation of RNA: DNA duplexes and subsequent DNA 
cleavage(Wong et al. 2015). In contrast to this Moreno, indicated that poly GGGG sequences 
improved guide RNA stability and whilst Cas9 loading was slower, when the guide was 
associated with the genome the poly GGGG served to stabilised the DNA:RNA duplex (Moreno-
Mateos et al. 2015). The increased stability of the guide itself and of the RNA: DNA duplex was 
predicted to improve guide efficacy. 
The disparity of these findings was resolved upon the examination of the experimental 
designs; Wu based his findings upon the highest efficacy U6 transcribed guides from Doench’s 
2014 study, whereas Moreno-Mateos produced guides by in vitro transcription. It was 
speculated that the latter study, which injected a defined concentration of guide mRNA, 
placed more emphasis upon guide stability and mRNA degradation; whereas, guides delivered 
in a U6 plasmid format are continually transcribed.  In light of this the presence of a poly GGGG 
sequence and a higher GC content, appear to be more favourable to the formation of 
secondary structures, enabling a greater persistence of mRNA guides post-delivery and thus a 
higher efficacy. These findings indicate that rule-sets of guide composition should be 
considered as dynamic and influence by the experimental situation in which they are 
employed. 
Intriguingly, Moreno’s indications that in-vitro transcribed guides should have a higher GC 
content and/ or poly GGGG sequences were corroborated by studies, that injected mice 
oocytes with guide mRNA (Haeussler et al. 2016). As a consequence of this Doench’s rule sets 
are argued to define U6 transcribed guides, whereas experiments aiming to produce guides by 
in-vitro transcription methods should adhere to Moreno’s guide design parameters. A range of 
computational tools have since been designed adhering to parameters highlighted in the 
aforementioned studies, a few examples include: CRISPRScan (Moreno-Mateos et al. 2015), 
CRISPOR (Haeussler et al. 2016), Benchling (Benchling 2015) and SgRNA designer (sgRNA 
Designer 2017). 
Importantly, sequence determinants are not the only parameter that influences CRISPR/Cas9 
guide efficacy, the microenvironment of the genome to which the guide is targeted, is also an 
important consideration. Firstly, Protospacer Adjacent Motif (PAM) recognition site 
composition is important ‘NGGX’, PAMs in which N is a guanine and X a thymine nucleotide 
have been shown to produce higher level efficacy; this is likely attributable to favourable R-
loop formation (Doench et al. 2014). Further studies have also indicated the importance of 
chromatin accessibility and PAM multiplicity.  Biochemical hallmarks of high DNAse I 
hypersensitivity, Histone 4-lysine-3, and low CpG methylation were all found to coincide with 
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the design of higher efficacy guides(Chari et al. 2015a; Wong et al. 2015; Xu et al. 2015; Liu et 
al. 2016a). Furthermore, a high frequency of PAM at the genomic target site is associated with 
poor gene-modification outcomes; this is speculated to be due to the Cas9 nuclease having to 
undergo a lot of genomic surveillance before target site recognition (Malina et al. 2015; Jinek 
et al. 2014).   
In addition to all of the efficacy algorithms coded above, all of the computational in silico guide 
prediction tools stated, also use specificity governing rules. The first guide specificity rule sets 
were derived from four main studies (Hsu et al. 2013a; Pattanayak et al. 2013; Mali et al. 2013; 
Fu et al. 2013). These studies utilised a mixture of transcriptional studies, with the catalytically 
dead Cas9 (dCas9), and direct cleavage studies. Hsu et al’s study represents a milestone to the 
understanding of CRISPR guide specificity. This study highlighted: i)The nature of the 
nucleotide mismatches e.g. A-G  ii)The position of the mismatch being PAM proximal or PAM 
distal, ii) The number of mismatches occurring and whether they were concurrent or dispersed 
throughout the guide are all parameters that influence a guides propensity to cleave an off-
target site. These findings were recently used by Doench to produce a Cutting Frequency 
Determination (CFD) score, whereby the propensity for a guide to cut on-target relative to off 
target is presented as a ratio. The closer this ratio is to the value 1, the more optimal the 
predicted guide design (Doench et al. 2016).   
The research presented here, highlights the extent to which the understanding of CRISPR guide 
design and targeting has advanced since the beginning of this investigation. This improved 
understanding of guide composition, genomic microenvironment and specificity, would have 
undoubtedly influenced the assessments of target sites and the guides selected for use within 
this study. Notably, 8 of the 9 total guides designed for this study, had neither a guanine at 
position 1 or 20, requiring the 5’ guanine to be appended to enable transcription. 
Furthermore, the guide identified as common to human and mouse sequences, and thus 
identified as an ideal candidate for development, harboured a poly TTTT region. Consistent 
with the rule sets, the common guide /human guide two, was associated with relatively low 
activity when transcribed by the U6 RNA III polymerase promoter.  Moreover, this guide 
produced low mRNA levels following in vitro transcription precluding its use in an experimental 
setting.  In contrast human guide 1 which was shown to be the most efficacious guide 
throughout this investigation harboured some beneficial sequence determinants. These 
included: a cytosine in position 17, centrally located adenine nucleotides and an adenine 
nucleotide at position 1, which is most favoured after guanine. 
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Interestingly, when the region was analysed again with the use of CRISPOR, a more advanced 
in silico guide prediction software (See Chapter 3); all guides attained threshold score of 50 for 
specificity, but only guide 1 scored a suitable efficacy score. This guide enabled the integration 
of the MD1 transgene downstream of endogenous promoters, attaining the primary aims of 
this investigation. This stated when the method was transitioned to patient myoblasts, 
integration was identified at low levels. This could be speculated to be due to a number of 
parameters including reduced transient transfection efficiency, limited introduction of DSB and 
even an altered level of HDR repair occurring within this cell line.  
Nonetheless, human guide 1 remains a candidate for continued investigation of the genetic-
correction strategy proposed based on the predicted specificity profile and the reduced 
propensity for off-target effects. Future work would aim to scrutinise guide 1 more thoroughly 
and investigate supplementary methods to improve HDR outcomes. In addition, the common 
intron 1 sequence should continue to be analysed with more recent guide design tools. On 
identification, target sites within the genome should be assessed on the basis of biochemical 
hallmarks of DNAI hypersensitivity, acetylation and the presence of SNPs. If both profiles 
appear favourable, the site should be sequence and mismatch detection assays undertaken. 
The combination of these two strategies would ensure the most successful outcomes for this 
gene-editing strategy moving forward. 
7.2.2 Improved Homology Directed Repair and the Prospect for Non-Homologous 
End Joining-mediated Integration Approaches 
Numerous strategies have been presented throughout this investigation with regard to 
enhancing the integration of the MD1 cDNA at the DMD intron 1 site. Briefly, these include: 
the inhibition of the NHEJ pathway (Maruyama et al. 2015), the synchronisation of the cell 
cycle at G2 and S phases (Lin et al. 2014) and overexpression or enhancement of (HDR) 
mediatory proteins (Di Primio et al. 2005; Wang et al. 2017). These considerations were made 
due to the inherently low efficiency of a HDR-based strategy, due to its limitation to late G2/ S 
phases of the cell cycle (Heyer et al. 2010). Importantly the modification of the exogenous 
repair template, to include endonuclease target sites outside the arms of homology, has also 
been shown to enhance the occurrence of HDR. Although the exact mechanism of how this 
works has not been delineated, it is speculated that the cleavage of the exogenous repair 
template in situ serves to improve integration outcomes. Moreover, dispensing with extensive 
homology arms, introducing endonucleases at the termini of short nucleotide stretches of 
microhomology, or directly adjacent to the cDNA transgene, has been shown to enable NHEJ-
mediated integration (Sakuma et al. 2015; Suzuki et al. 2016). As NHEJ is generally regarded as 
301 
 
a high efficiency process not constrained by the cell cycle, this finding could serve to redefine 
gene-editing approaches.  
This investigation used a classical HDR approach, producing a targeted DSB in the genome and 
utilising an exogenous cDNA repair template to facilitate the integration of the MD1 transgene 
from Exon 2 onwards. Importantly, the cDNA repair template conventionally requires arms of 
homology ranging from 0.2-1kb upstream and downstream of the DSB, that are completely 
isogenic to the genome (Byrne et al. 2015). However, the length of homology arms increases 
to 2kb, when a HDR approach is used in the context of induced Pluripotent Stem Cells (iPSCs) 
(Byrne et al. 2015;  Zhang et al. 2017). These extensive arms of homology increase the size of 
the exogenous repair template considerable and make delivery strategies more challenging. 
 In this instance 1kb arms of homology were included directly adjacent to the cDNA cassette, 
to maximise successful integration outcomes in HEK293T and immortalised patient myoblasts 
harbouring deletions of exons 45 - 52. Interestingly, during the production of this thesis, Zhang 
et al demonstrated that the inclusion of endonuclease genomic target sequence, directly 
adjacent to arms of homology increased cDNA integration efficiency. Reportedly, this approach 
produced 2 and 5 fold increases in integration efficiency, when using an mCherry transgene in 
HEK293T and IPSCs cultures respectively (Zhang et al. 2017). This study also indicated optimal 
levels of HDR were achieved using 600-900bp arm of homology flanked by cleavage sites, using 
this double cut system. The utilisation of this approach could streamline exogenous repair 
template designs and improve HDR outcomes in iPSC and other therapeutic cell candidates. 
Zhang’s study highlights that modification of the exogenous repair template used in this 
investigation could also improve HDR efficiency. Before considering the inclusion of restriction 
sites, the arms of homology within the exogenous repair template require refinement. Firstly, 
the arms of homology were constructed from consensus sequences to ensure timely de novo 
synthesis could occur. However, if the arms of homology are not completely isogenic to 
genomic sequences adjacent to the DSB, this can reduce integration efficiency (te Riele et al. 
1992; Zhang et al. 2017). To improve the current exogenous repair template construction, PCR 
designs should be tiled across the 1kb either side of the cleavage site; the region should then 
be amplified and sequenced in Δ45-52 Immortalised Patient myoblasts. This would aid the 
identification and elimination of any sequence polymorphisms and improve HDR outcomes. 
Secondly, there is a 49 and 32 nucleotide gap, between the left and right arms of homology 
and the guide 1 cleavage site respectively. This is present as the highest efficacy guide at the 
region of homology had not yet been identified, thus the arms of homology were designed to 
flank the highly homologous 100 nucleotides. Numerous studies have shown that arms of 
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homology designed in closer proximity to the DNA cleavage site are associated with improved 
HDR outcomes(te Riele et al. 1992; Byrne et al. 2015; Zhang et al. 2017). Thus arms of 
homology should be extended to the Guide 1 cleavage site; this could be performed using 
extended self-annealed oligo cloning. In spite of these limitations the current exogenous repair 
template enabled successful integration of the MD1 exon 2 onwards transgene at high enough 
efficiency for HEK293T cells to survive zeocin selection. Although evidence indicated some 
MD1 integration occurred in immortalised patient myoblasts, the culture was unable to survive 
the selection process; these strategies alone or in combination could improve the HDR 
enabling the persistence of MD1+ve-Myoblasts. 
7.2.2.1 A Non-Homologous End Joining Approach to Integration 
 In addition to the modification of arms of homology, improving the first generation repair 
template, which encoded a Cyan Fluorescent protein (CFP) with the initiating methionine 
removed between FseI and NotI restriction sites, could provide a model system to examine 
improved integration approaches. It was originally speculated that successful integration of 
this first generation exogenous repair template into human DMD intron 1, would yield a partial 
dystrophin-CFP fusion protein driven by the Dp427m promoter; thereby providing a visual 
indication of HDR.  Provisional experiments yielded no such visual indication; this could be 
attributed to a variety of reasons: the fusion protein adopting an unfavourable conformation 
and being degraded, aberrant splicing hindering CFP fluorescence and in the absence of a 
promoter driven CFP, the prospect of a dysfunctional fluorescent protein cannot be excluded. 
It would be beneficial to simplify the first generation repair template, to encode only a 
fluorescent marker driven by a CMV or Spc512 promoter, between left and right arms of 
homology. This construction would also enable a visual indication of integration and an 
indirect measurement by FACs analysis. Such a template could prove instrumental in assessing 
the optimal HDR enhancement strategies prior to translating such approaches to the MD1 
exogenous repair template. Furthermore, due to the low efficiency of the HDR pathway, there 
is a growing trend in the field to exploit the NHEJ and Micro homology-Mediated End Joining 
(MMEJ) DNA repair pathways for transgene integration (Heyer et al. 2010). The main 
difference between these two  methods being the proximity of genomic endonuclease 
restriction sites encoded on the exogenous repair template (Sakuma et al. 2015; Suzuki et al. 
2016). These alternative approaches could be trialled using this CFP with the outlook to 
transition a successful strategy to the exogenous MD1 template, without prolonged antibiotic 
selection. 
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 Two milestone studies that demonstrated the utility of the NHEJ DNA repair pathway in 
mediating cDNA integration was Obligate Ligation-Gated Recombination ‘ObLiGaRe’ and 
Homology Independent Targeted Integration ‘HITI’ (Maresca et al. 2013; Suzuki et al. 2016). 
These approaches are reliant upon the inclusion of an endonuclease recognition site in reverse 
orientation directly adjacent to the cDNA for integration. In this manner the exogenous repair 
template and the genomic DNA locus are simultaneously cleaved, and the cDNA ‘ligated’ into 
the genome.  Notably, ObLiGaRe utilised Zinc Finger Nucleases (ZFNs) whereas HITI used 
CRISPR/Cas9 but the underlying strategy remains the same. Interestingly, ObLiGaRe 
demonstrated that following a modification of the AAVSI site to contain high efficacy ZFN 
target sites, integration of a 15kb inducible transgene was possible (Maresca et al. 2013). In 
contrast, HITI exploited the propensity for NHEJ to occur in in both proliferating and post 
mitotic cells; using this approach to target and correct rat neurons of a genetic defect causing 
retinitis pigmentosa (Suzuki et al. 2016). During the latter method, constructs below 5kb were 
cloned into AAV vectors and injected into the subretinal space of rat models. 
The research presented has some important implications to furthering this investigation; i) It is 
possible through this method to introduce a 15kb cDNA ii) Utilising an NHEJ approach this 
method is able to target proliferative and post-mitotic cells iii) This approach also circumvents 
the requirement of HDR for extensive arms of homology and occurs throughout the cell cycle. 
Utilising this NHEJ-mediated approach for this investigation, co-transduction of AAVs encoding 
Staphylococcus aureus or Split Streptococcus pyrogenes with AAV-MD1 could be 
envisaged(Wright et al. 2015; Ran et al. 2015). Furthermore, this system could facilitate the 
integration of the larger transgenes such as Quasi Δ45-55 and full length dystrophin, which still 
remain the potential gold standard in therapeutic application. 
Whilst this approach has many advantages over conventional HDR, this method is arguably less 
precise than the former. If a plasmid repair template is utilised, it would necessitate the 
removal of its bacterial backbone and production in a minicircle format (Kay et al. 2010). This is 
due to the integration of the plasmid backbone being as likely as the transgene of interest. A 
further guard against this would be to use negative selection, by encoding a toxin in the 
plasmid backbone such as Herpes Simplex Virus –Thymidine kinase (HSV-TK). If this is 
integrated into DMD intron 1 rather than the MD1 transgene, then it can process ganciclovir if 
is exposed to, producing a toxin that results in cell death(Elion 1982; Schwartz et al. 1991). In 
addition, there is an increased risk of multiple insertion events in a head-to-tail format at the 
genomic locus of interest (Suzuki et al. 2016).  A final concern is related to the orientation of 
transgene integration particularly as spCas9 produced a blunt flush genomic cut. One strategy 
proposed to overcome this is to use bacterial orthologues of Cas9 that produce DNA cleavage 
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with cohesive overhangs, such as Cpf1 (Zetsche et al. 2015). Alternatively, 10-25 nucleotides of 
sequence isogenic to the DNA adjacent to the cleavage site could be included between the 
transgene and endonuclease cleavage site. This MMEJ utilises DNA 3’ end resection  during 
DNA repair to generate 5’ overhangs; this could provide ‘directional ligation’ of the MD1 
transgene into the genome(Sakuma et al. 2015). The approaches presented are promising and 
exciting alternative to HDR integration but warrant more extensive research and application.  
7.3 In Vivo Translation:  
7.3.1 Cell Engraftment Approaches in Pre-clinical Animal Models and DMD 
Patients. 
To further refine the near universal gene-editing strategy presented, an in-vivo demonstration 
of safety and efficacy is required in pre-clinical DMD animal models. This could be achieved 
through an ex vivo genetic modification and subsequent engraftment strategy, in which 
genetically modified muscle precursor cells are administered to dystrophin deficient mice. 
Since the first demonstration of myoblast engraftment in the 1970s, cell based therapies have 
focused upon the treating muscular dystrophies through the administration of mono-
=nucleated precursor cells (Partridge 1978). The premise for this therapeutic approach being 
wild type or genetically corrected mono-nucleated precursors can either: fuse to each other 
producing mature unaffected myofibres or fuse to regenerating patient muscle fibres. In the 
case of the latter, the donor nucleus enters the syncytial myofibre, and enables the synthesis 
of donor derived proteins overcoming the genetic mutation; this was first exemplified through 
injection of normal muscle precursor cells into the mdx mouse. It was demonstrated by these 
studies that the injected normal muscle precursor could fuse with pre-existing or regenerating 
mdx muscle fibres, rendering many of them dystrophin positive and rescuing from the 
dystrophin deficiency (Partridge et al. 1989).  
In the context of the current study, the genetically modified muscle precursor cells would 
contain the MD1 transgene from exon 2 onwards, integrated downstream of endogenous 
promoters. Importantly, the reconstituted MD1, is unlikely to restore all dystrophin protein 
associated functions; particularly as it lacks spectrin-like repeats 16 and 17 that neuronal Nitric 
Oxide Synthase (nNOS) is indicated to associate with (Lai et al. 2009). This stated, the MD1 
transgene is speculated to contain the minimal necessary protein domains to restore structural 
associations between the F-actin and Dystrophin Associated Protein Complex (DAPC) (Harper 
et al. 2002). Additionally, its use in gene augmentation approaches in mouse and canine 
preclinical models have demonstrated amelioration of dystrophic pathology (Foster et al. 
2008; Koo et al. 2011; Le Guiner et al. 2017) . Moreover, muscle derived cells were , genetically 
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corrected via a lentiviral transduction using a lentivirus encoding minidystrophin cDNAs and 
engrafted into TA muscles of mdx nude mice. This showed some success but was unable to 
achieve high enough expression levels to affect physiological function (Meng et al. 2016). This 
study used lentiviral transduction to attain transgene integration, native cDNA sequences of 
mini-dystrophin constructs and a muscle specific promoter different from the endogenous 
dystrophin promoter. It is speculated that the advantages of the approach presented being: 
targeted integration, sequence optimisation and expression from the endogenous dystrophin 
promoter, all represent parameters that may permit more favourable outcomes.   
Pertinent to the success of such an approach is the careful selection of muscle precursor cells 
to genetically correct and engraft. On a practical note GMP guidelines indicate cell candidates: 
should be readily available, easy to isolate /amplify and have a homing capacity to the site of 
muscle regeneration (Negroni et al. 2016). Furthermore an ideal cell candidate for the 
treatment of DMD, should also be: suitable for systemic delivery, as this would allow body 
wide correction rather than a single muscle post-intramuscular injection and be able to 
reconstitute the stem cell pool (Briggs & Morgan 2013). Currently, there are a plethora of cell 
candidates continually being identified and trialled, arguable the most examined are: 
myoblasts, satellite cells, pericytes/mesoangioblasts, CD133+ cells, Human Embryonic Stem 
cells and Induced Pluripotent Stem Cells.   
In the context of preclinical studies, an immune tolerant, dystrophin deficient mouse would 
provide the best model to examine this strategy. The recently developed Rag2-LL2rb-DMD- 
mouse, that lacks T, B and NK cells and has dystrophic phenotype could prove to be one such 
suitable candidate (Vallese et al. 2013). Alternatively, the NSG-mdx4cv mouse could also be 
utilised, which illustrates dystrophin deficiency with a reduction of NK cells (Arpke et al. 2013). 
Both of these models would prove suitable for allogenic engraftment approaches, this being 
where the donor cellular material is distinct from the host(Briggs & Morgan 2013). As a 
consequence, if improved viability and persistence of immortalised Δ45-52 patient myoblasts 
could be attained following genetic modification, these cells could be expanded and injected 
intramuscularly. Whilst it is generally noted that myoblast engraftment is associated with low 
efficiency, owing to low survival and migration post injection (Lipton & Schultz 1979; Morgan 
et al. 1987; Beauchamp et al. 1999); such an approach would likely be sufficient to provide an 
initial indication of efficacy in vivo. Furthermore the engraftment efficiency could be improved 
in pre-clinical models if the muscle is ‘primed’ by inducing damage and subsequent muscle 
regeneration by pre-treatment with: irradiation (Morgan et al. 1993), myotoxins/ cardiotoxins 
(Harris 2003) or cryoinjury (Morgan et al. 1987). 
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The strategy presented is only likely to provide correction of a specific, defined and accessible 
muscle. While it is argued correction of single muscle could provide an improved quality of life 
to DMD patients, by for example maintaining upper limb motility if targeting the biceps brachii 
(Briggs & Morgan 2013; Skuk et al. 2007); skeletal muscle constitutes 50% of our body mass 
and dilated cardiomyopathy is currently the leading cause of premature death in DMD, hence, 
there is a requirement for systemic restoration of dystrophin (Bushby et al. 2010b; Long et al. 
2016; Pini et al. 2017). Interestingly, satellite cells and myoblast progeny are not suitable for 
systemic delivery (Briggs & Morgan 2013). The most characterised cellular candidates with 
good tolerability following intra-arterial systemic delivery in preclinical models are the blood 
and bone marrow derived CD133+ (Torrente et al. 2004) and vessel derived pericytes/ 
mesoangioblasts (Díaz-Manera et al. 2010; Sampaolesi et al. 2003; Sampaolesi et al. 2006; 
Tedesco et al. 2012). Thus for the true therapeutic potential of this gene-editing strategy to be 
achieved, gene modification needs to be trialled in one of these two cell candidates prior to 
intra-arterial injection. One elegant study by Tedesco et al in 2012 used fibroblasts and 
myoblasts from limb girdle muscular dystrophy (LGMD) patients, to generate iPSCs. Once an 
iPSC culture was obtained and mesoangioblasts- like cells were subsequently derived and 
genetically corrected to treat LMGD patients. Importantly iPSCs can theoretically proliferate 
indefinitely thereby providing a substantial and essential source of mesoangioblasts is these 
are used for cell-based therapies. 
Importantly, while preclinical models of muscular dystrophy tend to promising levels of 
correction and/or functional improvements following cellular engraftment approaches, this is 
challenging to transition to human patients, as evidenced by the relative successes and 
challenges of three clinical trials (Skuk et al. 2007; Périé et al. 2014; Cossu et al. 2015).  
The first Phase I clinical trial by Skuk et al utilised HLA-matched allogenic myoblast 
transplantation in three muscle groups of a 26 year old DMD patient on Tacrolimus, an 
immunosuppressive therapy, these being: the gastrocnemius, biceps brachii and thenar 
eminence. In spite of the low myoblast transplantation efficiency observed by previous clinical 
trials in the 1990s; this study asserted that more knowledge in relation to the numeracy and 
distribution of injections was required. Earlier studies by this group indicated that muscle 
precursor cells only fuse and have regenerative capacity for myofibres they come into contact 
with, being defined by the trajectory of the injection (Skuk et al. 2002; Skuk et al. 2006). As a 
result of these findings a high density injection protocol in which 25-100 injections are placed 
within 1 – 2mm of each other, was undertaken. Two biopsies taken 1 month and 18 months 
post transplantation indicated 27% and 34.5% dystrophin positive fibres in the gastrocnemius 
respectively.  However, other muscle groups failed to show dystrophin positive fibres upon 
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biopsy and other than improved metacarpal flexion no functional improvement was observed. 
This trial was selected as a further Phase I/II variant of this approach, transplanting 30 million 
myoblast per cm3 per 3, 6 and 9cm3 of the extensor carpi radialis (Clinical Trial reference: 
NCT02196467) is currently underway. 
The second arguably more successful Phase I/IIa clinical trial in Ocular Pharyngeal Muscular 
Dystrophy (OPMD) by Perie et al, combined Heller myotomy and an autologous 
transplantation (of healthy unaffected myoblasts, derived from other muscle groups) in 12  
patients. Importantly, OPMD is characterised by dysphagia, a difficulty in swallowing and ptosis 
a drooping of eyelids; hence the trial was concerned with safety and the time taken to drink 
80mls as end points (Périé et al. 2014). Notably, all 12 patients showed functional 
improvement as assessed by the mean time taken to drink reducing almost 2 fold from 23.7 
pre-transplantation to 10.2 seconds 2 years post-transplantation. One critique of this study is 
that they was no Heller Myotomy alone patient control group was included due to low patient 
number; which would be beneficial particularly as myotomy in isolation is initially associated 
with an immediate functional improvement in swallowing. This stated a secondary progressive 
reoccurrence of dysphagia is normally observed 39 months after myotomy; interestingly of the 
10 patients that agreed to long term follow up at 56 months following myotomy and myoblast 
transplantation, 8 were clinically stable.  
Overall, these trials highlight some success in the field of myoblast transplantation, the latter 
an elegant example of the benefit of autologous engraftment, dispensing with the 
requirement for life-long immunosuppressive therapies. Whilst such approaches hold promise 
such studies are once again limited by the propensity to correct a single, defined and 
accessible muscle. Thus these studies highlight that application of myoblast transplantation in 
a therapeutic setting is limited and will not provide the body wild correction sought by DMD 
patients. Furthermore, a repeated high density injection of myoblasts does not appear to be a 
feasible long –term treatment of muscular dystrophies.   
The final Phase I/IIa  proof-of-principle clinical trial demonstrated large scale production of 
mesoangioblasts in line with good manufacturing practice was achievable (Cossu et al. 2015). 
The primary aim of the study was to assess the safety and tolerability of delivering HLA-
matched mesoangioblasts by intra-arterial infusion, in 5 DMD patients. The results presented 
were deemed promising with functional stabilisation of 2 of the 3 ambulant patients included 
in the trial.  Although no functional improvement was identified throughout the course of the 
trial; authors attribute this to the low cell number of mesoangioblasts used and indicate an 
increase in cell number may improve clinical efficacy. However, results of this trial should be 
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interpreted with caution, particularly as comparison of pre and 2 months post-transplantation 
biopsies highlighted quantifiable increases in dystrophin protein in 2/5 patients; the 
differences in dystrophin levels being 3-11% and 11-22% respectively. Furthermore 3/5 
patients showed evidence of sub-cutaneous asymptomatic ‘livedo reticularis’ a purplish 
mottled colour of the skin, which can indicate impaired circulation. This in combination with 
one patient having a thalamic stroke following the fourth and final infusion of mesoangioblasts 
indicates that further investigation of how mesoangioblast infusion influences circulation is 
warranted. This stated the patiently cohort included in the trial is relatively small, hence if the 
protocol can be improved to reduce side effects, mesoangioblasts could still show efficacy if 
the cell number is escalated. 
This trial illustrates the propensity for cells to be delivered systemically in the treatment of 
DMD, with some subtle dystrophin restoration observed at sub-optimal cell numbers. This is a 
notable advancement in the field of cell-based therapies, although the side effects observed, 
indicate further assessment of safety and tolerability is required. Notably, one further cell 
candidate is currently in clinical trial. The clinical trial aims to assess the safety and efficacy of 
autologous transplantation of patient bone marrow derived mesenchymal stem cells in the 
treatment of DMD (Trial Code NCT03067831); using muscle strength as a primary outcome, 
the results of which are anticipated in 2020. 
The on-going examination of cellular candidates in preclinical models and in clinical trials, 
highlights that cell based therapies in the treatment of muscular dystrophies continues to be a 
dynamic and evolving field of research.  In combination,  with greater production of cellular 
material becoming more achievable owing to the ability to re-programme somatic cells to 
become iPSCs and produce certain cell lineages (Takahashi et al. 2007; Goudenege et al. 2012; 
Tedesco et al. 2012); It can be seen that the advancing field of gene-therapeutics and cell 
based strategies could supplement each other in the future  advancement of regenerative 
therapeutic approaches. 
7.3.2 Viral Delivery Strategies  
Direct administration of gene editing reagents, may represent an alternative delivery strategy 
to cell engraftment approaches. Although improved in-silico guide design and Cas9 protein 
specificity would be required, if developed, this approach could hold therapeutic promise in 
the future. In addition to improvement of these parameters, an efficient delivery vector would 
also be of utmost importance to ensure the success of this approach; pertinent to this is the 
recent packaging of SpCas9 in a range of viral vectors including Adenoviral (Maggio et al. 
2016), Lentiviral (Ousterout et al. 2015) and Adeno-Associated Virus(Wright et al. 2015). In the 
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case of the latter, the large size of the SpCas9 transgene (4.1kb), precluded its complete 
packaging into AAV, which have a genome of 4.7kb and upper packaging limit of 5kb (Wu et al. 
2010b). Thus the SpCas9 transgene was split in half and reconstituted by dual AAV 
transduction experimentally (Wright et al. 2015). In addition, the continued examination of 
alternative Cas9 proteins have served to identify the smaller Staphylococcus Aureus Cas9 and 
Cpf1 derived from Acidominococcus and Lachnospiraceae, which can be readily packaged into 
AAV(Ran et al. 2015; Zetsche et al. 2015). In addition to overcoming the packaging constraints 
of AAV, these bacterial orthologues have unique PAM recognition sequences and specificity 
profiles and thus are promising expansions to the gene-editing tool kit. 
The viral packaging of SpCas9 and SaCas9 served to rejuvenate interest in in-vivo correction 
strategies of the premature stop codon in the mdx mouse. Four studies were performed in 
pursuit of this: using AdV serotype 5 (Xu et al. 2016), AAV8 (Tabebordbar et al. 2016; Nelson et 
al. 2016) and AAV9 (Long et al. 2016). Initially, Wu et al demonstrated NHEJ mediated deletion 
of exons 21-23 in newborn mdx mouse pups, utilising a dual adenoviral transduction approach; 
in which vectors encoded spCas9-2A-GFP and guide RNAs respectively. Impressively, the 
injection of these two vectors in the gastrocnemius produced a 23kb genomic deletion and 
restored dystrophin expression to 50% of that observed in healthy mice (Xu et al. 2016). 
Interestingly, the subsequent three studies that followed utilised the SaCas9, which owing to 
its alternative guide requirements enabled precise NHEJ deletion of exon 23 in isolation. 
Nelson et al performed an Intramuscular injection of AAV8 into mdx mice, prompting the NHEJ 
mediated removal of exon 23. A 2% correction of exon 23 at the genomic level was detected, 
however an analysis at the transcriptome level highlighted that 59% of transcripts harboured a 
deletion of exon 23 (Nelson et al. 2016).  It was posited that this was due to protection of 
these transcripts from nonsense mediated decay. Intriguingly, this low level of genomic 
correction also produced improvement in mdx muscle histology and functional assessments. 
Finally, Intraperitoneal and intravenous injections were also trialled showing improvement in 
cardiac muscles. 
A similar study to Nelson’s used mdx Ai9 mice; using the Ai9 reporter allele for initial visual 
identification of gene modification, as the removal of a premature stop codon in this sequence 
enabled dTomato expression; this was prior to progressing to the correction of the mdx 
mutation (Tabebordbar et al. 2016). Secondly, they trialled AAV9 serotypes by a range of 
delivery systems including: Intramuscular injection into the tiabialis anterior, intraperitoneal 
and intravenous injections. At an individual tiabialis anterior muscle level approximately 39% 
of mRNA transcripts, assessed by RT-PCR and sequencing harboured exon 23 deletion. This 
translated to improvement in neuronal nitric oxide synthase (nNOS) localisation and muscle 
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specific force. Promisingly, this extended to intraperitoneal and intravenous delivery, for which 
exon 23 excision varied from 3 -18% (Tabebordbar et al. 2016). Furthermore, upon crossing Ai9 
mice Pax7+ZsGreen+ satellite cells, which allow for the identification of satellite cells by green 
fluorescence; it was discovered that exon 23 excision extended to satellite cells. In light of the 
high regenerative capacity of satellite cells in muscle physiologically, this is an important 
finding to the muscular dystrophy field. Further characterisation of the extent of satellite cell 
correction is warranted particularly, as the propensity for AAVs to transduce and correct 
satellite cells is asserted as a current limitation of using this viral vector for a gene editing 
strategy (Philpott et al. 2002; Counsell et al. 2017)   
A final study used SaCas9 NHEJ-mediated removal of exon 23, to assess the efficiency of 
intramuscular, intraperitoneal and retro-orbital injections, using dystrophin presence in 
cardiac muscle as an end-point (Long et al. 2016).  Intriguingly, this study found that all 
methods of delivery resulted in some restoration in vascular smooth muscle cells, attributed to 
the entry of the AAV9 into intravascular circulation. This stated retro-orbital was shown to 
provide the best dystrophin restoration, with a 2 fold improvement upon other methods in 
skeletal muscle providing a measure of 53.2 ± 18.5% and a marginal increase in 
cardiomyocytes. It was also observed that AAVs were unable to cross the blood brain barrier 
and address the neurological aspect of DMD.  
These studies provide some important demonstrations of the therapeutic potential of gene-
editing: i) Both SpCas9 and the bacterial orthologue SaCas9 can be vectorised using AdVs and 
AAVs, ii) The bacterial system utilised influences target-site availability and by extension the 
amount of genomic material that needs to be excised in an NHEJ-approach iii) Low levels of 
genomic correction can confer functional improvement particularly if the transcript is 
protected or correction occurs in cells with high muscle regenerative capacity iv) Numerous 
routes of administration are successful but influence muscle-group dystrophin restoration v) 
Alternative strategies may be required to provide correction of muscle and neurological clinical 
phenotypes.   
In addition to the correction of the premature stop codon genetic defect in mdx mice, two  
pertinent studies highlighted the therapeutic prospect of using NHEJ-mediated deletion to 
remove the Δ45-55 mutational hotspot, which could be applicable to 62% of patients 
(Ousterout et al. 2015; Maggio et al. 2016). The former used a Lentiviral delivery system and 
showed low to undetectable levels of gene modification in patient myoblasts, requiring 
enrichment to detect the truncated dystrophin. In contrast, the latter demonstrated NHEJ-
mediated deletion of exons 45-55 using an all-in-one construction of SpCas9 in an adenoviral 
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vector. Impressively, 10% of patient myoblasts were shown to harbour internal deletion of 
dystrophin, in the absence of selection (Maggio et al. 2016). These demonstrations remain at 
the in vitro demonstration stage and have yet to be tested in-vivo.  
Notably, all of the studies presented used an NHEJ-mediated deletion strategy, arguably 
indicating that HDR-therapeutics/gene integration approaches are lagging behind in the gene-
editing field currently. The most recent demonstration with CRISPR/Cas9 being the correction 
of mdx zygotes by the injection of mRNA guides and Cas9 alongside a ssODN exogenous donor 
(Long et al. 2014). Importantly, while the modification of Beta thalassemia in human embryos 
was recently undertaken using the Cas9 gene-editing system; this approach is associated with 
a plethora of ethical considerations and is currently not a treatment strategy for DMD patients 
(P. Liang et al. 2015). 
Collectively these publications highlight the potential of a viral-based strategy, to deliver the 
gene-editing reagents required to achieve the near-universal therapeutic strategy presented. 
In the context of a HDR-mediated MD1 integration strategy, dual adenoviral transduction using 
‘gutted’ adenoviruses could be envisaged; one vector encoding an all-in-one spCas9 construct 
and a second delivering the exogenous repair template encoding either the full length or Δ45-
55 sequence optimised dystrophin variant.  This could be pertinent to the continued 
advancement of the strategy presented, particularly as the Δ45-55 and full length sequence 
optimised dystrophin variants whilst characterised remained untested in the context of 
integration. The large packaging capacity of the gutted AdV being approximately 37kb makes it 
a suitable candidate for the delivery of the approximate 11kb full-length dystrophin cDNA 
alongside selection markers (Mitani et al. 1995; Gonçalves & de Vries 2006). Importantly, there 
is president of the gutted adenoviral delivering full length dystrophin in gene augmentation 
studies; with intramuscular injections into mdx mice demonstrating 25-30% dystrophin 
restoration 1 month post transduction and improved resilience to contraction induced injury 
(DelloRusso et al. 2002). In addition, this study utilised native dystrophin, it is likely the 
enhanced protein expression associated with sequence optimised dystrophin would produce a 
more favourable outcome. 
One limitation to the use of adenoviral vectors therapeutically, is their immunogenicity. It has 
been shown that the components of the AdV: its capsid, dsDNA genome and transcriptome 
can all trigger innate immune responses in hosts (Machitani et al. 2011; Alonso-Padilla et al. 
2016).Further innate immune responses have also been indicated resulting from the trafficking 
of the AdV from the cytoplasm to the nuclear pore post-entry into the cell (Teigler et al. 2014). 
In addition when delivered systemically, the most suitable route of administration for the 
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treatment of DMD the AdVs are sequestered by the liver, a major source of pro-inflammation. 
Importantly, improvements to AdV construction and experimental design have been 
developed. It has been shown construction of the adenoviral capsids from adenoviral 
serotypes other than 5 and the shielding of the virus with polymers, reduces inflammatory 
responses (Roberts et al. 2006; Capasso et al. 2014). Secondly, the sequestration of the AdV 
vector by the liver, reduces efficient transduction and increases the chance of an immune 
response.  To improve upon this Piccolo et al showed that the scavenger receptors: SR-A and 
SREC-L that mediate AdV uptake by kuppfer cells in the liver, could be blocked transiently   
with the use of peptides. This was shown to be well tolerated and keep interleukins at a stable 
level in preclinical models (Piccolo et al. 2014).  
A contrasting approach also prompted by these studies, is a HITI NHEJ-mediated integration of 
the dystrophin transgenes. Provisional, studies could focus upon the use of AAV-SaCas9 
vectors coupled to an AAV-MD1-RT with flanking guide sequences in reverse orientation to its 
occurrence in the genome. This could provide a higher efficiency as the NHEJ DNA repair 
pathway occurs throughout the cell cycle. The use of AAV serotype 8 or 9 would be beneficial 
as they have a more favourable immunity profile relative to AdVs, furthermore they have a 
natural tropism to cardiac and skeletal muscle (Zincarelli et al. 2008; Ferrand et al. 2015). Due 
to the limited <5kb packaging capacity of AAVs, the integration of the larger transgenes could 
be attempted but would likely be constrained to the use of AdVs or possibly Lentiviruses, as 
the delivery of full length dystrophin using this vector was recently shown (Counsell et al. 
2017).  
7.3.3 Non-viral Delivery Approaches: 
An alternative approach to the delivery of gene-editing reagents is to use a non-viral carrier to 
protect /shield the biological entity from degradation (Sun et al. 2015). Lee et al 2017 elegantly 
demonstrated the delivery Cas9 RNP and an exogenous ssODN donor, both in vitro and in vivo 
with the use of DNA-coated gold nanoparticles. The construction of these nanoparticles was 
dependent upon: i) the affinity of the Cas9 Nuclease for the guide RNA and for the DNA 
coating the gold particle and ii) the electrostatic attraction between the Cas9 protein and the 
gold nanoparticle (Lee et al. 2017). Being concerned with the development of HDR-
therapeutics, this study demonstrated in vitro the conversion of eGFP to BFP, in a HEK293T-
eGFP cell line, with the use of Cas9 ribonucleotide proteins (RNPs) at 11.3% efficiency. This 
strategy was then extended to address the premature stop codon in exon23 of the mdx 
mouse. Intra-muscular injection of 4 week old mdx mice were undertaken post cardiotoxin 
treatment of tibialis anterior muscles.  This was shown to restore 5.4% of dystrophin 
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expression, as ascertained 2 weeks post injection. Furthermore, some functional improvement 
was observed in treated mice with the four limb hang test.  
A second study by Sun et al of non-viral delivery of Cas9 RNPs, illustrated the use of self-
assembled DNA nanoclews. The DNA nanoclews, a yarn-like nanoparticle, were delivered to 
U20s.eGFP cells; the reduction in fluorescence was used to indicate the presence of sequence 
modifications resulting from DNA cleavage. In vitro, this system indicated a 36% reduction in 
fluorescence. Importantly when extended to  U2Os.eGFP tumour bearing mice, by a direct 
injection into the tumour this efficiency was shown to be 25%(Sun et al. 2015).   
The use of non-viral delivery strategies represent an attractive alternative to the use of viral 
vectors, being well tolerated by hosts even upon repeat administration(Lee et al. 2017). 
Moreover, the use of Cas9 RNPs would be beneficial in a therapeutic strategy owing to their 
transient expression profile and engineering for enhanced specificity (S. Kim et al. 2014; 
Slaymaker et al. 2016; Kleinstiver et al. 2016). This would serve to reduce Genome-wide off-
target effects, a concern that has served to limit the use of Cas9 in a therapeutic setting. 
However, in the context the near-universal therapeutic strategy presented, it would be 
challenging to deliver the large exogenous repair template required being approximately 
9.8kb. Moreover, the reduced efficiency relative to viral vectors and the local delivery 
presented by the above strategies, present further hurdles to attaining therapeutic thresholds 
of dystrophin body-wide. Overall, these strategies remain promising for defined organs or 
tumours; however, further research is warranted to develop higher efficiency platforms 
amenable to systemic delivery.  
7.4 Concluding Remarks 
The study aimed to investigate a genome-editing strategy with near universal therapeutic 
applicability to Duchenne Muscular Dystrophy patients. By using the newly re-purposed 
CRISPR-Cas9 prokaryotic immune system, targeting intron 1 of the DMD gene, in combination 
with an exogenous repair template encoding microdystrophin; a proof of principle 
demonstration of this genome surgery approach was achieved in HEK293T cells. In addition, a 
provisional indication of microdystrophin integration was also observed in immortalised 
patient myoblasts.  The research presented has extensive scope for development, alternative 
dystrophin transgenes, exogenous repair template constructs and delivery systems of gene-
editing reagents. The efficacy could also be improved with altered guide design. Furthermore 
in light of on-going research in the field of cell based therapies and the ability to package Cas9 
nucleases into viral and non-viral vectors it has high therapeutic potential, in the treatment of 
DMD.  
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